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1. INTRODUCTION
1.1. Preamble
It is important that the medical professions play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the detection, management, and prevention
of disease states. Rigorous and expert analysis of the avail-
able data documenting absolute and relative benefits and
risks of those procedures and therapies can produce helpful
guidelines that improve the effectiveness of care, optimize
patient outcomes, and favorably affect the overall cost of
care by focusing resources on the most effective strategies. 
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged in
the production of such guidelines in the area of cardiovascu-
lar disease since 1980. This effort is directed by the
ACC/AHA Task Force on Practice Guidelines, whose charge
is to develop and revise practice guidelines for important car-
diovascular diseases and procedures. Writing committees are
charged with the task of performing an assessment of the
evidence and acting as an independent group of authors to
develop written recommendations for clinical practice.
Experts in the subject under consideration are selected from
both organizations to examine subject-specific data and write
or update guidelines. The process includes additional repre-
sentatives from other medical practitioner and specialty
groups where appropriate. Writing groups are specifically
charged to perform a formal literature review, weigh the
strength of evidence for or against a particular treatment or
procedure, and include estimates of expected health out-
comes where data exist. Patient-specific modifiers, comor-
bidities, and issues of patient preference that might influence
the choice of particular tests or therapies are considered, as
well as frequency of follow-up and cost-effectiveness. When
available, information from studies on cost will be consid-
ered; however, review of data on efficacy and clinical out-
comes will be the primary basis for recommendations in
these guidelines. 
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual, potential, or perceived con-
flicts of interest that might arise as a result of an outside rela-
tionship or personal interest of a member of the writing
panel. Specifically, all members of the writing panel are
asked to provide disclosure statements of all such relation-
ships that might be perceived as real or potential conflicts of
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interest. These statements are reviewed by the parent task
force, reported orally to all members of the writing panel at
each meeting, and updated and reviewed by the writing
committee yearly and as changes occur. Please see Appendix
1 for author relationships with industry and Appendix 2 for
peer reviewer relationships with industry.
The practice guidelines produced are intended to assist
healthcare providers in clinical decision making by describ-
ing a range of generally acceptable approaches for the diag-
nosis, management, and prevention of specific diseases or
conditions. These guidelines attempt to define practices that
meet the needs of most patients in most circumstances. These
guideline recommendations reflect a consensus of expert
opinion after a thorough review of the available, current sci-
entific evidence and are intended to improve patient care. If
these guidelines are used as the basis for regulatory/payer
decisions, the ultimate goal is quality of care and serving the
patient’s best interests. The ultimate judgment regarding care
of a particular patient must be made by the healthcare
provider and patient in light of all of the circumstances pre-
sented by that patient. 
These guidelines were approved for publication by the gov-
erning bodies of the American College of Cardiology  (ACC)
and the AHA and have been officially endorsed by the fol-
lowing collaborating organizations: Society for
Cardiovascular Angiography and Interventions; Society for
Vascular Medicine and Biology; Society for Vascular
Surgery; and Society of Interventional Radiology; as well as
by the American Association of Cardiovascular and
Pulmonary Rehabilitation; National Heart, Lung, and Blood
Institute; Society for Vascular Nursing; TransAtlantic Inter-
Society Consensus; and Vascular Disease Foundation. The
guidelines will be reviewed annually by the ACC/AHA Task
Force on Practice Guidelines and will be considered current
unless they are updated, revised, or sunset and withdrawn
from distribution. The executive summary and recommenda-
tions are published in the March 21, 2006 issue of the
Journal of the American College of Cardiology and the
March 21, 2006 issue of Circulation. The full text is pub-
lished on the ACC and AHA World Wide Web sites. Copies
of the full text and the executive summary are available from
both organizations. 
Elliott M. Antman, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
Raymond J. Gibbons, MD, FACC
Immediate Past-Chair, ACC/AHA Task Force on 
Practice Guidelines
1.2. Definitions
Peripheral arterial disease (PAD) encompasses a range of
noncoronary arterial syndromes that are caused by the
altered structure and function of the arteries that supply the
brain, visceral organs, and the limbs. Numerous pathophysi-
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ological processes can contribute to the creation of stenoses
or aneurysms of the noncoronary arterial circulation, but ath-
erosclerosis remains the most common disease process
affecting the aorta and its branch arteries. These guidelines
primarily address the diagnosis and management of athero-
sclerotic, aneurysmal, and thromboembolic PAD. 
Whereas the term “peripheral arterial disease” encompass-
es a large series of disorders affecting arterial beds exclusive
of the coronary arteries, this writing committee chose to limit
the scope of the work of this document to disorders of the
abdominal aorta, renal and mesenteric arteries, and lower
extremity arteries. The guideline is thus presented as an
introduction, followed by 4 sections that address these
anatomic arterial regions. Clinical management guidelines
for other arterial beds (e.g., the thoracic aorta, carotid and
vertebral arteries, and upper extremity arteries) have been
excluded from the current guideline to focus on the infradi-
aphragmatic arterial system and in recognition of the robust
evidence base that exists for the aortic, visceral, and lower
extremity arteries. The guideline is also organized to follow
an anticipated “chronology” of clinical care of patients with
PAD. As such, the full-text guideline is written with the pre-
sumption that many readers will search the guideline for spe-
cific advice on management of PAD patients at different
phases of their illness. Thus, in selected instances, recom-
mendations and some portions of the text are repeated.
The clinical manifestations of PAD are a major cause of
acute and chronic illness; are associated with decrements in
functional capacity and quality of life; cause limb amputa-
tion; and increase risk of death. The systemic nature of the
atherosclerotic process also contributes to development of
concomitant disease of the arteries to the heart and brain.
Consequently, patients with PAD often face an associated
increased risk of cardiovascular ischemic events, such as
myocardial infarction (MI), ischemic stroke, and death.
Overall, the manifestations of PAD are thus associated with
a large personal, social, and economic burden in the United
States, Europe, South America, and Asia, and PAD is
increasingly recognized as a health burden worldwide.
Inasmuch as the burden of PAD is widespread, these guide-
lines are intended to assist all clinicians who might provide
care for such patients. In particular, these guidelines are
designed to aid primary care clinicians, vascular and cardio-
vascular specialists, trainees in the primary care and vascular
specialties, nurses, physical therapists, and rehabilitative per-
sonnel who seek clinical tools that can improve the proper
evaluation and management of patients with PAD and asso-
ciated thromboembolic disease. This document provides rec-
ommendations and supporting evidence for the short- and
long-term management of patients with PAD in both inpa-
tient and outpatient settings. Recommended diagnostic and
therapeutic strategies are supported by the best available evi-
dence and expert opinion. The application of these strategies,
combined with carefully reasoned clinical judgment, pro-
motes the use of preventive strategies, improves the rates of
diagnosis of each syndrome, and decreases the rates of
amputation, ischemic renal failure, mesenteric ischemia,
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Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or treat-
ment.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well
established by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/treat-
ment is not useful/effective and in some cases
may be harmful.
Level of Evidence
• Level of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
• Level of Evidence B: Data derived from a single random-
ized trial or nonrandomized studies.
• Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
Table 1 delineates the classification of recommendations
and level of evidence. 
This guideline was developed by a writing committee
whose members had expertise in vascular medicine and car-
diovascular medicine, vascular surgery, vascular and inter-
ventional radiology, and hypertension and renal disease, with
committee membership derived from the ACC, the AHA, the
Society for Vascular Surgery, the Society of Interventional
Radiology, the Society for Vascular Medicine and Biology,
the Society for Cardiovascular Angiography and
Interventions, the ACC Board of Governors, and the
ACC/AHA Task Force on Practice Guidelines. 
This writing committee recognizes the prodigious effort
and international contribution of the “Management of
Peripheral Arterial Disease” document developed by the
TransAtlantic Inter-Society Consensus (TASC) Working
Group (http://www.tasc-pad.org/) (1). The TASC is an inter-
nationally derived, collaboratively created consensus that
provides an evidence-based, detailed review of the diagnosis
and treatment of intermittent claudication, acute limb
ischemia, and critical limb ischemia (CLI). The efforts of
TASC have defined the standard of excellence in the treat-
ment of peripheral arterial disease. At this writing, the TASC
Working Group is in the process of updating its 2000 docu-
ment. Readers are encouraged to consult, in addition to this
guideline, the revised TASC document when it becomes
available. 
The ACC/AHA Writing Committee was charged with
building on the work of TASC to create a guideline for a
broader audience to include primary care clinicians as well
as vascular specialists. This guideline also encompasses a
larger, yet still limited, scope. In addition to lower extremity
PAD, this guideline includes a focus on aortic and branch
aneurysmal rupture, MI, stroke, and death. The ultimate goal
of the guideline is to improve the quality of life for people
with PAD. 
The Committee to Develop Guidelines for Peripheral
Arterial Disease conducted comprehensive searching of the
scientific and medical literature relevant to PAD. Literature
searches were conducted in PubMed/MEDLINE and a clini-
cal trials database. Searches were limited to publications in
English and human subjects. The committee reviewed all
compiled reports from computerized searches and conducted
additional searching by hand. Committee members also rec-
ommended applicable articles outside the scope of formal
searches. 
In addition to broad-based searching on PAD, specific tar-
geted searches were performed on the following subtopics:
amputation, aneurysm, ankle-brachial index, antihyperten-
sive drugs, antiplatelet and antithrombotic drugs, arteriogra-
phy, beta blockade, “blue-toe” syndrome, calcification,
catheter-based intervention, chronic limb ischemia, claudica-
tion, compression, computed tomography, coprevalance of
cardiovascular/carotid disease, diabetes, diagnosis, endovas-
cular treatment, etiology, exercise/rehabilitation, femoral
pseudoaneurysms, follow-up, homocysteine lowering, imag-
ing, location and prevalence, lower extremity pulse exam,
magnetic resonance angiography, management of ischemia,
measurement, medical/pharmacological management,
mesenteric, natural history, pathology, pregnancy risk, pre-
operative assessment/evaluation, prevalence, renal function,
smoking cessation, statins, stent, surgical intervention,
thrombolysis, ultrasound, vascular surgery. The list of
subtopics is not exhaustive.
As a result of these searches, more than 1300 references
were used as the major evidence base in the final Guideline,
with many times this number of references reviewed by the
Committee. Using evidence-based methodologies developed
by the ACC/AHA Task Force on Practice Guidelines, the
committee wrote guideline text and recommendations.
Literature citations were generally restricted to published
manuscripts appearing in journals listed in Index Medicus.
Because of the scope and importance of certain ongoing clin-
ical trials and other emerging information, published
abstracts were cited when they were the only published
information available.
It is hoped that readers will be best served as they utilize
this guideline by their examination of the methods of evi-
dence review that guide all writing committees
(http://www.acc.org/clinical/manual/manual_introltr.htm). A
classification of recommendation and a level of evidence
have been assigned to each recommendation. Classifications
of recommendations and levels of evidence are expressed in
the ACC/AHA format as follows.
Classification of Recommendations
Class I: Conditions for which there is evidence for
and/or general agreement that a given proce-
dure or treatment is beneficial, useful, and
effective.
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Table 1. Applying Classification of Recommendations and Level of Evidence
“Size of Treatment Effect”
*Data available from clinical trials or registries about the usefulness/efficacy in different sub-populations, such as gender, age, history of diabetes, history of prior MI, history of heart failure, and prior aspirin use. A recommendation
with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available,
there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All recommendations in this guideline have been written in full sentences that express a complete
thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that
this will increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
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aneurysmal disease, renal arterial, and visceral arterial dis-
ease. Thus, the purposes of this guideline are to (1) aid in the
recognition, diagnosis, and treatment of PAD of the aorta and
lower extremities, addressing its prevalence, impact on qual-
ity of life, cardiovascular ischemic risk, and risk of CLI; (2)
aid in the recognition, diagnosis, and treatment of renal and
visceral arterial diseases; and (3) improve the detection and
treatment of abdominal and branch artery aneurysms. 
The term “peripheral arterial disease” includes a diverse
group of disorders that lead to progressive stenosis or occlu-
sion, or aneurysmal dilation, of the aorta and its noncoronary
branch arteries, including the carotid, upper extremity, vis-
ceral, and lower extremity arterial branches. PAD is the pre-
ferred clinical term that should be used to denote stenotic,
occlusive, and aneurysmal diseases of the aorta and its
branch arteries, exclusive of the coronary arteries. 
Historically, the term “peripheral vascular disease” has
been used to most inclusively describe the noncardiac dis-
eases that affect the circulation as a whole. Thus, this term
encompasses a myriad of pathophysiological syndromes that
affect the arterial, venous, and lymphatic circulations;
accordingly, it includes all vascular diseases that alter end-
organ perfusion. Arterial diseases include those disorders
that cause either fixed obstruction or abnormal vascular reac-
tivity of the arteries that supply a given tissue; the obstruc-
tion impairs blood delivery and can produce ischemia.
Venous diseases include those disorders that impair normal
venous function, usually involve both altered venous struc-
ture and function, and may include thromboembolism. These
disorders include venous valvular incompetence and venous
hypertension, deep venous thrombosis, pulmonary
embolism, the postthrombotic syndrome, and varicose veins.
Lymphatic diseases are a consequence of congenital or
acquired processes that may cause progressive destruction or
abnormal function of the microvascular lymphatic networks;
these disorders are usually clinically manifested as lym-
phedema. Thus, the term “peripheral vascular disease” is
broadly inclusive of all vascular disorders.
The term “peripheral arterial occlusive disease” is used in
a manner analogous to that of PAD, although it specifically
excludes the functional (vasoreactive) or aneurysmal disor-
ders that affect the noncoronary arteries. “Lower extremity
arterial disease” includes disorders that affect the leg arteries
and does not include diseases of the aorta, carotid, upper
extremity, or visceral arteries. 
“Arteriosclerosis obliterans” includes those arterial dis-
eases that are defined by the process of atheroma formation
and calcium deposition in the arterial wall.
“Atherothrombosis” similarly defines the mutual roles of
atherosclerosis and thrombosis in the formation of arterial
stenoses that lead to plaque rupture and thrombotic occlu-
sion. “Atherosclerotic vascular disease” includes those arte-
rial syndromes that have an atherosclerotic origin, exclusive
of aneurysmal, thromboembolic, arteritic, and vasoreactive
causes. 
For the purposes of this guideline, we utilize the term
“peripheral arterial disease” to broadly encompass the vas-
cular diseases caused primarily by atherosclerosis and
thromboembolic pathophysiological processes that alter the
normal structure and function of the aorta, its visceral arteri-
al branches, and the arteries of the lower extremity. 
Peripheral arterial disease is often a consequence of sys-
temic disease processes that affect multiple arterial circula-
tions, although clinically recognized disease in more than 1
organ system is not always present. These systemic patho-
physiological processes are diverse and include atherosclero-
sis, degenerative diseases, dysplastic disorders, vascular
inflammation (arteritis), and both in situ thrombosis and
thromboembolism. Clinicians who provide care for individ-
uals with PAD should recognize this diversity of pathophys-
iological causes of this syndrome because this recognition is
required to create an inclusive differential diagnosis and
comprehensive long-term treatment plan. The most common
cause of PAD worldwide is atherosclerosis, and thus the epi-
demiology and clinical consequences of PAD are closely
associated with classic atherosclerosis risk factors (e.g.,
smoking, diabetes, hypertension, hyperlipidemia, family his-
tory, and the postmenopausal state) and more recently
defined risk factors (e.g., hyperhomocysteinemia and a vari-
ety of others) (2-5). 
Peripheral arterial disease may also be caused by degener-
ative disorders that lead to a loss of the structural integrity
and subsequent dilation of the arterial wall. The pathophysi-
ology of some specific progressive arterial degenerative dis-
eases is relatively well understood (such as the collagen
abnormalities that underlie Marfan and Ehlers-Danlos syn-
dromes) (6-10), whereas the vascular defect responsible for
most degenerative diseases remains elusive (e.g., Erdheim’s
cystic medial necrosis, arteriomegaly, neurofibromatosis,
and most of the so-called atherosclerotic aneurysms).
Arterial wall degeneration can lead to aneurysm formation or
dissection that may result in arterial rupture or occlusion. 
The most common dysplastic disease is fibromuscular dys-
plasia (FMD), which may affect many noncoronary arterial
beds, especially the renal arteries, carotid arteries, and iliac
arteries (11,12). The vasculitic diseases may also affect any
arterial bed, and the spectrum of clinical syndromes associ-
ated with vasculitis is broad (13-20). Large vessels (the aorta
and its first- and second-order branches) may be involved by
giant cell arteritis (Takayasu’s disease), Behçet’s syndrome,
relapsing polychondritis, and vasculitis associated with
arthropathies. Medium-sized vessels (conduit muscular
arteries and branches) are classically the target of polyarteri-
tis nodosa or temporal arteritis (a form of giant cell arteritis),
although Wegener’s or lymphoid granulomatosis, Churg-
Strauss syndrome, and Kawasaki disease also affect vessels
of this size. Radiation-associated arteritis can affect vessels
of any size. Small-vessel disease (arterioles and microves-
sels) occurs most frequently in association with systemic dis-
orders such as rheumatoid arthritis, systemic lupus erythe-
matosus, serum sickness, and other connective tissue or
autoimmune diseases. Thromboangiitis obliterans (Buerger’s
disease) is an arterial obliterative and thrombotic process that
is most frequently (but not invariably) observed in young
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Section 2.1.1) should undergo comprehensive pulse
examination and inspection of the feet. (Level of
Evidence: C)
3. Individuals over 50 years of age should be asked if
they have a family history of a first-order relative with
an abdominal aortic aneurysm. (Level of Evidence: C)
Vascular diseases are common, and prompt treatment can
diminish disability and death. Preservation of individual
health (improved functional status and survival) and achieve-
ment of public health goals (e.g., diminished rates of ampu-
tation and fewer cardiovascular ischemic events and death)
can be fostered by establishment of an accurate vascular
diagnosis. As for all illnesses, excellence in care begins with
the collection of an accurate history of the present illness,
review of systems, and physical examination. 
Vascular Review of Systems
In an ideal clinical world, each patient would offer their cli-
nician a detailed accounting of symptoms that impair normal
body functions or cause pain or disability, which would pro-
vide clues to an underlying disease state. However, patients
do not always report symptoms that may be vital to their
health, and they do not always associate specific symptoms
with underlying arterial disease (e.g., the walking impair-
ment of claudication, the presence of a poorly healing
wound, or abdominal pain in the presence of an abdominal
aneurysm). In this context, clinicians can specifically request
these data by asking patients to offer a review of symptoms
(ROS). The ROS is used to unmask symptoms in the follow-
ing domains: head, eye, ear, nose, throat, and the lymphatic,
dermatologic, pulmonary, cardiac, gastrointestinal, geni-
tourinary, musculoskeletal, neurological, or rheumatologic
systems. Traditionally, there has been no routine vascular
ROS, and this may contribute to the documented underdiag-
nosis of vascular diseases. This guideline, drafted with the
mandate to improve care for patients with PAD, offers sug-
gestions for creation of a vascular ROS. 
Key components of the vascular ROS (not usually includ-
ed in the ROS of the extremities) and family history include
the following:
• Any exertional limitation of the lower extremity muscles
or any history of walking impairment. The characteristics
of this limitation may be described as fatigue, aching,
numbness, or pain. The primary site(s) of discomfort in
the buttock, thigh, calf, or foot should be recorded, along
with the relation of such discomfort to rest or exertion. 
• Any poorly healing or nonhealing wounds of the legs or
feet.
• Any pain at rest localized to the lower leg or foot and its
association with the upright or recumbent positions.
• Postprandial abdominal pain that reproducibly is provoked
by eating and is associated with weight loss.
individuals who smoke tobacco; it behaves like a vasculitis
and can affect arteries of all sizes (smaller distal limb arter-
ies more frequently than larger proximal arteries), as well as
superficial veins (21-23). 
The primary prothrombotic diseases may be caused by (a)
specific abnormalities in the clotting system (e.g., protein C,
protein S, or antithrombin III deficiencies; factor V Leiden or
prothrombin mutations; hyperhomocysteinemia; or other
abnormalities); (b) the presence of a lupus anticoagulant or
anticardiolipin antibody; and (c) the prothrombotic state
associated with many malignancies and inflammatory bowel
disease (24). Thromboembolic arterial occlusive disease
affects both large (macroembolic) and small (microembolic)
vessels (25-29). Macroemboli usually originate from a car-
diac source (such as thrombus in the left atrial appendage,
atrial fibrillation, ventricular thrombus secondary to MI or
heart failure), whereas microemboli may have either a car-
diac source (typically a diseased native valve or a thrombo-
genic prosthetic valve) or an arterial source (most often a
ruptured cholesterol-containing plaque that produces distal
atheroembolization). 
The term “vasospastic diseases” refers to the pathological
vasoconstriction that may affect any muscular vessel in the
body (30-33). Migraine headache, cerebral vasospasm asso-
ciated with intracranial bleeding, Prinzmetal’s angina,
Raynaud’s phenomenon, and ergot toxicity are all well-rec-
ognized vasospastic syndromes. In the extremities,
vasospasm may occur as a primary event (primary
Raynaud’s phenomenon) or secondary to an underlying dis-
ease process such as scleroderma or systemic lupus erythe-
matosus (secondary Raynaud’s phenomenon). 
1.3. Vascular History and Physical Examination
RECOMMENDATIONS
Class I
1. Individuals at risk for lower extremity PAD (see
Section 2.1.1, Table 2) should undergo a vascular
review of symptoms to assess walking impairment,
claudication, ischemic rest pain, and/or the presence
of nonhealing wounds. (Level of Evidence: C)
2. Individuals at risk for lower extremity PAD (see
Table 2. Individuals at Risk for Lower Extremity Peripheral Arterial
Disease
Age less than 50 years, with diabetes and one other atherosclerosis
risk factor (smoking, dyslipidemia, hypertension, or hyperhomo-
cysteinemia)
Age 50 to 69 years and history of smoking or diabetes
Age 70 years and older
Leg symptoms with exertion (suggestive of claudication) or ischemic
rest pain
Abnormal lower extremity pulse examination
Known atherosclerotic coronary, carotid, or renal artery disease
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• Auscultation of the abdomen and flank for bruits.
• Palpation of the abdomen and notation of the presence of
the aortic pulsation and its maximal diameter. 
• Palpation of pulses at the brachial, radial, ulnar, femoral,
popliteal, dorsalis pedis, and posterior tibial sites.
Performance of Allen’s test when knowledge of hand per-
fusion is needed. 
• Auscultation of both femoral arteries for the presence of
bruits.
• Pulse intensity should be assessed and should be recorded
numerically as follows: 0, absent; 1, diminished; 2, nor-
mal; 3, bounding.
• The shoes and socks should be removed, the feet inspect-
ed, the color, temperature, and integrity of the skin and
intertriginous areas evaluated, and the presence of ulcera-
tions recorded. 
• Additional findings suggestive of severe PAD, including
distal hair loss, trophic skin changes, and hypertrophic
nails, should be sought and recorded.
2. LOWER EXTREMITY PAD
2.1. Epidemiology
2.1.1. Risk Factors
The major cause of lower extremity PAD is atherosclerosis.
Risk factors for atherosclerosis such as cigarette smoking,
diabetes, dyslipidemia, hypertension, and hyperhomocys-
teinemia increase the likelihood of developing lower extrem-
ity PAD, as they do for other manifestations of atherosclero-
sis (Figure 1). 
• Family history of a first-degree relative with an abdominal
aortic aneurysm (AAA).
The Vascular Physical Examination
Ideally, critical components of the bedside clinical evaluation
are common among all clinicians and congruent between pri-
mary care and specialty practices. Such a common core
physical examination and methods to record its findings are
fundamental if clinical data are to be transferred (a) from one
caregiver to the next within a practice or (b) from primary
caregiver to consultant. Such an approach has been central to
the establishment of the best clinical practices for heart dis-
ease (in which all practitioners utilize a common examina-
tion of neck veins, palpation of the point of maximal
impulse, intensity of heart sounds, and intensity and location
of murmurs); pulmonary disease (in which all practitioners
utilize a common examination of diaphragmatic excursion,
inspiratory effort, and clarity of breath sounds); and neuro-
logical disease (in which all practitioners utilize a common
examination of cranial nerve function and global sensory and
motor function). The pulse examination, although critical to
good care, has well-defined limitations. Recognition of the
limited sensitivity, specificity, and predictive value of the
pulse examination has led to recognition that this examina-
tion must be supplemented by objective vascular testing (see
Section 2.5) (34).
Key components of the vascular physical examination
include the following:
• Measurement of blood pressure in both arms and notation
of any interarm asymmetry.
• Palpation of the carotid pulses and notation of the carotid
upstroke and amplitude and presence of bruits.
Figure 1. Risk of developing lower extremity PAD. The range for each risk factor is estimated from epidemiological studies (see text).
The relative risks take into consideration current smokers versus former smokers and nonsmokers, presence versus absence of dia-
betes and hypertension, and highest versus lowest quartile of homocysteine and C-reactive protein. The estimate for hypercholes-
terolemia is based on a 10% risk for each 10 mg per dL rise in total cholesterol. Adapted from J Vasc Surg, 31, Dormandy JA,
Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group, Management of peripheral arterial disease
(PAD), S1-S296, Copyright 2000, with permission from Elsevier (1).
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Cigarette smoking is an exceptionally powerful etiologic
risk factor for lower extremity PAD (35). It is 2 to 3 times
more likely to cause lower extremity PAD than coronary
artery disease (36). Large epidemiological studies have
found that smoking increases the risk of lower extremity
PAD by 2- to 6-fold and the risk of intermittent claudication
by 3- to 10-fold (3,37-40). More than 80% of patients with
lower extremity PAD are current or former smokers (38,40).
The risk of lower extremity PAD increases in a powerful
dose-dependent manner with the number of cigarettes
smoked per day and the number of years smoked (36,41-43).
Diabetes mellitus increases the risk of lower extremity
PAD by 2- to 4-fold (35,40,44-46) and is present in 12% to
20% of persons with lower extremity PAD (40,45). In the
Framingham Heart Study, diabetes increased the risk of
intermittent claudication by 3.5- and 8.6-fold in men and
women, respectively (37). The risk of developing lower
extremity PAD is proportional to the severity and duration of
diabetes (46,47). The risk of developing CLI is also greater
in diabetics than nondiabetics (48,49). Diabetic patients with
lower extremity PAD are 7- to 15-fold more likely to under-
go a major amputation than nondiabetics with lower extrem-
ity PAD (49-51).
Lipid abnormalities that are associated with lower extrem-
ity PAD include elevated total and low-density lipoprotein
(LDL) cholesterol, decreased high-density lipoprotein
(HDL) cholesterol, and hypertriglyceridemia (3,43,45,52).
The risk of developing lower extremity PAD increases by
approximately 5% to 10% for each 10 mg per dL rise in total
cholesterol (44,53,54). In epidemiological studies, total cho-
lesterol levels are generally higher in patients with intermit-
tent claudication than in those without lower extremity PAD
(38,52,55). Similarly, levels of LDL are higher and HDL lev-
els are lower in patients with lower extremity PAD than in
age-matched controls (40,54,56-58). Elevated levels of
triglycerides have been reported to be associated with lower
extremity PAD in some studies but not in others (59-63). The
relationship between hypertriglyceridemia and lower
extremity PAD usually remains intact, albeit with some
interstudy variability, when adjusted for the presence of other
risk factors (3,35,52).
Hypertension is associated with lower extremity PAD,
although the association is generally weaker than that with
cerebrovascular and coronary artery disease (35,54,63,64).
Hypertension increased the risk of developing lower extrem-
ity PAD in some studies but not in others (3,38,54,65). In the
Framingham Heart Study, hypertension increased the risk of
intermittent claudication 2.5- to 4-fold in men and women,
respectively, and the risk was proportional to the severity of
high blood pressure (37). 
Elevated levels of homocysteine are associated with a 2- to
3-fold increased risk for developing atherosclerotic arterial
disease (66,67). The European Concerted Action Project has
estimated that fasting homocysteine concentrations greater
than the 80th percentile (i.e., greater than 12.1 micromoles
per liter) are associated with a 2-fold increased risk of ather-
osclerotic vascular disease, including PAD, coronary artery
disease, and stroke, independent of traditional risk factors
(68). A meta-analysis of studies relating homocysteine to ath-
erosclerotic vascular disease found an odds ratio (OR) for
coronary artery disease and stroke of approximately 1.5 for
each 5 micromoles per liter increment in homocysteine level
and a comparable association with lower extremity PAD
(66). In one study, a 5 micromole per liter rise in total homo-
cysteine increased the risk of lower extremity PAD by 44%
(69). Approximately 30% to 40% of patients with lower
extremity PAD have high levels of homocysteine (5).
Elevated homocysteine levels are prevalent in both younger
and elderly patients with lower extremity PAD (70,71).
Approximately 25% of patients with intermittent claudica-
tion have plasma homocysteine levels exceeding the 95th
percentile (72). Hyperhomocysteinemia also appears to
increase the risk of progression of lower extremity PAD
(5,73). The etiologic role of homocysteine remains unknown,
because no positive homocysteine-lowering lower extremity
PAD interventional trials have been reported.
Elevated levels of C-reactive protein, a serological marker
of systemic inflammation, are associated with lower extrem-
ity PAD. Among previously healthy people participating in
the Physicians’ Health Study, there was a 2.1-fold increased
risk of developing lower extremity PAD in those men whose
C-reactive protein concentrations were in the highest quartile
(4). This study also noted that C-reactive protein levels were
higher in individuals who subsequently developed lower
extremity PAD and highest in those who ultimately required
vascular surgery (4). Moreover, in this study population, lev-
els of soluble intercellular adhesion molecule-1, a leukocyte
adhesion molecule that is upregulated by inflammatory
cytokines, were independently associated with the future
development of lower extremity PAD (74).
2.1.2. Prevalence
Lower extremity PAD is a common syndrome that affects a
large proportion of most adult populations worldwide
(35,54). The prevalence of lower extremity PAD has been
defined by a series of epidemiological investigations that
have used either claudication as a symptomatic marker of
lower extremity PAD or an abnormal ankle-to-brachial sys-
tolic blood pressure to define the population affected. In gen-
eral, the prevalence of lower extremity PAD is dependent on
the age of the cohort studied, the underlying atherosclerosis
risk factor profile of the cohort, and the presence of other
concomitant manifestations of atherosclerosis (e.g., clinical
coronary or cerebrovascular disease or past organ transplan-
tation) (35,54).
PAD can be present in subclinical forms that can be detect-
ed by use of sensitive vascular imaging techniques. Such
techniques may reveal early manifestations of arterial dis-
ease before it is detected by either limb pressure measure-
ments or clinical symptoms. When so defined, as, for exam-
ple, by measurement of the intimal-medial thickness in the
carotid or femoral artery, early forms of PAD are easily
detected in populations at risk. The Atherosclerosis Risk In
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tent claudication. Diabetes and stage 2 or greater hyperten-
sion were associated with more than a 2-fold increase in
intermittent claudication, whereas clinical evidence of coro-
nary artery disease almost tripled the risk (40). 
Criqui and colleagues have evaluated the prevalence of
PAD among a population of 613 men and women in south-
ern California utilizing a battery of 4 noninvasive tests (the
Rose questionnaire, pulse examination, ABI, and pulse-wave
velocity) to assess the prevalence of lower extremity PAD
(77) (Figure 2). Use of the Rose questionnaire severely
underestimated the prevalence of lower extremity PAD,
which demonstrates the insensitivity of this tool to assess
true population rates for lower extremity PAD. Use of the
history and physical examination alone also was associated
with a low sensitivity for detecting lower extremity PAD
(78). Lower extremity PAD detection increased 2 to 7 times
over the detection rate of the Rose questionnaire when the
ABI (ankle-brachial index) and pulse-wave velocity tech-
niques were applied. On the other hand, an abnormal limb-
pulse examination overestimated the prevalence by 2-fold.
When the objective noninvasive ABI and pulse-wave veloc-
ity techniques were used, the prevalence of lower extremity
PAD in this population was 2.5% among individuals 60 years
and younger, 8.3% among those aged 60 to 69 years, and
18.8% among those 70 years and older (78). 
The San Luis Valley Diabetes Study evaluated the preva-
lence of lower extremity PAD among diabetics in a Hispanic
and a white population (79). The abnormal ankle/arm ratios
used in this study were an ABI of 0.94 at rest, 0.73 after exer-
cise, and 0.78 after reactive hyperemia. The prevalence of
lower extremity PAD was 13.7% with this diagnostic criteria.
Notably, a history of intermittent claudication or an absent
Communities (ARIC) study surveyed 4 race and gender stra-
ta to demonstrate that mean carotid far-wall intimal-medial
thickness was consistently greater in participants with preva-
lent clinical cardiovascular disease than in disease-free sub-
jects. Similarly, the prevalence of cardiovascular disease was
consistently greater in ARIC participants with progressively
thicker intimal-medial thickness (75). These data document
the substantially greater arterial wall thickness observed in
middle-aged adults with prevalent cardiovascular disease. 
As a symptomatic expression of lower extremity PAD,
claudication defines a subset of the total population with the
disease. The Framingham Heart Study initially described the
high prevalence of lower extremity PAD by assessing the
prevalence of claudication in a large cohort study of 2336
men and 2873 women between the ages of 28 and 62 years
who were initially assessed at standardized examinations
every 2 years since 1948 (76). The Rose claudication ques-
tionnaire was used to define the prevalence of intermittent
claudication as a marker of lower extremity PAD. This study
demonstrated that the annual incidence of lower extremity
PAD increased with age and in response to the prevalence of
atherosclerosis risk factors (76). The age-specific annual
incidence of intermittent claudication for ages 30 to 44 years
was 6 per 10000 men and 3 per 10000 women, and this inci-
dence increased to 61 per 10 000 men and 54 per 10 000
women within the ages of 65 to 74 years. In this initial
Framingham cohort, the investigators noted that intermittent
claudication was twice as prevalent among men as among
women (76). A risk profile of age, sex, serum cholesterol,
hypertension, cigarette smoking, diabetes, and coronary
artery disease was associated with an increased risk of devel-
oping claudication. Male sex, increasing age, and smoking
conferred a 1.5-fold increased risk for developing intermit-
Figure 2. Prevalence of peripheral arterial disease (PAD) by age. Reprinted with permission from Criqui MH, Fronek A, Barrett-
Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-5 (77).
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pulse examination were uncommon findings within this pop-
ulation (79). 
The Edinburgh Artery Study in 1988 randomly selected
1592 individuals aged 55 to 74 years with intermittent clau-
dication determined by the World Health Organization ques-
tionnaire, the ABI, and the hyperemia test. These participants
were followed up prospectively for 5 years for subsequent
cardiovascular events and death (80). The prevalence of
intermittent claudication was 4.5%, and the incidence was
15.5 per 1000 person-years (80). In individuals who were
symptomatic initially, 28.8% continued to have pain after 5
years, 8.2% underwent revascularization or amputation, and
1.4% developed ischemic ulcers. The prevalence of intermit-
tent claudication in a series of epidemiological surveys is
displayed in Figures 3 and 4. 
Lower extremity PAD is also common in other populations
with a high prevalence of atherosclerosis risk factors, includ-
ing individuals in geriatric practices, long-term care facilities
(81,82), and the transplant population (83,84). In these
cohorts, lower extremity PAD alters quality of life and is
associated with adverse clinical outcomes. 
The relevance of these epidemiological data to current
medical practice has been most recently assessed in both a
regional lower extremity PAD detection program (85) and a
Figure 3. Prevalence of intermittent claudication in various studies. Reprinted from J Vasc Surg, 31, Dormandy JA, Rutherford RB,
for the TransAtlantic Inter-Society Consensus (TASC) Working Group, Management of peripheral arterial disease (PAD), S1-S296,
Copyright 2000, with permission from Elsevier (1).
Figure 4. Mean prevalence of intermittent claudication in large population studies. Reprinted from J Vasc Surg, 31, Dormandy JA,
Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group, Management of peripheral arterial disease
(PAD), S1-S296, Copyright 2000, with permission from Elsevier (1).
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national survey of lower extremity PAD in primary care
practices, the PAD Awareness, Risk and Treatment: New
Resources for Survival (PARTNERS) study (86). The PART-
NERS study was a large cross-sectional survey designed to
determine the prevalence of lower extremity PAD in
American primary care practices. This study used the ABI
technique in a targeted cohort of 6979 patients evaluated in
350 large-volume primary care practices in 25 American
cities. Patients 70 years and older or aged 50 to 69 years with
a history of cigarette smoking or diabetes were evaluated
prospectively during the course of routine office practice.
The diagnosis of lower extremity PAD was established by
either a prior chart diagnosis or by demonstration of an ABI
of 0.90 or less during the study screening. By this technique,
lower extremity PAD was detected in a high fraction (29%)
of the study population. Within this population, 13% of these
patients had lower extremity PAD only, and 16% had both
lower extremity PAD and another form of atherosclerotic
cardiovascular disease (a clinical manifestation of coronary
artery disease, cerebrovascular disease, or aortic aneurysmal
disease). Although lower extremity PAD was prevalent in
this targeted population, the diagnosis was new in 55% of
those patients with PAD only and in 35% of patients who had
both lower extremity PAD and cardiovascular disease. The
prevalence of tobacco use (23% current, 37% former),
hypertension (69%), hyperlipidemia (47%), and diabetes
(38%) was elevated in the lower extremity PAD-only cohort. 
Comparable epidemiological surveys have now corroborated
these patterns of lower extremity PAD in essentially every
population studied (87-91). Thus, current epidemiological
and community survey data demonstrate a high prevalence
of lower extremity PAD in individuals in the United States,
Europe, and Asia that increases with advancing age and with
exposure to atherosclerosis risk factors. 
2.2. Prognosis and Natural History
2.2.1. Coprevalence of Coronary Artery Disease
and Carotid Disease
The prognosis of patients with lower extremity PAD is char-
acterized by an increased risk for cardiovascular ischemic
events due to concomitant coronary artery disease and cere-
brovascular disease (35,92). These cardiovascular ischemic
events are more frequent than ischemic limb events in any
lower extremity PAD cohort (Figure 5) (93). There is approx-
imately a 2- to 4-fold excess of coronary artery disease and
Figure 5. The natural history of atherosclerotic lower extremity peripheral arterial disease (PAD). Individuals with atherosclerotic lower
extremity PAD may be: (a) asymptomatic (without identified ischemic leg symptoms, albeit with a functional impairment); (b) present
with leg symptoms (classic claudication or atypical leg symptoms); or (c) present with critical limb ischemia. All individuals with PAD
face a risk of progressive limb ischemic symptoms, as well as a high short-term cardiovascular ischemic event rate and increased
mortality. These event rates are most clearly defined for individuals with claudication or critical limb ischemia (CLI), and less well
defined for individuals with asymptomatic PAD. CV indicates cardiovascular; MI, myocardial infarction. Adapted with permission from
Weitz JI, Byrne J, Clagett GP, et al. Circulation. 1996;94:3026-49 (93).
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2.2.3. Prognosis of the Limb
The prognosis of the limb is determined by the extent of arte-
rial disease, the acuity of limb ischemia, and the feasibility
and rapidity of restoring arterial circulation to the foot. For
the patient with chronic arterial occlusive disease and con-
tinued progression of symptoms to CLI (e.g., development of
new wounds, rest pain, or gangrene), the prognosis is very
poor unless revascularization can be established. For patients
with acute occlusive events (i.e., sudden embolic occlusion
of an extremity with little underlying arterial disease), the
long-term prognosis of the limb is related to the rapidity and
completeness of revascularization before the onset of irre-
versible ischemic tissue or nerve damage (see Section
2.6.3.2).
Few studies of the natural history of PAD have been per-
formed to objectively quantify disease progression.
Claudication symptoms usually remain stable and do not
worsen or improve at rapid rates (93). The temporal progres-
sion of symptoms across arterial beds in patients with known
atherosclerotic disease has also been studied on a limited
basis. A large series of patients with claudication have been
followed up with respect to their subsequent clinical out-
come in the study by Muluk et al., which has demonstrated
that many patients may present with claudication in the
absence of any coronary ischemic symptoms and that a his-
tory of angina and MI is not a useful predictor of death (118).
Moreover, in that study, a history of claudication, by itself,
was not an adequate predictor of major amputation risk after
10 years of follow-up. Additional studies in the same group
of patients demonstrated that 2 clinical factors, reduced ABI
and diabetes mellitus, were associated with the development
of ischemic rest pain and ischemic ulceration. These studies
suggested that other local pathophysiological factors (e.g.,
inflammatory factors and local plaque rupture) may be better
linked to the adverse clinical course of lower extremity
events experienced by some individuals with claudication.
Delineation of these factors will require future longitudinal
cohort studies.
2.3. Other Causes of Lower Extremity PAD
It is commonly assumed by both practitioners and patients
alike that atherosclerosis is the sole cause of both stenotic
and aneurysmal lower extremity PAD, because of the pre-
dominance of this particular etiology in the coronary circula-
tion. However, as noted in the introduction to this guideline,
PAD is caused by a diversity of etiologies beyond athero-
sclerosis. Thus, clinicians should be wary of assuming such
an origin in the absence of consideration of a broad differen-
tial diagnosis. Aneurysms may be associated with athero-
sclerosis or they may be due to underlying hereditary (famil-
ial) or acquired (e.g., due to smoking or trauma) etiologies.
Renal arterial disease may be due to atherosclerosis, FMD,
or arteritides. Lower extremity PAD may be atherosclerotic,
thromboembolic, inflammatory, or traumatic. It can be due to
aneurysmal disease, trauma, adventitial cysts, entrapment
cerebrovascular disease in patients with lower extremity
PAD (35,92,94). The relative prevalence of coronary and
cerebral atherosclerosis depends on the criteria used to estab-
lish the diagnosis. Among patients presenting with lower
extremity PAD, approximately one third to one half have evi-
dence of coronary artery disease based on clinical history
and electrocardiogram and two thirds based on an abnormal
stress test. Significant coronary artery disease of at least 1
coronary artery has been reported in up to 60% to 80% of
those with lower extremity PAD (62,95-98). Approximately
12% to 25% of patients with lower extremity PAD have
hemodynamically significant carotid artery stenoses detected
by duplex ultrasound (99-101). In one study, approximately
one third of individuals with significant carotid artery steno-
sis had symptoms of cerebrovascular ischemia (100). The
severity of lower extremity PAD correlates with the severity
and extent of significant carotid artery stenosis (102).
Conversely, approximately one third of men and one fourth
of women with known coronary or cerebrovascular disease
also have lower extremity PAD (35). Thus, physicians caring
for patients with lower extremity PAD should be aware of the
frequent coexistence of coronary and cerebrovascular dis-
ease. Specific recommendations for screening for coronary
and cerebrovascular disease in the patient with lower extrem-
ity PAD are beyond the scope of this document.
2.2.2. Risk of Cardiovascular Events
As a consequence of coexisting coronary and cerebrovascu-
lar disease, there is an increased risk of MI, stroke, and car-
diovascular death in patients with lower extremity PAD.
There is a 20% to 60% increased risk for MI and a 2- to 6-
fold increased risk of death due to coronary heart disease
events (38,103-107). The risk of stroke is increased by
approximately 40%. In the ARIC study, men with lower
extremity PAD were 4 to 5 times more likely to have a stroke
or transient ischemic attack than those without lower extrem-
ity PAD, although in women, the association was not signif-
icant (108). In the Edinburgh Artery Study, lower extremity
PAD severity correlated with the incidence of transient
ischemic attack and stroke (103). The annual mortality rate
derived from epidemiological studies of patients with lower
extremity PAD is 4% to 6% and is highest in those with the
most severe disease (106,109-111).
In more contemporary published clinical trials, the annual
mortality rate of patients with lower extremity PAD is lower;
the combined event rate for MI, stroke, and vascular death is
approximately 4% to 5% per year and increases to 6% per
year if revascularization is included. Lower event rates in
clinical trial populations is likely due to both referral bias and
the higher standard of care inherent to the clinical trial envi-
ronment (98,112,113). The 1-year mortality rate in patients
with CLI is approximately 25% and may be as high as 45%
in those who have undergone amputation (106,114-117).
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The majority of individuals with lower extremity PAD do
not experience recognizable limb ischemic symptoms, and
by this definition, they are “asymptomatic.” However, the
classification of a patient as asymptomatic has traditionally
implied that the individual has neither (a) limb ischemic
symptoms nor (b) other “symptomatic” consequences of sys-
temic atherosclerosis. For the purposes of this guideline,
asymptomatic lower extremity PAD implies the absence of
classic leg claudication symptoms. As noted below, this def-
inition is under revision because data demonstrate that lower
extremity PAD, even without classic claudication, is often
associated with leg dysfunction, diminished functional sta-
tus, and increased cardiovascular ischemic risk. In other
words, individuals with classic asymptomatic lower extrem-
ity PAD have measurable limb dysfunction and adverse car-
diovascular outcomes. Individuals with asymptomatic lower
extremity PAD may also have other causes of leg pain (e.g.,
lumbar disk disease, spinal stenosis, sciatica, or radiculopa-
thy), muscle strain, neuropathy, or compartment syndrome. 
Prevalence of Asymptomatic Lower Extremity PAD
by Traditional Epidemiological Classification
Intermittent claudication is the most common symptom in
patients with lower extremity PAD. Patient interviews, how-
ever, can be both an insensitive and poorly reproducible tool
to define lower extremity PAD symptoms. In epidemiologi-
cal surveys, population-based classification of lower extrem-
ity PAD symptom status is performed by use of standardized
questionnaires. These have traditionally included the World
Health Organization Rose questionnaire (119), the
Edinburgh Modification of the Rose questionnaire
(120,121), and others. Data from such surveys in both the
United States and Europe have demonstrated that asympto-
matic lower extremity PAD is 2 to 5 times more prevalent
than symptomatic lower extremity PAD. 
Criqui et al. evaluated the prevalence of lower extremity
PAD and leg ischemic symptoms in an older population of
613 men and women in southern California, with an average
age of 66 years, using a battery of 4 noninvasive tests (seg-
mental blood pressure, Doppler-derived flow velocity, post-
occlusive reactive hyperemia, and pulse-reappearance half-
time) (77). In this survey, 11.7% of the population had large-
vessel lower extremity PAD on noninvasive testing, in which
“large-vessel” lower extremity PAD was equivalent to the
common ABI definition of lower extremity PAD. The preva-
lence of intermittent claudication in this population was
2.2% in men and 1.7% in women. Abnormal femoral or pos-
terior tibial pulses were present in 20.3% of men and 22.1%
of women. Thus, the fraction of individuals with intermittent
claudication dramatically underestimated the true prevalence
of lower extremity PAD. Moreover, use of the peripheral
pulse examination alone dramatically overestimated the true
prevalence of lower extremity PAD. Overall, symptomatic
lower extremity PAD was present in approximately one fifth
of the population with objective evidence of lower extremity
PAD. This study demonstrated that a high fraction of indi-
syndromes, or congenital abnormalities. Accurate diagnosis
and identification of the specific cause are necessary if indi-
vidual patients are to receive ideal pharmacological,
endovascular, surgical, or rehabilitative interventions. This
guideline has therefore been structured with an attempt to
ensure that the diverse spectrum of causes are considered for
each clinical manifestation of lower extremity PAD. Readers
should note that such a differential diagnosis varies by
anatomic site, patient demographic cohort, and clinical pres-
entation.
2.4. Clinical Presentation
2.4.1. Asymptomatic
RECOMMENDATIONS
Class I
1. A history of walking impairment, claudication,
ischemic rest pain, and/or nonhealing wounds is rec-
ommended as a required component of a standard
ROS for adults 50 years and older who have athero-
sclerosis risk factors and for adults 70 years and older.
(Level of Evidence: C)
2. Individuals with asymptomatic lower extremity PAD
should be identified by examination and/or measure-
ment of the ABI so that therapeutic interventions
known to diminish their increased risk of MI, stroke,
and death may be offered. (Level of Evidence: B)
3. Smoking cessation, lipid lowering, and diabetes and
hypertension treatment according to current national
treatment guidelines are recommended for individu-
als with asymptomatic lower extremity PAD. (Level of
Evidence: B)
4. Antiplatelet therapy is indicated for individuals with
asymptomatic lower extremity PAD to reduce the risk
of adverse cardiovascular ischemic events. (Level of
Evidence: C)
Class IIa
1. An exercise ABI measurement can be useful to diag-
nose lower extremity PAD in individuals who are at
risk for lower extremity PAD (Table 2) who have a
normal ABI (0.91 to 1.30), are without classic claudi-
cation symptoms, and have no other clinical evidence
of atherosclerosis. (Level of Evidence: C)
2. A toe-brachial index or pulse volume recording meas-
urement can be useful to diagnose lower extremity
PAD in individuals who are at risk for lower extremi-
ty PAD who have an ABI greater than 1.30 and no
other clinical evidence of atherosclerosis. (Level of
Evidence: C)
Class IIb
Angiotensin-converting enzyme (ACE) inhibition may
be considered for individuals with asymptomatic
lower extremity PAD for cardiovascular risk reduc-
tion. (Level of Evidence: C)
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viduals with lower extremity PAD does not have claudica-
tion, as classically defined. 
The San Luis Valley Diabetes Study evaluated the preva-
lence of lower extremity PAD among diabetics in a Hispanic
and a non-Hispanic white population (79). In that study, the
diagnosis of lower extremity PAD was established by an ABI
of 0.94 at rest, 0.73 after exercise, and 0.78 after reactive
hyperemia. The prevalence of lower extremity PAD was
13.7% with these diagnostic criteria. In this population, a his-
tory of intermittent claudication was an uncommon finding.
The predominance of asymptomatic patients in lower
extremity PAD populations was also demonstrated in the
Rotterdam Study (40). The age- and sex-specific prevalence
of lower extremity PAD and intermittent claudication was
measured in a population-based study of 7715 elderly sub-
jects (40% men, 60% women) aged 55 years and older with
the ABI and the World Health Organization/Rose question-
naire, respectively. Lower extremity PAD was considered
present when the ABI was less than 0.90 in either leg. The
prevalence of lower extremity PAD was 19.1% (95% confi-
dence interval [CI] 18.1% to 20.0%): 16.9% in men and
20.5% in women. Symptoms of intermittent claudication
were reported by 1.6% (95% CI 1.3% to 1.9%) of the study
population (2.2% in men, 1.2% in women). Of those with
lower extremity PAD, 6.3% reported symptoms of intermit-
tent claudication (8.7% in men, 4.9% in women).
Conversely, the presence of claudication symptoms was also
an imperfect marker (i.e., had poor specificity) for lower
extremity PAD, because an ABI less than 0.90 was found in
only 69% of those with claudication symptoms. This study
confirmed that the vast majority of lower extremity PAD
patients have no classic claudication symptoms. 
The Edinburgh Artery Study evaluated a cohort of 1592
individuals aged 55 to 74 years for the presence of intermit-
tent claudication and lower extremity PAD as determined by
the World Health Organization questionnaire, the ABI, and
assessments of reactive hyperemia. The prevalence of inter-
mittent claudication was 4.5%, and the incidence was 15.5
per 1000 person-years (120,121). In individuals who were
symptomatic initially, 28.8% continued to have pain after 5
years, 8.2% underwent revascularization or amputation, and
1.4% developed ischemic ulcers (121). Of those individuals
who were asymptomatic, 8.0% had advanced PAD with sig-
nificant blood flow impairment (120).
Asymptomatic Lower Extremity PAD, Limb
Symptoms, and Limb Function
These data on the prevalence of asymptomatic lower extrem-
ity PAD traditionally relied on survey instruments that clas-
sified all patients into 2 major categories (asymptomatic and
claudication). Yet, many individuals with lower extremity
PAD have leg symptoms that are atypical (e.g., the discom-
fort does not entirely resolve promptly with rest) owing to
comorbid conditions. In recognition of this clinical reality,
more recent lower extremity PAD symptom investigations
have used more sensitive and specific questionnaires that
characterize symptoms within each limb and permit record-
ing of atypical leg pain. One such instrument is the Walking
Impairment Questionnaire (122). The San Diego claudica-
tion questionnaire is a standardized questionnaire based on
the Rose claudication questionnaire that is usually adminis-
tered by certified health interviewers. This questionnaire
allows for lateralization of leg symptoms (right, left, or both)
and categorizes leg symptoms as either classic claudication
(meeting all Rose criteria below), atypical leg pain that is
exertional (but does not meet all Rose criteria), or no leg
pain. The use of this tool in a community survey of nearly
7000 elderly, high-risk individuals in primary care practices
in the United States in the PARTNERS survey (86) demon-
strated a high lower extremity PAD prevalence of 29%; in
addition, leg symptoms were evaluated with the San Diego
questionnaire. Of those individuals in whom the only mani-
festation of atherosclerosis was lower extremity PAD (there
was no concomitant clinical evidence of other cardiovascular
disease), individuals were segregated into 2 cohorts based on
whether their personal physicians had established the lower
extremity PAD diagnosis before the performance of the ABI
measure during office-based lower extremity PAD screening.
Of those individuals with previously diagnosed lower
extremity PAD, 26% were asymptomatic, 62% had atypical
leg pain, and only 13% had typical claudication. Of those
individuals with newly diagnosed lower extremity PAD,
48% were asymptomatic, 46% had atypical leg pain, and
only 6% had typical claudication. In summary, the ratio of
leg symptoms in a population screened for lower extremity
PAD depends on the population surveyed, the symptom
assessment instrument used, and the inclusion of individuals
with previously established lower extremity PAD versus pre-
viously undiagnosed individuals. For most individuals with
lower extremity PAD in office practices, efforts to detect
early lower extremity PAD are likely to identify individuals
at high cardiovascular ischemic risk, who do not have classic
claudication, and in whom atypical leg symptoms are com-
mon.
With these more sensitive questionnaires and other tools
that assess leg function, it is now clear that individuals with
asymptomatic lower extremity PAD have a worse quality of
life and limb function than an age-matched cohort.
McDermott et al. evaluated the ABI and measures of upper
and lower extremity functioning in 933 women in the
Women’s Health and Aging Study (123). Within this cohort,
328 subjects (35%) had lower extremity PAD as defined by
an ABI less than 0.90. Asymptomatic lower extremity PAD
was common, with 63% of these individuals reporting no
exertional leg pain. However, even among these individuals
with asymptomatic lower extremity PAD, worsening of
lower extremity function was documented by a series of
objective measurements. Thus, individuals with a low ABI
but no claudication were characterized by a slower walking
velocity, poorer standing balance score, slower time to arise
from a seated position, and fewer blocks walked per week,
even after adjustments were made for age, sex, race, cigarette
smoking, and other comorbidities. Additional data have been
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should achieve risk reduction and specific treatment targets
comparable to individuals with established coronary artery
disease (129a,294).
Clinical Implications: Asymptomatic Lower
Extremity PAD in Office-Based and Community-
Based Detection Programs
In addition to individuals who have overt clinical lower
extremity PAD who present with claudication or more severe
limb ischemic symptoms, a larger cohort of individuals are at
risk for lower extremity PAD on the basis of their age and
risk factors. Individuals who are at risk include those 70
years and older, those 50 years and older who have a history
of any atherosclerosis risk factor (smoking, diabetes, hyper-
tension, or elevated cholesterol levels), and individuals with
diabetes who are 49 years old or younger who have such ath-
erosclerosis risk factors. Establishment of the lower extrem-
ity PAD diagnosis in these at-risk individuals has the poten-
tial to alter the intensity of treatment goals. 
The ABI allows for lower extremity PAD detection at all
stages of the disease process; however, the ABI does not
always provide reliable data to detect lower extremity PAD,
as is more extensively reviewed in Section 2.5. For individ-
uals with noncompressible ankle arteries and ABI values
greater than 1.30, the toe-brachial index, pulse volume
recordings, and Doppler waveform measurements can pro-
vide diagnostic information to document the presence of
lower extremity PAD. For individuals at risk of lower
extremity PAD with borderline or normal ABI values (0.91
to 1.30), an exercise ABI test can also unmask the lower
extremity PAD diagnosis. Although these tests have been
demonstrated to be useful tools to accomplish lower extrem-
ity PAD detection, the impact of early PAD detection on
either limb or cardiovascular ischemic event outcomes or on
survival has not yet been evaluated in prospective trials. It
may not be possible to ethically design or complete these tri-
als, because the benefits of systemic atherosclerosis risk
reduction interventions (whether biobehavioral or pharmaco-
logical) have been established in other atherosclerotic syn-
dromes. In the absence of lower extremity PAD-specific
interventional data, it is imperative that individuals with
newly detected lower extremity PAD be provided with accu-
rate information regarding cardiovascular and limb ischemic
risk and be provided with access to individualized treatments
to diminish such risk. 
The initial responsibility for the detection of lower extrem-
ity PAD should be with the primary care provider, because
such providers are best positioned to determine an at-risk
population and to initiate educational, lifestyle, and cardio-
vascular risk reduction therapies. Public screening programs
may also play a role in lower extremity PAD disease detec-
tion, especially if programs are directly linked to effective
educational and treatment interventions. Programs of lower
extremity PAD detection, whether applied in office practice
or in community-based detection programs, should ideally
utilize the epidemiological database to apply the detection
reported by McDermott et al. from a cross-sectional study of
460 individuals with lower extremity PAD and 130 without
lower extremity PAD that provided a comprehensive classi-
fication of limb symptoms at rest and with exertion. In all
cohorts, including individuals with lower extremity PAD but
no limb symptoms either at rest or with exertion, decreased
functional status was documented (124). Newman et al. eval-
uated the 5888 individuals in the Cardiovascular Health
Study to corroborate that lower extremity PAD and leg pain
are coprevalent, that the standard Rose questionnaire under-
estimates the presence of leg symptoms, and that more sen-
sitive survey tools can better identify the functional impair-
ment experienced by these individuals (125). Overall, cur-
rent data document that lower extremity PAD is common,
that the traditional term “asymptomatic” may inaccurately
imply that limb function is normal, and that lower extremity
PAD is invariably and independently associated with
impaired lower extremity functioning.
Thus, most individuals with lower extremity PAD do not
have classic (typical) claudication but may have more subtle
impairments of lower extremity function. For these individ-
uals with asymptomatic lower extremity PAD, there is cur-
rently no evidence that additional vascular laboratory diag-
nostic tests (e.g., segmental pressure studies, duplex ultra-
sound, magnetic resonance angiography [MRA], or contrast
angiography) provide incremental information that can
improve outcomes. Similarly, there are no data that suggest
that limb arterial revascularization of these patients is asso-
ciated with any net improvement in limb function or limb
symptoms. As well, no clinical investigations have hereto-
fore been performed to evaluate the relative benefit of phar-
macological interventions on leg function in patients with
lower extremity PAD but without classic symptoms of clau-
dication. 
Asymptomatic Lower Extremity PAD and
Cardiovascular Outcomes
Individuals with asymptomatic lower extremity PAD do not
enjoy a benign prognosis, because most have systemic ather-
osclerotic disease. Individuals with asymptomatic lower
extremity PAD are characterized by a risk factor profile com-
parable to that of those with symptomatic lower extremity
PAD (64,126). For example, the Limburg PAOD Study eval-
uated a cross section of 3650 subjects aged 40 to 78 years. In
that survey, patients with asymptomatic lower extremity
PAD had a risk-factor and comorbidity profile comparable to
that of symptomatic patients (64). Overall, the high preva-
lence of diabetes, a history of past or current smoking, hyper-
tension, and/or hypercholesterolemia placed such individuals
at a markedly increased risk of atherosclerotic ischemic
events, including MI and stroke (64,127), and higher degrees
of internal carotid artery stenosis (128,129). On the basis of
these data, current U.S. national hypertension and lipid treat-
ment guidelines include all patients with lower extremity
PAD, regardless of symptom status, as a high-risk category.
In these guidelines, all patients with lower extremity PAD
e17
ACC - www.acc.org
AHA - www.americanheart.org
Hirsch et al. 2005
ACC/AHA Practice Guidelines
2.4.2. Claudication
RECOMMENDATIONS
Class I
1. Patients with symptoms of intermittent claudication
should undergo a vascular physical examination,
including measurement of the ABI. (Level of Evidence:
B)
2. In patients with symptoms of intermittent claudica-
tion, the ABI should be measured after exercise if the
resting index is normal. (Level of Evidence: B)
3. Patients with intermittent claudication should have
significant functional impairment with a reasonable
likelihood of symptomatic improvement and absence
of other disease that would comparably limit exercise
even if the claudication was improved (e.g., angina,
heart failure, chronic respiratory disease, or orthope-
dic limitations) before undergoing an evaluation for
revascularization. (Level of Evidence: C)
4. Individuals with intermittent claudication who are
offered the option of endovascular or surgical thera-
pies should: (a) be provided information regarding
supervised claudication exercise therapy and pharma-
cotherapy; (b) receive comprehensive risk factor mod-
ification and antiplatelet therapy; (c) have a signifi-
cant disability, either being unable to perform normal
work or having serious impairment of other activities
important to the patient; and (d) have lower extremi-
ty PAD lesion anatomy such that the revascularization
procedure would have low risk and a high probability
of initial and long-term success. (Level of Evidence: C)
Class III
Arterial imaging is not indicated for patients with a
normal postexercise ABI. This does not apply if other
atherosclerotic causes (e.g., entrapment syndromes or
isolated internal iliac artery occlusive disease) are sus-
pected. (Level of Evidence: C)
Claudication is defined as fatigue, discomfort, or pain that
occurs in specific limb muscle groups during effort due to
exercise-induced ischemia. Individuals with claudication
have sufficient blood flow so that limb ischemic symptoms
are absent at rest. With increased local muscular demand for
metabolic support during exercise, blood flow in individuals
with lower extremity PAD and claudication is inadequate to
meet this demand, and limb muscular fatigue and/or pain
results. Lower extremity ischemia is usually due to athero-
sclerotic lower extremity PAD and occasionally other caus-
es, including emboli, radiation arteritis, Buerger’s disease
(thromboangiitis obliterans), other arteritides, coarctation,
popliteal entrapment, cystic adventitial disease, FMD, and
trauma. Vascular claudication due to lower extremity PAD is
produced by exercise and is relieved with rest and is there-
fore traditionally referred to as “intermittent claudication,” or
simply “claudication.” The pathophysiology of claudication
tool to a population at risk. The most cost-effective tool for
lower extremity PAD detection is the ABI, which has been
used in numerous field surveys and cross-sectional practice
surveys, as cited in this guideline. 
Office-Based Clinical History
The detection of lower extremity PAD requires the deliberate
collection of a vascular (lower extremity PAD) history and
review of systems (see Section 1.3, Vascular History and
Physical Examination). However, primary care clinicians
should not assume that patients with lower extremity PAD
and claudication will spontaneously offer a classic exertion-
al history of leg pain, just as patients with angina only rarely
offer a classic history of central chest pressure, accompanied
by a positive Levine sign (“a clenched fist placed over the
sternum to describe the location and squeezing quality of the
pain”). As well, clinicians should be aware that descriptions
of “claudication” may be atypical, including not only pre-
dominant exertional muscle symptoms but also symptoms
from concomitant diseases that can mask classic claudica-
tion. “Typical” lower extremity ischemic symptoms may
have such an indolent onset that patients attribute their exer-
cise intolerance to the deconditioning of aging and may not
bring this history as a chief complaint to their primary
provider. The exercise limitation may be noted first by a
spouse or other close family member rather than by the
patient. In this context, patients with lower extremity PAD
may be incorrectly assumed to be asymptomatic. Thus, a his-
tory of walking impairment or of other leg ischemic symp-
toms should usually be included in a standard ROS of
patients at risk for lower extremity PAD. 
Use of Other Diagnostic Tools in Asymptomatic
Lower Extremity PAD Patients
As noted above, individuals without clinically evident lower
extremity PAD symptoms or associated cardiovascular
ischemic symptoms have not been shown to benefit from
more aggressive and costly efforts to localize lower extrem-
ity PAD anatomy (e.g., by use of duplex ultrasound or other
tools of the noninvasive vascular laboratory or by MRA or
other imaging techniques). In addition, there is currently no
evidence that patients with asymptomatic lower extremity
PAD benefit from the performance of other cardiovascular
risk-assessment tools (beyond establishment of the lower
extremity PAD diagnosis itself; e.g., by use of pharmacolog-
ical stress testing, coronary calcium scores, carotid intimal-
medial thickness studies, or coronary angiography). In the
absence of data suggesting that additional testing can further
stratify lower extremity PAD patients into a higher-risk
group or that these data offer treatment options beyond stan-
dard risk reduction interventions, such studies are not rec-
ommended.
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sis. Claudication is usually also associated with reduced
ankle blood pressures in the affected leg, which causes a
diminished ABI. Some patients may have normal ankle pres-
sures at rest with abnormal low ankle systolic pressures (and
thus low ABI values) detectable only after exercise (see
Section 2.5.4). Individuals with long-standing diabetes,
patients with chronic renal failure, and the very elderly have
densely calcified vessels that are poorly compressible and
may have spuriously high ankle pressures and ABI values. 
The ABI should be measured in all patients with claudica-
tion. For individuals who present with classic claudication
and in whom the ABI is borderline or normal (0.91 to 1.30)
or supranormal (greater than 1.30), alternative diagnostic
strategies should be used, including the toe-brachial index,
segmental pressure examination, or duplex ultrasound, to
confirm the lower extremity PAD diagnosis (see Section
2.5). This strategy is necessary to distinguish claudication
from pseudoclaudication, provides an estimate of the overall
severity of occlusive disease in the extremity, and serves as a
baseline to assess temporal changes due to disease progres-
sion or intervention. The ABI correlates only weakly with
treadmill-based walking ability for any individual patient.
For example, some patients with a low ABI report minimal
walking impairment, whereas some with a higher ABI report
marked walking impairment (133). This is due at least in part
to the wide range of comorbidities that can coexist with inter-
mittent claudication in patients who have PAD (124).
Systemic atherosclerotic disease, medical comorbidities, and
back, hip, and knee symptoms may have a greater impact on
an individual’s quality of life than claudication, such that
lower extremity revascularization may not significantly
improve quality of life (134). Because the natural history of
claudication is relatively benign (from the limb perspective),
with few patients progressing to CLI or amputation
(118,135), decisions regarding revascularization of individu-
als with claudication should be based on improving quality
of life. Patients with a low ABI, a significant walking
impairment, and no or mild comorbidities would be expect-
ed to benefit the most from any claudication intervention,
including exercise, pharmacotherapy, or revascularization
(133).
is considerably more complex than can be accounted for by
the supply–demand mismatch that results from stenotic dis-
ease itself (132). However, diagnosis and treatment can be
guided by an understanding of the lower extremity PAD arte-
rial anatomy. 
The anatomic site of the arterial stenosis is often associat-
ed with specific leg symptoms. Occlusive disease in the iliac
arteries may produce hip, buttock, and thigh pain, as well as
calf pain. Occlusive disease in the femoral and popliteal
arteries is usually associated with calf pain. Occlusive dis-
ease in the tibial arteries may produce calf pain or, more
rarely, foot pain and numbness. The pathophysiology of clau-
dication is complex; it is not merely a response to limitations
in blood flow but also includes a wide range of skeletal mus-
cle (e.g., metabolic), neurological, and inflammatory effects
(132). Critical limb ischemia may cause rest pain, ulcera-
tions, or gangrene, as discussed in Section 2.4.3. The severi-
ty of the ischemia can be classified according to either the
Fontaine or Rutherford categories (Table 3). These cate-
gories are most commonly used in research settings but may
also have value in improving the clarity of communication of
lower extremity PAD severity within office practices and in
referral from primary practitioner to vascular specialist (1). 
Vascular claudication must be distinguished from other ill-
nesses that cause exertional leg pain, which have been called
“pseudoclaudication.” These other causes include severe
venous obstructive disease, chronic compartment syndrome,
lumbar disease and spinal stenosis, osteoarthritis, and
inflammatory muscle diseases. Distinguishing features of
these various causes of leg pain are summarized in Table 4
(1). The clinical history should also include risk factors for
atherosclerotic disease, such as smoking, diabetes, hyperten-
sion, hyperlipidemia, and a family history of atherosclerotic
disease. In addition to the historical factors that distinguish
intermittent claudication from other causes of leg pain, the
physical examination should document the presence of
diminished pulses in the femoral, popliteal, posterior tibial,
and dorsalis pedis arteries. Signs of systemic atherosclerosis
(86), as a clue to a vascular cause of claudication, include
femoral bruits, which may be present owing to turbulence
from focal stenoses. Bruits may also be present in the carotid
arteries and renal arteries as a sign of systemic atherosclero-
Table 3. Classification of Peripheral Arterial Disease: Fontaine’s Stages and Rutherford’s Categories
Fontaine Rutherford
Stage Clinical Grade Category Clinical
I Asymptomatic 0 0 Asymptomatic
IIa Mild claudication I 1 Mild claudication
IIb Moderate-severe claudication I 2 Moderate claudication
I 3 Severe claudication
III Ischemic rest pain II 4 Ischemic rest pain
IV Ulceration or gangrene III 5 Minor tissue loss
IV 6 Ulceration or gangrene
Reprinted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group, Management of peripheral arte-
rial disease (PAD), S1-S296, Copyright 2000, with permission from Elsevier (1). 
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Table 4. Differential Diagnosis of Intermittent Claudication
Location of Pain Characteristic Onset Relative Effect of Other
Condition or Discomfort Discomfort to Exercise Effect of Rest Body Position Characteristics
Intermittent Buttock, thigh, or Cramping, aching, After same degree Quickly relieved None Reproducible
claudication calf muscles and fatigue, weakness, of exercise
rarely the foot or frank pain
Nerve root Radiates down leg, Sharp lancinating Soon, if not Not quickly relieved Relief may be History of
compression usually posteriorly pain immediately (also often present at aided by back problems
(e.g., herniated after onset rest) adjusting back
disc) position
Spinal stenosis Hip, thigh, Motor weakness After walking or Relieved by Relief by lumbar Frequent history of
buttocks (follows more prominent standing for same stopping only spine flexion back problems, 
dermatome) than pain length of time if position (sitting or stooping provoked by  
changed forward) intra-abdominal 
pressure
Arthritic, Foot, arch Aching pain After variable Not quickly relieved May be relieved Variable, may 
inflammatory degree of (and may be present by not bearing relate to 
processes exercise at rest) weight activity level
Hip arthritis Hip, thigh, Aching discomfort, After variable Not quickly relieved More comfortable Variable, may 
buttocks usually localized degree of (and may be sitting, weight relate to
to hip and gluteal exercise present at rest) taken off legs activity level, 
region weather changes
Symptomatic Behind knee, Swelling, With exercise Present at rest None Not intermittent
Baker's cyst down calf soreness, 
tenderness
Venous Entire leg, but Tight, bursting After walking Subsides slowly Relief speeded History of iliofemoral 
claudication usually worse in pain by elevation deep vein thrombosis,
thigh and groin signs of venous 
congestion, edema
Chronic Calf muscles Tight, bursting After much exercise Subsides very Relief speeded Typically heavy 
compartment pain (e.g., jogging) slowly by elevation muscled athletes
syndrome
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group, Management of peripheral arterial disease (PAD), S1-S296, Copyright 2000,
with permission from Elsevier (1).
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2.4.3. Critical Limb Ischemia
RECOMMENDATIONS
Class I
1. Patients with CLI should undergo expedited evalua-
tion and treatment of factors that are known to
increase the risk of amputation (see text). (Level of
Evidence: C)
2. Patients with CLI in whom open surgical repair is
anticipated should undergo assessment of cardiovas-
cular risk. (Level of Evidence: B)
3. Patients with a prior history of CLI or who have
undergone successful treatment for CLI should be
evaluated at least twice annually by a vascular spe-
cialist owing to the relatively high incidence of recur-
rence. (Level of Evidence: C)
4. Patients at risk of CLI (ABI less than 0.4 in a nondia-
betic individual, or any diabetic individual with
known lower extremity PAD) should undergo regular
inspection of the feet to detect objective signs of CLI.
(Level of Evidence: B)
5. The feet should be examined directly, with shoes and
socks removed, at regular intervals after successful
treatment of CLI. (Level of Evidence: C)
6. Patients with CLI and features to suggest atheroem-
bolization should be evaluated for aneurysmal disease
(e.g., abdominal aortic, popliteal, or common femoral
aneurysms). (Level of Evidence: B)
7. Systemic antibiotics should be initiated promptly in
patients with CLI, skin ulcerations, and evidence of
limb infection. (Level of Evidence: B)
8. Patients with CLI and skin breakdown should be
referred to healthcare providers with specialized
expertise in wound care. (Level of Evidence: B)
9. Patients at risk for CLI (those with diabetes, neuropa-
thy, chronic renal failure, or infection) who develop
acute limb symptoms represent potential vascular
emergencies and should be assessed immediately and
treated by a specialist competent in treating vascular
disease. (Level of Evidence: C)
10. Patients at risk for or who have been treated for CLI
should receive verbal and written instructions regard-
ing self-surveillance for potential recurrence. (Level of
Evidence: C)
Critical limb ischemia is defined as limb pain that occurs at
rest or impending limb loss that is caused by severe compro-
mise of blood flow to the affected extremity. The term “crit-
ical limb ischemia” should be used for all patients with
chronic ischemic rest pain, ulcers, or gangrene attributable to
objectively proven arterial occlusive disease. The term CLI
implies chronicity and is to be distinguished from acute limb
ischemia (1). Unlike individuals with claudication, patients
with CLI have resting perfusion that is inadequate to sustain
viability in the distal tissue bed. Although it may be chal-
lenging at times to ascertain the limb prognosis in patients
presenting with lower extremity ischemic rest pain, ulcera-
tion, or gangrene, CLI is defined de facto by most vascular
clinicians as those patients in whom the untreated natural
history would lead to major limb amputation within 6
months. Critical limb ischemia is usually caused by obstruc-
tive atherosclerotic arterial disease; however, it can also be
caused by atheroembolic or thromboembolic disease, vas-
culitis, in situ thrombosis related to hypercoagulable states,
thromboangiitis obliterans, cystic adventitial disease,
popliteal entrapment, or trauma. Factors that can contribute
to the development or exacerbation of CLI include syn-
dromes that are known to reduce blood flow to the microvas-
cular bed, such as diabetes, severe low cardiac output states,
and, rarely, vasospastic diseases. Other conditions that accel-
erate or compound CLI include those in which demand for
blood and nutrient supply is increased markedly, such as
infection, skin breakdown, or traumatic injury.
Atherosclerotic arterial occlusive disease that precipitates
CLI is most often diffuse or multisegmental, involving more
than 1 arterial anatomic “level.” Frequently, because of the
systemic nature of the atherosclerotic process and a predilec-
tion for symmetrical disease, the contralateral limb may also
be affected by ischemic symptoms and may also demonstrate
objective signs of ischemia on examination.
Patients with CLI present with a spectrum of clinical man-
ifestations, depending on the degree of ischemia and the time
course of its development. The Rutherford clinical categories
(described previously) are used to classify the degree of
ischemia and salvageability of the limb; CLI is also a com-
ponent of the Fontaine clinical classification system (Table
3).
Critical limb ischemia is associated with a very high inter-
mediate-term morbidity and mortality. Patients with lower
extremity PAD have a 3 to 5 times overall greater risk of car-
diovascular mortality than those without this disease. Those
with more advanced lower extremity PAD, as manifested by
CLI, have even greater risk of experiencing cardiovascular
ischemic events (86,103,106,136,137). Thus, care strategies
for individuals with CLI must recognize the cardiovascular
ischemic burden. Ideal care strategies for individuals with
CLI will therefore include recognition of the possibility of
severe coronary artery disease, cerebral vascular disease, or
aortic aneurysmal disease and include the impact of these ill-
nesses on patient outcomes with or without specific CLI
interventions. In addition, such long-term integrated care
plans will offer risk factor modification for secondary pre-
vention of cardiovascular ischemic events, to maximize the
possibility of achieving an improved long-term morbidity
and mortality (113,136,138,139).
Clinical Presentation
Patients with CLI usually present with limb pain at rest, with
or without trophic skin changes or tissue loss. The discom-
fort is often worse when the patient is supine (e.g., in bed)
and may lessen when the limb is maintained in the depend-
ent position. Typically, narcotic medications are required for
analgesia; the pain commonly may disturb sleep and render
the patient severely disabled, often unable to walk. The qual-
ity of life for patients with severe CLI can be worse than that
of patients with terminal cancer (1,140,141). Some individu-
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CLI, it remains fundamentally important for the clinician to
determine the time course of development of the ischemia. If
the clinical history and physical examination suggest rela-
tively rapid progression, then early or “semiurgent” revascu-
larization may be required to prevent further deterioration
and irreversible tissue loss. In addition to careful assessment
of the time course of the ischemic syndrome, a vascular his-
tory should be obtained. This should include evaluation for
arterial disease in other territories, assessment of global risk
factors for atherosclerosis (described in Section 2.1.1), and
clarification of any specific precipitating factors or events
(e.g., trauma, infection, surgical manipulation, or removal of
a toenail) that may have caused initial skin ulceration. The
objectives for the diagnostic evaluation of patients with CLI
are summarized in Table 6. Specific investigations that are
helpful in evaluating patients with CLI are summarized in
Table 7. 
Physical Examination
Evaluation of patients for CLI requires systematic assess-
ment of pulses and tissue perfusion to identify the level of
obstructive lesions and potential involvement of other threat-
ened extremities. Signs of chronic ischemia, including
dependent rubor, early pallor on elevation of the extremity,
and reduced capillary refill, should be confirmed. Peripheral
manifestations of atheroemboli, such as livido reticularis,
should be sought, as should their potential sources (e.g.,
AAA). Distinctions should be made between ulcers that are
arterial and those that are venous or neurotrophic (Tables 8,
9, and 10). In the absence of neuropathy, arterial ulcers are
usually exquisitely painful and tender to palpation. Motor
and sensory function should also be assessed in the lower
extremities. Patients with open ischemic ulcers involving the
extremities often have associated local infection or cellulitis.
als with diabetes and CLI may present with severe CLI and
tissue loss but no pain because of concomitant neuropathy. 
Critical limb ischemia may develop in a small subset of indi-
viduals who are already being closely monitored within a
medical practice for lower extremity PAD and claudication.
However, severe limb ischemic symptoms may also be the
initial presentation of lower extremity PAD, with rest pain,
ulceration, or even frank gangrene serving as the first mani-
festation of lower extremity arterial insufficiency. This acute
onset of symptoms may suggest thromboembolic disease,
sudden multisegmental in situ thrombosis, thromboangiitis
obliterans, or an inflammatory arteritis. The diagnosis of CLI
may be obscured by associated neuropathic conditions.
Individuals with baseline diabetic neuropathy may have
impaired or absent sensation in the distal limb arterial terri-
tories most at risk for ischemia. Furthermore, susceptibility
to infection and the presence of microvascular disease in
individuals with diabetes makes it more likely that ischemia
in these patients will progress rapidly. Finally, the ischemic
process itself can be primarily responsible for causing neu-
ropathy: once gangrene is present, the patient’s sensory
nerves may be damaged, and the patient may no longer feel
the pain associated with ulceration. Tissue damage may
thereby progress undetected or ignored. Those factors that
are known to increase the risk of limb loss in patients with
CLI are delineated in Table 5. 
History
It is important for clinicians who evaluate patients with CLI
to distinguish between ischemia that is acute versus chronic,
because the diagnostic and therapeutic approaches and prog-
noses differ significantly. Acute limb ischemia (described in
Section 2.4.4) requires urgent evaluation and intervention,
whereas CLI usually does not. However, for individuals with
Table 5. Factors That Increase Risk of Limb Loss in Patients With Critical Limb Ischemia
Factors that reduce blood flow to the microvascular bed:
Diabetes
Severe renal failure
Severely decreased cardiac output (severe heart failure or shock)
Vasospastic diseases or concomitant conditions (e.g., Raynaud’s phenomenon, prolonged cold exposure)
Smoking and tobacco use
Factors that increase demand for blood flow to the microvascular bed: 
Infection (e.g., cellulitis, osteomyelitis)
Skin breakdown or traumatic injury
Table 6. Objectives for Diagnostic Evaluation of Patients With Critical Limb Ischemia
The diagnostic evaluation of patients with critical limb ischemia should be directed toward the following
objectives:
Objective confirmation of the diagnosis
Localization of the responsible lesion(s) and a gauge of relative severity
Assessment of the hemodynamic requirements for successful revascularization (vis-à-vis proximal vs. 
combined revascularization of multilevel disease)
Assessment of individual patient endovascular or operative risk
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group,
Management of peripheral arterial disease (PAD), S1-S296, Copyright 2000, with permission from Elsevier (1).
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(e.g., abdominal aortic, popliteal, or common femoral
aneurysms). Atheroembolism is suggested by onset of signs
and symptoms of CLI after recent endovascular catheter
manipulation, the onset of associated systemic fatigue or
muscle discomfort, symmetrical bilateral limb symptoms,
livido reticularis, or rising creatinine values.
General Approach to Management of CLI in 
Office Practice
Treatment of CLI is dependent on increasing blood flow to
the affected extremity to relieve pain, heal ischemic ulcera-
tions, and avoid limb loss. Individuals with minimal or no
skin breakdown or in whom comorbid conditions prevent
consideration of revascularization can occasionally be treat-
ed by medical therapies in the absence of revascularization.
Such therapies are much more likely to be successful when
CLI is detected promptly and tissue necrosis is minimal. To
accomplish this, patients who are at risk for or have been
treated for CLI should be informed that symptoms of CLI
should be brought to medical attention promptly. Medical
care strategies have included the use of antiplatelet agents,
In the diabetic population or in immunocompromised indi-
viduals, these infections tend to be polymicrobial and require
systemic antibiotic therapy (1). Individuals who have had
prior symptoms of CLI remain at future risk of development
of recurrent symptoms or signs of CLI. Thus, regular sur-
veillance during subsequent physical examinations should be
performed, with thorough inspection of the feet, including
the heels, toes, and interdigital spaces, to evaluate the patient
for early signs of skin breakdown or ulceration. 
Office Testing Strategies
The evaluation of patients presenting with CLI should
include a complete blood count, chemistries (including fast-
ing blood glucose and renal function tests), electrocardio-
gram, and ABI. In the absence of noncompressible vessels,
measurement of an absolute systolic blood pressure 50 mm
Hg or lower at the ankle and 30 mm Hg at the toe will often
imply that amputation may be required in the absence of suc-
cessful revascularization (1,140). Individuals with CLI who
present with clinical features to suggest atheroembolization
should be evaluated for more proximal aneurysmal disease
Table 7. Investigations for Evaluating Patients With Critical Limb Ischemia (CLI)
To achieve the objectives listed in Table 6 above, the following investigations should be used in patients
with CLI:
Clinical history and examination, including the coronary and cerebral circulation
Hematologic and biochemical tests: complete blood count, platelet count, fasting blood glucose, hemoglo-
bin A1c, creatinine, fasting lipid profile, and urinalysis (for glycosuria and proteinuria)
Resting electrocardiogram
Ankle or toe pressure measurement or other objective measures for the severity of ischemia
Imaging of the lower limb arteries in patients considered for endovascular or surgical intervention
Duplex scan of the carotid arteries should be considered in selected patients at high risk (defined as indi-
viduals with cerebrovascular ischemic symptoms or in whom the risk of carotid revascularization is less 
than the short-term risk of stroke) 
A more detailed coronary assessment may be performed in selected patients in whom coronary ischemic 
symptoms would otherwise merit such an assessment if CLI were not present (such coronary assess-
ments should usually not impede associated CLI care)
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group,
Management of peripheral arterial disease (PAD), S1-S296, Copyright 2000, with permission from Elsevier (1).
Table 8. Differential Diagnosis of Common Foot and Leg Ulcers
Origin Cause Location Pain Appearance
Main arteries Atherosclerotic Toes, foot Severe Irregular, pink base
lower extremity PAD, 
Buerger’s disease, 
acute arterial 
occlusion
Venous Venous disease Malleolar Mild Irregular, pink base
Skin infarct Systemic disease, Lower third of leg Severe Small after infarction,
embolism, often multiple
hypertension
Neurotrophic Neuropathy Foot sole None Often deep, infected
PAD indicates peripheral arterial disease.
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group, Management of peripheral
arterial disease (PAD), S1-S296, Copyright 2000, with permission from Elsevier (1). 
e23
ACC - www.acc.org
AHA - www.americanheart.org
Hirsch et al. 2005
ACC/AHA Practice Guidelines
Table 9. Foot Physical Examination and Differential Diagnosis of Neuropathic and Neuroischemic Ulcers
Neuropathic Ulcer Neuroischemic Ulcer
Painless Painful
Normal pulses Absent pulses
Typically punched-out appearance Irregular margins
Often located on sole or edge of foot or metatarsal head Commonly located on toes
Presence of calluses Calluses absent or infrequent
Loss of sensation, reflexes, and vibration sense Variable sensory findings
Increase in blood flow (arteriovenous shunting) Decrease in blood flow
Dilated veins Collapsed veins
Dry, warm foot Cold foot
Bone deformities No bony deformities
Red appearance Pale, cyanotic
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group,
Management of peripheral arterial disease (PAD), S1-S296, Copyright 2000, with permission from Elsevier (1).
Table 10. Etiologic Classification of Foot and Leg Ulcers
Venous obstruction and insufficiency
Arterial etiologies
Larger arteries
Atherosclerotic lower extremity PAD
Thromboemboli, atheroemboli
Thromboangiitis obliterans
Microcirculatory
Diabetic microangiopathy
Vasculitis
Collagen vascular diseases
Neuropathic
Diabetes mellitus
Infectious
Leprosy 
Mycotic
Hematologic
Sickle cell anemia
Polycythemia
Leukemia
Thalassemia
Thrombocytosis
Malignancy
Squamous cell carcinoma
Kaposi's sarcoma
Secondary metastases
Lymphosarcoma, mycosis fungoides
Miscellaneous
Gout
Pyoderma gangrenosum
Necrobiosis lipoidica
Vitamin B12 deficiency
Drugs
Artifactual or factitious
PAD indicates peripheral arterial disease.
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-
Society Consensus (TASC) Working Group, Management of peripheral arterial disease
(PAD), S1-S296, Copyright 2000, with permission from Elsevier (1). 
anticoagulant medications, intravenous prostanoids, rheolog-
ic agents, and maintenance of the limb in a dependent posi-
tion. However, none of these clinical interventions has been
evaluated adequately or proven to offer predictable improve-
ments in limb outcomes in prospective clinical trials. Passage
of time will sometimes be associated with adequate
improvements in the arterial supply–demand balance to per-
mit improvement in symptoms. For example, collateral ves-
sels may form to enable resolution of CLI and reduction in
pain. Treatment of infection may decrease the metabolic
demands that impede wound healing, and use of non–weight-
bearing orthotics may diminish the contribution of repeated
trauma to skin breakdown. Investigation of angiogenic ther-
apies, via administration of gene or protein, to enhance col-
lateral blood flow has offered promise as a potential strategy
to treat CLI (see Section 2.6.3.1.2). However, these are not
yet proven interventions and are not available as established
therapies.
Importance of Collaboration Between 
Primary Care and Vascular Specialty Care 
in the Treatment of CLI
In the absence of revascularization, most patients with CLI
are expected to require amputation within 6 months.
Therefore, timely referral to a vascular specialist is indicated
to expedite treatment, prevent further deterioration, and
reverse the ischemic process. Such a referral, along with con-
tinued interactive long-term care collaboration, is essential if
all potential options for limb salvage are to be considered and
understood by the patient. 
For example, patients with ulcers, gangrene, or lower
extremity rest pain (i.e., CLI) require full evaluation of the
anatomic basis of the ischemia. Detailed arterial mapping
requires vascular expertise to (a) identify the etiology of the
ischemia and (b) define the options available for revascular-
ization. 
Patients with CLI often have concomitant severe coronary
artery disease or cerebrovascular disease. This suggests an
indication for performance of investigations to define poten-
tially severe coronary artery disease or extracranial carotid
artery disease and revascularization of these circulations.
The evaluation of the risk, benefit, and optimal timing of
revascularization of multiple arterial circulations is among
the most complex in medical decision making. It can be chal-
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lenging to stage coronary or carotid revascularization proce-
dures in individuals with CLI and a jeopardized limb who do
not present with recent coronary or cerebrovascular ischemic
symptoms. The diagnostic evaluation and treatment (whether
percutaneous or surgical) of coronary or cerebrovascular dis-
ease to treat asymptomatic disease in CLI patients may lead
to delay in performance of limb revascularization and may
theoretically increase the risk of limb loss. Limited data sug-
gest that individuals who present with low to moderate risk
and who can tolerate administration of beta-blockers periop-
eratively do not benefit from dobutamine stress echocardio-
graphy and an extensive cardiovascular risk reduction inves-
tigation (142). Proof that preprocedural (coronary and
carotid) revascularization lowers short-term cardiovascular
ischemic risk of limb revascularization interventions is not
yet available.
2.4.4. Acute Limb Ischemia
RECOMMENDATIONS
Class I
Patients with acute limb ischemia and a salvageable
extremity should undergo an emergent evaluation
that defines the anatomic level of occlusion and that
leads to prompt endovascular or surgical revascular-
ization. (Level of Evidence: B) 
Class III
Patients with acute limb ischemia and a nonviable
extremity should not undergo an evaluation to define
vascular anatomy or efforts to attempt revasculariza-
tion. (Level of Evidence: B)
Acute limb ischemia arises when a rapid or sudden
decrease in limb perfusion threatens tissue viability. This
form of CLI may be the first manifestation of arterial disease
in a previously asymptomatic patient or may occur as an
acute event that causes symptomatic deterioration in a
patient with antecedent lower extremity PAD and intermit-
tent claudication. Although the progression of PAD from
intermittent claudication to CLI may occur gradually, it may
also reflect the cumulative effect of multiple acute local
thrombotic events that progressively increase the intensity of
ischemia. The classification of acute ischemic syndromes
had been modified over time with the Society for Vascular
Surgery/International Society for Cardiac Vascular Surgery
(SVS/ISCVS) reporting standards being used frequently
(143). Although attempts have been made to define various
levels of ischemia, it is frequently not possible to precisely
delineate the status of the patient with an acutely ischemic
limb, because many of the classification schemes are based
on subjective clinical criteria and not discrete end points.
Table 11 displays the SVS/ISCVS classification scheme and
provides the most useful clinical method to describe this
entity. 
The severity of acute limb ischemia depends on the loca-
tion and extent of arterial obstruction and the capacity of the
collaterals to perfuse the ischemic territory. Severity may be
influenced by the status of systemic perfusion (cardiac out-
put and peripheral resistance). Acute limb ischemia is often
associated with thrombosis due to atherosclerotic plaque rup-
ture, thrombosis of a lower extremity bypass graft, or lower
extremity embolism originating from the heart or a proximal
arterial aneurysm. When embolic occlusion affects a vascu-
lar bed not previously conditioned by collaterals, the result-
ing ischemic syndrome is typically severe. Collateral devel-
opment in relation to the severity and chronicity of pre-exist-
ing ischemia due to atheromatous obstructive arterial disease
lessens the severity of ischemia when acute thrombotic arte-
rial occlusion develops. Arterial embolism is more likely
than arterial thrombosis to cause sudden, severe, limb-threat-
ening ischemia. The hallmark clinical symptoms and physi-
cal examination signs of acute limb ischemia include the 5
“Ps” that suggest limb jeopardy: pain, paralysis, paresthesias,
pulselessness, and pallor. Some clinicians would also include
a sixth “P,” polar, to indicate a cold extremity. In certain clin-
ical settings, however, arterial embolism can occur without
symptoms, whereas thrombosis can produce sudden, severe
limb ischemia. The clinical diagnosis of arterial embolism is
suggested by (a) the sudden onset or sudden worsening of
symptoms, (b) a known embolic source (including atrial fib-
rillation, severe dilated cardiomyopathy, left ventricular
aneurysm, atheromatous plaque in the aorta or proximal limb
arteries, or mural thrombus lining the wall of an aortic or
arterial aneurysm), (c) the absence of antecedent claudication
or other manifestations of obstructive arterial disease, or (d)
the presence of normal arterial pulses and Doppler systolic
blood pressures in the contralateral limb. 
Arterial emboli typically lodge at branch points in the arte-
rial circulation where the caliber of the arterial lumen dimin-
ishes. Embolism to the aortoiliac bifurcation (“saddle embo-
lus”) may produce bilateral lower-limb ischemia occasional-
ly associated with reversible paraplegia and a high mortality
rate (143,144). Embolic occlusions at sites of arterial bifur-
cation may cause more profound ischemia when collaterals
of perfusion are interrupted, as occurs when the profunda
femoris artery is compromised by embolism to the more
proximal common femoral artery.
Acute limb ischemia may also occur as a result of acute
arterial thrombosis superimposed on a stenotic atherosclerot-
ic plaque. A common site of thrombosis is the superficial
femoral artery, although occlusion may occur anywhere from
the aorta to the digital arteries. Rarely, an extrinsic local fac-
tor such as popliteal entrapment, cystic adventitial disease, or
repetitive trauma may be the precursor of arterial thrombosis.
The location of the obstruction in relation to other axial arter-
ies in the region of the obstructed vessel and the collateral
flow they provide also affects the severity of ischemia. The
longer the obstructive lesion, the more collateral pathways
that are interrupted. Thrombosis tends to propagate proxi-
mally in an artery, up to the next large side branch. The low-
flow state distal to the obstructing thrombus also encourages
distal propagation of thrombus. This is the rationale for treat-
ing patients promptly with systemic anticoagulation.
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erally 1 limb segment below the level of arterial obstruction.
These levels should be correlated with pulse palpation and
should be marked or recorded during the initial examination
as a baseline for subsequent comparison. Evaluation of “cap-
illary” return, which reflects the emptying and refilling of
subpapillary venules, is subject to considerable environmen-
tal and interobserver variation, but capillary return is usually
slow or absent in acute limb ischemia.
Some, but not all, patients with sensory loss describe
numbness or paresthesias, but pre-existing sensory deficits in
diabetic patients can lead to confusion. Sensory deficits may
be subtle in the early phase of acute limb ischemia; appreci-
ation of light touch, 2-point discrimination, vibratory per-
ception, and proprioception are usually lost before percep-
tion of deep pain and pressure. Motor deficits indicate
advanced, limb-threatening ischemia, in part because foot
movement is produced mainly by more proximal muscles.
Dorsiflexion or plantar flexion of the great toe is produced by
muscles that originate just below the knee that are innervat-
ed by the peroneal nerve that passes through the anterior tib-
ial compartment. Ischemia may be less profound in these
proximal locations than distally, so detection of early motor
weakness requires testing the intrinsic muscles of the foot in
comparison with the contralateral foot. The intrinsic foot
muscles cause movement of the toes and help support the
arches of the foot. Persistent pain, sensory loss, and toe mus-
cle weakness are among the most important findings that
identify the patient with threatened limb loss. Muscle rigor,
tenderness, and pain on passive movement are late signs of
advanced ischemia predictive of tissue loss.
Differential Diagnosis
The differential diagnosis of acute limb ischemia involves
exclusion of conditions that mimic arterial occlusion, identi-
fication of nonatherosclerotic causes of arterial occlusion,
and differentiation of ischemia caused by an arterial throm-
bosis from embolism. Nonatherosclerotic causes of acute
limb ischemia include arterial trauma, vasospasm, arteritis,
The clinical history should determine the onset and course
of ischemia and any background information pertaining to
origin, differential diagnosis, and concurrent disease.
Symptoms in acute limb ischemia relate primarily to pain
and dysfunction. The pattern of onset may have etiological
implications (i.e., embolism tends to present more abruptly
than thrombosis), whereas the character and distribution of
pain may aid the differential diagnosis. The limb pain asso-
ciated with severe acute limb ischemia may be similar in
intensity to the rest pain of chronic severe ischemia.
However, the pain of acute limb ischemia is less often local-
ized to the forefoot, often extends above the ankle, and is less
influenced by dependency. The pain of acute limb ischemia
may sometimes be absent or may diminish due to the recruit-
ment of collaterals or because neurosensory loss interferes
with perception. Weakness and numbness are commonly
associated with persistent severe acute limb ischemia, and it
is important to determine whether the limb dysfunction is
worsening or improving over time. It is also crucial to deter-
mine whether the patient had previous claudication or arteri-
al interventions, whether the patient had arterial or aortic
aneurysm, and whether there is an established diagnosis of
heart disease with particular reference to atrial fibrillation,
patient foramen ovale or atrial septal defect, or ventricular
dysfunction. The patient should also be evaluated for con-
current diseases and risk factors for atherosclerosis.
Typically, pulselessness, pallor, paresthesias, paralysis, and
coolness characterize acutely ischemic limbs, and assess-
ment of these features is aided by comparison with the con-
tralateral limb. It may be difficult to determine whether pulse
deficits are new or old in patients with PAD without a histo-
ry of previous symptoms, a recorded examination, or the
finding of similar pulse deficits in the contralateral leg. Pedal
pulses may be normal in cases of microembolism owing to
proximal disruption of atheromatous plaque. Skin pallor may
be observed early after the onset of ischemia, but over time,
cyanosis becomes more common. Coolness, particularly
when the opposite extremity is warm, is a typical finding,
and an abrupt line of transition in temperature or color is gen-
Table 11. Clinical Categories of Acute Limb Ischemia
Arterial Venous
Description/ Doppler Doppler
Category Prognosis Sensory Loss Muscle Weakness Signals Signals
Viable Not immediately None None Audible Audible
threatened
Threatened Salvageable if Minimal (toes) None (Often) inaudible Audible
marginally promptly treated or none
Threatened Salvageable with More than toes; Mild, moderate (Usually) inaudible Audible
immediately immediate associated with
revascularization rest pain
Irreversible Major tissue loss Profound, Profound Inaudible Inaudible
or permanent anesthetic paralysis
nerve damage (rigor)
Reprinted with permission from Katzen BT. Clinical diagnosis and prognosis of acute limb ischemia. Rev Cardiovasc Med 2002;3(Suppl 2):S2-S6.
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hypercoagulable states, compartment syndromes, arterial
dissection, and external arterial compression, such as occurs
with a popliteal cyst.
Vasospasm may rarely produce the same symptoms as
acute limb ischemia. Other conditions that may mimic arte-
rial occlusion are low cardiac output, especially when super-
imposed on chronic lower extremity occlusive disease; acute
deep venous thrombosis, especially when associated with
features of phlegmasia cerulea dolens; and acute compres-
sive peripheral neuropathy. The latter conditions should be
distinguishable by palpable pulses, unless chronic arterial
occlusive disease or an intense vasoconstrictor response
coexists. In acute compressive neuropathy, skin temperature
may be normal or above normal, which is quite unusual for
ischemia that causes similar pain. In cases of venous throm-
bosis, cyanosis and coolness may be present, and pulses may
be difficult to palpate in the presence of edema, but edema
does not occur with acute arterial occlusion unless diagnosis
is delayed long enough to allow dependent swelling to
develop.
Difficulties in palpating arterial pulses may be resolved by
detection of unobstructed arterial Doppler signals over distal
arteries. This is helpful in cases of vasospasm when distal
pulses may be difficult to feel; the velocity signals may
sound blunted but remain biphasic. Patients with advanced
congestive heart failure may develop acute limb ischemia,
particularly when chronic arterial insufficiency is present.
Treatment
Acute limb ischemia is a situation that requires prompt diag-
nosis and treatment to preserve the limb. (See Section 2.6.3
for discussion and recommendations for treatment.) Early
treatment is also necessary to prevent systemic illness and/or
death that might result from the metabolic abnormalities
associated with tissue necrosis. Although the technical abil-
ity to recanalize or revascularize occluded arteries that per-
fuse ischemic tissues has improved significantly, the patho-
physiology of the local and systemic clinical sequelae asso-
ciated with reperfusion of an ischemic limb is only partially
understood. Revascularization of an ischemic extremity may
be complicated by reperfusion injury to the damaged tissues
and may precipitate systemic responses, including cardiac,
renal, and pulmonary dysfunction.
2.4.5. Prior Limb Arterial Revascularization
RECOMMENDATIONS
Class I
Long-term patency of infrainguinal bypass grafts
should be evaluated in a surveillance program, which
should include an interval vascular history, resting
ABIs, physical examination, and a duplex ultrasound
at regular intervals if a venous conduit has been used.
(Level of Evidence: B)
Class IIa
1. Long-term patency of infrainguinal bypass grafts
may be considered for evaluation in a surveillance
program, which may include conducting exercise
ABIs and other arterial imaging studies at regular
intervals (see duplex ultrasound recommendations,
Section 2.5.5). (Level of Evidence: B)
2. Long-term patency of endovascular sites may be eval-
uated in a surveillance program, which may include
conducting exercise ABIs and other arterial imaging
studies at regular intervals (see duplex ultrasound
recommendations, Section 2.5.5). (Level of Evidence:
B)
Patients who have previously undergone revascularization
procedures require careful long-term care and vascular fol-
low-up to detect both the recurrence of disease at revascu-
larized sites and the development of new arterial disease at
remote sites. In spite of increasing short-term success rates
for both endovascular and surgical revascularization proce-
dures, the possibility of recurrence remains throughout the
lifetime of the patient. Early revascularization interventions
for recurrent hemodynamic compromise are preferred,
because delay in detection or treatment can lead to higher
morbidity and poorer outcome (145-150).
Participation in a follow-up surveillance program is imper-
ative for patients undergoing both percutaneous and surgical
revascularization. However, the recommended frequency of
surveillance visits depends on the burden of disease in the
individual patient, the specific procedure that was performed
and its expected outcome, and the clinical syndrome for
which the patient originally presented. Aortic and common
iliac arterial level procedures have greater durability than
infrainguinal procedures and therefore require less frequent
surveillance. In contrast, infrainguinal revascularization for
CLI, either by surgical or percutaneous methods, is associat-
ed with higher restenosis and graft failure rates and therefore
requires more intense surveillance. There are inadequate
data to permit creation of consensus-based standards to
define exact time intervals for surveillance visits after each
type of revascularization procedure. In the absence of evi-
dence-based standards, the clinical time frame customarily
has been based on the judgment of the vascular specialist, by
evaluation of the specific level and type of revascularization
procedure and by taking into account specific patient char-
acteristics (Tables 12, 13, and 14). 
The detection of a flow-limiting lesion has significant
implications that permit improved maintenance of the long-
term patency of the instrumented native vessel or graft. The
benefits of early intervention for preservation of long-term
patency have been well established, particularly for autoge-
nous vein grafts. As a result, past recommendations have
been made that follow-up of autogenous vein bypass graft be
performed with duplex ultrasonography at intervals of 1, 3,
6, 12, 18, and 24 months postoperatively and then annually
thereafter (1). Prompt evaluation with invasive techniques
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ABI determinations may be useful in some individuals.
These modalities are clearly useful for patients in whom
there is evidence of recurrent narrowing at the interventional
site. Similarly, distal or small-caliber endovascular sites
(with or without stenting) at high risk of restenosis may merit
more careful noninvasive evaluation. Whereas the role of
surveillance duplex imaging of autogenous and prosthetic
grafts has been evaluated (see Section 2.6.3.4.3), the utility
and role of duplex ultrasound and other noninvasive diag-
nostic modalities (MRA and computed tomographic angiog-
raphy [CTA]) for such routine surveillance of endovascular
sites have yet to be determined. 
There is no uniformly accepted threshold for repeat angiog-
raphy and intervention in the patient with evidence of recur-
rent stenosis. Patients who have recurrent symptoms in asso-
ciation with evidence of hemodynamic compromise require
restudy and repeat intervention. Likewise, evidence of rapid-
ly progressive restenosis, even in the absence of symptoms,
should provide a clue that may identify individuals who
might benefit from future invasive management. For grafts
as well as native vessels, a stenosis of less than 50% appears
to be associated with favorable prognosis and patency. In
contrast, a stenosis greater than 70% is a harbinger of poor
long-term patency, and thus, reintervention may be warrant-
ed (154,155).
2.5. Diagnostic Methods
Patients with vascular disorders can usually be assured that
an accurate anatomic diagnosis will be made with modern
noninvasive vascular diagnostic techniques (e.g., ankle- and
toe-brachial indices, segmental pressure measurements,
pulse volume recordings, duplex ultrasound imaging,
Doppler waveform analysis, and exercise testing). These
tests will usually provide adequate information for creation
of a therapeutic plan. When required, these physiological and
anatomic data can be supplemented by use of MRA and CTA
and selective use of invasive aortic and lower extremity
angiographic techniques. This section will review the evi-
dence base that defines the benefits and limitations of each of
(angiography) is then indicated when noninvasive methods
suggest hemodynamically significant lesions (e.g., greater
than 50% stenosis) (151,152). Some patients with failing
lower extremity grafts due to stenosis documented by duplex
ultrasound may proceed to operative repair without angiog-
raphy.
Whereas autogenous vein grafts generally become compro-
mised within their midportion and at anastomotic sites, pros-
thetic grafts fail more frequently as a result of impaired
native vessel outflow or poor arterial inflow (153).
Accordingly, the benefit of surveillance with duplex ultra-
sound is less well established for prosthetic grafts. 
Postprocedure surveillance after percutaneous or endovas-
cular procedures is less well studied, and standards are less
well established. Regular visits, with assessment of interval
change in symptoms, vascular examination, and ABI meas-
urement are considered the standard of care. Postexercise
Table 13. Surveillance Program for Infrainguinal Vein Bypass Grafts
Patients undergoing vein bypass graft placement in the lower extrem-
ity for the treatment of claudication or limb-threatening ischemia
should be entered into a surveillance program. This program should
consist of:
Interval history (new symptoms)
Vascular examination of the leg with palpation of proximal, graft,
and outflow vessel pulses
Periodic measurement of resting and, if possible, postexercise 
ABIs
Duplex scanning of the entire length of the graft, with calculation 
of peak systolic velocities and velocity ratios across all identi-
fied lesions
Surveillance programs should be performed in the immediate postop-
erative period and at regular intervals for at least 2 years
Femoral-popliteal and femoral-tibial venous conduit bypass at 
approximately 3, 6, and 12 months and annually
ABI indicates ankle-brachial index.
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-
Society Consensus (TASC) Working Group, Management of peripheral arterial disease
(PAD), S1-S296, Copyright 2000, with permission from Elsevier (1). 
Table 14. Surveillance Program for Infrainguinal Prosthetic Grafts
Patients undergoing prosthetic femoropopliteal or femorotibial bypass
for claudication or limb-threatening ischemia should be entered into a
graft surveillance program that consists of:
Interval history (new symptoms)
Vascular examination of the leg with palpation of proximal and 
outflow vessel pulses
Measurement of ABIs at rest and, if possible, after exercise testing
Surveillance programs should be performed in the immediate postop-
erative period and at regular intervals (timing of surveillance and effi-
cacy have not been ideally defined) for at least 2 years
ABI indicates ankle-brachial index.
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-
Society Consensus (TASC) Working Group, Management of peripheral arterial disease 
(PAD), S1-S296, Copyright 2000, with permission from Elsevier (1). 
Table 12. Surveillance Program for Aortoiliac and Infrainguinal
Transluminal Angioplasty
Patients undergoing aortoiliac and infrainguinal transluminal angio-
plasty for lower extremity revascularization should be entered into a
surveillance program, which consists of:
Interval history (new symptoms)
Vascular examination of the leg with palpation of proximal and
outflow vessel 
pulses
Resting and, if possible, postexercise ABI recording
Surveillance programs should be performed in the immediate post-
PTA period and at intervals for at least 2 years
ABI indicates ankle-brachial index; PAD, peripheral arterial disease; and PTA, percuta-
neous transluminal angioplasty.
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-
Society Consensus (TASC) Working Group, Management of peripheral arterial disease 
(PAD), S1-S296, Copyright 2000, with permission from Elsevier (1). 
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older with a history of smoking or diabetes. (Level of
Evidence: C)
2. The ABI should be measured in both legs in all new
patients with PAD of any severity to confirm the diag-
nosis of lower extremity PAD and establish a baseline.
(Level of Evidence: B)
3. The toe-brachial index should be used to establish the
lower extremity PAD diagnosis in patients in whom
lower extremity PAD is clinically suspected but in
whom the ABI test is not reliable due to noncompress-
ible vessels (usually patients with long-standing dia-
betes or advanced age). (Level of Evidence: B)
4. Leg segmental pressure measurements are useful to
establish the lower extremity PAD diagnosis when
anatomic localization of lower extremity PAD is
required to create a therapeutic plan. (Level of
Evidence: B)
Ankle-Brachial Index
The ABI is a measurement that provides objective data that
serves as the standard for the diagnosis of lower extremity
PAD in field epidemiological surveys, in vascular laborato-
ries, and in office practice. The ABI offers prognostic data
that are useful to predict limb survival, wound healing, and
patient survival. The ABI can be used either as a screening
tool for lower extremity PAD or to monitor the efficacy of
therapeutic interventions. The ABI is performed by measur-
ing the systolic blood pressure from both brachial arteries
and from both the dorsalis pedis and posterior tibial arteries
after the patient has been at rest in the supine position for 10
minutes (Figure 6). Optimal recordings are obtained with
blood pressure cuffs that are appropriately sized to the
patient’s lower calf (immediately above the ankle), and sys-
tolic pressures are recorded with a handheld 5- or 10-mHz
Doppler instrument. In normal individuals, there should be a
minimal (less than 12 mm Hg) interarm systolic pressure
gradient during a routine examination. Inasmuch as the inci-
dence of atherosclerotic subclavian and axillary arterial
occlusive disease is higher in individuals with atherosclerot-
ic lower extremity PAD, both arm pressures must be record-
ed. If the arm blood pressures are not equal, then the pres-
ence of a subclavian or axillary arterial stenosis is presumed
present, and the higher blood pressure is used for subsequent
blood pressure ratio calculations. Pulse wave reflection in
healthy individuals causes the ankle pressure to be 10 to 15
mm Hg higher than the brachial arterial systolic pressure,
and thus the normal ankle-arm brachial index systolic blood
pressure ratio is greater than 1.00. Calculated ABI values
should be recorded to 2 decimal places. 
The ABI has been validated against lower extremity con-
trast angiography to determine its sensitivity, specificity, and
accuracy as a lower extremity PAD diagnostic tool. Lijmer et
al. used a receiver operating characteristic (ROC) analysis to
demonstrate that with an ABI diagnostic threshold of 0.91,
the sensitivity of the ABI was 79% and specificity was 96%
to detect stenoses of 50% or more reduction in lumen diam-
these vascular diagnostic techniques, as summarized in Table
15. 
The noninvasive vascular laboratory provides a powerful
set of tools that can objectively assess the status of lower
extremity arterial disease and facilitate the creation of a ther-
apeutic plan. Although there are many diagnostic vascular
tests available, the clinical presentation of each patient can
usually be linked to specific and efficient testing strategies
(Table 16). The combined use of physiological noninvasive
data and imaging studies can provide information vital to the
choice of interventional approaches. The physiological non-
invasive tests (e.g., ankle, toe, and segmental blood pressures
and ratios) are relatively inexpensive, can be performed at no
risk, and provide prognostic information. These examina-
tions in patients with lower extremity PAD permit the clini-
cian to (a) objectively establish the presence of the lower
extremity PAD diagnosis, (b) quantitatively assess the sever-
ity of disease, (c) localize lesions to specific limb arterial
segments, and (d) determine the temporal progression of dis-
ease or its response to therapy. 
Quality assurance of noninvasive vascular laboratory tech-
niques is maintained by the Intersocietal Commission for
Accreditation of Vascular Laboratories (ICAVL;
www.icavl.org), which serves as an intersocietal, interdisci-
plinary peer review organization that represents each med-
ical specialty and vascular technology professional organiza-
tion that is involved in noninvasive vascular testing. The pri-
mary goals of the ICAVL are to recognize testing facilities
performing high-quality studies (as verified by a program of
ongoing quality assurance), to issue certificates of recogni-
tion of such quality service, and to maintain a registry of
accredited laboratories. The “Essentials and Standards for
Accreditation of Vascular Laboratories” address the qualifi-
cations of medical and technical personnel, instrumentation,
testing protocols, diagnostic criteria, quality assurance,
patient safety policies, and facilities. Accreditation has also
been provided by the American College of Radiology.
Accreditation has led to improved quality of testing,
increased standardization of testing protocols and diagnostic
criteria, improved quality assurance procedures, an increase
in the number of certified technologists, and improved ongo-
ing noninvasive vascular diagnostic educational opportuni-
ties. Such an ongoing system to assess other noninvasive
(e.g., MRA or CTA) and invasive vascular techniques does
not yet exist.
2.5.1. Ankle- and Toe-Brachial Indices, 
Segmental Pressure Examination
RECOMMENDATIONS
Class I
1. The resting ABI should be used to establish the lower
extremity PAD diagnosis in patients with suspected
lower extremity PAD, defined as individuals with
exertional leg symptoms, with nonhealing wounds,
who are 70 years and older or who are 50 years and
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Table 15. Noninvasive and Invasive Vascular Diagnostic Tools: Benefits and Limitations
Diagnostic Tool* Benefits Limitations
Ankle-brachial indices A quick and cost-effective way to establish or May not be accurate when systolic blood 
(ABIs) refute the lower extremity PAD diagnosis (see text) pressure cannot be abolished by inflation 
of an air-filled blood pressure cuff (non-
compressible pedal arteries), as occurs in a 
small fraction of diabetic or very elderly 
individuals
Toe-brachial indices A quick and cost-effective way to establish or refute the Requires small cuffs and careful technique to 
lower extremity PAD diagnosis (see text) preserve accuracy
Can measure digital perfusion when small-vessel arterial
occlusive disease is present
Useful in individuals with noncompressible pos-
terior tibial or dorsalis pedis arteries
Segmental pressure examination Useful to establish or refute the PAD diagnosis (see text) May not be accurate when systolic blood pres-
Useful to provide anatomic localization of lower sure cannot be measured by inflation of an air-
extremity PAD when these data are required to create a filled blood pressure cuff owing to noncom-
therapeutic plan pressible pedal arteries, as occurs in a small
Can provide data to predict limb survival, wound healing, fraction of diabetic or very elderly individuals
and patient survival
Useful to monitor the efficacy of therapeutic interventions
Pulse volume recording Useful to establish the diagnosis of PAD in vascular Usefulness maintained in patients with noncom-
laboratories or office practice pressible vessels (ABI value greater than 1.3)
Helpful in predicting the outcome in CLI and risk of Qualitative, not quantitative, measure of perfu-
amputation sion
Can be used to monitor limb perfusion after revascu- May not be accurate in more distal segments
larization procedures Less accurate than other noninvasive tests in
providing arterial anatomic localization of 
PAD
May be abnormal in patients with low cardiac
stroke volume
Continuous-wave Doppler Useful to assess lower extremity PAD anatomy, “Pulse normalization” downstream from
ultrasound severity, and progression stenoses can diminish test sensitivity
Can provide localizing information in patients Test specificity greater for patent superfi-
with poorly compressible arteries cial femoral arteries than for aortoiliac
Can provide quantitative data after successful occlusive disease
lower extremity revascularization Does not provide visualization of arterial
anatomy
Limited accuracy in tortuous, overlapping,
or densely calcified arterial segments, and
insensitive for iliac arteries (in context of 
obesity, bowel gas, and vessel tortuosity)
Duplex ultrasound Can establish the lower extremity PAD Useful tool to provide graft surveillance
diagnosis, establish anatomic localization, and after femoral-popliteal or femoral tibial or
define severity of focal lower extremity arterial pedal surgical bypass with venous (but not
stenoses prosthetic) conduit
Can be useful to select candidates for endovascular Accuracy is diminished in proximal
or surgical revascularization aortoiliac arterial segments in some indi-
viduals (e.g., due to obesity or the presence
of bowel gas)
Dense arterial calcification can limit diag-
nostic accuracy
Sensitivity is diminished for detection of 
stenoses downstream from a proximal
stenosis
Diminished predictive value in surveil-
lance of prosthetic bypass grafts
Continued on Next Page
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Table 15. Continued
Diagnostic Tool* Benefits Limitations
Toe-tip exercise testing, with Useful to diagnose lower extremity PAD when resting ABI Provides qualitative (rather than quantitative) 
pre-exercise and postexercise ABIs values are normal exercise diagnostic results
Can be performed in the absence of a treadmill, Lower workload may not elicit symptoms in all 
with increased convenience and low cost individuals with claudication
Treadmill exercise testing, with Helps differentiate claudication from pseudoclaudication Requires use of a motorized treadmill, with or 
and without pre-exercise and in individuals with exertional leg symptoms without continuous electrocardiogram moni
postexercise ABIs toring, as well as staff familiar with exercise
Useful to diagnose lower extremity PAD when resting testing protocols
ABI values are normal
Objectively documents the magnitude of symptom
limitation in patients with claudication, especially when
used with a standardized treadmill protocol
Demonstrates the safety of exercise and provides data
to individualize exercise prescriptions in individuals with
claudication before initiation of a formal program of
therapeutic exercise training
Useful to measure the objective functional response to 
claudication therapeutic interventions
Magnetic resonance angiography Useful to assess PAD anatomy and presence of Tends to overestimate the degree of stenosis·
(MRA) significant stenoses May be inaccurate in arteries treated with metal 
Useful to select patients who are candidates for stents
endovascular or surgical revascularization Cannot be used in patients with contraindica-
tions to the magnetic resonance technique 
(e.g., pacemakers, defibrillators, intracranial 
metallic stents, clips, coils, and other devices)
Computed tomographic Useful to assess PAD anatomy and presence of Single-detector computed tomography
angiography (CTA) significant stenoses lacks accuracy for detection of stenosis
Useful to select patients who are candidates for Spatial resolution lower than digital subtraction
endovascular or surgical revascularization angiography
Helpful to provide associated soft tissue diagnostic Venous opacification can obscure arterial filling
information that may be associated with PAD Asymmetrical opacification of the legs may
presentation (e.g., aneurysms, popliteal entrapment, obscure arterial phase in some vessels
and cystic adventitial disease) Accuracy and effectiveness not as well deter-
Patients with contraindications to magnetic resonance mined as MRA
angiography (e.g., pacemakers or defibrillators) Treatment plans based on CTA have not been 
may be safely imaged compared with those of catheter angiography·
Metal clips, stents, and metallic prostheses do not cause Requires iodinated contrast and ionizing radia-
significant CTA artifacts tion (although radiation exposure is less than 
Scan times are significantly faster than for MRA with catheter angiography)
Because CTA requires administration of iodinat-
ed contrast, use is limited in individuals with 
established renal dysfunction
Contrast angiography Definitive method for anatomic evaluation of Invasive evaluation is associated with risk of 
PAD when revascularization is planned bleeding, infection, vascular access complica-
tions (e.g., dissection or hematoma), athero-
embolization, contrast allergy, and contrast 
nephropathy
May provide limited visualization of tibial-pedal 
vessels in patients with CLI and poor inflow 
to the leg
Below-knee vessels may be difficult to identify 
by digital subtraction angiography
Multiple projections may be necessary to visual-
ize eccentric lesions
*Tools are listed in order from least invasive to most invasive and from least to most costly.
CLI indicates critical limb ischemia; PAD, peripheral arterial disease.
e31
ACC - www.acc.org
AHA - www.americanheart.org
Hirsch et al. 2005
ACC/AHA Practice Guidelines
Ouriel and Zarins demonstrated that the ABI may provide
better discrimination than the absolute ankle pressure alone
for distinguishing between normal limb arteries and those
with lower extremity PAD (163). These authors also demon-
strated that neither the absolute ankle pressure nor the ABI
can differentiate normal limbs from asymptomatic limbs
with arteriographically determined disease, because neither
pressure-based assessment nor the ABI at rest can predict the
hemodynamic supply-demand relationship with exercise.
This may be a key reason why the ABI does not reliably pre-
dict the magnitude of ischemic symptoms.
Abnormal ABI values represent a continuous variable less
than 0.90. ABI values are often considered to be mildly to
moderately diminished when they are between 0.41 and 0.90
and severely decreased when less than or equal to 0.40.
These relative categories have prognostic value. For exam-
ple, an ABI value greater than 0.50 suggests that progression
to critical leg ischemia is unlikely during the subsequent 6.5
years of follow-up (164). In contrast, when the ABI is less
than 0.40, patients are more likely to experience ischemic
rest pain. Similarly, the low ankle systolic blood pressure in
such individuals bodes poorly for the healing of ischemic
wounds. The presence of a severely decreased ABI thus iden-
tifies individuals who are at particularly high risk of subse-
quent development of rest pain, ischemic ulceration, or gan-
grene (162). 
McLafferty et al. investigated the value of the ABI to assess
the progression of lower extremity PAD after vascular sur-
gery (165). In that investigation, a change in ABI of 0.15 was
used as the criterion to define progression of the disease, and
baseline and postoperative angiography or duplex scanning
was performed approximately 3 years later. In this clinical
context, the ABI had a sensitivity of 41%, specificity of 84%,
positive predictive value of 59%, and an accuracy of 68% for
eter (156). Similarly, Fowkes, using a comparable ABI
threshold of 0.90, showed that the ABI has a sensitivity of
95% and a specificity of 100% compared with angiography
(120). Fiegelson et al. (157) measured a sensitivity of 89%
and a specificity of 99% compared with angiography, using
only posterior tibial measurements with a threshold of 0.8.
That study demonstrated that the ABI had a positive predic-
tive value of 90%, a negative predictive value of 99%, and an
overall accuracy of 98%. Nassoura et al. assessed the diag-
nostic discrimination of the ABI compared with angiography
after vascular occlusive injury due to trauma (158) and
demonstrated that the ABI had a sensitivity of 72%, a speci-
ficity of 100%, a positive predictive value of 100%, and a
negative predictive value of 96%. Thus, the overall accuracy
of the ABI to establish the lower extremity PAD diagnosis
has been well-established. 
The interobserver variability of the ABI measurement has
been evaluated in multiple investigations. Baker and Dix
tested 35 men with claudication at 7 different times each and
found a standard deviation of 0.07, which led them to con-
clude that the change in ABI must be greater than 0.15 (2
standard deviations) to be significant (159). Their results
were identical to those obtained by Carter (160). Strandness
et al. reported the variability of ABI measurements per-
formed on 4 subjects on 3 different days with different
observers, which yielded an ABI interday standard deviation
of 0.06 (161). Yao assessed the ABI on different days in 179
patients using 4 technicians to determine a measurement
variance of 0.08 (162). When 69 patients were assessed on 6
different days using the same technician, the measurement
variance was 0.05. These results suggest that most of the
variance is due to the measurement method, not to differ-
ences between observers. Overall, the ABI is considered to
have a reproducibility of approximately 0.10. 
Table 16. Typical Noninvasive Vascular Laboratory Tests for Lower Extremity PAD Patients by Clinical
Presentation
Clinical Presentation Noninvasive Vascular Test
Asymptomatic lower extremity PAD ABI
Claudication ABI, PVR, or 
segmental pressures
Duplex ultrasound
Exercise test with ABI to assess functional status
Possible pseudoclaudication Exercise test with ABI
Postoperative vein graft follow-up Duplex ultrasound
Femoral pseudoaneurysm; iliac Duplex ultrasound
or popliteal aneurysm
Suspected aortic aneurysm; Abdominal ultrasound, CTA, or MRA
serial AAA follow-up
Candidate for revascularization Duplex ultrasound, MRA, or CTA
AAA indicates abdominal aortic aneurysm; ABI, ankle-brachial index; CTA, computed tomographic angiography; MRA, magnetic reso-
nance angiography; PAD, peripheral arterial disease; PVR, pulse volume recording.
Adapted from Primary Cardiology, 2nd ed., Braunwald E, Goldman L, eds., “Recognition and management of peripheral arterial disease,”
Hirsch AT, 659-71, Philadelphia, Pa: WB Saunders, Copyright 2003, with permission from Elsevier (155a).
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strongly suggest lower extremity PAD, the presence of a nor-
mal or high ABI should not be presumed to rule out this diag-
nosis, and an alternative diagnostic test (e.g., toe-brachial
pressure, Doppler waveform analysis, pulse volume record-
ing, exercise ABI test, or duplex ultrasound) should be per-
formed. 
The importance and potentially unique value of the ABI
have been expanded by epidemiological studies
(44,105,107,109). The diagnosis of lower extremity PAD by
an abnormal ABI is predictive of other clinical stigmata of
systemic atherosclerotic disease. Newman and coworkers
have confirmed the inverse relationship between the ABI and
atherosclerosis risk factors, as well as its relationship with
the presence of both cardiovascular and cerebrovascular dis-
ease (44). For example, the presence of a low ABI was pre-
dictive of total and cardiovascular mortality (relative risk of
cardiovascular mortality in the low ABI cohort was increased
approximately 3- to 4-fold) in a cohort of 1537 elderly men
detecting disease progression, thus demonstrating the poten-
tial utility of this technique to monitor lower extremity PAD
progression after surgical intervention. 
The ABI may not be accurate in individuals in whom sys-
tolic blood pressure cannot be abolished by inflation of an
air-filled blood pressure cuff. The incidence of noncom-
pressible arteries is highest in diabetics and elderly patients;
in these individuals, it may be impossible to abolish the sys-
tolic pressure signal despite cuff inflation to pressures in
excess of 200 mm Hg. Despite the artifactually high systolic
pressure, these individuals may have arterial disease, and
cardiovascular event rates have been noted to be increased in
one population that was characterized by a high prevalence
of diabetes and other risk factors (166). This finding has not
been confirmed in other population studies. Patients with
either severely stenotic or totally occluded iliofemoral arter-
ies may also have a normal ABI value at rest if sufficient col-
laterals are present. Thus, for patients in whom symptoms
Figure 6. Ankle-brachial index. DP indicates dorsalis pedis; and PT, posterior tibial artery. Adapted with permission from Hiatt WR.
Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-21 (158a). Copyright © 2001
Massachusetts Medical Society. All rights reserved.
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has an associated (and reimbursed) current procedural termi-
nology code (171).
Segmental Pressure Measurements
Arterial pressures can also be measured with plethysmo-
graphic cuffs placed sequentially along the limb at various
levels (172,173). In most vascular laboratories, these blood
pressure cuffs are placed at the upper thigh, the lower thigh,
the upper calf, and the lower calf above the ankle. Use of a
3-cuff system (with only 1 thigh cuff) is another acceptable
method. The systolic blood pressures obtained from the
lower extremities can also be indexed relative to the brachial
artery pressure, in a manner analogous to the ABI. These
measurements provide a noninvasive corollary to intra-arte-
rial pressure measurements. 
In contrast to ABI studies, the segmental pressure analysis
is able to accurately determine the location of individual
arterial stenoses. For example, the presence of a prominent
systolic pressure gradient between the brachial artery pres-
sure and the upper thigh systolic pressure signifies the pres-
ence of an aortoiliac stenosis. A pressure gradient located
between the upper and lower thigh cuffs would signify a
lesion of the superficial femoral artery. Gradients between
the lower thigh and upper calf cuffs identify a distal superfi-
cial femoral or popliteal arterial stenosis, and gradients
between the upper and lower calf cuffs identify infrapopliteal
disease. In most laboratories, a gradient of greater than 20
mm Hg between adjacent segments is interpreted to repre-
sent a physiologically important focal stenosis. Thus, seg-
mental pressure measurements can identify the location and
magnitude of many arterial stenoses noninvasively. As with
the ABI, segmental pressure measurements may be artifactu-
ally elevated or uninterpretable in patients with noncom-
pressible vessels.
Toe-Brachial Index Measurements
Many individuals with long-standing diabetes, elderly
patients, and individuals who require dialysis for end-stage
renal disease may have noncompressible leg arterial seg-
ments due to medial calcification. This may preclude accu-
rate assessment of either the ABI or segmental pressure
measurements in a subset of these patient cohorts. Such non-
compressible arteries are suggested when the ABI is greater
than 1.3 or when there is an abnormal augmentation in a
measured lower extremity systolic pressure beyond the nor-
mal physiological amplification of systolic pressure from the
heart to the limb arterial segment (usually greater than 20
mm Hg or 20% higher than the brachial systolic pressure). In
such individuals, diagnostic information to establish the
lower extremity PAD diagnosis can be obtained by the meas-
urement of toe systolic pressure and calculation of the toe-
brachial index, and toe-brachial index values less than 0.7
are usually considered diagnostic for lower extremity PAD
(174-179). The toe pressure measurement remains a sensitive
diagnostic test in such patients because digital arteries are
usually spared the calcinosis that alters compressibility of
and women followed in the Systolic Hypertension in the
Elderly Program (SHEP) (105). McKenna et al. documented
a 5-year mortality of approximately 30% and 50% in patients
with an ABI of 0.70 and 0.40, respectively (109). The rela-
tionship between ABI and morbidity and mortality in
patients with lower extremity PAD has also been quantitated
by Sikkink et al., who demonstrated that the 5-year cumula-
tive survival rate was 63% for subjects with a resting ABI
less than 0.50, 71% for subjects with an ABI between 0.50
and 0.69, and 91% for subjects with an ABI between 0.70
and 0.89 (167). Thus, 5-year survival in patients with lower
extremity PAD is well predicted by the ABI value itself.
Despite the increasing use of more sophisticated vascular
diagnostic tests (e.g., intimal medial thickness, vascular
compliance, or arterial duplex ultrasonography), the ABI is
linked to a robust epidemiological database, which permits
prediction of future cardiovascular ischemic events.
The epidemiological database and vascular laboratory
experience with ABI testing have led to increasing use of the
ABI examination in office practice. It has been proposed that
the ABI should be considered a routine test for all patients
who are at risk of lower extremity PAD. As described previ-
ously, the PARTNERS investigation evaluated use of the ABI
applied to a target population of individuals aged 70 years
and older or 50 years of age and in whom other atheroscle-
rosis risk factors (especially tobacco use and diabetes) would
be expected to increase the prevalence of lower extremity
PAD (86). The average time required to perform the ABI in
primary care office practices is approximately 15 minutes,
and these ABI data are valued by clinicians (168). The utili-
ty of the ABI to detect lower extremity PAD has long been
endorsed by the American Diabetes Association and the
AHA, which had published an original recommendation to
perform this test in individuals with insulin-dependent dia-
betes who were aged 35 years and older and patients with 20
years’ duration of diabetes (169). This application of the ABI
to office practice has been updated by an American Diabetes
Association consensus statement that suggested that the ABI
be performed in all individuals with diabetes who are aged
50 and older, in diabetic individuals younger than age 50
who have other atherosclerosis risk factors, and in individu-
als with diabetes of more than 10 years’ duration (170).
Application of the ABI is now considered appropriate in tar-
geted populations known from the epidemiological database
to be at risk (Table 2), including individuals 49 years of age
and younger with a history of diabetes and 1 other risk fac-
tor; those 50 to 69 years of age with a history of smoking or
diabetes; those 70 years of age and older; those with an
abnormal lower extremity pulse examination; and individu-
als with known atherosclerotic coronary, carotid, or renal
artery disease. Nevertheless, at the present time, the cost of
measurement of the ABI in office practice with handheld
equipment without pulse volume recording (PVR) or
Doppler waveform tracings is usually not reimbursed by
healthcare payers. In contrast, measurement of the ABI in
association with standardized vascular laboratory equipment
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more proximal arteries. This test is performed by placement
of a small occlusive cuff on the proximal portion of the great
or second toe, with the return of toe pulsatility (which repre-
sents the systolic perfusion pressure) assessed by use of a
plethysmographic detection device. 
2.5.2. Pulse Volume Recording
RECOMMENDATION
Class IIa
Pulse volume recordings are reasonable to establish
the initial lower extremity PAD diagnosis, assess local-
ization and severity, and follow the status of lower
extremity revascularization procedures. (Level of
Evidence: B)
Arterial inflow into the lower extremities is pulsatile, and
such inflow leads to measurable changes in lower-limb vol-
ume with each cardiac cycle. Measurement of these cyclical
volume changes can be documented by a plethysmographic
technique to provide qualitative or quantitative data regard-
ing the adequacy of limb perfusion in patients with lower
extremity PAD. Pulse volume recordings provide a method
to evaluate the arterial pressure waveform profile via the use
of either a pneumoplethysmograph or a mercury-in-silastic
strain gauge. Both of these devices can be applied in a seg-
mental manner from the thigh to the ankle to assess the
change in limb volume between diastole and systole. When
such data are recorded on chart paper, the magnitude of the
pulse volume provides an index of large-vessel patency and
correlates with blood flow. 
Pneumoplethysmographic devices are in most widespread
use both in vascular laboratories and as a component of
office-based vascular diagnostic devices, with a large thigh
cuff placed proximally and with calf and ankle cuffs used
more distally. An arm (brachial) cuff PVR tracing is also
recorded to provide an index of normal pulsatility in a pre-
sumably well-perfused limb. When such data are recorded on
chart paper, the magnitude of the pulse upstroke and pulse
volume (amplitude) provide a global physiological measure-
ment of large-vessel patency and correlates with blood flow.
Any sequential diminution in pulsatility (upstroke and ampli-
tude) signifies the presence of a flow-limiting stenosis in the
more proximal arterial segment (173,180). Pulsatility is usu-
ally a qualitative (or rarely, semiquantitative) measurement,
with normal values set by each vascular laboratory.
The accuracy of the PVR has been assessed by comparison
to direct measurements of arterial pressure gradients in the
aortoiliac segments in 52 limbs of 45 patients with lower
extremity PAD (181). Measurement of low PVR amplitude
correlated with arterial segmental pressure gradients of 10
mm Hg at rest or with gradients of 20 mm Hg induced by
injection of the vasodilator papaverine. The accuracy of
combined segmental pressure measurements and PVRs has
been assessed with an angiographic “gold standard” in a
prospective study of 50 patients with lower extremity PAD
(182). Doppler waveform tracings from the femoral,
popliteal, and tibial arteries were used to calculate the pul-
satility index and inverse damping factor and compared with
the arteriographic data by independent observers. Both the
combined PVR-segmental pressure and the Doppler wave-
form techniques offered an overall diagnostic accuracy in the
90% to 95% range. The PVR-segmental pressure technique
accurately predicted the severity of iliac and superficial
femoral artery obstruction and distinguished iliac from prox-
imal superficial femoral artery disease. However, the PVR-
segmental pressure method was less accurate in more distal
(e.g., tibial artery) segments.
Pulse volume recording tracings have been evaluated and
can serve as a facile method to assess the adequacy of limb
perfusion in the early postoperative hours after aortofemoral
surgical reconstruction (183). In this context, PVR pulsatili-
ty correlated well with electromagnetic measures of arterial
blood flow and provided information useful in predicting
technical procedural limitations.
The PVR has been evaluated for its ability to predict limb
prognosis (propensity for amputation). Kaufman et al. stud-
ied the relationship of PVR tracings to limb outcome in 517
patients with lower extremity PAD (184). Pulse volume
recording tracings correlated well with ankle systolic blood
pressure and provided similar prognostic information.
Within 1 year of follow-up, 97.9% of 96 patients with jeop-
ardized limbs and flat tracings underwent limb salvage sur-
gery, 85.7% of patients with jeopardized limbs and nearly
flat tracings underwent surgery, and 41.9% of those with
minimal symptoms and nearly flat recordings required surgi-
cal revascularization (p less than 0.001). The prognostic
value of PVR tracings in predicting risk of amputation has
also been evaluated in a small patient cohort with diabetes
before and after renal transplantation. Makisalo et al. studied
129 consecutive diabetic (n equals 34) and nondiabetic (n
equals 95) renal transplantation patients and measured the
predictive value of clinical factors (e.g., pretransplant lower
extremity PAD and claudication) and noninvasive vascular
perfusion measurements (ABI, toe-brachial index, and
PVRs) on lower-limb amputations, renal allograft survival,
and patient survival during a 5-year period of follow-up
(178). A low PVR amplitude (below 5 mm) was observed
before transplantation in 82% of the diabetic patients and
36% of the nondiabetic patients. During the 5-year follow-up
period, abnormal toe-brachial index and PVR values (and
diabetes) at the time of transplantation were the greatest pre-
dictors for proximal foot amputations. In summary, the pres-
ence of a low pulse volume serves as a measurable hallmark
that correlates with other signs of limb jeopardy and an
adverse prognosis.
In summary, the PVR technique is useful as an initial diag-
nostic test for patients with suspected lower extremity PAD
and to assess limb perfusion after revascularization proce-
dures, and it can predict risk of CLI and amputation. Pulse
volume recordings can provide a tool to evaluate small-ves-
sel disease when applied to the feet. They are also useful in
individuals with noncompressible vessels in whom ABIs and
segmental pressures are spuriously elevated. Although PVRs
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Analysis of the morphology of the Doppler waveform can
add useful localizing information to that obtained by seg-
mental blood pressure recording alone. For example, a uni-
laterally depressed proximal thigh measurement could be
due to occlusive disease in either the ipsilateral common or
external iliac arteries or the proximal portion of the superfi-
cial femoral artery. A low-resistance Doppler waveform or a
pulsatility index of less than approximately 4.0 for the com-
mon femoral artery would indicate that occlusion most like-
ly involves the common or external iliac artery, whereas a
high-resistance Doppler waveform or a pulsatility index
greater than 4.0 would suggest that the iliac arteries are rela-
tively free of disease and that occlusion primarily involves
the proximal superficial femoral artery, frequently in con-
junction with lesions of the deep femoral artery (190). For
unknown reasons, some patients with occlusion of the super-
ficial femoral artery, in the absence of aortoiliac disease,
demonstrate a low-resistance waveform and a depressed pul-
satility index of the common femoral artery. This constella-
tion of findings results in false-positive studies that suggest
aortoiliac disease, decreases the positive predictive value of
the test, and lessens the specificity of the test for aortoiliac
occlusive disease compared with results obtained in patients
with patent superficial femoral arteries (190,191). Doppler
waveform analysis also can provide useful localizing infor-
mation in patients with poorly compressible arteries and in
patients with a normal resting ABI.
The benefits of Doppler waveform analysis, along with
recognition of its limitations, can be maximized if the blood
flow waveform analysis is combined with ultrasound gray-
scale visualization of the arterial wall. Such “duplex” imag-
ing now represents one of the most widely used noninvasive
vascular laboratory techniques.
2.5.4. Treadmill Exercise Testing With and
Without ABI Assessments and 6-Minute 
Walk Test
RECOMMENDATIONS
Class I
1. Exercise treadmill tests are recommended to provide
the most objective evidence of the magnitude of the
functional limitation of claudication and to measure
the response to therapy. (Level of Evidence: B)
2. A standardized exercise protocol (either fixed or grad-
ed) with a motorized treadmill should be used to
ensure reproducibility of measurements of pain-free
walking distance and maximal walking distance.
(Level of Evidence: B)
3. Exercise treadmill tests with measurement of pre-
exercise and postexercise ABI values are recommend-
ed to provide diagnostic data useful in differentiating
arterial claudication from nonarterial claudication
(“pseudoclaudication”). (Level of Evidence: B)
are useful and cost-effective, especially as a screening tool
in office practices or vascular laboratories, other noninva-
sive techniques can provide more quantitative perfusion data
and better arterial anatomic lower extremity PAD localiza-
tion.
2.5.3. Continuous-Wave Doppler Ultrasound
RECOMMENDATION
Class I
Continuous-wave Doppler ultrasound blood flow
measurements are useful to provide an accurate
assessment of lower extremity PAD location and
severity, to follow lower extremity PAD progression,
and to provide quantitative follow-up after revascu-
larization procedures. (Level of Evidence: B)
Continuous-wave Doppler ultrasound is used to obtain
velocity waveforms and to measure systolic blood pressure
at sequential segments of the upper or lower extremities and
is a traditional component of a noninvasive peripheral arte-
rial evaluation. Use of this technique permits initial estima-
tion of disease location and severity, follow-up of disease
progression, and quantitation of the effects of revasculariza-
tion therapies (185). 
One commonly used quantitative indirect measure for
detection of proximal occlusive disease is the peak-to-peak
pulsatility index, defined as the peak systolic velocity (or
frequency shift) minus the minimum or most reversed dias-
tolic velocity (or frequency shift), divided by the mean
blood flow velocity (or frequency shift; Figure 7). Normally,
the pulsatility index increases from the more proximal to the
more distal segments of the lower extremities (186). A
decrease in the pulsatility index between adjacent proximal
and distal anatomic segments implies the presence of occlu-
sive disease between these 2 locations. The degree of decline
in the pulsatility index value is usually proportional to the
severity of occlusive disease (187). However, downstream
from moderate stenosis, the velocity pulse waveform may
revert to a normal waveform within a short distance (approx-
imately 3 to 5 vessel diameters), depending on the severity
of stenosis (188,189). This latter phenomenon of “pulse nor-
malization” distal to some arterial stenoses is a diagnostic
limitation. Thus, the presence of a high-resistance-type
waveform (defined as rapid forward systolic flow, followed
by a short period of rapid reversed flow, and then low-veloc-
ity forward flow in late diastole) does not provide irrefutable
evidence of the absence of more proximal occlusive disease.
Figure 7. Pulsatility index. Vmax indicates peak systolic velocity;
Vmin, minimum diastolic velocity; Vmean, mean blood flow velocity.
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end point. After completing the test, the patient is asked to
resume the supine position, and both brachial and ankle pres-
sures are recorded at 1-minute intervals until they reach the
pre-exercise baseline. In this way, the onset of claudication,
maximal walking distance, and absolute and percentage
decreases in ankle blood pressure or ABI at the first postex-
ercise minute can be obtained (195).
Measurement of the ankle blood pressure and the ABI at
rest and immediately after exercise yields objective data to
grade the dynamic functional significance of an arterial
stenosis. The postexercise ankle systolic pressure and ABI
measurement relies on the principle that walking induces
profound peripheral vasodilatation and decreased leg periph-
eral resistance. In normal individuals, the brachial and ankle
blood pressures rise together and maintain their normal rela-
tionship with exertion. In contrast, in the presence of arterial
occlusive disease, an abnormal hemodynamic response
results. In individuals with lower extremity PAD, despite the
increased central blood pressure, maximal exercise-induced
ischemic vasodilation in the claudicating limb is associated
with development of a significant blood pressure gradient
across the lower extremity arterial stenosis. Thus, in the indi-
vidual with vasculogenic claudication, the postexercise ankle
blood pressure (and usually the ABI) will fall from its base-
line value. For example, in individuals with symptoms of
thigh and buttock claudication due to iliac arterial stenoses,
the resting ABI may be normal. Measurement of a normal
index at baseline with a subsequent diagnostic ABI fall
immediately after exercise may reveal the functional signifi-
cance of a high-grade stenosis that significantly limits ambu-
lation. In contrast, the patient with pseudoclaudication due to
spinal stenosis (or other nonarterial functional limitation)
will demonstrate a normal postexercise ABI, despite exer-
cise-limiting symptoms suggestive of claudication
(162,195). Both the absolute fall in postexercise ankle blood
pressure and the percent fall in ABI value have been used as
diagnostic criteria after exercise, with variable diagnostic
thresholds (162,195,196). 
Exercise ABI and ankle blood pressure measurements may
therefore be useful in establishing the diagnosis of lower
extremity PAD when there is a high index of suspicion of
lower extremity PAD, yet measures of the ABI at rest are
normal. A simplified form of exercise testing can utilize a
pedal plantar flexion test when a treadmill is not available in
office practice. In this test, individuals with suspected lower
extremity PAD but in whom the ABI is normal at rest are
asked to stand flat-footed and perform 50 sequential, symp-
tom-limited ankle plantar flexions and thus raise the heels
maximally off the floor. Postexercise ABI values measured
with this “tip-toe” test are similar to those recorded after
treadmill exercise (197). The role of treadmill exercise tests
in individuals who will initiate a program of supervised exer-
cise is discussed more completely in Section 2.6.2.1.
There are limitations to the use of treadmill testing that
relate to patient characteristics (e.g., comorbid conditions
that prevent treadmill walking) and to access to motorized
devices or to personnel trained to operate them. For example,
4. Exercise treadmill tests should be performed in indi-
viduals with claudication who are to undergo exercise
training (lower extremity PAD rehabilitation) so as to
determine functional capacity, assess nonvascular
exercise limitations, and demonstrate the safety of
exercise. (Level of Evidence: B)
Class IIb
A 6-minute walk test may be reasonable to provide an
objective assessment of the functional limitation of
claudication and response to therapy in elderly indi-
viduals or others not amenable to treadmill testing.
(Level of Evidence: B)
Exercise testing may be extremely useful (a) in establish-
ing the diagnosis of lower extremity PAD when resting
measures of the ABI are normal, (b) to objectively document
the magnitude of symptom limitation in patients with lower
extremity PAD and claudication, (c) to objectively measure
the functional improvement obtained in response to claudi-
cation interventions, (d) to differentiate claudication from
pseudoclaudication in individuals with exertional leg symp-
toms, and (e) to provide objective data that can demonstrate
the safety of exercise and to individualize exercise prescrip-
tions in patients with claudication before initiation of a for-
mal program of exercise training. 
Most exercise testing for patients with lower extremity
PAD and claudication should use motorized treadmills pro-
grammed to provide less intense progressive workloads than
are commonly used for healthy individuals or patients with
coronary heart disease (e.g., the Gardner-Skinner, Hiatt, or
Naughton protocols) (192-194). The treadmill test should
record the time of onset of leg symptoms, laterality and spe-
cific muscle group(s) involved, the presence of associated
coronary ischemic symptoms, and the total walking time.
Continuous electrocardiographic monitoring, although not
required to evaluate lower extremity PAD, may provide use-
ful diagnostic data regarding inducible myocardial ischemia
in many individuals, even if the patient with claudication
cannot achieve 85% of their age-predicted peak heart rate or
workload. 
During treadmill testing, the patient should be asked to
indicate when any exercise-limiting symptoms occur;
whether symptoms represent typical claudication, atypical
limb discomfort, joint pain, or general fatigue; or if exercise
is limited by chest pain or other cardiovascular symptoms.
Patients should be asked to walk to their maximally tolerat-
ed claudication symptom to most accurately define peak
walking time during treadmill exercise, because failure to do
so may lead to underestimation of the true peak walking
capacity of the patient. Exercise should be stopped when
mandated by symptoms or if objective signs of myocardial
ischemia are observed (e.g., abnormal blood pressure
response at peak exercise, more than 2.0 mm of ST depres-
sion, or significant dysrhythmias). For patients who do not
develop specific limb or cardiovascular symptoms, exercise
may be terminated when patients achieve a high functional
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peak systolic velocity ratios have been found to be the most
accurate diagnostic criterion. A ratio greater than 2 is com-
monly used to diagnose a stenosis greater than 50% diameter
(201,202,205,207), although other ratios have been used
(203,204,206,210). Some studies have attempted to further
calibrate the duplex technique to distinguish between
degrees of stenosis between 50% and 75% versus 75% and
99% (203,204,207,210). 
The sensitivity and specificity for the diagnosis of stenoses
greater than 50% diameter from the iliac arteries to the
popliteal arteries are each approximately 90% to 95%. A
meta-analysis compared the accuracy of the duplex Doppler
technique performed with or without color imaging guid-
ance. For a specificity of 95%, the sensitivity of color-guid-
ed duplex was 93% compared with 83% for noncolor duplex
methods (211). Accuracy of the duplex examination depends
on the ability of the technique to visualize the vessel ade-
quately. Therefore, accuracy is diminished in examinations
of the iliac arteries if bowel gas or tortuosity obscures the
iliac vessels. Dense calcification can also obscure flow, par-
ticularly if flow is slow. If there are multiple stenoses down-
stream from a first stenosis, the downstream stenoses are
detected with less sensitivity, approximating 60% to 65%,
perhaps owing to slow flow and the presence of collateral
vessels (203,212). 
Duplex ultrasound can be used for preintervention decision
making. This technique can predict whether a patient has
anatomy suitable for angioplasty with an accuracy of 84% to
94% (210,213). It has been used as a substitute for arteriog-
raphy for infrainguinal bypass grafting to select the most
appropriate tibial vessel for distal anastomosis (214-216),
although the final determination may require intraoperative
angiography (217). However, some authors have suggested
that duplex methods are inferior to angiography for evalua-
tion of tibial arteries for distal bypass (218). An outcomes
study has recently been published that demonstrates no dif-
ference in patency of infrapopliteal bypass grafts in nonran-
domized cohorts of patients evaluated by preoperative
duplex versus angiographic methods (214).
Duplex ultrasound has been used for postrevascularization
surveillance of graft patency with mixed results. Vein grafts
fail because of the development of stenoses either within the
body of the graft, at the anastomosis, or upstream or down-
stream from the graft. These stenoses may threaten the graft
even if the patient is asymptomatic and the ABI is
unchanged. Duplex ultrasound surveillance studies allow
detection of these stenoses before graft thrombosis with
greater sensitivity than evaluation by clinical history (limb
ischemic symptoms), physical examination, or use of the
resting ABI (155,219-224). Case series have indicated that
revision of such asymptomatic stenoses improves long-term
graft patency. For example, Mattos et al. found that vein
grafts that were revised on the basis of positive duplex ultra-
sound findings have a 90% 1-year patency rate, similar to
grafts with initially normal duplex examinations (219).
Grafts that were not revised despite the presence of a duplex
ultrasound-detected stenosis had a patency rate of only 66%
treadmill walking performance can be associated with sig-
nificant anxiety in the elderly. Corridor walking, such as that
associated with the 6-minute walk, has been evaluated
recently and can potentially offer a more representative
measure of walking ability during daily life. Current data
demonstrate that the 6-minute walk test is reliable in patients
with lower extremity PAD and is sensitive to change in walk-
ing endurance after exercise interventions. Thus, a 6-minute
walk test can serve as an alternative objective method of
assessing walking endurance in older men and women (198-
200). 
2.5.5. Duplex Ultrasound 
RECOMMENDATIONS
Class I
1. Duplex ultrasound of the extremities is useful to diag-
nose anatomic location and degree of stenosis of PAD.
(Level of Evidence: A)
2. Duplex ultrasound is recommended for routine sur-
veillance after femoral-popliteal or femoral-tibial-
pedal bypass with a venous conduit. Minimum sur-
veillance intervals are approximately 3, 6, and 12
months, and then yearly after graft placement. (Level
of Evidence: A)
Class II
1. Duplex ultrasound of the extremities can be useful to
select patients as candidates for endovascular inter-
vention. (Level of Evidence: B)
2. Duplex ultrasound can be useful to select patients as
candidates for surgical bypass and to select the sites of
surgical anastomosis. (Level of Evidence: B)
Class IIb
1. The use of duplex ultrasound is not well established to
assess long-term patency of percutaneous translumi-
nal angioplasty. (Level of Evidence: B)
2. Duplex ultrasound may be considered for routine sur-
veillance after femoral-popliteal bypass with a syn-
thetic conduit. (Level of Evidence: B)
Duplex ultrasound of the extremities can be used to diag-
nose the anatomic location and degree of stenosis of lower
extremity PAD. Duplex ultrasound also has broad clinical
utility for evaluation of aneurysms, arterial dissection,
popliteal artery entrapment syndrome, evaluation of lympho-
celes, and assessment of soft tissue masses in individuals
with vascular disease. Although duplex ultrasound includes
images, either in black and white or color format, the primary
clinically relevant information derived from duplex studies
has been validated from analysis of the velocity of blood
flow (201-209). Quantitative criteria used to diagnose
stenoses are based on peak systolic velocity and peak sys-
tolic velocity ratios within or beyond the stenosis compared
with the adjacent upstream segment, the presence or absence
of turbulence, and preservation of pulsatility. In general,
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at 1 year. However, 2 randomized trials have offered con-
flicting results. Lundell et al. reported a 3-year primary
assisted patency rate of vein grafts monitored with duplex
ultrasound of 78% versus 53% for those followed up clini-
cally and with the ABI (225). Ihlberg et al. (226), in contrast,
reported no such differences in 1-year primary assisted
patency. Despite the discrepant results from these random-
ized trials, duplex surveillance of vein grafts is widely
accepted as valuable and necessary (226). Surveillance inter-
vals are usually 4 to 6 weeks after graft placement, then 3, 6,
9, and 12 months and annually for venous conduit. Intervals
for surveillance of synthetic grafts have not been well
defined.
Duplex ultrasound surveillance of synthetic grafts is of
questionable value. Several studies have found no improve-
ment in patency of grafts when clinician decisions were
guided in settings in which synthetic grafts were monitored
with duplex studies (225,227,228). Several other studies
have successfully detected stenoses or found some improve-
ment in patency (229,230). The lack of consistent value
offered by this testing strategy may be due to duplex-associ-
ated technical challenges, such as an inability to visualize the
stenosis; vascular anatomic care challenges (e.g., the discov-
ery of stenoses that are not amenable to revision); or proce-
dural challenges, such that the subsequent graft revision does
not serve to improve long-term graft patency.
Duplex surveillance after angioplasty procedures is also of
questionable value. Immediately after angioplasty, several
studies suggested that velocities in the treated segment may
be abnormally elevated and do not predict decreased subse-
quent patency rates (231-233). This may be due to percuta-
neous transluminal angioplasty (PTA)–produced vessel dis-
sections that successfully remodel over time. Two contradic-
tory studies suggest that elevated velocities immediately
after PTA do predict early PTA failure (234,235). Duplex
ultrasound is useful in evaluations for recurrent chronic
stenoses (148,234,236-238). Although it is reasonable to
assume that revisions of post-PTA restenoses that are detect-
ed by duplex ultrasound studies might improve long-term
patency, there are no published studies that have evaluated
this, and therefore, this assumption is unsupported.
2.5.6. Computed Tomographic Angiography
RECOMMENDATIONS
Class IIb
1. Computed tomographic angiography of the extremi-
ties may be considered to diagnose anatomic location
and presence of significant stenosis in patients with
lower extremity PAD. (Level of Evidence: B)
2. Computed tomographic angiography of the extremi-
ties may be considered as a substitute for MRA for
those patients with contraindications to MRA. (Level
of Evidence: B)
Computed tomographic angiography of the extremities has
been used in preliminary studies to diagnose the anatomic
location and degree of stenosis of PAD. Computed tomo-
graphic angiography requires intravenous injection of iodi-
nated contrast, which opacifies the arteries. The angiograph-
ic image is constructed from multiple cross-sectional images
and then presented as a maximum-intensity projection, simi-
lar to the appearance of standard arteriography. The image
can be rotated 3-dimensionally in space to view any oblique
projection. 
Use and assessment of CTA for the extremities is at an
early developmental stage. Early studies have used technol-
ogy in which 1 cross-sectional image was acquired at a time
(single-detector technology). This limited the length of the
vessel that could be imaged because of limits from X-ray
tube heating, time to acquire multiple images, and total vol-
ume of contrast used. New multidetector technology allows
acquisition of as few as 4 and as many as 64 simultaneous
cross-sectional images. This has permitted CTA to be per-
formed progressively faster, with less contrast material, thin-
ner sections, and greater detail (239-244). The latest genera-
tion of computed tomography scanners may acquire up to 64
or more simultaneous images. The clinical variability inher-
ent when computed tomography scanners of a range of tech-
nical sophistication are deployed limits the generalizability
of statements of accuracy (derived from published reports) in
a rapidly changing imaging environment. 
Results from single-detector computed tomography studies
have shown excellent accuracy for detection of occlusions,
with sensitivities and specificities of 94% to 100% (245).
Accuracy for detection of stenoses is lower. Rieker et al.
reported a sensitivity of only 36% to 58% for detection of
stenoses greater than 75% diameter when interpreting the
maximum-intensity projection, although sensitivity improved
to 73% to 88% when each of the individual cross-sectional
images was also analyzed (245). Tins et al. found that CTA
and catheter angiography provided concordant results 85% of
the time, but CTA was characterized by worse interobserver
agreement (78% vs. 87%). Computed tomographic angiogra-
phy missed short stenoses owing to use of a slice thickness of
4 to 5 mm (246).
Several studies have reported results using multidetector
computed tomography techniques (240-244,247,248). These
have been relatively small series, inclusive of only 18 to 65
patients, but results have been excellent. Sensitivity for
stenosis greater than 50% has ranged from 89% to 100%
with specificity ranging from 92% to 100%. One study
examined 85 infrainguinal bypass grafts in 65 patients with
CTA compared with duplex ultrasound and/or angiography
as the “gold standard.” Sensitivity for stenosis greater than
50% was 97% to 100%, with a specificity of 100% (242).
Not all of these studies were performed with investigators
blinded to the results of the angiogram used as the gold stan-
dard comparison. Computed tomography studies could be
performed from the celiac artery to the feet with 100 to 180
mL of contrast. Image acquisition time was 35 to 66 seconds.
Radiation dose was one fourth the dose used in catheter
angiography. In clinical use, radiation doses are dependent
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on the computed tomography scanner and protocol used and
may vary considerably. 
The CTA method has potential diagnostic advantages com-
pared with catheter angiography. The 3-dimensional (3D)
images can be freely rotated in space, which permits evalua-
tion of eccentric stenoses. The intravenous injection of con-
trast during CTA will fill all collateral vessels and opacify
arteries distal to occlusions that may be occult by catheter
angiography (231,233,245,247). Computed tomographic
angiography images tissues surrounding the opacified lumen
of the artery and has demonstrated that some popliteal
stenoses and occlusions are due to aneurysms, popliteal
entrapment, and cystic adventitial disease, which are not
detected with catheter angiography (249). Computed tomo-
graphic angiography also has potential disadvantages com-
pared with catheter angiography. Spatial resolution is lower
than with digital subtraction angiography. Venous opacifica-
tion can obscure arterial filling. Asymmetrical opacification
of the legs may cause CTA to miss the arterial phase in some
vessels. The huge number of cross-sectional images generat-
ed (up to 2000 currently) may overwhelm the workstations
used for image processing (247).
CTA has potential advantages over MRA. Patients with
pacemakers or defibrillators, who are excluded from imaging
within magnetic resonance machines, may be imaged safely
with CTA. Metal clips, stents, and prostheses usually do not
cause significant CTA artifacts that limit diagnostic utility.
Computed tomographic angiography has higher resolution
and can provide images of calcification in the vessel wall.
Scan times are significantly faster with CTA than with MRA.
Claustrophobia is far less of a problem. Computed tomo-
graphic angiography also has potential disadvantages com-
pared with MRA. It requires iodinated contrast, which may
be nephrotoxic in azotemic patients. It also requires ionizing
radiation, although the radiation dose is less than with
catheter angiography (247).
Despite these potential advantages, the accuracy and effec-
tiveness of CTA are not yet as well determined as with MRA.
Only a few studies have been published to compare the 2
techniques, and these have included small numbers of
patients who have undergone lower extremity preprocedural
CTA. Interpretations of CTA-derived data have not been
blinded consistently. Physician confidence in the treatment
decision may be lower with CTA than with catheter angiog-
raphy. Thus, use of CTA might lead to a much higher rate of
recommendation for further imaging studies (250). Similarly,
postrevascularization surveillance of individuals via use of
CTA has not been studied. Therefore, although the applica-
tion of lower extremity CTA is considered extremely prom-
ising, recommendations for its routine clinical use are yet not
as robust as for MRA.
2.5.7. Magnetic Resonance Angiography
RECOMMENDATIONS
Class I
1. Magnetic resonance angiography of the extremities is
useful to diagnose anatomic location and degree of
stenosis of PAD. (Level of Evidence: A)
2. Magnetic resonance angiography of the extremities
should be performed with gadolinium enhancement.
(Level of Evidence: B)
3. Magnetic resonance angiography of the extremities is
useful in selecting patients with lower extremity PAD
as candidates for endovascular intervention. (Level of
Evidence: A)
Class IIb
1. Magnetic resonance angiography of the extremities
may be considered to select patients with lower
extremity PAD as candidates for surgical bypass and
to select the sites of surgical anastomosis. (Level of
Evidence: B)
2. Magnetic resonance angiography of the extremities
may be considered for postrevascularization
(endovascular and surgical bypass) surveillance in
patients with lower extremity PAD. (Level of
Evidence: B) 
In a manner similar to duplex ultrasound, MRA of the
extremities can be used to diagnose the anatomic location
and degree of stenosis of PAD. Magnetic resonance angiog-
raphy evaluation is based on imaging the arteries, similar to
standard arteriography. Assessment of the accuracy of MRA
depends on the MRA technique used and the standard against
which it is compared. Magnetic resonance angiography tech-
niques continue to evolve and improve. Techniques
employed include 2-dimensional time of flight, 3D imaging,
and contrast enhancement with gadolinium, subtraction, car-
diac gating, and bolus chase. These techniques may be used
in combination, because each has its advantages and disad-
vantages (251). Magnetic resonance angiography has been
compared with catheter angiography and intraoperative
angiography. For studies that compare the ability of MRA
versus catheter angiography to detect pedal vessels in
patients with CLI, the standard of accuracy has been intraop-
erative angiography.
A multicenter comparison of MRA with catheter angiogra-
phy that used intraoperative angiography as the standard
found that both techniques had similar accuracy. Sensitivity
and specificity for identification of patent segments were
each 81% to 85%. For identification of normal segments
(i.e., segments suitable for bypass), the sensitivity of contrast
angiography was slightly less than MRA (77% vs. 82%), but
its specificity was better (92% vs. 84%) (252). A meta-analy-
sis of MRA compared with catheter angiography demon-
strated that the sensitivity and specificity of MRA for detec-
tion of stenoses greater than 50% were both in the range of
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2.5.8. Contrast Angiography
RECOMMENDATIONS
Class I
1. Contrast angiography provides detailed information
about arterial anatomy and is recommended for eval-
uation of patients with lower extremity PAD when
revascularization is contemplated. (Level of Evidence:
B)
2. A history of contrast reaction should be documented
before the performance of contrast angiography and
appropriate pretreatment administered before con-
trast is given. (Level of Evidence: B)
3. Decisions regarding the potential utility of invasive
therapeutic interventions (percutaneous or surgical)
in patients with lower extremity PAD should be made
with a complete anatomic assessment of the affected
arterial territory, including imaging of the occlusive
lesion, as well as arterial inflow and outflow with
angiography or a combination of angiography and
noninvasive vascular techniques. (Level of Evidence:
B)
4. Digital subtraction angiography is recommended for
contrast angiographic studies because this technique
allows for enhanced imaging capabilities compared
with conventional unsubtracted contrast angiogra-
phy. (Level of Evidence: A)
5. Before performance of contrast angiography, a full
history and complete vascular examination should be
performed to optimize decisions regarding the access
site, as well as to minimize contrast dose and catheter
manipulation. (Level of Evidence: C)
6. Selective or superselective catheter placement during
lower extremity angiography is indicated because this
can enhance imaging, reduce contrast dose, and
improve sensitivity and specificity of the procedure.
(Level of Evidence: C)
7. The diagnostic lower extremity arteriogram should
image the iliac, femoral, and tibial bifurcations in pro-
file without vessel overlap. (Level of Evidence: B)
8. When conducting a diagnostic lower extremity arteri-
ogram in which the significance of an obstructive
lesion is ambiguous, transstenotic pressure gradients
and supplementary angulated views should be
obtained. (Level of Evidence: B) 
9. Patients with baseline renal insufficiency should
receive hydration before undergoing contrast angiog-
raphy. (Level of Evidence: B)
10. Follow-up clinical evaluation, including a physical
examination and measurement of renal function, is
recommended within 2 weeks after contrast angiogra-
phy to detect the presence of delayed adverse effects,
such as atheroembolism, deterioration in renal func-
tion, or access site injury (e.g., pseudoaneurysm or
arteriovenous fistula). (Level of Evidence: C)
90% to 100%, with greatest accuracy when gadolinium-
enhanced MRA was used (253). The most current studies
report similar results, with agreement between MRA and
catheter angiography of 91% to 97% (254). A meta-analysis
compared the accuracy of gadolinium-enhanced MRA versus
color duplex ultrasound and found that the sensitivity for
detecting arterial segments with greater than 50% diameter
stenosis was better for MRA than for duplex ultrasound
(98% vs. 88%), with similar specificities (96% vs. 95%)
(255).
Some studies claim that MRA is superior to catheter
angiography in detection of outflow vessels suitable for dis-
tal bypass in patients with CLI (256,257). Kreitner et al.
found that in 24 diabetic patients with CLI, 38% had pedal
vessels detected by MRA that were not detected by catheter
angiography (256). Such vessels treated with surgical bypass
may enjoy satisfactory patency (258). The claim that MRA is
more sensitive than catheter angiography for distal vessels is
controversial and is affected by the quality of the compara-
tive catheter angiogram (259,260). At least 1 study has
shown MRA to be inferior to catheter angiography, particu-
larly for patients with limb-threatening ischemia (261).
Magnetic resonance angiography has unique limitations. It
tends to overestimate the degree of stenosis because of tur-
bulence. Time-of-flight studies may overestimate occlusions
owing to loss of signal from retrograde collateral flow. Metal
clips can cause artifacts that mimic vessel occlusions.
Similarly, some metal stents will obscure vascular flow
(262). Patients with pacemakers and defibrillators and some
cerebral aneurysm clips cannot be scanned safely (262,263).
Magnetic resonance angiography performed with gadolini-
um has on rare occasions been associated with renal toxicity
in patients with elevated creatinine levels (264).
Magnetic resonance angiography may be used for preoper-
ative planning. Early studies suggested that MRA was not
sufficiently accurate for preoperative planning (265).
However, other studies have demonstrated agreement
between preoperative plans based on MRA versus catheter
angiography of at least 90%, and some centers no longer per-
form diagnostic catheter angiography before revasculariza-
tion (253,266-268).
Magnetic resonance angiography has been used anecdotal-
ly for assessment of surgical and endovascular revasculariza-
tion. Series of small numbers of patients have shown that the
sensitivity and specificity of MRA compared with catheter
angiography for detection of stenoses in vein or synthetic
bypass grafts is 90% to 100% (269-271). For immediate
postprocedure evaluation of angioplasty sites, agreement
with catheter angiography is 80% to 95% (272,273). There
have been no published studies that validate improved
patient outcomes from postrevascularization MRA surveil-
lance.
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Class IIa
1. Noninvasive imaging modalities, including MRA,
CTA, and color flow duplex imaging, may be used in
advance of invasive imaging to develop an individual-
ized diagnostic strategic plan, including assistance in
selection of access sites, identification of significant
lesions, and determination of the need for invasive
evaluation. (Level of Evidence: B)
2. Treatment with n-acetylcysteine in advance of con-
trast angiography is suggested for patients with base-
line renal insufficiency (creatinine greater than 2.0 mg
per dL). (Level of Evidence: B)
Contrast angiography has heretofore been considered the
“gold standard” for defining both normal vascular anatomy
and vascular pathology. It remains the most readily available
and widely used imaging technique. Images are easily dis-
played and interpreted by the vast majority of physicians car-
ing for patients with vascular disease. Technical improve-
ments in X-ray imaging equipment, including the application
of digital subtraction techniques to enhance image quality
and detection of abnormalities, and progressive improve-
ments in image resolution have enabled better definition of
affected vascular territories with contrast and have resulted
in a better safety profile. The simultaneous miniaturization of
catheters available for angiography and the development of
more selective shapes has further enhanced the safety profile
of this standard technique.
Although angiography remains the current “gold stan-
dard,” significant advances in duplex, magnetic resonance,
and computed tomographic imaging techniques may make
these newer modalities preferable to angiography for cer-
tain situations (e.g., CLI with poor inflow to the leg and
below-knee vessels that are difficult to identify by digital
subtraction angiography). In addition, noninvasive imaging
with duplex, MRA, and/or CTA methods may allow for bet-
ter preparation before initiation of an invasive procedure.
Identification of a culprit lesion, preparation of the appro-
priate equipment, and selection of the best access sites are
all facilitated by information obtained by these noninvasive
imaging modalities. Thus, there is now a wide variety of
practice patterns with respect to the use of noninvasive
imaging modalities for therapeutic planning. At some cen-
ters, it has become the standard to obtain MRA or CTA
images in advance of any invasive diagnostic studies (bar-
ring a contraindication to the particular noninvasive tech-
nique, such as a pacemaker, which precludes the use of
MRA). At other centers, it is still the standard that a diag-
nostic angiogram is obtained with digital subtraction tech-
niques before an intervention is planned. Detailed imaging
algorithms have not yet been developed that include clini-
cal details from the individual patient, the modalities and
expertise available at a given site, and the relative costs.
The goal of combining these imaging techniques will be to
minimize risk and optimize outcome for the patient while
maintaining economic viability for the healthcare system.
Currently, contrast angiography remains the dominant
diagnostic tool used to stratify patients before intervention.
When used for this purpose, complete imaging of the affect-
ed territory is usually recommended. Knowledge of inflow
and outflow patterns, as well as characterization of the
lesion, may affect decisions regarding therapy. From a tech-
nical standpoint, the closer the catheter is to the target vessel
to be imaged, the better the image definition is and the less is
the volume of contrast that is required. Accordingly, selec-
tive and superselective catheter placement is useful in opti-
mizing image quality. This is particularly recommended in
the setting of renal insufficiency or when occlusive distal
vessels may not be visualized by a more proximal bolus
injection of contrast. The acquisition of views from orthogo-
nal angles, which has been the rule in coronary angiography,
is less prevalent in peripheral imaging, largely because of the
extensive territory to be covered in a complete diagnostic
peripheral runoff angiogram (as opposed to a coronary
angiogram). Nonetheless, for areas where there is doubt or
uncertainty regarding the presence or absence of a significant
lesion, angulated views can be useful to better delineate and
define the severity of the lesion and clarify its potential con-
tribution to the clinical syndrome. This does, however,
require injection of additional contrast material and prolongs
the angiographic procedure. Axial imaging techniques (e.g.,
MRA and CTA) may offer an advantage for visualizing some
of these eccentric, ambiguous lesions, because these tech-
niques offer a 3D view.
Digital subtraction technique provides superior definition
of the vascular tree compared with unsubtracted imaging.
The former eliminates much of the artifact due to bony struc-
tures and dense body tissues. Selection of the appropriate
amount of contrast and application of proper image-acquisi-
tion techniques, including masking and digital enhancement,
are required to optimize the accuracy of the images obtained.
Improper technique or image display can cause false inter-
pretation.
Angiography is, at present, the only universally accepted
method for guiding percutaneous peripheral interventional
procedures. Adjunctive hemodynamic parameters, such as
pressure gradient and duplex velocity measurements, as well
as use of supportive imaging modalities, such as intravascu-
lar ultrasound, angioscopy, and optical coherence tomogra-
phy, can be useful and occasionally have been used in lieu of
digital subtraction angiography to guide procedures.
Angiography has several liabilities. First, it carries with it
the risks associated with any invasive procedure. Such risks
include those related to vascular access (e.g., bleeding, infec-
tion, and vessel disruption). In addition, there is a small but
important risk of contrast reaction; the risk of a severe reac-
tion is approximately 0.1% (274,275). A careful history is
imperative before administration of contrast agents to deter-
mine whether there is any suggestion of a previous allergic
reaction or predisposition to develop such a reaction. The
history of an allergic reaction may serve as a relative proce-
dural contraindication if a patient requires the data derived
from the arteriographic procedure to plan appropriate care.
e42
Hirsch et al. 2005
ACC/AHA Practice Guidelines
ACC - www.acc.org
AHA - www.americanheart.org
Proper selection and pretreatment of such patients can miti-
gate, although not eliminate, the risk of significant contrast-
related morbidity and mortality. The availability of alterna-
tive low-osmolality/nonionic contrast agents has reduced the
number of allergic reactions.
Contrast agents are also associated with a small but impor-
tant incidence of nephrotoxicity. Patients who are at
increased risk of contrast nephropathy include those with
severe baseline renal dysfunction, diabetes, low cardiac out-
put state, or dehydration. Any combination of these is more
problematic than an individual risk factor. Recent studies
have suggested that use of low-osmolar contrast agents (e.g.,
iodixanol) or pretreatment with n-acetylcysteine may reduce
the incidence of renal compromise (276-279). Fenoldopam
does not appear to confer significant renal protective effects
(280). In patients who are high risk for nephrotoxicity, data
suggest that vigorous hydration before administration of con-
trast may serve as the most important strategy to prevent
postprocedural deterioration in renal function. Because the
occurrence of nephrotoxicity appears to be dose-dependent,
it is also important to minimize contrast usage. This dose
minimization can be accomplished by using digital subtrac-
tion techniques and placing catheters close to the site to be
imaged (selective angiography). The dose–nephrotoxicity
relationship is complex and cannot be calculated precisely.
Preliminary data suggest that nephrotoxicity might be further
minimized by use of preprocedural hemofiltration in individ-
uals with chronic renal failure (defined as a creatinine meas-
urement greater than 2.0 mg per dL) (281).
Finally, complications typically associated with invasive
techniques and catheter manipulation, such as atheroem-
bolization, dissection, and inadvertent vessel-wall disruption
or perforation, are all adverse events that can occur with
invasive angiography. Vigilant observation and careful
manipulation of guidewire and catheter location are impera-
tive. Certain adverse events, including access-site complica-
tions, nephrotoxicity, and atheroembolism, may not be evi-
dent immediately after the procedure, and follow-up evalua-
tion is recommended within 2 weeks after contrast angiogra-
phy to detect and treat these events.
2.6. Treatment
2.6.1. Cardiovascular Risk Reduction
To reduce adverse cardiovascular events associated with
lower extremity PAD, lifelong treatment should include
modification or elimination of atherosclerotic risk factors,
such as cigarette smoking, diabetes mellitus, dyslipidemia,
and hypertension, and promotion of daily exercise and use of
a nonatherogenic diet.
2.6.1.1. Lipid-Lowering Drugs
RECOMMENDATIONS
Class I
Treatment with a hydroxymethyl glutaryl (HMG)
coenzyme-A reductase inhibitor (statin) medication is
indicated for all patients with PAD to achieve a target
LDL cholesterol level of less than 100 mg per dL.
(Level of Evidence: B)
Class IIa
1. Treatment with an HMG coenzyme-A reductase
inhibitor (statin) medication to achieve a target LDL
cholesterol level of less than 70 mg per dL is reason-
able for patients with lower extremity PAD at very
high risk of ischemic events. (Level of Evidence: B)
2. Treatment with a fibric acid derivative can be useful
for patients with PAD and low HDL cholesterol, nor-
mal LDL cholesterol, and elevated triglycerides.
(Level of Evidence: C)
Treatment of dyslipidemia reduces the risk of adverse car-
diovascular events in patients with atherosclerosis.
Cholesterol-lowering therapy with an HMG coenzyme-A
reductase inhibitor (statin) reduces the risk of nonfatal MI
and cardiovascular death in patients with coronary artery dis-
ease by 24% to 34% (282-284). The Heart Protection Study
randomized patients with coronary artery disease, cere-
brovascular disease, PAD, and/or diabetes mellitus and a
total cholesterol level greater than 135 mg per dL to simvas-
tatin or placebo (112). The study included 6748 patients with
PAD, in whom there was a 25% risk reduction over 5 years
of follow-up. A revision of the National Cholesterol
Education Program Adult Treatment Panel III guidelines,
which reviewed the totality of lipid-lowering interventional
investigations, has evaluated the risk and benefit of statin
therapies by population risk categories and target LDL levels
(129a). In this classification system, individuals with lower
extremity PAD are designated as either “high risk” or “very
high risk” depending on associated risk factors. For individ-
uals with PAD, “very high risk” can be defined as the pres-
ence of established PAD plus (a) multiple major risk factors
(especially diabetes), (b) severe and poorly controlled risk
factors (especially continued cigarette smoking), or (c) mul-
tiple risk factors of the metabolic syndrome (especially high
triglycerides [greater than or equal to 200 mg per dL] plus
non-HDL cholesterol greater than or equal to 130 mg per dL
with low HDL cholesterol [greater than or equal to 40 mg per
dL]).
On the basis of these findings, it is recommended that
patients with PAD and an LDL cholesterol level of 100 mg
per dL or greater be treated with a statin. The recommended
LDL cholesterol goal is less than 100 mg per dL, but when
risk is very high, an LDL cholesterol goal of less than 70 mg
per dL is a therapeutic option on the basis of available clini-
cal trial evidence. This therapeutic option may also extend to
patients with lower extremity PAD who are at very high risk
and who have a baseline LDL cholesterol less than 100 mg
per dL.
Fibric acid derivatives increase HDL cholesterol and lower
triglyceride levels. The efficacy of this class of drug in
patients with PAD is not known. In patients with coronary
artery disease and low HDL cholesterol levels, one study
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adverse cardiovascular events. Concerns have been raised
about the use of beta-adrenergic blockers in the treatment of
patients with lower extremity PAD. Beta-blockers reduced
the risk of MI and death in patients with coronary athero-
sclerosis (295). A meta-analysis of 11 placebo-controlled
studies in patients with intermittent claudication found that
beta-adrenergic blockers did not adversely affect walking
capacity (296).
Angiotensin-converting enzyme inhibitors are a class of
drugs used in the treatment of hypertension. Angiotensin-
converting enzyme inhibitors reduce the risk of death and
nonfatal cardiovascular events in patients with coronary
artery disease and left ventricular dysfunction (297,298).
Because the evidence base for the efficacy of ACE inhibitors
in asymptomatic patients is nonexistent, recommendations
for their use must be extrapolated from symptomatic popula-
tions. The Heart Outcomes Prevention Evaluation study ran-
domized patients with coronary artery disease, cerebrovascu-
lar disease, PAD, and/or diabetes to the ACE inhibitor
ramipril or placebo. The study included 4051 patients with
PAD. Ramipril reduced the risk of MI, stroke, or vascular
death in patients with PAD by approximately 25%, a level of
efficacy comparable to that achieved in the entire study pop-
ulation (299). It is recommended that ACE inhibitors be con-
sidered as treatment for patients with asymptomatic lower
extremity PAD to reduce the risk of adverse cardiovascular
events. 
2.6.1.3. Diabetes Therapies
RECOMMENDATIONS
Class I
Proper foot care, including use of appropriate
footwear, chiropody/podiatric medicine, daily foot
inspection, skin cleansing, and use of topical moistur-
izing creams, should be encouraged and skin lesions
and ulcerations should be addressed urgently in all
diabetic patients with lower extremity PAD. (Level of
Evidence: B)
Class IIa
Treatment of diabetes in individuals with lower
extremity PAD by administration of glucose control
therapies to reduce the hemoglobin A1C to less than
7% can be effective to reduce microvascular compli-
cations and potentially improve cardiovascular out-
comes. (Level of Evidence: C)
It is not known whether aggressive treatment of diabetes to
optimize blood glucose levels decreases the risk of adverse
cardiovascular events in patients with lower extremity PAD.
Retrospective analysis of the Diabetes Control and
Complications trial, a study of patients with type I diabetes
mellitus, found that intensive insulin therapy reduced the risk
of lower extremity PAD events, such as claudication, periph-
eral revascularization, or amputation, by 22%, but that result
did not achieve statistical significance (300). In the United
found that gemfibrozil reduced the risk of nonfatal MI or car-
diovascular death by 22% (285). Lipid-lowering therapy
with niacin and binding resins such as cholestyramine
reduces the progression of femoral artery atherosclerosis, but
there are no data that these therapies reduce the risk of
adverse cardiovascular events (286,287). 
Cholesterol-lowering therapy may improve symptoms of
intermittent claudication (288,289). A retrospective analysis
of the 4S trial (Scandinavian Simvastatin Survival Study)
found that simvastatin therapy reduced the risk of new or
worsening claudication (289). A prospective trial demon-
strated that atorvastatin increased the distance walked to the
onset of claudication, but not the maximal walking distance,
in patients with lower extremity PAD (290). Two additional
single-center studies have suggested a similar benefit regard-
ing claudication onset time with simvastatin treatment
(291,292). The relative benefit of the lipid-modifying thera-
pies for claudication symptoms remains unclear.
2.6.1.2. Antihypertensive Drugs
RECOMMENDATIONS
Class I
1. Antihypertensive therapy should be administered to
hypertensive patients with lower extremity PAD to
achieve a goal of less than 140 mm Hg systolic over 90
mm Hg diastolic (nondiabetics) or less than 130 mm
Hg systolic over 80 mm Hg diastolic (diabetics and
individuals with chronic renal disease) to reduce the
risk of MI, stroke, congestive heart failure, and car-
diovascular death. (Level of Evidence: A)
2. Beta-adrenergic blocking drugs are effective antihy-
pertensive agents and are not contraindicated in
patients with PAD. (Level of Evidence: A)
Class IIa
The use of angiotensin-converting enzyme inhibitors
is reasonable for symptomatic patients with lower
extremity PAD to reduce the risk of adverse cardio-
vascular events. (Level of Evidence: B)
Class IIb
Angiotensin-converting enzyme inhibitors may be
considered for patients with asymptomatic lower
extremity PAD to reduce the risk of adverse cardio-
vascular events. (Level of Evidence: C)
Treatment of high blood pressure is indicated to reduce the
risk of cardiovascular events such as stroke, heart failure,
and death (293). Guidelines for treatment of hypertension
have been published (294). Antihypertensive therapy may
decrease limb perfusion pressure and potentially exacerbate
symptoms of claudication or CLI. These possibilities should
be taken into consideration when administering antihyper-
tensive drugs to patients with PAD. However, most patients
are able to tolerate therapy without worsening of symptoms
and should be treated appropriately to reduce the risk of
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drome, and continued use is associated with a particularly
adverse outcome (21).
2.6.1.5. Homocysteine-Lowering Drugs
RECOMMENDATION
Class IIb
The effectiveness of the therapeutic use of folic acid
and B12 vitamin supplements in individuals with lower
extremity PAD and homocysteine levels greater than
14 micromoles per liter is not well established. (Level
of Evidence: C)
The B complex vitamins, folic acid, cobalamin (B12), and
pyridoxine (B6), have been used as therapy to decrease
homocysteine levels. The Food and Drug Administration
(FDA) has required that cereal grain products contain at least
140 micrograms of folic acid per 100 g of product. Folic acid
at a dose of 400 micrograms per day will reduce plasma
homocysteine levels by approximately 5 micromoles per liter
(66). A meta-analysis of 12 trials that included 1114 people
found that folic acid, at doses of 0.5 to 5 mg daily, decreased
homocysteine concentrations by 25% and that vitamin B12, at
doses averaging 0.5 mg daily, decreased homocysteine levels
by an additional 7% (311). Vitamin B6 (at an average of 6.5
mg daily) had no significant additional benefit. Folic acid
supplementation may exacerbate relative cobalamin defi-
ciency, particularly in older individuals (312). Despite effi-
cacy in reducing plasma homocysteine levels, there is cur-
rently no evidence that treatment with folic acid and/or
cobalamin favorably affects vascular outcome; however,
prospective trials are in progress (67,313). Treatment with B
complex vitamin is generally safe, and treatment with folic
acid and cobalamin can be devised to target a reduction of
homocysteine levels to less than 10 micromoles per liter.
However, pending the demonstration of clinical benefit from
prospective trials, the therapeutic use of folate for patients
with lower extremity PAD whose fasting plasma homocys-
teine level is greater than 14 micromoles per liter is not well
established. 
2.6.1.6. Antiplatelet and Antithrombotic Drugs
RECOMMENDATIONS
Class I
1. Antiplatelet therapy is indicated to reduce the risk of
MI, stroke, or vascular death in individuals with ath-
erosclerotic lower extremity PAD. (Level of Evidence:
A)
2. Aspirin, in daily doses of 75 to 325 mg, is recommend-
ed as safe and effective antiplatelet therapy to reduce
the risk of MI, stroke, or vascular death in individuals
with atherosclerotic lower extremity PAD. (Level of
Evidence: A)
Kingdom Prospective Diabetes Study, patients with type II
diabetes mellitus were randomized to aggressive treatment
with sulfonylureas or insulin versus conventional treatment.
Patients were treated over a period of 10 years. Intensive
treatment reduced the risk of MI by 16%, a finding of bor-
derline significance, but it did not decrease the risk of death,
stroke, or amputation (301). Aggressive treatment of diabetes
does decrease the risk for microvascular events such as
nephropathy and retinopathy (300,301). Therefore, to reduce
the risk of microvascular events, pending prospective trials
in patients with diabetes and lower extremity PAD, it is rec-
ommended that diabetic patients with lower extremity PAD
be treated aggressively to reduce their glycosylated hemo-
globin to less than 7% as per the American Diabetes
Association (302). 
Meticulous attention to foot care is necessary to reduce the
risk of skin ulceration, necrosis, and subsequent amputation.
This includes the use of appropriate footwear to avoid pres-
sure injury, daily inspection and cleansing by the patient, the
use of moisturizing cream to prevent dryness and fissuring,
and chiropody. Frequent foot inspection by patients and
physicians will enable early identification of foot lesions and
ulcerations and facilitate prompt referral for treatment (303). 
2.6.1.4. Smoking Cessation
RECOMMENDATION
Class I
Individuals with lower extremity PAD who smoke cig-
arettes or use other forms of tobacco should be
advised by each of their clinicians to stop smoking and
should be offered comprehensive smoking cessation
interventions, including behavior modification thera-
py, nicotine replacement therapy, or bupropion. (Level
of Evidence: B)
No prospective randomized trials have examined the
effects of smoking cessation on cardiovascular events in
patients with lower extremity PAD. Observational studies
have found that the risk of death, MI, and amputation is sub-
stantially greater in those individuals with PAD who contin-
ue to smoke than in those who stop smoking (304-306). In
some but not all studies, exercise time is greater in patients
who discontinue smoking than in current smokers (307,308).
It is recommended that efforts be made to achieve smoking
cessation in patients with lower extremity PAD. Physician
advice coupled with frequent follow-up achieves 1-year
smoking cessation rates of approximately 5% compared with
only 0.1% in those attempting to quit smoking without a
physician’s intervention (309). Pharmacological interven-
tions such as nicotine replacement therapy and bupropion
achieve 1-year smoking cessation rates of approximately
16% and 30%, respectively (310). Tobacco cessation inter-
ventions are particularly critical in individuals with throm-
boangiitis obliterans, because it is presumed that components
of tobacco may be causative in the pathogenesis of this syn-
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those randomized to clopidogrel, the risks were 0.35% and
1.99%, respectively. 
It is recommended that patients with lower extremity PAD
be treated with antiplatelet therapy to reduce the risk of MI,
stroke, or vascular death. On the basis of the single compar-
ative trial published to date, clopidogrel appears to be more
effective than aspirin in preventing ischemic events in indi-
viduals with symptomatic PAD (98). The combination of
clopidogrel plus aspirin versus aspirin alone has been exam-
ined in patients who had presented with acute coronary syn-
drome. Combination aspirin and clopidogrel therapy was
associated with a 20% relative risk reduction for MI, stroke,
or cardiovascular death (316). To date, there is no evidence
to support the efficacy of combined aspirin and clopidogrel
treatment versus a single antiplatelet agent in patients with
lower extremity PAD. 
Several studies have suggested that antiplatelet therapy
may reduce the risk of progression to arterial occlusion in
patients with lower extremity PAD. The Antithrombotic
Trialists’ Collaboration found that antiplatelet therapy com-
pared with no additional treatment reduced the risk of arteri-
al occlusion over a 19-month period by 30% (317). One
meta-analysis that involved 54 randomized, controlled trials
in patients with intermittent claudication found that aspirin
compared with placebo reduced the risk of arterial occlusion,
and ticlopidine reduced the need for revascularization proce-
dures (318).
Information regarding the efficacy of oral anticoagulants,
that is, coumarin derivatives such as warfarin, in reducing
adverse cardiovascular events in patients with atherosclero-
sis is derived primarily from studies of patients with coro-
nary artery disease. Meta-analyses comprising 37 trials of
anticoagulant therapy in more than 20000 patients with coro-
nary artery disease evaluated the efficacy and safety of oral
anticoagulation (warfarin) alone versus the control, stratified
by intensity of anticoagulation, as well as the efficacy of
warfarin versus aspirin in patients with coronary artery dis-
ease (319,320). 
High-intensity oral anticoagulant therapy, defined as an
International Normalized Ratio (INR) of 2.8 to 4.8, was asso-
ciated with a 22% odds reduction in mortality and a 43%
odds reduction in MI, but this intensive anticoagulation was
associated with a 4.5-fold increase in major bleeding.
Moderate-intensity anticoagulation, defined as an INR of 2
to 3, was associated with a nonsignificant odds reduction of
26% for cardiovascular death and stroke and 52% for MI, but
it increased bleeding by 7.7-fold. Comparison of moderate-
to high-intensity oral anticoagulation versus aspirin found a
21% odds reduction in death, MI, or stroke but was associat-
ed with a 2.1-fold increased risk in major bleeding. Thus,
among patients with coronary artery disease, moderate- and
high-intensity oral anticoagulation with coumarin derivatives
reduces the risk of MI and death but confers an increased rate
of bleeding. One trial compared the efficacy of oral antico-
agulants with aspirin on infrainguinal graft patency in
patients with lower extremity PAD. Patients were random-
ized to coumarin derivatives to achieve a target INR of 3.0 to
3. Clopidogrel (75 mg per day) is recommended as an
effective alternative antiplatelet therapy to aspirin to
reduce the risk of MI, stroke, or vascular death in
individuals with atherosclerotic lower extremity PAD.
(Level of Evidence: B)
Class III
Oral anticoagulation therapy with warfarin is not
indicated to reduce the risk of adverse cardiovascular
ischemic events in individuals with atherosclerotic
lower extremity PAD. (Level of Evidence: C)
The effect of antiplatelet therapy on cardiovascular events
has been systematically reviewed by the Antithrombotic
Trialists’ Collaboration (314). A meta-analysis comprising
287 studies compared the efficacy of antiplatelet therapy ver-
sus control in approximately 135 000 high-risk patients with
vascular diseases manifested as acute and previous MI, acute
and previous stroke, or other high-risk conditions, such as
lower extremity PAD (314). Among those patients with PAD
treated with antiplatelet therapy, there was a 22% odds
reduction for adverse cardiovascular events, including MI,
stroke, or vascular death. This analysis included 42 trials
comprising 9716 patients with PAD in whom there was a
23% proportional reduction in adverse cardiovascular
events. Similar benefits were realized by patients with inter-
mittent claudication, those having peripheral angioplasty,
and those having peripheral bypass graft procedures (314).
There was a 23% reduction of vascular events in patients
with intermittent claudication, 22% in those with peripheral
arterial grafts, and 29% in those undergoing peripheral
angioplasty (314). The antiplatelet therapy used in many of
the lower extremity PAD trials was aspirin; however, some
included ticlopidine, a thienopyridine drug, and one included
picotamide, a thromboxane synthase inhibitor. 
The Antithrombotic Trialists’ Collaboration meta-analysis
also compared the efficacy of different doses of aspirin
(314). The proportional reduction in vascular events was
32% with 75 to 150 mg daily, 26% with 160 to 325 mg daily,
and 19% with 500 to 1500 mg daily, the results being rela-
tively comparable among these dose ranges. There was a sig-
nificantly smaller (13%) reduction in cardiovascular events
in patients being treated with less than 75 mg of aspirin per
day. The ORs for a major extracranial bleed among patients
taking 75 to 150 mg of aspirin and those taking 160 to 325
mg of aspirin daily were 1.5 and 1.4, respectively (314).
Higher doses of aspirin result in increased risk of gastroin-
testinal side effects and bleeding rates (315). One trial com-
pared the efficacy of aspirin (325 mg daily) to the thienopy-
ridine derivative clopidogrel (75 mg daily) in 19 185 patients
with a history of MI, stroke, or PAD. Clopidogrel reduced the
risk of adverse cardiovascular events by 8.7%. Among the
6452 patients with PAD, clopidogrel reduced the risk of MI,
stroke, or vascular death by 23.8% more than aspirin (98).
The risks of intracranial and gastrointestinal bleeding in
patients randomized to aspirin were 0.49% and 2.66%, and in
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Regular walking in a supervised claudication exercise pro-
gram can be expected to result in an increase in the speed,
distance, and duration walked, with decreased claudication
symptoms at each workload or distance (322-328). These
functional benefits accrue gradually and become evident
over 4 to 8 weeks and increase progressively over 12 or more
weeks. The biological mechanisms underlying such repro-
ducible benefit are complex and are beyond the scope of this
guideline (132). However, there is inadequate evidence to
attribute this functional benefit, as is often believed, to the
growth of new collaterals (angiogenesis); in contrast, clinical
improvement is more likely to be due to alterations in skele-
tal muscle metabolism, muscle hypertrophy, improvements
in endothelial function, or altered gait. 
The data supporting the efficacy of supervised exercise
programs to alleviate claudication symptoms are robust and
are summarized in Table 17. A meta-analysis of 21 studies by
Gardner and Poehlman included both nonrandomized and
randomized trials of exercise training and showed that pain-
free walking time improved by an average of 180% and max-
imal walking time increased by 120% in claudication
patients who underwent exercise training (323). This meta-
analysis also provided data to summarize clinical predictors
of responsiveness to exercise interventions. The greatest
improvements in walking ability occurred when each exer-
cise session lasted longer than 30 minutes, when sessions
took place at least 3 times per week, when the exercise
modality used was walking to near-maximal pain, and when
the program lasted 6 months or longer. A meta-analysis from
the Cochrane Collaboration that considered only random-
ized, controlled trials concluded that exercise improved max-
imal walking ability by an average of 150% (range 74% to
230%) (329). 
Supervised exercise can induce increases in maximal walk-
ing ability that exceed those attained with drug therapies,
which have been estimated to result in improvements in
maximal walking distance of 20% to 25% with pentoxi-
fylline and 40% to 60% with cilostazol (337,338). Exercise-
induced improvements in walking ability translate to increas-
es in routine daily activity (199,339). In one uncontrolled
study by Gardner et al., 6 months of exercise training
improved treadmill walking ability, accompanied by a 31%
increase in routine daily activity as measured by accelerom-
etry (199). Self-reported physical activity increased by 62%,
which confirms that patients themselves appreciated this
functional improvement. Controlled studies have also
demonstrated higher levels of routine daily activity in
patients with claudication after exercise training (340). Such
sustained increases in physical activity, if associated with
improvements in cardiovascular risk factors, have the poten-
tial to reduce the risk of cardiovascular ischemic events,
thereby potentially improving the poor prognosis for survival
in this population (341,342). 
The time course of the response to a program of exercise
has not been fully established. Exercise-induced clinical ben-
efits have been observed as early as 4 weeks and have been
observed to continue to improve after 6 months of participa-
4.5 or to aspirin 80 mg daily orally (321). A similar number
of graft occlusions occurred in each treatment group, but the
risk of major bleeding was increased approximately 2-fold in
those treated with oral anticoagulants. In that study, there
was a nonsignificant (11%) reduction in the risk of a second-
ary end point that consisted of the composite of vascular
death, MI, stroke, or amputation.
Meta-analyses of 7 trials of moderate-intensity oral antico-
agulation plus aspirin versus aspirin alone to prevent cardio-
vascular events in patients with coronary artery disease
found a 12% odds reduction in cardiovascular death, MI, and
stroke that favored combination therapy (320). There was a
1.7-fold increased risk for major bleeding with oral antico-
agulation plus aspirin versus aspirin alone. Low-intensity
oral anticoagulation (INR less than 2) plus aspirin versus
aspirin alone did not reduce the risk of cardiovascular events
(319,320). 
The combination therapy of oral anticoagulation plus
aspirin may reduce the risk of cardiovascular events and is
associated with an approximately 2-fold increased risk of
bleeding. Taken together, there is insufficient evidence to
support a recommendation for oral anticoagulation therapy
with coumarin derivatives, alone or in combination with
aspirin, as a means to reduce cardiovascular events in
patients with PAD, and consideration for use of coumarin
derivatives must be tempered by the increased risk of bleed-
ing. For patients with lower extremity PAD in whom an addi-
tional indication for use of warfarin exists (such as individu-
als with lower extremity PAD and either atrial fibrillation or
a prosthetic heart valve), the risk and benefit of therapy with
an antiplatelet medication alone, warfarin alone, or their
combination must be assessed individually. 
2.6.2. Claudication
2.6.2.1. Exercise and Lower Extremity 
PAD Rehabilitation
RECOMMENDATIONS
Class I
1. A program of supervised exercise training is recom-
mended as an initial treatment modality for patients
with intermittent claudication. (Level of Evidence: A)
2. Supervised exercise training should be performed for
a minimum of 30 to 45 minutes, in sessions performed
at least 3 times per week for a minimum of 12 weeks.
(Level of Evidence: A)
Class IIb
The usefulness of unsupervised exercise programs is
not well established as an effective initial treatment
modality for patients with intermittent claudication.
(Level of Evidence: B)
A program of supervised exercise may be considered a pri-
mary efficacious treatment modality to alleviate claudication
symptoms for all patients with intermittent claudication.
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Table 17. Randomized, Controlled Trials Evaluating the Efficacy of Exercise Rehabilitation
No. of 
First Author Year Reference Patients Intervention Duration, mo Change in ACD (%)
Larsen 1966 (330) 6
Treatment group 7 Daily walks 183†‡
Control group 7 Placebo tablet –6
Holm 1973 (331) 4
Treatment group 6 Exercise 133†‡
Control group 6 Placebo tablet NC
Dahllof 1974 (332) 6
Treatment group 11 Exercise 117†‡
Control group 23 Placebo tablet NC
Dahllof 1976 (333) 4
Treatment group 8 Exercise 135†‡
Control group 10 Placebo tablet 75†
Lundgren 1989 (327) 6
Treatment group 1 25 Surgery plus 263†‡
exercise
Treatment group 2 25 Surgery 173†‡
Treatment group 3 25 Exercise 151†‡
Creasy 1990 (334) 6
Treatment group 1 13 Exercise 442†‡§
Treatment group 2 20 Angioplasty 57
Hiatt 1990 (326) 3
Treatment group 9 Supervised exercise 123†‡
Control group 10 Control 20
Mannarino 1991 (335) 6
Treatment group 1 10 Exercise plus 105†‡
antiplatelet
Treatment group 2 10 Exercise 86†‡
Treatment group 3 10 Antiplatelet 38†
Hiatt 1994 (324) 3
Treatment group 1 9 Supervised exercise 74†‡
Treatment group 2 8 Strength training 36†
Control 10 Control –1
Regensteiner 1997 (325) 3
Treatment group 1 10 Supervised exercise 137†‡
Treatment group 2 10 Home exercise 5
Patterson 1997 (336) 6
Treatment group 1 19 Supervised exercise 195†‡
Treatment group 2 19 Home exercise 83†
*Use of questionnaire to evaluate community-based functional status.
†p less than 0.05 compared with baseline; ‡p less than 0.05 for difference between groups.
§Data given are for the 12-month follow-up point.
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group, Management of peripheral arterial disease (PAD), S1-S296, Copyright 2000, with permission from Elsevier
(1).
Functional 
Assessment*
None
None
None
None
None
None
Improved
No change
None
Improved
No change
No change
Improved
No change
Improved
Improved
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tion (343,344). Gardner et al. reported that improvements in
walking ability after 6 months of supervised exercise reha-
bilitation 3 times per week were sustained when patients
continued to participate in an exercise maintenance program
for an additional 12 months (344). 
The results of these clinical investigations provided ade-
quate scientific data to support the creation of the new cur-
rent procedural terminology code (93668) in the United
States for exercise rehabilitation for patients with claudica-
tion (171). The key elements of such a therapeutic claudica-
tion exercise program for patients with claudication are sum-
marized in Table 18. Because patients with claudication
often have concomitant clinical or occult coronary artery dis-
ease, hypertension, and diabetes, adverse cardiovascular and
physiological responses during exercise training are possi-
ble, and this risk should be evaluated clinically before initia-
tion of the therapeutic program. However, there is no evi-
dence that patients with claudication need to undergo stress
imaging or invasive angiographic studies before initiating an
exercise program. Such safety has been maintained, with
serious adverse events rarely documented in clinical practice
or in research investigations, by prudent application of an
initial standard treadmill exercise test. This test should be
performed with 12-lead electrocardiographic monitoring
before a therapeutic exercise program is initiated, so that
ischemic symptoms, ST–T-wave changes, or arrhythmias
may be identified (345). Although these patients will, by def-
inition, have claudication-limited exercise (and therefore
will not achieve a true maximal exercise performance), the
findings from the exercise test can be used to determine that
there are no untoward cardiovascular responses at the exer-
cise level reached. The exercise test also provides informa-
tion about claudication thresholds and heart rate and blood
pressure responses for establishing an exercise prescription.
Patient enrollment in a medically supervised exercise pro-
gram with electrocardiographic, heart rate, blood pressure,
and blood glucose monitoring is encouraged. It is also pru-
dent to use monitoring routinely during the initial exercise
sessions; individual clinical responses then would determine
the need for monitoring in subsequent sessions. Many car-
diac rehabilitation exercise programs can accommodate
patients with claudication, providing an environment con-
ducive for “lifestyle change” that underlies long-term com-
pliance to exercise and risk factor modification. 
A typical supervised exercise program requires the per-
formance of treadmill or track-based exercise for 45 to 60
minutes performed 3 or more times a week for a minimum of
12 weeks. Such exercise is monitored by a physical therapist,
nurse, or exercise physiologist. Treadmill exercise appears to
be more effective than other exercise modalities, presumably
because treadmill walking most closely reproduces walking
in the community setting. The initial workload of the tread-
mill is set to a speed and grade that elicit claudication symp-
toms within 3 to 5 minutes. Patients are asked to continue to
walk at this workload until they achieve claudication of mod-
erate severity. This is followed by a brief period of rest to
permit symptoms to resolve. The exercise-rest-exercise cycle
Table 18. Key Elements of a Therapeutic Claudication Exercise
Training Program (Lower Extremity PAD Rehabilitation)
Primary clinician role
Establish the PAD diagnosis using the ABI measurement or other
objective vascular laboratory evaluations 
Determine that claudication is the major symptom limiting exercise
Discuss risk/benefit of claudication therapeutic alternatives, includ-
ing pharmacological, percutaneous, and surgical interventions
Initiate systemic atherosclerosis risk modification
Perform treadmill stress testing 
Provide formal referral to a claudication exercise rehabilitation pro-
gram
Exercise guidelines for claudication*
Warm-up and cool-down period of 5 to 10 minutes each
Types of exercise
Treadmill and track walking are the most effective exercise for
claudication 
Resistance training has conferred benefit to individuals with
other forms of cardiovascular disease, and its use, as tolerated,
for general fitness is complementary to but not a substitute for
walking
Intensity
The initial workload of the treadmill is set to a speed and grade
that elicit claudication symptoms within 3 to 5 minutes
Patients walk at this workload until they achieve claudication of
moderate severity, which is then followed by a brief period of
standing or sitting rest to permit symptoms to resolve
Duration
The exercise-rest-exercise pattern should be repeated throughout
the exercise session
The initial duration will usually include 35 minutes of intermit-
tent walking and should be increased by 5 minutes each session
until 50 minutes of intermittent walking can be accomplished
Frequency
Treadmill or track walking 3 to 5 times per week
Role of direct supervision
As patients improve their walking ability, the exercise workload
should be increased by modifying the treadmill grade or speed (or
both) to ensure that there is always the stimulus of claudication pain
during the workout
As patients increase their walking ability, there is the possibility that
cardiac signs and symptoms may appear (e.g., dysrhythmia, angina,
or ST-segment depression). These events should prompt physician
re-evaluation 
*These general guidelines should be individualized and based on the results of treadmill
stress testing and the clinical status of the patient. A full discussion of the exercise pre-
cautions for persons with concomitant diseases can be found elsewhere for diabetes
(Ruderman N, Devlin JT, Schneider S, Kriska A. Handbook of Exercise in Diabetes.
Alexandria, Va: American Diabetes Association; 2002) (362a), hypertension (ACSM's
Guidelines for Exercise Testing and Prescription. In: Franklin BA, ed. Baltimore, Md:
Lippincott Williams & Wilkins; 2000) (362b), and coronary artery disease (Guidelines
for Cardiac Rehabilitation and Secondary Prevention/American Association of
Cardiovascular and Pulmonary Rehabilitation. Champaign, Ill: Human Kinetics; 1999)
(362c).
PAD indicates peripheral arterial disease; ABI, ankle-brachial index. 
Adapted with permission from Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT.
Medical progress: exercise training for claudication. N Engl J Med 2002;347:1941-51
(362d). Copyright © 2002 Massachusetts Medical Society. All Rights Reserved.
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endurance and upper-body strength in poorly conditioned
patients (356,357). 
The potential beneficial synergy of exercise training and
pharmacological therapies has been incompletely evaluated
(335,358-360). Although there are biological reasons that
could support potentially more rapid or sustained improve-
ments in pain-free or maximal walking distance when
patients are treated concomitantly with exercise and claudi-
cation medications (e.g., cilostazol or pentoxifylline), there
are currently inadequate data to support any efficacy conclu-
sion. 
In addition to the benefits of daily exercise on limb
ischemic symptoms, regular exercise is associated with
improved blood pressure, an improved serum lipid profile
(including increased HDL values and decreased triglyceride
values), and improved glycemic control. Two studies have
demonstrated that these theoretical systemic benefits are
achievable (361,362). 
In summary, there is a strong evidence base to support a
central role of structured exercise programs for all patients
with claudication. Structured exercise is also likely to bene-
fit patients who are treated with pharmacotherapies,
endovascular therapies, and vascular surgical bypass.
Supervised exercise can create an environment in which ath-
erosclerosis risk factor normalization may be achieved more
effectively. Supervised exercise should therefore be provided
as a key component of a comprehensive claudication treat-
ment program.
2.6.2.2. Medical and Pharmacological Treatment
for Claudication
2.6.2.2.1. CILOSTAZOL.
RECOMMENDATIONS
Class I
1. Cilostazol (100 mg orally 2 times per day) is indicated
as an effective therapy to improve symptoms and
increase walking distance in patients with lower
extremity PAD and intermittent claudication (in the
absence of heart failure). (Level of Evidence: A)
2. A therapeutic trial of cilostazol should be considered
in all patients with lifestyle-limiting claudication (in
the absence of heart failure). (Level of Evidence: A)
Cilostazol is a phosphodiesterase type 3 inhibitor that
increases cyclic adenosine monophosphate. Cilostazol has
vasodilator and platelet inhibitory properties (363,364), but
the precise mechanism of action in patients with intermittent
claudication is not known. Cilostazol has been shown to
dlecrease plasma HDL cholesterol and triglyceride concentra-
expression of vascular cell adhesion molecule-1, inhibit vas-
is repeated several times during the hour of supervision.
Such a program requires that patients be reassessed as they
continue the program so that the workload, modified by
treadmill grade or speed (or both), can be increased to allow
patients to achieve increased pain-free and maximal walking
distances until program completion. Typical benefits of such
a program include a more than 100% improvement in peak
exercise performance (322-326,329), significant improve-
ments in walking speed and distance noted with the Walking
Impairment Questionnaire and improvements in physical
function and vitality on the SF-36 (36-item short-form health
survey) questionnaire. 
Many patients with claudication also have reduced muscle
mass (346) and a lack of muscle strength and endurance,
which exacerbates their physical impairment. Resistance
training, when appropriately prescribed, is generally recom-
mended by the AHA for most individuals with other mani-
festations of cardiovascular disease because of its beneficial
effects on strength and endurance, cardiovascular function,
metabolism, coronary risk factors, and psychosocial well-
being (347). Nevertheless, in patients with claudication,
resistance training does not directly improve walking ability,
whereas walking itself is most effective in increasing claudi-
cation-limited walking capacity (323,324,340). 
Clinicians should recognize that minimal data support the
efficacy of the informal “go home and walk” advice that still
makes up the most typical exercise prescription for claudica-
tion (348,349). Although some patients might theoretically
achieve benefit from such casual exercise prescriptions
(336,350), the determinants of success and documentation of
efficacy are not yet defined. In contrast, a supervised hospi-
tal- or clinic-based program, which ensures that patients are
receiving a standardized exercise stimulus in a safe environ-
ment, is effective (325,351). 
Supervised exercise, endovascular procedures, and limb
arterial bypass surgery can each effectively provide func-
tional benefits, and yet comparative prospective trials are
few, with variable results that may depend on the population
studied, length of treatment, and method of application of
each intervention. In one trial, exercise training was demon-
strated to be superior to angioplasty (334,352), whereas this
result was not corroborated by a comparative meta-analysis
(353). In other trials, surgical bypass was determined to pro-
vide superior benefits to exercise (354). There are inadequate
data to compare such distinct claudication interventions
effectively. It is likely that supervised exercise training can
serve as a beneficial adjunct to further augment the improve-
ments in walking that can be gained by both endovascular
procedures and surgical bypass (355). 
The efficacy of exercise programs to improve the function-
al status of patients with lower extremity PAD who undergo
amputation, which affects from 5% to 10% of patients with
lower extremity PAD, has not been evaluated prospectively.
However, it is known that arm ergometry stress testing is an
alternative for patients who cannot perform leg exercise to
assess cardiovascular status, and arm ergometry exercise
training has been demonstrated to improve cardiovascular
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nificant difference in pain-free or maximal walking distance
between the placebo and pentoxifylline treatment groups,
whereas cilostazol improved both pain-free and maximal
walking distance (370). The recommended dose is 400 mg
orally 3 times per day. Pentoxifylline does not increase the
ABI at rest or after exercise (360). Adverse effects associat-
ed with pentoxifylline include sore throat, dyspepsia, nausea,
and diarrhea (370). No life-threatening side effects of pen-
toxifylline have been reported; however, trials reported to
date have been too small to assess this outcome reliably.
Accordingly, pentoxifylline may be considered to treat
patients with intermittent claudication; however, the antici-
pated outcome is likely to be of marginal clinical importance. 
2.6.2.2.3. OTHER PROPOSED MEDICAL THERAPIES.
RECOMMENDATIONS
Class IIb
1. The effectiveness of L-arginine for patients with inter-
mittent claudication is not well established. (Level of
Evidence: B)
2. The effectiveness of propionyl-L-carnitine as a thera-
py to improve walking distance in patients with inter-
mittent claudication is not well established. (Level of
Evidence: B)
3. The effectiveness of ginkgo biloba to improve walking
distance for patients with intermittent claudication is
marginal and not well established. (Level of Evidence:
B)
Class III
1. Oral vasodilator prostaglandins such as beraprost
and iloprost are not effective medications to improve
walking distance in patients with intermittent claudi-
cation. (Level of Evidence: A)
2. Vitamin E is not recommended as a treatment for
patients with intermittent claudication. (Level of
Evidence: C)
3. Chelation (e.g., ethylenediaminetetraacetic acid) is
not indicated for treatment of intermittent claudica-
tion and may have harmful adverse effects. (Level of
Evidence: A)
Vasodilator Prostaglandins. Vasodilator prostaglandins have
been studied as potential therapy for treatment of patients
with intermittent claudication. These drugs include
prostaglandin E1 (PGE-1) and stable derivatives of prostacy-
clin, such as iloprost and beraprost. Vasodilator
prostaglandins cause vasodilation and inhibition of platelet
aggregation by activating adenylyl cyclase and increasing
cyclic adenosine monophosphate. Vasodilator prostaglandins
are considered investigational for this indication, and none
have been approved by the FDA for use in patients with
PAD. Intravenous administration of PGE-1 and a PGE-1 pro-
drug once or twice daily for 4 to 8 weeks has been reported
to increase pain-free and maximal walking distance in place-
bo-controlled trials (384-387). Daily intravenous administra-
walking distance by 40% to 60% compared with placebo
after 12 to 24 weeks of therapy (161,337,338,369,370). In
dose-ranging trials, cilostazol administered at 100 mg twice
daily was more effective than 50 mg twice daily (161,369).
Cilostazol increased ABI modestly in these studies, but the
hemodynamic effect could not account for the improvement
in claudication (337,338,370,371). A meta-analysis of these
trials indicated that cilostazol also improved walking ability
and health-related quality of life (372).
The most common side effects of cilostazol include
headache, diarrhea, abnormal stools, palpitations, and dizzi-
ness (370). Other phosphodiesterase inhibitors, such as mil-
rinone and vesnarinone, are associated with increased mor-
tality in patients with congestive heart failure and reduce sys-
tolic left ventricular function (373,374). None of the trials
conducted to date have found a significant increase in mor-
tality or major cardiovascular events in patients treated with
cilostazol, and the long-term safety of this drug is under
investigation.
In data that were presented to the FDA’s Cardiovascular
and Renal Drugs Advisory Committee and derived from
more than 2000 patients who were followed up for up to 6
months, death due to cardiovascular causes occurred in 0.6%
of patients treated with cilostazol and 0.5% of patients treat-
ed with placebo. Pending more definitive information, the
FDA has mandated a black-box warning that cilostazol
should not be used in patients with heart failure.
2.6.2.2.2. PENTOXIFYLLINE.
RECOMMENDATIONS
Class IIb
1. Pentoxifylline (400 mg 3 times per day) may be con-
sidered as second-line alternative therapy to cilostazol
to improve walking distance in patients with intermit-
tent claudication. (Level of Evidence: A)
2. The clinical effectiveness of pentoxifylline as therapy
for claudication is marginal and not well established.
(Level of Evidence: C)
Pentoxifylline is a methylxanthine derivative that is
approved for use in patients with intermittent claudication. It
is a hemorheologic agent that has been reported to decrease
blood and plasma viscosity, increase erythrocyte and leuko-
cyte deformability, inhibit neutrophil adhesion and activa-
tion, and lower plasma fibrinogen concentrations in some
studies but not in others (375-379). Meta-analyses of ran-
domized, placebo-controlled, double-blind clinical trials
have found that pentoxifylline causes a marginal but statisti-
cally significant improvement in pain-free and maximal
walking distance by 21 to 29 meters and 43 to 48 meters,
respectively (360,380). According to 2 of the larger trials
comprising 128 and 150 individuals, respectively, the aver-
age percentage increase in pain-free and maximal walking
distance was 30% and 20%, respectively (381-383). One ran-
domized, controlled trial comprising 471 patients compared
pentoxifylline with cilostazol and placebo. There was no sig-
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such as L-arginine, ginkgo biloba, and vitamin E, as well as
chelation therapy. L-Arginine is the precursor for nitric oxide
that is synthesized in the endothelium by a constitutive iso-
form of nitric oxide synthase. Nitric oxide induces vasodila-
tion and inhibits platelet aggregation by activating guanylyl
cyclase and increasing cyclic guanosine monophosphate.
Endothelium-dependent vasodilation mediated by nitric
oxide is impaired in patients with atherosclerosis, including
those with PAD (399). L-Arginine improves endothelium-
dependent vasodilation in patients with hypercholes-
terolemia and atherosclerosis (386,400). One placebo-con-
trolled trial found that intravenous administration of L-argi-
nine, 8 g twice per day, improved pain-free and maximal
walking distance after 3 weeks of treatment (386). Another
placebo-controlled trial examined the efficacy of a food bar
that contained 3.3 g of L-arginine (as well as antioxidant vita-
mins and minerals, folic acid, and B-complex vitamins)
(401). After 2 weeks, there was modest improvement in pain-
free and maximal walking distance in patients who ingested
2 bars per day. A larger placebo-controlled trial examining
the efficacy of this food bar enriched with L-arginine has
been completed, with negative results, but has not been pub-
lished. Given the available findings to date, it is premature to
make any recommendations regarding the efficacy of L-argi-
nine as therapy for patients with intermittent claudication.
Carnitine is a cofactor for skeletal muscle metabolism.
Patients with PAD have abnormal skeletal muscle metabo-
lism, which includes the accumulation of acyl-coenzyme A
intermediates and acylcarnitine. L-Carnitine and its con-
gener, propionyl-L-carnitine, increase the availability of L-
carnitine for skeletal muscle and may subsequently improve
exercise capacity in patients with intermittent claudication.
One randomized, placebo-controlled trial found that L-carni-
tine, 2 g orally twice per day, improved absolute walking dis-
tance (402). Three placebo-controlled trials reported that
propionyl–L-carnitine, 1 g orally twice per day, improved
maximal walking distance by 54% to 73%; in one study, the
effect was significant only in those patients whose baseline
walking distance was less than 250 meters (403-405). There
did not appear to be any serious adverse events in the patients
treated with propionyl–L-carnitine compared with those
treated with placebo. On the basis of these findings, propi-
onyl-L-carnitine shows promise as a therapy to improve
walking distance in patients with intermittent claudication.
At this time, however, it is not an approved drug for this indi-
cation. 
Ginkgo biloba is an herb that includes flavonoids and ter-
pine trilactones, such as ginkgolides. Its purported actions
include decreased red blood cell aggregation, decreased
blood viscosity, and inhibition of platelet activating factor. A
systematic review evaluated findings from 8 placebo-con-
trolled trials of ginkgo biloba extract in patients with inter-
mittent claudication (406). Patients received 120 to 160 mg
per day of ginkgo biloba or placebo for 12 to 24 weeks. The
weighted mean difference in pain-free walking distance was
34 meters in patients randomized to ginkgo biloba compared
with those randomized to placebo. No single well-powered,
tion of vasodilator prostaglandins is not practical for most
patients with intermittent claudication. One placebo-con-
trolled 6-month trial found that oral beraprost improved
pain-free and maximal walking distance (388). Two random-
ized, controlled trials of 6 months’ duration of patients with
intermittent claudication failed to demonstrate any effect on
walking distance with either oral beraprost or iloprost,
although cardiovascular ischemic events were reduced in the
beraprost-treated group (389). Frequent adverse effects
included headache, flushing, and gastrointestinal distress.
Given these observations, it is unlikely that these drugs will
be approved for use in patients with claudication.
Angiogenic Growth Factors. Angiogenic growth factors,
such as vascular endothelial growth factor (VEGF), basic
fibroblast growth factor (bFGF), and hypoxia-inducible fac-
tor-1, have engendered considerable enthusiasm as potential
therapeutic interventions to improve symptoms in patients
with PAD. These drugs have been shown to promote collat-
eral blood vessel formation and increase limb blood flow in
experimental models of hindlimb ischemia (390,391).
Angiogenic growth factors have been administered as
recombinant proteins or via gene transfer with naked plasmid
DNA or adenoviral vectors encoding the angiogenic growth
factor (392,393). In a small phase 1, double-blind, placebo-
controlled study, administration of bFGF via the femoral
artery on 1 or 2 consecutive days increased calf blood flow 1
month and 6 months later (394). In a randomized, placebo-
controlled study, intra-arterial administration of recombinant
fibroblast growth factor–2 at a dose of 30 micrograms per
kilogram on 1 occasion increased peak walking time at 90
days by 19%, although its administration on 2 occasions 30
days apart did not significantly improve peak walking time
compared with placebo (395). There have been no significant
adverse events reported in patients treated with recombinant
fibroblast growth factor–2 compared with those receiving
placebo. One study that involved the intravenous administra-
tion of bFGF to patients with claudication was terminated
prematurely when 4 of 16 subjects who received bFGF
developed proteinuria that exceeded 1 g per 24 hours (396).
A small phase 1 study examined the safety and efficacy of
intramuscular administration of an adenoviral VEGF isoform
121 and monitored patients for up to 1 year (397). Edema
and rash were common early adverse events. Among 15
patients who received VEGF, there was 1 death at day 160
and 1 malignancy at day 274. A larger double-blind, ran-
domized, placebo-controlled trial of intramuscular adminis-
tration of VEGF isoform 121 in 105 patients with claudica-
tion failed to demonstrate any clinical efficacy but did pro-
voke limb edema (398). Given the available evidence, it is
premature to make any recommendations regarding the rela-
tive efficacy and safety of angiogenic growth factors for the
treatment of intermittent claudication. 
Nutritional Supplements. Several alternative (complementa-
ry) forms of therapy have been studied in patients with inter-
mittent claudication. These include nutritional supplements
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2.6.2.3. Role of Revascularization for Claudication
Because of the variability of individual limb ischemic symp-
toms and variable impact of these symptoms on quality of
life, patients should be selected for revascularization on the
basis of the severity of their symptoms; a significant disabil-
ity as assessed by the patient; failure of medical therapies;
lack of significant comorbid conditions; vascular anatomy
suitable for the planned revascularization; and a favorable
risk/benefit ratio. These recommendations have been sum-
marized previously in an international PAD consensus state-
ment and are summarized in Table 19 (1). Patients selected
for possible revascularization may then undergo additional
imaging studies as required, such as duplex ultrasound,
MRA or CTA, and/or catheter angiography, to determine
whether their arterial anatomy is suitable for percutaneous or
surgical revascularization. 
2.6.2.4. Endovascular Treatment for Claudication
RECOMMENDATIONS
Class I
1. Endovascular procedures are indicated for individu-
als with a vocational or lifestyle-limiting disability due
to intermittent claudication when clinical features
suggest a reasonable likelihood of symptomatic
improvement with endovascular intervention and (a)
there has been an inadequate response to exercise or
pharmacological therapy and/or (b) there is a very
favorable risk-benefit ratio (e.g., focal aortoiliac
occlusive disease). (Level of Evidence: A)
prospective, randomized, blinded trial has been performed to
corroborate this meta-analysis. These findings suggest that
ginkgo biloba may be considered as alternative therapy to
treat patients with intermittent claudication; however, the
outcome is likely to be of marginal clinical importance.
Vitamin E is a lipid soluble antioxidant that protects
polyunsaturated fatty acids from oxidation. Vitamin E may
improve red blood cell deformability and therefore transport
through the microcirculation, because polyunsaturated fatty
acids are incorporated into the erythrocyte membrane. A sys-
tematic review evaluated 5 placebo-controlled trials com-
prising 265 subjects that compared vitamin E with placebo in
patients with intermittent claudication (407). Each of these
was conducted between 1953 and 1975. The trials were
small, measured different physical outcomes, and were of
generally poor quality. No conclusions could be drawn
regarding the efficacy of vitamin E for intermittent claudica-
tion. The Alpha-tocopherol, Beta carotene Cancer Prevention
Study randomized patients to 50 mg of vitamin E (alpha-
tocopherol) per day, 20 mg of beta carotene per day, both, or
placebo in a 2-by-2 factorial design. Intermittent claudication
was reported via the Rose questionnaire. No effect of alpha-
tocopherol on claudication was observed during a mean fol-
low-up of 3.7 years (408). Two large trials examined the effi-
cacy of vitamin E on adverse cardiovascular events in
patients with atherosclerosis, including those with PAD
(112,299). There was no benefit of vitamin E compared with
placebo on cardiovascular outcomes such as MI, stroke, or
vascular death. Taken together, these data indicate that vita-
min E is not recommended as a treatment for patients with
intermittent claudication.
Chelation Therapy. Disodium ethylenediaminetetraacetic
acid (EDTA) combines with polyvalent cations, such as cal-
cium ions, and forms a soluble nonionic complex that can be
excreted. It is used in the treatment of heavy metal poisoning
and has been used in the treatment of patients with intermit-
tent claudication. On the basis of the somewhat antiquated
understanding of the biology of atherosclerosis, EDTA is
purported to leach calcium out of atherosclerotic plaques,
resulting in plaque regression and reduction in the severity of
stenoses. It is administered intravenously 2 or more times per
week. Two systematic reviews evaluated placebo-controlled
trials of EDTA in patients with intermittent claudication and
concluded that there was no evidence to support the use of
EDTA in these patients (409,410). The systematic reviews
included 4 trials, 3 deemed to be of good quality, that evalu-
ated the effect of EDTA on walking distance (411-414).
Overall, there were no significant changes in pain-free or
maximal walking distance. One trial also obtained
angiograms and found no effect of treatment with EDTA on
severity of atherosclerosis (412). Potential serious adverse
effects of EDTA include hypocalcemia, which may be life-
threatening, renal insufficiency, proteinuria, and gastroin-
testinal distress. Given its lack of efficacy and important
safety concerns, EDTA should not be used to treat patients
with intermittent claudication.
Table 19. Indications for Revascularization in Intermittent
Claudication
Before a patient with intermittent claudication is offered the option of
any invasive revascularization therapy, whether endovascular or surgi-
cal, the following considerations must be taken into account:
a predicted or observed lack of adequate response to exercise ther-
apy and claudication pharmacotherapies
the presence of a severe disability, with the patient either being
unable to perform normal work or having very serious impair-
ment of other activities important to the patient
absence of other disease that would limit exercise even if the clau-
dication was improved (e.g., angina or chronic respiratory dis-
ease)
the anticipated natural history and prognosis of the patient
the morphology of the lesion, which must be such that the appro-
priate intervention would have low risk and a high probability of
initial and long-term success
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-
Society Consensus (TASC) Working Group, Management of peripheral arterial disease
(PAD), S1-S296, Copyright 2000, with permission from Elsevier (1).
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tibial arteries as salvage therapy for a suboptimal or
failed result from balloon dilation (e.g., persistent
translesional gradient, residual diameter stenosis
greater than 50%, or flow-limiting dissection). (Level
of Evidence: C)
Class IIb
1. The effectiveness of stents, atherectomy, cutting bal-
loons, thermal devices, and lasers for the treatment of
femoral-popliteal arterial lesions (except to salvage a
suboptimal result from balloon dilation) is not well-
established. (Level of Evidence: A)
2. The effectiveness of uncoated/uncovered stents,
atherectomy, cutting balloons, thermal devices, and
lasers for the treatment of infrapopliteal lesions
(except to salvage a suboptimal result from balloon
dilation) is not well established. (Level of Evidence: C)
Class III
1. Endovascular intervention is not indicated if there is
no significant pressure gradient across a stenosis
despite flow augmentation with vasodilators. (Level of
Evidence: C)
2. Primary stent placement is not recommended in the
femoral, popliteal, or tibial arteries. (Level of
Evidence: C)
3. Endovascular intervention is not indicated as prophy-
lactic therapy in an asymptomatic patient with lower
extremity PAD. (Level of Evidence: C)
2. Endovascular intervention is recommended as the
preferred revascularization technique for TASC type
A (see Tables 20 and 21 and Figure 8) iliac and
femoropopliteal arterial lesions. (Level of Evidence: B)
3. Translesional pressure gradients (with and without
vasodilation) should be obtained to evaluate the sig-
nificance of angiographic iliac arterial stenoses of
50% to 75% diameter before intervention. (Level of
Evidence: C)
4. Provisional stent placement is indicated for use in the
iliac arteries as salvage therapy for a suboptimal or
failed result from balloon dilation (e.g., persistent
translesional gradient, residual diameter stenosis
greater than 50%, or flow-limiting dissection). (Level
of Evidence: B)
5. Stenting is effective as primary therapy for common
iliac artery stenosis and occlusions. (Level of Evidence:
B)
6. Stenting is effective as primary therapy in external
iliac artery stenoses and occlusions. (Level of
Evidence: C)
Class IIa
Stents (and other adjunctive techniques such as lasers,
cutting balloons, atherectomy devices, and thermal
devices) can be useful in the femoral, popliteal, and
Table 20. Morphological Stratification of Iliac Lesions
TASC type A iliac lesions:
1. Single stenosis less than 3 cm of the CIA or EIA (unilateral/bilat-
eral)
TASC type B iliac lesions:
2. Single stenosis 3 to 10 cm in length, not extending into the CFA
3. Total of 2 stenoses less than 5 cm long in the CIA and/or EIA and 
not extending into the CFA
4. Unilateral CIA occlusion
TASC type C iliac lesions:
5. Bilateral 5- to 10-cm-long stenosis of the CIA and/or EIA, not 
extending into the CFA
6. Unilateral EIA occlusion not extending into the CFA
7. Unilateral EIA stenosis extending into the CFA
8. Bilateral CIA occlusion
TASC type D iliac lesions:
9. Diffuse, multiple unilateral stenoses involving the CIA, EIA, and 
CFA (usually more than 10 cm long)
10. Unilateral occlusion involving both the CIA and EIA
11. Bilateral EIA occlusions
12. Diffuse disease involving the aorta and both iliac arteries
13. Iliac stenoses in a patient with an abdominal aortic aneurysm or 
other lesion requiring aortic or iliac surgery
Endovascular procedure is the treatment of choice for type A lesions, and surgery is the
procedure of choice for type D lesions.
CFA indicates common femoral artery; CIA, common iliac artery; EIA, external iliac
artery; TASC, TransAtlantic Inter-Society Consensus.
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-
Society Consensus (TASC) Working Group, Management of peripheral arterial disease
(PAD), S1-S296, Copyright 2000, with permission from Elsevier (1).
Table 21. Morphological Stratification of Femoropopliteal Lesions
TASC type A femoropopliteal lesions:
1. Single stenosis less than 3 cm of the superficial femoral artery or 
popliteal artery
TASC type B femoropopliteal lesions:
2. Single stenosis 3 to 10 cm in length, not involving the distal 
popliteal artery
3. Heavily calcified stenoses up to 3 cm in length
4. Multiple lesions, each less than 3 cm (stenoses or occlusions)
5. Single or multiple lesions in the absence of continuous tibial 
runoff to improve inflow for distal surgical bypass
TASC type C femoropopliteal lesions:
6. Single stenosis or occlusion longer than 5 cm
7. Multiple stenoses or occlusions, each 3 to 5 cm in length, with or 
without heavy calcification
TASC type D femoropopliteal lesions:
8. Complete common femoral artery or superficial femoral artery 
occlusions or complete popliteal and proximal trifurcation occlu-
sions
Endovascular procedure is the treatment of choice for type A lesions, and surgery is the
procedure of choice for type D lesions. More evidence is needed to make firm recom-
mendations about the best treatment for type B and C lesions.
TASC indicates TransAtlantic Inter-Society Consensus.
Adapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic Inter-
Society Consensus (TASC) Working Group, Management of peripheral arterial disease
(PAD), S1-S296, Copyright 2000, with permission from Elsevier (1).
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Endovascular techniques to treat peripheral arterial occlu-
sive disease include PTA with balloon dilation, stents,
atherectomy, laser, cutting balloons, thermal angioplasty, and
fibrinolysis/fibrinectomy. Thrombolysis utilizes lytic agents
that act on fibrin (thus, eliciting “fibrinolysis,” as this
process is more commonly described when used with regard
to the coronary circulation), and thrombectomy uses direct
techniques to remove clot. (The terms “thrombolysis” and
“thrombolytic” are synonymous with the terms “fibrinolysis”
and “fibrinolytic,” as used in other ACC/AHA guidelines.)
These interventions are discussed in Sections 2.6.3.2 and
2.6.3.3. Endovascular (and surgical) treatments can be
selected on the basis of morphological features that stratify
lower extremity arterial anatomy into subgroups, as dis-
played in Table 20 and Figure 8 (iliac lesions) and Table 21
and Figure 9 (femoropopliteal lesions). 
Outcomes of PTA and stents depend on anatomic and clin-
ical factors (Table 22). Durability of patency after PTA is
greatest for lesions in the common iliac artery and decreases
distally. Durability also decreases with increasing length of
the stenosis/occlusion, multiple and diffuse lesions, poor-
quality runoff, diabetes, renal failure, smoking, and CLI
(415-430). Female gender has been reported to decrease
patency of external iliac artery stents (431). Hormone
replacement therapy has also been reported to decrease
patency of iliac stents in women (432). Overall outcomes of
PTA and stenting of native vessels are summarized in Table
22. Percutaneous transluminal angioplasty of vein bypass
graft stenoses has also been reported, with 1- to 3-year paten-
cy of the treated site of approximately 60% (433-435), com-
parable to that for surgical repair (433). Percutaneous trans-
luminal angioplasty of multiple vein graft stenoses has a
much lower 3-year patency of only 6% (434). Therefore,
patient selection is key in obtaining satisfactory outcomes. 
Selection of lesions for endovascular versus conservative
therapy is not well defined. Stenoses of 50% to 75% diame-
ter by angiography may or may not be hemodynamically sig-
nificant, and intravascular pressure measurements have been
recommended to determine whether these lesions are signif-
icant and to predict patient improvement if the lesion is treat-
ed (439,440). Unfortunately, there is no consensus on a diag-
nostic transstenotic pressure criteria or on methods to meas-
Figure 8. Summary of preferred options in interventional management of iliac lesions. Reprinted from J Vasc Surg, 31, Dormandy
JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group, Management of peripheral arterial disease
(PAD), S1-S296, Copyright 2000, with permission from Elsevier (1).
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mill walking distance, ABI, and pain scores (443), but these
results were not durable. After 2 years of follow-up, the
groups had comparable clinical outcomes (444). Most of the
patients in this trial had femoral-popliteal PTA. A prospec-
tive cohort study compared 18-month outcomes of PTA, sur-
gical bypass, and conservative treatment. Both surgery and
PTA produced marked improvements in ABI, walking dis-
tance, pain scores, and functional status compared with con-
servative treatment. The functional gains were approximate-
ly half those reported for patients receiving hip arthroplasty
and were similar to those for patients who underwent elec-
tive coronary angioplasty (445).
Several randomized trials have investigated the selection of
patients for surgical or endovascular revascularization. Holm
et al. reported no significant difference in 1-year primary and
secondary patency in a randomized trial of PTA versus sur-
gical bypass for treatment of iliac and femoral-popliteal dis-
ease. Sixty percent of patients were treated for CLI (446).
Wolf et al. similarly reported no significant difference in 4-
year primary patency, ABI, health status, and patient survival
in a randomized trial of PTA versus surgical bypass. Only
25% to 30% of patients were treated for CLI (447). 
Wilson et al. evaluated the relative efficacy and risk of PTA
and surgical revascularization in 255 patients with claudica-
tion and reported comparable outcomes and risk for patients
ure these pressures (441,442). One criterion would utilize a
mean gradient of 10 mm Hg before or after vasodilators;
another has suggested use of a mean gradient of 5 mm Hg, or
10, 15, or 20 mm Hg peak systolic; and a third criteria would
use a 15% peak systolic pressure gradient after administra-
tion of a vasodilator (425,439-441). Pressure measurements
may be obtained with 2 separate pressure transducers or by
obtaining pullback pressures with a single transducer.
Pressures obtained with the catheter positioned across the
stenosis may artifactually increase the pressure gradient by
reducing the residual lumen with the catheter. Endovascular
treatment of a stenosis that lacks a pressure gradient is not
indicated. No studies have been performed to assess the safe-
ty and efficacy of treating asymptomatic but hemodynami-
cally significant lesions to prevent progression of disease
(prophylactic angioplasty), and therefore this strategy is not
recommended.
Selection of patients for endovascular versus conservative
(medical) therapy has been evaluated in several trials. A
small randomized trial of PTA versus supervised exercise
found that PTA improved the ABI more than exercise at 15
months, but claudication and walking distance were better in
the exercise group (352). Another randomized trial of PTA
versus exercise advice found that at 6 months, PTA yielded
significantly better results for claudication symptoms, tread-
Figure 9. Summary of preferred options for interventional treatment of femoropopliteal lesions. Reprinted from J Vasc Surg, 31,
Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group, Management of peripheral arte-
rial disease (PAD), S1-S296, Copyright 2000, with permission from Elsevier (1).
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Table 22. Overview of Primary Patency and Limb Salvage Rates After Endovascular Procedures for PAD of the Lower Extremities
30-Day Major
Severity of No. of Mortality, % Complication, %
Procedure Lesion Type Disease Reference Limbs (95% CI) (95% CI)
Iliac PTA 80% stenoses, 67% claudication, (436) 1473 1.0 (0 to 2.9) 4.3 (2.0 to 6.5)
20% occlusion 33% critical ischemia
Stenoses Claudication ND ND
Stenoses Critical ischemia ND ND
Occlusion Claudication ND ND
Occlusion Critical ischemia ND ND
Iliac stent 72% stenoses, 85% claudication, (436) 901 0.8 (0.7 to 0.9) 5.2 (3.5 to 6.9)
28% occlusion 15% critical ischemia
Stenoses Claudication ND ND
Stenoses Critical ischemia ND ND
Occlusion Claudication ND ND
Occlusion Critical ischemia ND ND
Femoropopliteal 64% stenoses, 65% claudication, (437, 438) 4800/1003† 0.9 (0.7 to 1.1) 8.1 (7.3 to 8.9)
PTA 36% occlusion 35% critical ischemia
Stenoses Claudication ND ND
Stenoses Critical ischemia ND ND
Occlusion Claudication ND ND
Occlusion Critical ischemia ND ND
Femoropopliteal Stenoses and 80% claudication, Meta-analysis‡ 600 — 5.9 (1.7 to 10)
stent occlusions 20% critical ischemia
Infrapopliteal Stenoses and 14% claudication, Meta-analysis§ 1282 — —
PTA occlusions 86% critical ischemia
CI indicates confidence interval; ND, no difference by subgroup can be demonstrated; and PAD, peripheral arterial disease.
*All patency rates and limb savage rates include initial technical failures.
†Mortality and complication rates are based on n equals 4800, patency rates are based on n equals 1003. 
‡Based on a random-effects meta-analysis of the results from various sources, each weighted with the inverse of the variance (17-27).
§Based on a random-effects meta-regression analysis of the results from various sources, each weighted with the inverse of the variance (28-46).
Reprinted from Kandarpa K, Becker, BJ, Hunink, M, et al. J Vasc Interv Radiol 2001;12:683-95 (438a).
Technical Success,
% (95% CI)
91 (86 to 96)
96
ND
80
ND
96 (91 to 100)
100
ND
80
ND
89 (87 to 91)
95
90
87
75
98 (97 to 100)
93 (90 to 96)
Primary Patency, % (95% CI)*
1 y 2 y 3 y 4 y 5 y
74 66 61 58 —
(71 to (63 to (59 to (56 to 
76) 68) 64) 61)
79 72 68 65 —
72 61 56 53 —
66 60 57 54 —
60 51 47 44 —
86 79 75 74 —
(84 to (76 to (72 to (69 to
89) 81) 78) 78)
91 84 80 77 —
87 76 70 67 —
72 67 64 61 —
69 60 56 53 —
59 54 52 49 45
(56 to (51 to (48 to (45 to (41 to 
62) 57) 55) 52) 49)
79 75 74 71 68
62 57 54 51 47
52 46 43 40 35
26 21 18 15 12
62 52 43 — —
(48 to (33 to (22 to 
80) 83) 86)
79 74 — — —
(68 to (65 to
90) 83)
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treated with either technique (448). The trials of Holm et al.
(448) and Wolfe et al. (446) both excluded patients with
long-segment disease (greater than 6 cm and greater than 10
cm, respectively). In these trials, patients had to be consid-
ered candidates for either PTA or surgical bypass, and it is
likely that patients with poor prognostic factors for PTA were
not included. In the study by Holm et al., only 5% of patients
considered for revascularization were actually entered into
the study (446). Therefore, these results cannot be general-
ized to patients with poor prognostic factors for PTA. For
example, patients with long-segment superficial femoral
artery disease and poor runoff have had dismal outcomes
with endovascular therapy (449). A cost-effectiveness analy-
sis compared PTA and bypass surgery with exercise therapy
for treatment of claudication. The cost-effectiveness of PTA
was $38 000 per quality-adjusted life year, which is in the
range of other accepted procedures. Bypass surgery cost-
effectiveness was $311 000 per quality-adjusted life-year
(450). 
Effectiveness is strongly affected by the severity of patient
symptoms before revascularization and severity of disease.
For femoral-popliteal disease, PTA was more cost-effective
than surgical bypass for the treatment of claudication (steno-
sis and occlusion) and for treatment of CLI (stenosis only).
Surgical bypass was more cost-effective for treatment of CLI
for occlusions (438). Percutaneous transluminal angioplasty
would always be the preferred initial treatment if the PTA 5-
year patency rate exceeded 30%. Another model of cost-
effectiveness of iliac artery PTA versus supervised exercise
has suggested that exercise might offer greater cost-effec-
tiveness (as measured by dollars per meter gained) than pri-
mary iliac artery angioplasty (451). Overall, the relative clin-
ical and health economic benefits of each claudication thera-
py must be considered in light of the individual clinical char-
acteristics of each patient. 
Selection of patients for iliac artery PTA or stenting has
been addressed in 1 randomized trial and 1 meta-analysis of
case series. The Dutch iliac stent trial compared iliac stenting
as primary therapy (primary stenting) to PTA with immedi-
ate stenting (provisional stenting) for PTA failures, defined
as greater than 10 mm of mean arterial pressure gradient with
or without vasodilators. Forty-three percent of the PTA group
required stents. Complications, 1-year patency, and clinical
outcomes were similar, which indicates that provisional
stenting and primary stenting are equally safe and effective
(452). Another randomized trial was suggestive of superiori-
ty for primary stenting (453). In a meta-analysis, iliac artery
stenting was found to have a higher technical success and
long-term patency than PTA, with a similar complication rate
(436). Similar to the Dutch iliac stent trial, the meta-analysis
showed parallel life-table outcomes of patency after the ini-
tial technical failures of PTA, which indicates that a good ini-
tial result from iliac PTA is as durable as iliac stenting.
Provisional stenting treats the initial technical failures of
PTA and is more cost-effective than PTA alone (454,455);
however, in routine clinical practice, most iliac lesions are
treated with primary stenting. 
Selection of patients for femoral-popliteal artery PTA or
stenting has been assessed in 4 randomized trials and 1 meta-
analysis of case series. The meta-analysis concluded that
only for treatment of occlusions in patients with CLI was
there a suggestion that stents were more durable than PTA
(456). The 4 randomized trials have uniformly found no dif-
ference in patency, ABI, or clinical improvement when com-
paring stents and PTA alone (457-460). A fifth randomized
trial that resulted in an FDA label for 1 stent for primary
femoral/popliteal stenting similarly showed no difference in
outcomes between stenting and PTA. Stenting does have a
higher technical success rate (457) and may have a role in
salvage of an immediate PTA failure and in treatment of
recurrent stenosis after PTA (461). 
Other techniques of endovascular revascularization have
shown no advantages over PTA/stents. A randomized trial of
atherectomy versus PTA for treatment of femoropopliteal
disease showed worse 2-year patency and clinical and hemo-
dynamic success for atherectomy (462). Another randomized
trial of atherectomy versus PTA showed no difference in 6-
month patency (463). A case series of atherectomy for treat-
ment of tibial lesions had dismal results (464). Similarly,
multiple randomized trials of laser angioplasty versus PTA
have shown no advantage of laser therapy (465-468).
Investigational randomized trials suggest that endovascular
brachytherapy may reduce restenosis rates of PTA and stent-
ing in the femoral-popliteal arteries (469-473). Techniques to
be investigated in randomized trials in the peripheral circula-
tion include fabric-covered stents (474,475) and drug-coated
stents (476,477).
The use of antiplatelet agents and anticoagulants to
improve the results of angioplasty and stenting is not well
defined. A meta-analysis reported increased patency and a
lower amputation rate with use of antiplatelet drugs after
PTA (478), but a review of 11 randomized trials found no dif-
ference in preventing reocclusion after PTA using aspirin or
oral anticoagulants (479).
On the basis of the above-reported outcomes of PTA/stent-
ing and surgery, consensus recommendations for selection of
patients for endovascular therapy in the management of
lower-limb peripheral arterial occlusion were made by an
international panel (1). The superiority of surgery versus
stenting for TASC type B and C iliac lesions was confirmed
in a case series, with poor runoff being the strongest prog-
nostic factor for stenting failure (480). For femoral-popliteal
lesions, Clark et al. found that AHA category 2 and 3 lesions
(similar to TASC type B and C) had nearly identical 36-
month patency (69% and 66%), whereas category 1 lesions
had a 36-month patency rate of 87% (423). Selection of
patients for endovascular therapy should be based on TASC
anatomic classifications, as well as severity of patient symp-
toms, comorbid conditions, and risks of surgical revascular-
ization. The summary consensus recommendations of TASC
for indications for aortoiliac revascularization for claudica-
tion suggest endovascular procedures as the treatment of
choice for type A lesions and surgical procedures as the treat-
ment of choice for type D lesions.
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Patients who present with symptoms of claudication before
50 years of age may have a more virulent form of athero-
sclerosis and have a poorer response to vascular surgical
interventions, frequently requiring graft revisions or replace-
ments (481). Olsen and associates noted a high mortality rate
secondary to cardiovascular events, a high amputation rate,
and an increasing disability rate in patients less than 40 years
of age who required surgical intervention for claudication
(482). In a study comparing the outcome of patients requir-
ing aortobifemoral bypass for PAD who were less than 50
years of age with those who were older, Reed and colleagues
noted poorer results in the younger patients (481). Younger
patients had lower patency rates and required more subse-
quent surgical intervention than did older patients. Green and
collaborators noted in a multi-institutional, prospective, ran-
domized trial of prosthetic femoral-popliteal bypass grafting
that patients younger than 65 years of age had a higher inci-
dence of graft occlusion (483). Therefore, despite the pres-
ence of significant claudication symptoms in an age group
that is often more physically active and employed, surgery
for these younger patients should be avoided if possible.
2.6.2.5.2. PREOPERATIVE EVALUATION.
RECOMMENDATION
Class I
A preoperative cardiovascular risk evaluation should
be undertaken in those patients with lower extremity
PAD in whom a major vascular surgical intervention
is planned. (Level of Evidence: B)
Lower extremity PAD is associated with the presence of
coronary artery disease and marks high short- and long-term
coronary ischemic risk, and therefore, a preoperative cardio-
vascular risk evaluation should be undertaken. The specific
testing strategy that might be used for a specific patient is
beyond the scope of this guideline. Perioperative ischemic
risk is increased for all lower extremity vascular surgical
procedures (inclusive of aortic, femoral, and infrapopliteal
segments). This risk is further increased in those patients
with an established history of ischemic heart disease, current
angina, or an abnormal electrocardiogram and may be chal-
lenging to assess in those individuals in whom a sedentary
lifestyle limits assessment of functional capacity. The preop-
erative cardiovascular risk evaluation is summarized in more
detail in the “ACC/AHA Guideline Update for Perioperative
Cardiovascular Evaluation for Noncardiac Surgery” (484). 
2.6.2.5.3. CORRELATION OF SYMPTOMS AND LESIONS.
Surgical intervention must be directed at the lesions
causative of the patient’s symptoms to relieve claudication.
The patient’s symptoms and vascular studies must be
anatomically consistent. Symptoms associated with lower
extremity PAD are usually manifested in the muscle groups
distal to the site of a hemodynamically significant stenosis or
occlusion. 
2.6.2.5. Surgery for Claudication
2.6.2.5.1. INDICATIONS. 
RECOMMENDATIONS
Class I
Surgical interventions are indicated for individuals
with claudication symptoms who have a significant
functional disability that is vocational or lifestyle lim-
iting, who are unresponsive to exercise or pharma-
cotherapy, and who have a reasonable likelihood of
symptomatic improvement. (Level of Evidence: B)
Class IIb
Because the presence of more aggressive atheroscle-
rotic occlusive disease is associated with less durable
results in patients younger than 50 years of age, the
effectiveness of surgical intervention in this popula-
tion for intermittent claudication is unclear. (Level of
Evidence: B)
Class III
Surgical intervention is not indicated to prevent pro-
gression to limb-threatening ischemia in patients with
intermittent claudication. (Level of Evidence: B)
Claudication usually does not progress to limb-threatening
ischemia, and therefore, there is no automatic mandate to
proceed to surgical intervention. Surgery is infrequently
needed to treat the individual with claudication and in gener-
al should only be considered after atherosclerosis risk factors
have been treated and an appropriate trial of exercise and/or
claudication pharmacotherapy has been utilized. Most major
vascular care centers report the use of surgical intervention in
only 25% of those individuals with claudication who are
referred to vascular surgeons. The indications for surgical
treatment of lower extremity ischemia are defined by the
severity of leg ischemic symptoms, with limb hemodynamic
data serving primarily to confirm the lower extremity PAD
and claudication diagnosis. Thus, intermittent claudication is
considered a relative indication for surgical treatment and is
usually reserved for individuals (a) who do not derive ade-
quate functional benefit from nonsurgical therapies, (b) who
have limb arterial anatomy that is favorable to obtaining a
durable clinical result, and (c) in whom the cardiovascular
risk of surgical revascularization is low. The 2 traditional
functional indications for surgical intervention are exercise
impairment sufficient to threaten the patient’s employment
or to require significant alterations in the patient’s lifestyle
after failure of nonsurgical or endovascular therapy. Because
the impact of job and lifestyle-threatening alterations is not
usually quantitated, the significance of these symptoms as an
indication for surgery must be decided on a per case basis by
the patient, primary clinician, and surgeon. Successful lower
extremity arterial surgical revascularization, however, can
effectively reduce or eliminate the symptoms of claudication.
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There are 3 major patterns of arterial obstruction. (a)
Inflow disease refers to the presence of stenotic or occlusive
lesions in the suprainguinal vessels, most commonly defined
as the infrarenal aorta and iliac arteries, that limit blood flow
to the common femoral artery. Inflow disease should be sus-
pected in individuals with gluteal or thigh claudication and
femoral pulse diminution or bruit. The presence of inflow
disease can be easily confirmed by use of noninvasive vas-
cular laboratory diagnostic techniques that can demonstrate
evidence of aortoiliac stenoses. (b) Outflow disease repre-
sents the presence of stenotic or occlusive lesions in the
lower extremity arterial tree below the inguinal ligament
from the common femoral artery to the level of the
infrapopliteal trifurcation. (c) Runoff disease is usually
defined in the context of stenotic or occlusive lesions in the
trifurcation vessels (anterior tibial, posterior tibial, and per-
oneal arteries) to the pedal arteries that cross the ankle. Both
outflow and runoff disease can be confirmed by noninvasive
vascular laboratory diagnostic studies as required to alter
treatment strategies. Although the pattern of anatomic lower
extremity PAD is highly variable between individuals, these
terms are useful in defining therapeutic approaches.
Occlusive lesions of the infrarenal aorta and/or iliac arter-
ies commonly lead to buttock and thigh claudication. If the
stenoses or occlusions are proximal to the origins of the
internal iliac arteries and are bilateral, vasculogenic erectile
dysfunction may also be present in men. Although buttock
and thigh claudication may represent the first exertional
ischemic symptoms, continued ambulation may lead to pro-
gression of symptoms that include calf claudication. 
Superficial femoral artery stenosis or occlusion is the most
common lesion associated with intermittent claudication.
This lesion leads to calf discomfort with ambulation and
relief with rest. There are no specific thigh or foot symptoms
associated with superficial femoral artery occlusive disease.
Because the deep femoral artery provides collateral circula-
tion to and reconstitution of the popliteal artery, isolated
superficial femoral artery occlusion rarely is the cause of
more advanced forms of ischemia.
Popliteal and tibial arterial occlusions are more commonly
associated with limb-threatening ischemia because of the
paucity of collateral vascular pathways beyond these lesions.
As isolated lesions, they are uncommonly the cause of inter-
mittent claudication.
Patients with combined inflow and outflow disease may
have broad symptoms of intermittent claudication that affect
the buttock, hip, thigh, and calf. 
2.6.2.5.4. SURGICAL PROCEDURES.
For individuals with claudication, initial revascularization
strategies will usually rely on endovascular techniques, with
surgical intervention reserved for individuals in whom arte-
rial anatomy is not favorable for endovascular procedures.
As noted in Section 2.6.2.4, comparable efficacy can often be
achieved with less risk by endovascular intervention when
both procedures are feasible (446-448). Once the decision to
proceed with surgical intervention is made and the site and
severity of occlusive lesions are defined through imaging
studies, the type of revascularization must be chosen. There
are several variables that must be considered by the surgeon
and patient in making this choice, including general medical
condition, age, gender, prior revascularization attempts, and
the desired outcome, such as walking short distances or nor-
malizing distal flow. In patients with combined inflow and
outflow disease, inflow problems are corrected first. A sig-
nificant improvement in inflow may diminish the symptoms
of claudication to the extent that supervised exercise therapy
or pharmacotherapies may be effective and, if distal revascu-
larization is needed, reduce the likelihood of distal graft
thrombosis from low flow.
2.6.2.5.4.1. Inflow Procedures: Aortoiliac 
Occlusive Disease
RECOMMENDATIONS
Class I
1. Aortobifemoral bypass is beneficial for patients with
vocational- or lifestyle-disabling symptoms and hemo-
dynamically significant aortoiliac disease who are
acceptable surgical candidates and who are unrespon-
sive to or unsuitable for exercise, pharmacotherapy,
or endovascular repair. (Level of Evidence: B)
2. Iliac endarterectomy and aortoiliac or iliofemoral
bypass in the setting of acceptable aortic inflow
should be used for the surgical treatment of unilater-
al disease or in conjunction with femoral-femoral
bypass for the treatment of a patient with bilateral
iliac artery occlusive disease if the patient is not a suit-
able candidate for aortobifemoral bypass grafting.
(Level of Evidence: B)
Class IIb
Axillofemoral-femoral bypass may be considered for
the surgical treatment of patients with intermittent
claudication in very limited settings, such as chronic
infrarenal aortic occlusion associated with symptoms
of severe claudication in patients who are not candi-
dates for aortobifemoral bypass. (Level of Evidence:
B) 
Class III
Axillofemoral-femoral bypass should not be used for
the surgical treatment of patients with intermittent
claudication except in very limited settings (see Class
IIb recommendation above). (Level of Evidence: B)
There are numerous patterns of aortoiliac occlusive disease
and procedures to surgically treat them (Table 23). Most
commonly, patients demonstrate diffuse disease of the
infrarenal aorta and iliac vessels, with the lesions of greatest
hemodynamic consequence located in the iliac arteries. The
most effective surgical procedure for treatment for this pat-
tern of atherosclerotic occlusive disease and the resultant
buttock and thigh claudication is aortobifemoral bypass.
Through a transabdominal or retroperitoneal approach, this
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Unilateral iliac stenoses or occlusions that cannot be treat-
ed effectively by angioplasty and stent placement can be
treated by iliac artery endarterectomy, aortoiliac bypass,
aortofemoral bypass, or iliofemoral bypass if the origin of
the iliac artery is free of disease. These procedures can be
performed through a small flank incision into the retroperi-
toneum and are usually well tolerated.
2.6.2.5.4.2. Outflow Procedures: 
Infrainguinal Disease.
RECOMMENDATIONS
Class I
1. Bypasses to the popliteal artery above the knee should
be constructed with autogenous vein when possible.
(Level of Evidence: A)
2. Bypasses to the popliteal artery below the knee should
be constructed with autogenous vein when possible.
(Level of Evidence: B)
Class IIa
The use of synthetic grafts to the popliteal artery
below the knee is reasonable only when no autogenous
vein from ipsilateral or contralateral leg or arms is
available. (Level of Evidence: A)
Class IIb
1. Femoral-tibial artery bypasses constructed with auto-
genous vein may be considered for the treatment of
claudication in rare instances for certain patients (see
text). (Level of Evidence: B)
2. Because their use is associated with reduced patency
rates, the effectiveness of the use of synthetic grafts to
the popliteal artery above the knee is not well-estab-
lished. (Level of Evidence: B)
Class III
Femoral-tibial artery bypasses with synthetic graft
material should not be used for the treatment of clau-
dication. (Level of Evidence: C)
As noted above, the superficial femoral artery and proxi-
mal popliteal artery are the most common anatomic sites of
stenosis or occlusion in individuals with symptoms of inter-
mittent claudication. Therefore, the most commonly per-
bypass is constructed by sewing the proximal end of a bifur-
cated polyester filament or polytetrafluoroethylene (PTFE)
graft, usually end-to-end, to the aorta immediately below the
origins of the renal arteries. The distal graft limbs are sewn
to the distal common femoral arteries or onto the proximal
deep femoral arteries if the superficial femoral arteries are
occluded to provide adequate outflow for the graft limbs and
improved collateral flow to the popliteal arteries. 
As noted above, results of aortobifemoral bypass grafting
are uniformly better in patients who present with symptoms
at age 50 years or greater. Diabetes, a well-known risk factor
for progressive atherosclerotic occlusive disease, does not
adversely impact the surgical treatment of aortoiliac disease.
Faries and associates, in a study of 504 patients undergoing
aortobifemoral bypass grafting, noted that diabetes was not a
risk factor for the need for subsequent surgical revision or
more distal revascularization procedures (497). 
If the aortoiliac lesions are confined to the area of the aor-
tic bifurcation, localized aortoiliac endarterectomy may be
considered. This procedure is effective but is uncommonly
performed, because few patients have such a limited mani-
festation of atherosclerosis. 
A less invasive approach may be appropriate for patients
with adequate aortic flow but stenoses or occlusions of both
iliac vessels. Such patients may not be considered acceptable
candidates for aortobifemoral bypass owing to comorbid car-
diovascular disease. If endovascular treatment of 1 iliac
artery is feasible and patency can be achieved with this less
invasive approach, a subsequent endarterectomy, unilateral
iliofemoral bypass, or femoral-femoral bypass can be con-
structed. In the absence of an inflow stenosis within the
donor iliac arterial segment, this procedure can effectively
provide flow to both lower extremities and eliminate the
symptoms of claudication.
Patients with severe infrarenal aortic atherosclerosis who
are at high cardiovascular or surgical risk for open aortob-
ifemoral bypass may be treated with axillofemoral-femoral
bypass. This bypass utilizes either polyester filament or
PTFE graft material to carry blood from the axillary artery to
1 of the femoral arteries. A second femoral-femoral bypass is
then constructed to provide perfusion of the contralateral
extremity. Because of lower patency rates, such bypasses are
reserved for those who have no alternatives for revascular-
ization. The procedure is uncommonly performed for claudi-
cation.
Table 23. Vascular Surgical Procedures for Inflow Improvement
Operative Expected Patency
Inflow Procedure Mortality (%) Rate (%) References
Aortobifemoral bypass 3.3 87.5 (5 years) (485)
Aortoiliac or aortofemoral bypass 1 to 2 85 to 90 (5 years) (486-488)
Iliac endarterectomy 0 79 to 90 (5 years) (489-491)
Femorofemoral bypass 6 71 (5 years) (492)
Axillofemoral bypass 6 49 to 80 (3 years) (493, 494)
Axillofemoral-femoral bypass 4.9 63 to 67.7 (5 years) (495, 496)
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strongly favored for bypasses to the popliteal artery below
the knee. Femoral-tibial bypass grafting with autogenous
vein should rarely be necessary for the treatment of intermit-
tent claudication because of the increased risk of amputation
associated with failure of such grafts. Bypasses to the tibial
arteries with prosthetic material should be avoided at all
costs for the treatment of the claudicant because of very high
risks of graft failure and amputation (511,512).
2.6.2.5.5. FOLLOW-UP AFTER VASCULAR
SURGICAL PROCEDURES.
RECOMMENDATIONS
Class I
1. Patients who have undergone placement of aortob-
ifemoral bypass grafts should be followed up with
periodic evaluations that record any return or pro-
gression of claudication symptoms, the presence of
femoral pulses, and ABIs at rest and after exercise.
(Level of Evidence: C)
2. Patients who have undergone placement of a lower
extremity bypass with autogenous vein should under-
go periodic evaluations for at least 2 years that record
any claudication symptoms; a physical examination
and pulse examination of the proximal, graft, and out-
formed infrainguinal bypass for the treatment of claudication
is the femoral-popliteal artery bypass (Table 24). This type of
bypass can be performed under general or regional anesthe-
sia (and, under rare circumstances, under local anesthesia), is
generally well tolerated, and will reduce or may eliminate the
symptoms of claudication. There are, however, specific fac-
tors that may modify the result of this procedure. The 2 major
factors are the type of conduit and the site of anastomosis to
the popliteal artery, whether above or below the knee. 
Nearly all studies that have compared vein with prosthetic
conduit for arterial reconstruction of the lower extremity
have demonstrated the superior patency of vein. Four large,
randomized, prospective studies summarized in Table 25
demonstrate findings consistent with the large body of evi-
dence on the choice of graft material for the construction of
bypasses to the above-knee popliteal artery (483,508-510).
The superior rates of immediate and long-term patency at all
time periods favor use of autogenous vein, whether in situ or
reversed. In its absence, PTFE or polyester filament may be
used with an expected lower but acceptable patency rate. The
need for retreatment or revision is greater with synthetic
material over time. With more distal anastomoses or the pres-
ence of hemodynamically significant tibial arterial occlusive
disease and poor outflow, there is accelerated failure of pros-
thetic grafts. Therefore, the use of autogenous vein is also
Table 24. Vascular Surgical Procedures for Outflow Improvement
Operative Expected Patency
Outflow Procedure Mortality (%) Rate (%) References
Fem-AK popliteal vein 1.3 to 6.3 66 (5 years) (437,498,499)
Fem-AK popliteal prosthetic 1.3 to 6.3 50 (5 years) (483,508-510)
Fem-BK popliteal vein 1.3 to 6.3 66 (5 years) (498,499)
Fem-BK popliteal prosthetic 1.3 to 6.3 33 (5 years) (437,498,499)
Fem-Tib vein 1.3 to 6.3 74 to 80 (5 years) (500a)
Fem-Tib prosthetic 1.3 to 6.3 25 (3 years) (502)
Composite sequential bypass 0 to 4 28 to 40 (5 years) (503,504)
Fem-Tib blind segment bypass 2.7 to 3.2 64 to 67 (2 years) (505)
Profundaplasty 0 to 3 49 to 50 (3 years) (506,507)
AK indicates above the knee; BK, below the knee; Fem, femoral; and Tib, tibial.
Table 25. Patency of Above-Knee Femoral Popliteal Bypass Grafts According to Prospective Randomized Trials
Graft No. of  % Patency (Years)
First Author Reference Material Patients 2 5 5 Assisted 6 6 Assisted
Johnson (509) SVG 226 81 73
PTFE 265 69 39
Klinkert (510) SVG 75 75.6 79.7
PTFE 76 51.9 57.2
AbuRahma (508) SVG 43 76 83
PTFE 43 68 68
Green (483) PTFE 43 68
Polyester fiber 45 68
PTFE indicates polytetraflouoroethylene; and SVG, saphenous vein graft.
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amputation for distal ischemia. Chronic CLI is associated
with a 1-year mortality rate greater than 20% (1). Nearly half
of the cases will require revascularization for limb salvage.
Among those who have unreconstructable disease, approxi-
mately 40% will require major amputation within 6 months
of initial diagnosis. This natural history mandates a more
aggressive approach to control of atherosclerosis risk factors
and treatment of underlying ischemia on the part of physi-
cians caring for this critically ill group of patients.
Critical limb ischemia occurs most frequently when 2 or
more levels of the distal arterial tree are compromised by
either hemodynamically significant stenoses or occlusion.
Although this usually manifests in aortoiliac and femoral-
popliteal segments or the femoral-popliteal and tibial seg-
ments, it may also occur in the setting of parallel arterial
segments, such as superficial and deep femoral artery occlu-
sions. The multiple levels of disease decrease the effective-
ness of major autogenous collateral vessel flow and reduce
systolic driving pressures in the periphery. As pressure is
lowered in the distal arterioles, and occasionally also raised
in the distal venules by inactivity and venous stasis, the pres-
sure gradient across capillary beds is decreased, which
reduces perfusion below the level required to sustain basal
tissue metabolism. This results in slowly progressive tissue
death and, ultimately, amputation if allowed to persist uncor-
rected. The most common manifestations of CLI are rest pain
in the forefoot and toes that is sufficiently severe as to inter-
fere with sleep and ischemic ulcers or ischemic gangrene of
the forefoot or toes. There may be calf atrophy, dependent
rubor and elevation pallor, loss of hair over the dorsum of the
foot, thickening of the toenails, and shiny, scaly skin due to
loss of subcutaneous tissue. These are indications of severe
tissue ischemia. Therefore, any patient who presents with
clinical evidence of CLI should be evaluated rapidly, with
initiation of treatment as soon as is clinically feasible.
Patients who are ambulatory (or who have been ambulatory
immediately before this episode of CLI), have a life
expectancy of more than 1 year (owing to comorbid condi-
tions), and whose general medical condition is adequate to
withstand surgical intervention should be considered for
lower extremity revascularization.
flow vessels; and duplex imaging of the entire length
of the graft, with measurement of peak systolic veloc-
ities and calculation of velocity ratios across all
lesions. (Level of Evidence: C)
3. Patients who have undergone placement of a synthet-
ic lower extremity bypass graft should, for at least 2
years after implantation, undergo periodic evalua-
tions that record any return or progression of claudi-
cation symptoms; a pulse examination of the proxi-
mal, graft, and outflow vessels; and assessment of
ABIs at rest and after exercise. (Level of Evidence: C)
Inflow Procedures. In a meta-analysis of 8123 aortob-
ifemoral bypasses, DeVries and Hunink documented a mean
5-year patency rate of 85.8%, with a range of 85% to 89%,
and a mean 10-year patency rate of 79.4%, with a range of
78% to 83% (485). Aortoiliac endarterectomy is infrequent-
ly performed today, but patencies similar to aortobifemoral
grafting have been reported when patients are selected care-
fully and the procedure is performed appropriately. In a
review by Brothers and Greenfield, the 10-year primary
patency rate ranged from 48% to 77% (513). 
Unilateral iliac percutaneous angioplasty and femoral-
femoral bypass are associated with only slightly lower paten-
cy. In large series, patencies of 78% to 92% at 1 year and
66% at 7 years have been reported (514,515). Perler and
Williams noted a similar patency for femoral-femoral bypass
in the setting of unilateral iliac occlusion without donor limb
disease, with patencies of 73% at 1 year and 59% at 5 and 7
years (515).
Iliac endarterectomy and aortoiliac bypass for the treatment
of unilateral iliac artery occlusive disease are durable proce-
dures for the restoration of inflow. In a large review, Szilagyi
and colleagues noted a 5-year patency rate of 90% (516). 
Axillofemoral-femoral bypasses have significantly poorer
patency than other inflow procedures. Johnson and Lee
reported a 1-year patency rate of 62% and a 5-year rate of
47% in a prospective, randomized, multicenter Veterans
Administration study (517). 
Outflow Procedures. The results of femoral above-knee
popliteal bypasses for each type of graft material are listed in
Table 26. Similar outcomes were noted by Hunink and col-
leagues in an analysis of literature from 1970 to 1996 that
reported patency in patients undergoing femoral-popliteal
bypass, as noted in Table 26 (437). Successful vascular sur-
gical intervention will reduce or eliminate symptoms in the
majority of patients. 
2.6.3. Critical Limb Ischemia and Treatment 
for Limb Salvage
Critical limb ischemia differs from intermittent claudication
by virtue of its natural history. Approximately 5% of patients
with intermittent claudication will require a revascularization
intervention for lifestyle-limiting ambulatory symptoms or
progression to CLI, and only 2% will ultimately require
Table 26. Patency of Bypass Grafts Placed for Treatment of
Claudication
5-Year Patency (%)
Material Mean Range
Vein 80 78 to 87
PTFE above knee 75 67 to 83
PTFE below knee 65 56 to 76
PTFE indicates polytetraflouoroethylene.
Reprinted with permission from Hunink MG, Wong JB, Donaldson MC, et al.
Patency results of percutaneous and surgical revascularization for femoropopliteal
arterial disease. Med Decis Making. 1994;14:71-81 (437).
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Class III
Oral iloprost is not an effective therapy to reduce the
risk of amputation or death in patients with CLI.
(Level of Evidence: B)
Vasodilator prostaglandins, including PGE-1, iloprost, and
ciprostene, have been evaluated in multiple placebo-con-
trolled trials as potentially efficacious agents in patients with
CLI who are not candidates for revascularization procedures.
These drugs have been administered either intra-arterially or
intravenously, either for relatively short periods (3 to 4 days)
or by more long-term infusions (7 to 28 days) (1). There have
been at least 8 short-term trials of parenteral administration
of PGE-1 or prostacyclin in patients with CLI. The results
have been inconsistent and for the most part have not demon-
strated efficacy in terms of amelioration of pain or healing of
ulcers (1,521-527). In addition, there have been at least 11
randomized, placebo-controlled trials of intravenous PGE-1,
or iloprost, administered for 7 to 28 days (1). Prostaglandin
E1 has been administered in various dosing schedules, for
example, 60 to 80 micrograms over 2 to 4 hours per day and
iloprost in doses of 0.5 to 2 ng per kg per min over 6 hours
each day. The majority of studies have found that parenteral
administration of either PGE-1 or iloprost reduced pain, as
assessed by analgesic consumption, ulcer size, and/or ampu-
tation (1,528-536). The largest of these trials was conducted
by the Ischemia Cronica degli Arti Inferiori study group and
comprised 1560 patients with CLI. In that trial, intravenous
PGE-1 administered for 28 days caused a statistically signif-
icant, albeit marginal, improvement in CLI manifested as
ischemic pain and ulcer healing at 6 months (530). There
were no significant reductions in the risk for amputation or
mortality. One study evaluated the efficacy of oral iloprost in
patients with CLI. Iloprost, administered in doses of 50 to
200 micrograms per day, did not significantly affect the pri-
mary end point of amputation or death at 1 year (537).
2.6.3.1.3. ANGIOGENIC GROWTH FACTORS.
RECOMMENDATION
Class IIb
The efficacy of angiogenic growth factor therapy for
treatment of CLI is not well established and is best
investigated in the context of a placebo-controlled
trial. (Level of Evidence: C)
As discussed previously, angiogenic growth factors have
been demonstrated to improve collateral blood vessel forma-
tion in experimental models of hind limb ischemia
(390,391). For this reason, they are considered as potentially
efficacious treatments for patients with CLI. The angiogenic
growth factors currently undergoing investigation include
recombinant bFGF and gene transfer of VEGF or hypoxia-
inducible factor-1a administered as plasmid DNA or with an
adenovirus vector encoding the angiogenic growth factor.
Initial studies of gene transfer therapy with a VEGF plasmid
DNA (phVEGF165) was accomplished via intra-arterial
There is a subgroup of patients with severely impaired dis-
tal perfusion who deny rest pain and have no evidence of
ischemic ulcers or ischemic gangrene. They are frequently
sedentary and report no symptoms of claudication or exer-
cise intolerance. These patients are considered to have sub-
clinical CLI (518). In the absence of indicators of ischemic
deterioration of the distal limb, they require no immediate
intervention. Patients with subclinical CLI, however, are at
high risk for rapid distal tissue compromise and loss after
even minor soft tissue trauma and should be carefully fol-
lowed up with periodic examinations.
2.6.3.1. Medical and Pharmacological 
Treatment for CLI
RECOMMENDATION
Class III
Parenteral administration of pentoxifylline is not use-
ful for the treatment of CLI. (Level of Evidence: B)
Medical therapies for CLI that decrease pain, promote
healing of skin lesions and ulceration, and reduce the risk for
amputation would be attractive alternatives to surgical recon-
struction procedures. Such therapies would need to improve
blood flow sufficiently to meet the resting metabolic needs of
limb tissue. Conceptually, this might be accomplished by a
drug that increased microcirculatory blood flow or that aug-
mented collateral blood supply to the ischemic portion of the
limb. The drug class that has undergone the most intensive
investigation in this regard is vasodilator prostaglandins.
More recently, phase 1 and phase 2 clinical trials have been
undertaken to assess the efficacy of angiogenic growth fac-
tors. However, at this time, there is no drug approved for
treatment of CLI.
2.6.3.1.1. PENTOXIFYLLINE AND CILOSTAZOL. Pentoxifylline is
a xanthine derivative that has vasodilator and hemorheolog-
ic properties that might be considered helpful in patients with
CLI. Two placebo-controlled trials have evaluated pentoxi-
fylline 600 mg intravenously, twice daily, in the treatment of
patients with CLI (519,520). In the first study, intravenous
infusion of pentoxifylline was associated with lessened pain
scores (519). In the other study, no significant benefit was
realized by the patients treated with pentoxifylline (520).
Cilostazol, a drug approved for the treatment of patients with
intermittent claudication, has not been adequately evaluated
to demonstrate efficacy in patients with CLI. 
2.6.3.1.2. PROSTAGLANDINS.
RECOMMENDATIONS
Class IIb
Parenteral administration of PGE-1 or iloprost for 7
to 28 days may be considered to reduce ischemic pain
and facilitate ulcer healing in patients with CLI, but
its efficacy is likely to be limited to a small percentage
of patients. (Level of Evidence: A)
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to consider include the urgency of the clinical presentation,
the presence of comorbidity, and the arterial anatomy. First,
the distinction must be made between patients presenting
with acute limb ischemia (described in Section 2.4.4) versus
limb-salvage situations that are subacute or chronic. The for-
mer require rapid intervention via endovascular or surgical
means. Therapy for the latter can be planned in a staged, or
even contingent, fashion. For example, less invasive tech-
niques can often be attempted initially, with the contingency
of open surgery should the PTA fail (542). On occasion, the
converse may also apply, wherein surgery is used as the first
step and percutaneous revascularization applied as a salvage
procedure in the event that surgery fails. 
Other clinical scenarios will also dictate the initial
approach to the patient with CLI. In patients presenting with
late-stage or life-threatening ischemia, or in those presenting
with gross infection with septic or gas gangrene, emergency
amputation of the extremity may be necessary to prevent cat-
astrophic or life-threatening circulatory collapse. The
requirement for revascularization in patients undergoing
limb removal will depend on whether perfusion to the ampu-
tation site is sufficient to enable healing. 
The presence of patient comorbidities also influences deci-
sions regarding optimal management in a given patient. The
presence of cardiovascular or cerebrovascular disease is a
major consideration in this population of patients. Patients
with cardiac ischemia, cardiomyopathy, congestive heart fail-
ure, severe lung disease, or renal failure are known to be at
greater risk for adverse perioperative events. It is generally
accepted that in such patients, initial percutaneous revascu-
larization, if feasible, is preferred over surgical approaches.
Details of each patient’s arterial anatomy will also guide
the choice of revascularization. A significant improvement in
inflow may diminish the symptoms of rest pain, but pulsatile
flow to the foot is generally necessary for the treatment of
ischemic ulcers or ischemic gangrene. Therefore, if infec-
tion, ischemic ulcers, or gangrenous lesions persist and the
ABI is less than 0.8 after correction of inflow, an outflow
procedure should be performed that bypasses all major distal
stenoses and occlusions (552). The angiographic evaluation
may also suggest the presence of arterial stenoses the func-
tional significance of which may not be clear. In this situa-
tion, measurement of transstenotic pressure gradients can
guide therapy. However, in the presence of severe outflow
disease, an inaccurately low pressure gradient may exist.
Severe outflow disease may so limit arterial flow that gradi-
ents are not developed, and in this context, use of a pharma-
cological arterial vasodilator to augment flow may be useful
to augment the measured gradient.
Regardless of initial treatment strategy, a key determinant
of the long-term outcome is the requirement for intensive
follow-up surveillance. Although no formal guidelines exist
for monitoring patients after percutaneous therapy for CLI,
there is general agreement that these individuals should be
subjected to regular evaluation, examination of the affected
limb, and noninvasive testing. Early and prompt reinterven-
administration in several nonrandomized, open-label trials
(538-540). Some patients in these trials experienced
improvement in blood flow, as well as angiographic and his-
tological evidence of new blood vessel formation. A subse-
quent open-label trial used intramuscular gene transfer of
phVEGF165 to 9 patients and reported new collateral blood
vessel formation, an increase in ABI, and healing of ischemic
ulcers in some of the participants (541). Larger placebo-con-
trolled trials are in progress to evaluate the efficacy of angio-
genic growth factors in patients with CLI.
2.6.3.2. Endovascular Treatments for CLI
RECOMMENDATIONS
Class I
1. For individuals with combined inflow and outflow dis-
ease with CLI, inflow lesions should be addressed
first. (Level of Evidence: C)
2. For individuals with combined inflow and outflow dis-
ease in whom symptoms of CLI or infection persist
after inflow revascularization, an outflow revascular-
ization procedure should be performed. (Level of
Evidence: B) 
3. If it is unclear whether hemodynamically significant
inflow disease exists, intra-arterial pressure measure-
ments across suprainguinal lesions should be meas-
ured before and after the administration of a vasodila-
tor. (Level of Evidence: C)
As defined in Section 2.4.3, the term “critical limb
ischemia” identifies the clinical scenario in which resting
metabolic requirements of an extremity outstrip its arterial
perfusion, which places tissue viability in jeopardy. The
patient presentation and clinical course with CLI may vary,
depending on patient and arterial lesion characteristics, and
may range from extremity pain at rest and with exertion to
trophic changes that include ulceration or gangrene. Critical
limb ischemia often occurs in conjunction with diabetes mel-
litus, chronic renal insufficiency, and other systemic disease
states associated with diffuse, multisegmental, and small-
vessel arterial narrowing in the extremities. Critical limb
ischemia may also be precipitated by certain unique disease
entities, including atheroembolism, thromboembolism, in
situ thrombosis, vasculitis, and thromboangiitis obliterans.
Strategies for management of patients with CLI have
evolved considerably in the past decade, in step with the dra-
matic advances in endovascular technology and technique.
Historically, patients presenting with CLI underwent arterial
bypass surgery or amputation of the affected extremity.
However, as catheter, wire, balloon, and stent technology
have all improved, percutaneous strategies are increasingly
being used to successfully treat CLI (417,542-545). Even
complex arterial lesions, such as lengthy occlusions of the
iliac, femoral, and tibial arteries, can often be addressed
effectively by less invasive strategies (546-551).
The optimal strategy for management of a patient with CLI
must be determined on a case-by-case basis. Important issues
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tion is indicated for restenosis to maximize the chances of
wound healing and to maintain the integrity of the limb.
Optimal management of patients with CLI requires the care
of practitioners with knowledge of the capabilities of both
percutaneous and surgical revascularization. Frequently, this
is best accomplished with a multidisciplinary approach.
Determination of optimal strategy in the future will likely be
based on accumulating evidence and data, wherein patient
and lesion substrate, functional outcome measures, and cost
analyses will be standardized to enable comparison among
pure endovascular, pure surgical, and combined percuta-
neous/surgical approaches (553). As the short- and long-term
outcomes of catheter-based interventions continue to
improve, it is likely that these techniques may be used in an
increasing spectrum of patients presenting with CLI.
2.6.3.3. Thrombolysis for Acute and Chronic 
Limb Ischemia
RECOMMENDATIONS
Class I
Catheter-based thrombolysis is an effective and bene-
ficial therapy and is indicated for patients with acute
limb ischemia (Rutherford categories I and IIa) of less
than 14 days’ duration. (Level of Evidence: A)
Class IIa
Mechanical thrombectomy devices can be used as
adjunctive therapy for acute limb ischemia due to
peripheral arterial occlusion. (Level of Evidence: B)
Class IIb
Catheter-based thrombolysis or thrombectomy may
be considered for patients with acute limb ischemia
(Rutherford category IIb) of more than 14 days’ dura-
tion. (Level of Evidence: B)
Catheter-based treatment of intra-arterial thrombus has
been used successfully as a treatment to recanalize acutely
occluded arteries associated with acute limb ischemia.
Catheter-based treatment of arterial thrombus includes local-
ized intra-arterial infusions of thrombolytic medications
and/or use of mechanical thrombectomy devices to fragment
and remove the clot. Intra-arterial, local catheter-based infu-
sions of thrombolytic agents have replaced systemic (intra-
venous) infusions of thrombolytic agents owing to poor effi-
cacy and increased adverse event rates with intravenous
administration of lytic drugs (554).
Randomized, controlled trials and registry reports indicate
that the use of thrombolytic therapy for acute limb ischemia
is effective as initial therapy. Graor and coworkers reported
a series in which thrombolysis was demonstrated to be supe-
rior to surgery for salvage of failed or failing bypass grafts
(555). Similar benefits of catheter-directed thrombolytic
therapies have been demonstrated with differing thrombolyt-
ic agents in both native arteries and thrombosed bypass
grafts (556-558). Three large, randomized, prospective clini-
cal trials have been performed. The Rochester trial random-
ized patients with acute native arterial or bypass graft occlu-
sions of less than 7 days’ duration to treatment with either
urokinase or surgery (559). These patients were selected
such that if revascularization was not successful, amputation
would be required. Amputation-free survival favored throm-
bolytic therapy (75% vs. 52% for surgery, p less than 0.05).
Limb salvage at 12 months was identical between the 2
groups (82%), but survival at 12 months was higher for the
lytic group (84% vs. 58% for surgery, p equals 0.01). This
survival difference was primarily attributable to an excess of
in-hospital major cardiopulmonary complications in the sur-
gery group (49% vs. 16% in the thrombolytic group, p equals
0.001). The Surgery versus Thrombolysis for Ischemia of the
Lower Extremity (STILE) trial randomized patients with
nonembolic occlusions who presented with new or progres-
sive limb ischemic symptoms of up to 6 months’ duration to
treatment with either urokinase or surgery (560,561). In
patients with symptom onset of less than 14 days, catheter-
based thrombolysis yielded a superior outcome to surgery.
The amputation rate for patients treated within 14 days of the
onset of symptoms was 6% for thrombolysis and 18% for
surgical therapy. For patients with symptoms of greater than
14 days’ duration, surgery was more effective and durable,
with less recurrent ischemia at 1 year (35% for surgery vs.
65% for lysis). The Thrombolysis or Peripheral Arterial
Surgery (TOPAS) trial randomized patients with acute native
arterial or bypass graft occlusions of less than 14 days’ dura-
tion to treatment with either intra-arterial urokinase or sur-
gery (562). Six-month and 12-month amputation-free sur-
vival was similar with the 2 treatments (65% to 75%). The
thrombolysis group required 40% fewer open procedures but
had a higher rate of major bleeding (12.5% vs. 5.5%), pri-
marily related to the vascular access site, which was exacer-
bated by concomitant heparin use. A meta-analysis compar-
ing lysis and surgery that included these randomized trials
and case series concluded that lysis improved 30-day and 6-
to 12-month limb salvage and reduced mortality compared
with surgery (563).
These randomized trials and case series suggest that the use
of intra-arterial thrombolytic therapy for acute limb ischemia
is reasonably effective and comparable to surgery. The
advantage of thrombolytic therapy is that it offers a low-risk
alternative to open surgery in complex patients with severe
comorbidities. Other advantages of pursuing immediate
angiography in patients with acute limb ischemia include
delineation of the limb arterial anatomy with visualization of
both inflow and runoff vessels. Finally, thrombolytic therapy
has an advantage, compared with surgical embolectomy, of
clearing intra-arterial thrombus from the distal runoff ves-
sels, thereby potentially enhancing long-term patency.
The choice of thrombolytic versus surgical revasculariza-
tion depends on several factors (1). Patients with profound
limb ischemia may not tolerate the time necessary to perform
thrombolysis. Infra-inguinal or distal arterial thrombolysis
has worse outcomes than more proximal or iliofemoral lysis
(561). Because of bleeding risks, thrombolysis may be con-
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2.6.3.4. Surgery for CLI
RECOMMENDATIONS
Class I
1. For individuals with combined inflow and outflow dis-
ease with CLI, inflow lesions should be addressed
first. (Level of Evidence: B)
2. For individuals with combined inflow and outflow dis-
ease in whom symptoms of CLI or infection persist
after inflow revascularization, an outflow revascular-
ization procedure should be performed. (Level of
Evidence: B)
3. Patients who have significant necrosis of the weight-
bearing portions of the foot (in ambulatory patients),
an uncorrectable flexion contracture, paresis of the
extremity, refractory ischemic rest pain, sepsis, or a
very limited life expectancy due to comorbid condi-
tions should be evaluated for primary amputation of
the leg. (Level of Evidence: C)
Class III
Surgical and endovascular intervention is not indicat-
ed in patients with severe decrements in limb perfu-
sion (e.g., ABI less than 0.4) in the absence of clinical
symptoms of CLI. (Level of Evidence: C)
The mortality associated with distal arterial vascular surgi-
cal reconstruction in appropriately selected candidates is 0%
to 6% (501,595). For major amputation of the lower extrem-
ity, the risks are significantly greater. Major amputation of
the lower extremity is associated with a 30-day mortality risk
of 4% to 30% and a 20% to 37% risk of significant morbid-
ity, such as MI, stroke, and infection (596-599). The difficul-
ties of rehabilitation and the high likelihood of inability to
ambulate with a prosthesis in many older patients portend a
significant negative long-term impact on the patient’s quali-
ty of life and independence (600). Therefore, as described in
Section 2.6.3.2, revascularization by endovascular tech-
niques, surgical techniques, or both should be considered the
primary approach to the treatment of patients with CLI
unless patient survival is very limited, the likelihood of inde-
pendent ambulation is poor because of tissue necrosis or
flexion contracture, or the patient’s general medical condi-
tion is poor.
The goal of surgical intervention in patients with CLI is the
elimination of clinical manifestations of severe lower
extremity PAD, whether rest pain, ischemic ulcers, or distal
ischemic gangrene. Surgery for the treatment of severe lower
extremity ischemia (as for endovascular treatment) must be
based on specific goals, such as the relief of rest pain or heal-
ing of ulcers, prior revascularization attempts, the type of
procedure required to accomplish the goals, and the patient’s
overall ability to successfully recover from the effort. In
patients with combined inflow and outflow disease, inflow
problems must be corrected first. 
traindicated in some patients. Contraindications have been
summarized, although these recommendations are based on
common practice and are not necessarily supported by pub-
lished studies. Because of comorbidities, surgery may be
contraindicated in some patients.
Most of the literature supporting the use of thrombolysis
has used urokinase as the lytic drug. Other drugs that have
been studied include pro-urokinase (not currently available),
alteplase, reteplase, tenecteplase, and streptokinase.
Streptokinase has been largely abandoned owing to lower
efficacy and increased bleeding complications compared
with urokinase (564,565). The optimal dosage and concen-
tration of alteplase, reteplase, and tenecteplase and the opti-
mal dose of adjunctive heparin are still under investigation.
Alteplase has been reported to be as effective as or more
effective than urokinase, with similar or higher bleeding
rates (557,566-572). Reteplase has been studied in small
series with outcomes similar to urokinase (573,574), with the
best dosage and concentration still under investigation (575).
The results of a pilot study with tenecteplase have been
reported (576). Although a number of comparative trials
have been published, there is no single agent that has consis-
tently demonstrated superiority (577-579). One randomized
trial (577) demonstrated more rapid thrombus dissolution
with tissue plasminogen activator than with urokinase (577-
579). 
Small series have reported the results of combined throm-
bolytic and intravenous antiplatelet therapy (glycoprotein
IIb/IIIa platelet inhibitors) and have suggested that the com-
bination may increase lysis effectiveness, decrease time to
complete lysis, and possibly increase bleeding (557,580-
583). The risk/benefit and cost/benefit ratio of these strate-
gies, compared with catheter-directed thrombolysis or
thrombectomy alone, remain to be demonstrated in larger
comparative trials. Nonrandomized trials and small series
have also reported on the use of mechanical thrombectomy
devices, which may avert the need for thrombolysis or per-
mit the use of decreased doses of thrombolytic drugs (Table
27) (584,585). Mechanical thrombectomy was used in 21
patients (22 vessels [limbs]) who presented to the hospital
within 2 weeks of the development of limb-threatening
ischemia. Fifty-two percent had contraindications to throm-
bolytics, and 57% had severe comorbidities. All of the target
vessels were occluded with thrombus on the initial
angiogram. Procedural success was achieved in 20 limbs
(91%). Acute limb salvage was achieved in 18 (95%) of 19
limbs in the 18 survivors, and 6-month limb salvage was
achieved in 16 (89%) of 18 limbs in the 17 survivors. The
authors concluded that rheolytic thrombectomy was effective
in restoring immediate blood flow in acute limb-threatening
ischemia, especially in high-risk surgical patients and
patients with contraindications to thrombolytic therapy
(584). 
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Table 27. Mechanical Thrombectomy Devices for the Treatment of Peripheral Arterial Occlusions
Device and 
First Author Conduit, MTD Success,* Adjunctive 
(Reference No.) Year n n (%) Duration, n n (%) Procedures
Oasis, 1999 51 Native: 44 (86) All acute 6 (11.8) Lysis: 5
Hopfner (143) Grafts: 7 (14) PTA: 20
PAT: 15
SA: 3
Angiojet
Muller-Hulsbeck 2000 112 Native: 99 (86) All acute 79 (71) Lysis: 20
(144) Grafts: 16 (14) PTA: 68
PAT: 11
Kasirajan (145) 2001 83 Native: 52 (63) Acute: 62 Complete: 51 (61) Lysis: 50
Grafts: 31 (37) Chronic: 21 Partial: 19 (23) PTA: 47
Silva (146) 1998 22 Native: 13 (59) All acute 21 (95) PTA: 21
Grafts: 9 (41)
Wagner (147) 1997 50 Native: 39 (78) All acute 26 (52) Lysis: 15
Grafts: 11 (22) PTA: 34
PAT: 9
Hydrolyser
Reekers (148) 1996 28 Native: 11 (39) Acute: 23 23 (82) Lysis: 11
Grafts: 17 (61) Chronic: 5 PTA: 20
PAT: 2
Henry (149) 1998 41 Native: 28 (68) All acute 34 (83) Lysis: 10
Grafts: 8 (20) PTA: 29
Other: 5 PAT: 17
Amplatz
Rilinger (150) 1997 40 All native All acute 30 (75) Lysis/PTA/
SA: 9
Tadavarthy (151) 1994 14 Native: 2 (14) Acute: 9 10 (71) Lysis: 4
Grafts: 10 (71) Chronic: 5 PTA/SA: 11
Other: 2
Gorich (152) 1998 18 All native All acute 14 (78) Lysis: 12
PAT: 9
MTD indicates mechanical thrombectomy device; n, number of patients; NA, not applicable; PAT, percutaneous aspiration thrombectomy; PTA, percutaneous transluminal angioplasty; SA, Simpson atherectomy.
*Definition of success varies among studies.
Reprinted with permission from Haskal ZJ. Mechanical thrombectomy devices for the treatment of peripheral arterial occlusions. Rev Cardiovasc Med 2002;3 Suppl 2:S45-S52 (594a).
Primary Patency (%) Complications (%)
1 month: 64 Hemorrhage: 8
6 months: 54 Emboli: 4.8
Acute occlusion: 3
Amputation: 17.7
Mortality: 8
6 months: 68 Embolization: 9.8
2 years: 60 Dissection: 8
3 years: 58 Perforation: 3.6
Amputation: 1.8
Mortality: 7
3 months: 90 Hemorrhage: 10.5
6 months: 78 Emboli: 2.3
Dissection: 3.5
Perforation: 2.3
Amputation: 11.6
Mortality: 9.3
NA Hemorrhage: 10
Embolism: 9
Dissection: 5
Occlusion: 18
Amputation: 5
Mortality: 14
1 year : 69 Hemorrhage: 6
Emboli: 6
Dissection:6
Perforation: 6
Amputation: 8
Mortality: 0
1 month: 50 Embolization: 18
Hemorrhage: 0
Acute occlusion: 10
Amputation: 11
Mortality: 0
1 month: 73 Acute occlusion: 12
Emboli: 2.4
Amputation: 0
Mortality: 0 
NA Hemorrhage: 2.5
Device failure: 7.5
Emboli: 0
Amputation: 5
Mortality: 0
6 months: 43 Hemorrhage: 14.3
Emboli: 14
Device failure: 7
Amputation: 0
Mortality: 0
NA Hemorrhage: 6
Device failure: 6
Amputation: 6
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If the aortoiliac lesions are confined to the area of the aor-
considered. This procedure is effective but is uncommonly
performed because few patients have such a limited mani-
festation of atherosclerosis. Aortoiliac endarterectomy
remains an excellent surgical option but is used infrequently
because of the often extensive nature of the occlusive disease
in patients with CLI. Nonetheless, when the operation is
indicated, the results demonstrate good patency, in the range
of 48% to 77% at 10 years (513). 
For patients with adequate aortic flow but stenoses or
occlusions of both iliac vessels who are not considered to be
acceptable candidates for aortobifemoral bypass, a some-
what less invasive approach may be appropriate. If 1 iliac
artery can be made widely patent by angioplasty and stent
placement, endarterectomy, or a unilateral iliofemoral
bypass, a femoral-femoral bypass can be constructed. In the
absence of an inflow stenosis within the donor iliac arterial
segment, this procedure can effectively improve flow to both
lower extremities. Unilateral iliac stenoses or occlusions that
cannot be treated effectively by angioplasty and stent place-
ment can be treated by iliac artery endarterectomy, aortoiliac
bypass, aortofemoral bypass, or iliofemoral bypass if the ori-
gin of the iliac artery is free of disease. These procedures can
be performed through a small flank incision into the
retroperitoneum and are usually well tolerated..
The surgical treatment of unilateral iliac disease by aortoil-
iac, iliofemoral, or femorofemoral bypass graft placement
provides excellent results for the restoration of inflow into
the lower extremity. Ipsilateral bypasses originating from the
aorta or proximal iliac artery have a 3-year patency rate in
the range of 90% (487,602). Femorofemoral bypass grafting
yields a 3-year patency rate that ranges from 60% to 80% and
a 5-year patency rate of 60% to 90% (514,603).
Patients with severe infrarenal aortic atherosclerosis who
are at high cardiovascular or surgical risk for open aortob-
ifemoral bypass may be treated with axillofemoral-femoral
bypass. This bypass uses either polyester filament or PTFE
graft material to carry blood from the axillary artery to 1 of
the femoral arteries. A second femoral-femoral bypass is then
constructed to provide perfusion of the contralateral extrem-
ity. Because this graft is based on the axillary artery, preop-
erative assessment of bilateral arm blood pressures, duplex
ultrasound flow assessments, and/or imaging of the aortic
arch and great vessels to the origin of the donor vessel should
be obtained. 
Axillofemoral and axillobifemoral grafts are significantly
inferior to aortobifemoral bypass grafts or aortoiliac
endarterectomy for the treatment of severe diffuse aortoiliac
disease. The 5-year patency rate for axillofemoral grafts
ranges from 19% to 50% (173,604). The results of axillob-
ifemoral bypass are somewhat better, with 5-year patency
rates ranging from 50% to 76% (605).
2.6.3.4.1. INFLOW PROCEDURES: 
AORTOILIAC OCCLUSIVE DISEASE.
RECOMMENDATIONS
Class I
1. When surgery is to be undertaken, aortobifemoral
bypass is recommended for patients with sympto-
matic, hemodynamically significant, aorto-bi-iliac dis-
ease requiring intervention. (Level of Evidence: A)
2. Iliac endarterectomy, patch angioplasty, or aortoiliac
or iliofemoral bypass in the setting of acceptable aor-
tic inflow should be used for the treatment of unilat-
eral disease or in conjunction with femoral-femoral
bypass for the treatment of a patient with bilateral
iliac artery occlusive disease if the patient is not a suit-
able candidate for aortobifemoral bypass grafting.
(Level of Evidence: B)
3. Axillofemoral-femoral bypass is indicated for the
treatment of patients with CLI who have extensive
aortoiliac disease and are not candidates for other
types of intervention. (Level of Evidence: B)
There are numerous patterns of aortoiliac occlusive disease
and procedures to surgically treat them (Table 24). Most
commonly, patients demonstrate diffuse disease of the
infrarenal aorta and iliac vessels, with the lesions of greatest
hemodynamic consequence located in the iliac arteries. The
most effective surgical procedure for the treatment for this
pattern of atherosclerotic occlusive disease is aortobifemoral
bypass. Through a transabdominal or retroperitoneal
approach, this bypass is constructed by sewing the proximal
end of a bifurcated polyester filament or PTFE graft, usually
end-to-end, to the aorta immediately below the origins of the
renal arteries. The distal graft limbs are sewn to the distal
common femoral arteries or onto the proximal deep femoral
arteries, if the superficial femoral arteries are occluded, to
provide adequate outflow for the graft limbs and improved
collateral flow to the popliteal arteries. 
Aortobifemoral grafting is associated with an operative
mortality of 3.3% and a morbidity of 8.3% (485). Major mor-
bidity is most commonly due to MI (0.8% to 5.2%) or renal
failure (0% to 4.6%) (536,601). The expected patency of aor-
tobifemoral bypass as the sole procedure for the treatment of
CLI is excellent. A meta-analysis of major studies published
after 1975 reported a limb-based 5-year primary patency rate
of 87.5% and a patient-based 5-year patency of 80.4% (485).
This changed little in the subsequent 5 years, with a limb-
based 10-year patency rate of 81.8% and a patient-based 10-
year patency of 72.1%. The site of distal anastomosis,
whether to the common femoral artery when the superficial
femoral artery is open or to the profunda femoris artery when
the superficial femoral artery is occluded, has little impact.
In a report of a large series of predominantly limb-salvage
patients, 5-year patency was 89% for grafts placed to the
common femoral artery and 92% for grafts placed to the pro-
funda femoris artery (601). 
tic bifurcation, localized aortoiliac endarterectomy may be
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large, randomized, prospective studies demonstrate that the
immediate and long-term patency of bypasses to the above-
knee popliteal artery favor use of autogenous vein, in situ or
reversed, at all time periods (483,508-510). In its absence,
PTFE or polyester filament may be used with an expected
lower but acceptable patency rate for above-knee bypasses.
Patency of prosthetic grafts is significantly lower once the
knee joint is crossed. In a meta-analysis of reported data on
1572 patients, Hunink and colleagues noted a 5-year patency
rate of 47% for prosthetic grafts to the above-knee popliteal
artery and a patency rate of only 33% when grafts were
brought down to the below-knee popliteal artery (437). The
need for retreatment or revision is greater with synthetic
material over time. With more distal anastomoses or the pres-
ence of hemodynamically significant tibial arterial occlusive
disease and poor outflow, there is accelerated failure of pros-
thetic grafts. Therefore, bypasses to the below-knee popliteal
artery or to a tibial or pedal vessel strongly favor the use of
autogenous vein. Bypasses to the tibial arteries with pros-
thetic material should be avoided and other sources of auto-
genous vein sought if the ipsilateral greater saphenous vein
is absent or unsuitable. Lesser saphenous vein, contralateral
greater saphenous vein, arm vein, and spliced veins may be
used, with an expected patency greater than prosthetic mate-
rial. When vein length is inadequate, a composite sequential
graft consisting of a prosthetic graft to the above-knee
popliteal artery and a jump graft of autogenous vein to the
distal vessel may be used. If no other option exists, then the
use of a prosthetic with an adjunctive procedure, such as
arteriovenous fistula or vein interposition or cuff, may
improve patency, although this has not been clearly proven. 
The least-diseased tibial or pedal artery with continuous flow
to the foot should be used as the outflow vessel for the con-
struction of a distal bypass, because equivalent results can be
achieved with all tibial and even pedal arteries (606,607).
Diabetes mellitus does not have a significant negative impact
on distal revascularization (497). It is most important to
achieve direct and uncompromised outflow to the foot.
The operative mortality of lower extremity revascularization
in this often critically ill population of patients ranges from
1% to 6% regardless of the specific graft configuration
(499,500,505,608). In a meta-analysis of reports for lower
extremity revascularization composed of at least 50% of
patients with CLI, there was a 70% 5-year patency rate for
femorotibial grafts created with vein but only a 27% patency
rate for those created with a prosthetic material (601).
2.6.3.4.3. POSTSURGICAL CARE.
RECOMMENDATIONS
Class I
1. Unless contraindicated, all patients undergoing revas-
cularization for CLI should be placed on antiplatelet
therapy (see Sections 2.4.2 and 2.6.1.6), and this treat-
ment should be continued indefinitely. (Level of
Evidence: A)
2. Patients who have undergone placement of aortob-
ifemoral bypass grafts should be followed up with
2.6.3.4.2. OUTFLOW PROCEDURES: 
INFRAINGUINAL DISEASE.
RECOMMENDATIONS
Class I
1. Bypasses to the above-knee popliteal artery should be
constructed with autogenous saphenous vein when
possible. (Level of Evidence: A)
2. Bypasses to the below-knee popliteal artery should be
constructed with autogenous vein when possible.
(Level of Evidence: A)
3. The most distal artery with continuous flow from
above and without a stenosis greater than 20% should
be used as the point of origin for a distal bypass. (Level
of Evidence: B)
4. The tibial or pedal artery that is capable of providing
continuous and uncompromised outflow to the foot
should be used as the site of distal anastomosis. (Level
of Evidence: B)
5. Femoral-tibial artery bypasses should be constructed
with autogenous vein, including the ipsilateral greater
saphenous vein, or if unavailable, other sources of
vein from the leg or arm. (Level of Evidence: B)
6. Composite sequential femoropopliteal-tibial bypass
and bypass to an isolated popliteal arterial segment
that has collateral outflow to the foot are both accept-
able methods of revascularization and should be con-
sidered when no other form of bypass with adequate
autogenous conduit is possible. (Level of Evidence: B)
7. If no autogenous vein is available, a prosthetic
femoral-tibial bypass, and possibly an adjunctive pro-
cedure, such as arteriovenous fistula or vein interposi-
tion or cuff, should be used when amputation is immi-
nent. (Level of Evidence: B)
Class IIa
Prosthetic material can be used effectively for bypass-
es to the below-knee popliteal artery when no autoge-
nous vein from ipsilateral or contralateral leg or arms
is available. (Level of Evidence: B)
As noted above, CLI occurs because of the multisegmental
nature of the occlusive disease. Lower extremity bypasses
for severe ischemia may be due to the need to bypass long
occlusions and multiple diseased arterial segments and thus
are frequently longer and have a more distal outflow anasto-
mosis (Table 25). The creation of an in situ or reversed
greater saphenous vein bypass to a tibial vessel is the most
commonly performed limb salvage procedure. This type of
bypass can be performed under general or regional (or, more
rarely, local) anesthesia and is generally well tolerated. There
are, however, specific factors that may modify the result of
this procedure. The 2 major factors are the type of conduit
and the outflow tract beyond the distal anastomosis.
Nearly all studies that have compared vein with prosthetic
conduit for arterial reconstruction of the lower extremity
have demonstrated the superior patency of vein. Several
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symptoms (Figure 10). Specific clinical information should
be used to identify individuals who merit pursuit of an objec-
tive lower extremity PAD diagnosis by measurement of an
ABI examination. Clinical data that should guide this assess-
ment include the presence of atherosclerosis risk factors
(especially age, smoking, and diabetes), clinical history (a
history of atherosclerotic coronary artery, carotid artery, or
renal artery disease and lower extremity symptoms), and an
abnormal lower extremity pulse examination. Subsequent
diagnostic testing and therapeutic interventions are depend-
ent on presenting symptoms. Use of lower extremity symp-
toms and ABI data should then be used to initiate therapeu-
tic interventions to decrease cardiovascular ischemic risk,
diminish claudication symptoms, and promptly identify indi-
viduals with CLI or who are at risk for amputation. 
2.7.2. Treatment Pathways
Many individuals with lower extremity PAD do not report
classic symptoms of claudication or CLI, yet they remain at
high risk of cardiovascular ischemic events. The algorithm
shown in Figure 11 aids establishment of the lower extremi-
ty PAD diagnosis in at-risk individuals by use of (a) the ABI
and exercise ABI and (b) the toe-brachial index and PVR for
individuals with noncompressible pedal pulses. Estab-
lishment of the lower extremity PAD diagnosis in asympto-
matic patients and individuals with atypical lower extremity
symptoms should lead to use of risk factor reduction and
antiplatelet medication interventions. 
Classic claudication symptoms (Figure 12) markedly
impair quality of life. Recognition of these symptoms should
lead to confirmation of the lower extremity PAD diagnosis
by use of the ABI (or occasionally other vascular diagnostic
tests). The patient’s therapeutic goal is an important factor in
determining whether treatment is required. Supervised exer-
cise and pharmacotherapy are therapeutic interventions that
can be applied without additional anatomic localization. For
individuals with inflow disease, endovascular and surgical
therapies may be particularly effective (Figure 13). 
Critical limb ischemia is defined by the presence of chron-
ic ischemic rest pain, ulcers, or gangrene caused by a severe
decrease in limb perfusion. Although severe ischemia is
chronic, the decrement in perfusion would lead to impending
limb loss without revascularization. A history suggestive of
CLI should lead to prompt confirmation of the ischemic ori-
gin, an assessment of lower extremity arterial anatomy, eval-
uation of limb viability and procedural benefit and risk, and
consideration for revascularization by endovascular or surgi-
cal techniques (Figure 14).
Acute limb ischemia represents a vascular emergency due
to the sudden decrease in lower extremity perfusion that
threatens limb viability if not promptly recognized and treat-
ed. The history of sudden limb pain and signs of acute
ischemia (pain, pulselessness, pallor, paresthesias, and paral-
ysis) should lead to emergent vascular diagnostic testing to
establish the ischemic cause (Figure 15). Inasmuch as an
assessment of limb viability must be performed and linked to
periodic evaluations that record any return or pro-
gression of ischemic symptoms, the presence of
femoral pulses, and ABIs. (Level of Evidence: B)
3. If infection, ischemic ulcers, or gangrenous lesions
persist and the ABI is less than 0.8 after correction of
inflow, an outflow procedure should be performed
that bypasses all major distal stenoses and occlusions.
(Level of Evidence: A)
4. Patients who have undergone placement of a lower
extremity bypass with autogenous vein should under-
go for at least 2 years periodic examinations that
record any return or progression of ischemic symp-
toms; a physical examination, with concentration on
pulse examination of the proximal, graft, and outflow
vessels; and duplex imaging of the entire length of the
graft, with measurement of peak systolic velocities
and calculation of velocity ratios across all lesions.
(Level of Evidence: A)
5. Patients who have undergone placement of a synthet-
ic lower extremity bypass graft should undergo peri-
odic examinations that record any return of ischemic
symptoms; a pulse examination of the proximal, graft,
and outflow vessels; and assessment of ABIs at rest
and after exercise for at least 2 years after implanta-
tion. (Level of Evidence: A)
To maximize the benefit of revascularization and to mini-
mize the risk of cardiovascular ischemic events (MI and
stroke), all postoperative patients with lower extremity PAD
should receive maximal cardiovascular ischemic risk reduc-
tion therapies (as outlined in Section 2.6.1) and be main-
tained on an oral antiplatelet medication, usually aspirin or
clopidogrel. Optimally, risk reduction therapies will be initi-
ated preoperatively and continued for the patient’s lifetime
(see Section 2.6.1). There are minimal data to suggest that
anticoagulation with warfarin may prolong graft patency;
most case series include small numbers of patients, and thus
the overall database is inconclusive as yet (609,610). A sin-
gle retrospective analysis of 293 patients who had undergone
infrainguinal bypass has suggested that ACE inhibitor use
might decrease mortality (611). 
To maintain optimal outcomes, patients should undergo
periodic graft surveillance for at least 2 years after place-
ment. For vein grafts, duplex imaging of the donor and recip-
ient arteries, proximal and distal anastomoses, and the entire
graft length is of benefit for the detection of grafts with
reduced flow secondary to intraluminal lesions. Duplex
imaging is of limited benefit for the detection of lesions with-
in synthetic grafts. Therefore, the periodic recording of ABIs
is sufficient. 
2.7. Algorithms
2.7.1. Diagnostic Pathway
The diagnosis of lower extremity PAD should be considered
in individuals who are at risk for lower extremity PAD, as
well as in those who present with lower extremity ischemic
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atively uncommon cause of hypertension (612-614).
Although excellent prevalence data have been obtained in
selected high-risk populations (e.g., patients with clinically
evident coronary artery disease or PAD) (615-619), few stud-
ies have adequately assessed the prevalence of RAS in the
general population (620). Hansen and associates studied
prevalence by performing renal artery duplex ultrasound in
individuals 65 years and older as part of their cardiovascular
health study to determine the population-based prevalence of
renovascular disease. Of 834 participants undergoing renal
artery duplex ultrasound, the overall prevalence rate of sig-
nificant renovascular disease was 6.8%. Renal artery disease
a plan for immediate revascularization via thrombolytic,
endovascular, or surgical therapies, a vascular specialty con-
sultation should be obtained as soon as possible. The poten-
tial for limb salvage, duration of ischemia, and arterial
anatomy are critical factors in determining the method of
revascularization (Figure 16). 
3. RENAL ARTERIAL DISEASE
3.1. Prevalence and Natural History
Renal artery stenosis (RAS) is both a common and a pro-
gressive disease in patients with atherosclerosis and is a rel-
Figure 10. Steps toward the diagnosis of peripheral arterial disease (PAD). *“Atypical” leg pain is defined by lower extremity dis-
comfort that is exertional, but that does not consistently resolve with rest, consistently limit exercise at a reproducible distance, or
meet all “Rose questionnaire” criteria. †The five “Ps” are defined by the clinical symptoms and signs that suggest potential limb jeop-
ardy: pain, pulselessness, pallor, paresthesias, and paralysis (with polar being a sixth “P”).
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(i.e., greater than 50%) have been reported in 11% to 18% of
patients (621-623). Prevalence studies have also demonstrat-
ed significant RAS in 22% to 59% of patients with PAD
(616-619,624-630). In one necropsy study, RAS greater than
50% was found in 53% of 295 unselected, consecutive exam-
inations (631). This high prevalence increased to 74% when
a subpopulation of individuals 70 years and older was evalu-
was present in 5.5% of women, 9.1% of men, 6.9% of white
participants, and 6.7% of black participants (620). 
Renal artery stenosis is particularly notable in certain high-
risk populations. Renal arterial disease has been documented
to be present in 30% of patients undergoing screening renal
artery angiography at the time of cardiac catheterization. In
these cohorts, significant obstructive renal artery stenoses
Figure 11. Diagnosis and treatment of asymptomatic peripheral arterial disease (PAD) and atypical leg pain. *Duplex ultrasonogra-
phy should generally be reserved for use in symptomatic patients in whom anatomic diagnostic data are required for care. †Other
causes of leg pain may include lumbar disk disease, sciatica, radiculopathy, muscle strain, neuropathy, and compartment syndrome.
‡It is not yet proven that treatment of diabetes mellitus will significantly reduce PAD-specific (limb ischemic) end points. Primary treat-
ment of diabetes mellitus should be continued according to established guidelines. #The benefit of angiotensin-converting enzyme-
(ACE) inhibition in individuals without claudication has not been specifically documented in prospective clinical trials but has been
extrapolated from other at-risk populations. ABI indicates ankle-brachial index; HbA1C, hemoglobin A1C; JNC-7, Seventh Report of
the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LOE, level of evidence;
NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III. Adapted from Hiatt WR. Medical treatment of
peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608-21 (158a). Copyright © 2001 Massachusetts Medical
Society. All rights reserved.
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to which lesions are associated with important clinical seque-
lae.
Atherosclerotic RAS is a progressive disease. In 4 retro-
spective studies comprising 202 patients followed up for 12
to 60 months, temporal progression of the degree of stenosis
occurred in 36% to 71% of patients, and renal artery occlu-
sion occurred in 16% (633-636). Progression to occlusion is
more common in renal arteries with more severe stenoses.
When the RAS was greater than 75% at the time of diagno-
ated postmortem. A second autopsy series evaluated 297
patients with proven MI to document atherosclerotic RAS of
greater than 75% in 12% (615). Bilateral RAS involvement
is common. In 6 different studies, bilateral RAS was found in
44% of 319 patients (632). Overall, these data suggest that if
1 or more clinical clues to the presence of RAS are present,
significant RAS can be found in up to 70% of such targeted
populations (625). Despite the high prevalence of RAS in
these atherosclerotic subgroups, it remains controversial as
Figure 12. Diagnosis of claudication and systemic risk treatment. *It is not yet proven that treatment of diabetes mellitus will signifi-
cantly reduce peripheral arterial disease (PAD)-specific (limb ischemic) endpoints. Primary treatment of diabetes mellitus should be
continued according to established guidelines. †The benefit of angiotensin-converting enzyme (ACE) inhibition in individuals without
claudication has not been specifically documented in prospective clinical trials, but has been extrapolated from other “at risk” popu-
lations. ABI indicates ankle-brachial index; HbA1C, hemoglobin A1C; JNC-7, Seventh Report of the Joint National Committee on the
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LOE, level of evidence; NCEP ATP III, National Cholesterol
Education Program Adult Treatment Panel III.
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3.1.1. Clinical End Points of 
Renal Artery Disease
The exact contribution of atherosclerotic renal arterial dis-
ease to the development of end-stage renal disease (ESRD)
is not well-defined by current data. It is unclear how many
patients enter dialysis secondary to RAS. Mailloux and col-
leagues reviewed the causes of ESRD in 683 patients entered
into their dialysis program over a 20-year period (640).
Eighty-three patients (12%) had documented RAS as a cause
of ESRD. Because these investigators only performed arteri-
ography in patients in whom RAS was highly suspected, it is
possible that the true incidence was underestimated.
Although the degree of global atherosclerotic risk factor con-
trol was variable in these studies, these data demonstrate that
the atherosclerotic process remains dynamic and progressive
in many individuals. The clinical significance of isolated
anatomic progression without clinical clues or indications for
intervention is still unclear.
Renal atrophy is a consequence of RAS and is associated
with lesion severity and lesion progression (641,642).
Several studies have documented worsening clinical out-
sis, occlusion occurred in 39% of cases over a 12- to 60-
month follow-up period (635). 
Several prospective natural history studies have described
the progression of RAS. In a series published by Dean and
coworkers, RAS progressed in 29% (10 of 35) of patients
and resulted in total occlusion in 11% of patients during a
mean follow-up of 28 months (range 6 to 102 months) (637).
Over a 3-year period, Zierler and associates found that 48%
of patients had progression of RAS from less than 60% to
greater than or equal to 60% stenosis (638). The renal arter-
ies that progressed to occlusion were each characterized by a
stenosis greater than or equal to 60% at baseline (study
entry). Progression of RAS occurred at an average rate of
approximately 7% per year. Using sonography, Caps et al.
monitored 295 kidneys in 170 patients for a mean of 33
months (639). Disease progression, based on sonographic
determination, was 35% at 3 years and 51% at 5 years. Nine
renal artery occlusions (3%) occurred over the course of the
study. All occlusions developed in patients with greater than
60% stenosis in the study that preceded the occlusion.
Occlusion occurred most often in patients with diabetes,
high-grade stenoses, and severe hypertension (639).
Figure 13. Treatment of claudication. *Inflow disease should be suspected in individuals with gluteal or thigh claudication and femoral
pulse diminution or bruit and should be confirmed by noninvasive vascular laboratory diagnostic evidence of aortoiliac stenoses.
†Outflow disease represents femoropopliteal and infrapopliteal stenoses, (the presence of occlusive lesions in the lower extremity
arterial tree below the inguinal ligament from the common femoral artery to the pedal vessels). PAD indicates peripheral arterial dis-
ease.
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Figure 14. Diagnosis and treatment of critical limb ischemia. *Based on patient comorbidities. †Based on anatomy or lack of conduit.
‡Risk factor normalization: immediate smoking cessation, treat hypertension per the Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines; treat lipids per National Cholesterol
Education Program Adult Treatment Panel III guidelines; treat diabetes mellitus (HbA1C [hemoglobin A1C] less than 7%; Class IIa). It
is not yet proven that treatment of diabetes mellitus will significantly reduce peripheral arterial disease (PAD)-specific (limb ischemic)
end points. Primary treatment of diabetes mellitus should be continued according to established guidelines. ABI indicates ankle-
brachial index; CTA, computed tomographic angiography; ECG, electrocardiogram; MRA, magnetic resonance angiography; PVR,
pulse volume recording; TBI, toe-brachial index; TEE, transesophageal echocardiography; US, ultrasound.
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comes (i.e., deterioration of renal function, loss of renal
mass, and lower survival rates) in patients with progressive
RAS (637,641,643). One prospective study evaluated renal
function in 41 patients with atherosclerotic RAS treated with
medical therapy (637). At a mean follow-up of 28 months
(range 6 to 102 months), 19 patients (46%) had increased
serum creatinine, 12 (29%) had a 25% to 50% decline in
glomerular filtration rates, and 14 (37%) had a decrease in
kidney size by more than 10% (637). Investigators at Duke
University demonstrated progression of RAS in patients
undergoing 2 sequential cardiac catheterizations separated
by 2.6 plus or minus 1.6 years (643). They observed an over-
all rate of RAS progression of 11.1% and a significant
decline in renal function in those patients who had lesion
progression. 
Amongst the most clinically relevant end points for indi-
viduals with chronic renal disease is the rate of progression
to renal replacement therapies. Dialysis-free survival
Figure 15. Diagnosis of acute limb ischemia. ABI indicates ankle-brachial index; CTA, computed tomographic angiography; ECG,
electrocardiogram; MRA, magnetic resonance angiography; PVR, pulse volume recording; TBI, toe-brachial index; TEE,  trans-
esophageal echocardiography; US, ultrasound. Adapted from J Vasc Surg, 26, Rutherford RB, Baker JD, Ernst C, et al.,
Recommended standards for reports dealing with lower extremity ischemia: revised version, 517-38, Copyright 1997, with permission
from Elsevier (518).
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prevention of ESRD and identify individuals at high cardio-
vascular risk.
The presence and severity of RAS, even before the devel-
opment of ESRD, imparts a poorer prognosis. In a series of
almost 4000 patients undergoing screening for RAS at the
time of cardiac catheterization, the 4-year survival rates for
patients with and without RAS were 57% and 89%, respec-
tively (p less than 0.001) (644). The 4-year survival rates for
individuals with RAS of 50%, 75%, and greater than 95%
were 70%, 68%, and 48%, respectively. Bilateral RAS was
associated with a 47% 4-year survival compared with 59%
for unilateral RAS (p less than 0.001). In the multivariate
analysis, the presence of RAS conferred a hazard ratio of
2.01 (95% CI 1.51 to 2.67, p less than 0.001) regardless of
the treatment of the underlying coronary artery disease (644). 
Finally, the severity of renal function impairment has been
associated with reduced survival in patients with RAS (646).
In patients with serum creatinine levels less than 1.4 mg per
dL, 3-year survival was 92% plus or minus 4%. For serum
creatinine levels between 1.5 and 1.9 mg per dL, 3-year sur-
vival was 74% plus or minus 8%, and for creatinine greater
than or equal to 2.0 mg per dL, it was only 51% plus or
(patients alive and free of dialysis) is inversely correlated
with the severity of renal ischemia. In one study, 2-year dial-
ysis-free survival was 97.3% for patients with unilateral RAS
and 82.4% for patients with bilateral RAS but only 44.7% in
patients with renovascular disease in a solitary (single) func-
tioning kidney (641). 
Patients with atherosclerotic RAS who progress to ESRD
and require dialysis have high mortality rates. In one study,
the mean life expectancy of individuals older than 65 with
RAS who had ESRD was only 2.7 years (644). The median
survival for ESRD patients with renovascular disease was 25
months, compared with 55 months for patients with ESRD
due to malignant hypertension and 133 months for patients
with ESRD due to polycystic kidney disease (645). This is
suspected to be due to the systemic atherosclerotic burden
and higher rates of cardiovascular ischemic events in those
individuals with atherosclerotic RAS. Two-, 5-, and 10-year
survival rates were 56%, 18%, and 5%, respectively, in indi-
viduals with atherosclerotic RAS. Prospective, randomized,
controlled trials will be required to determine whether the
early diagnosis of RAS will provide an opportunity for the
Figure 16. Treatment of acute limb ischemia. PAD indicates peripheral arterial disease; PVR, pulse volume recording; US, ultra-
sonography. Adapted from J Vasc Surg, 26, Rutherford RB, Baker JD, Ernst C, et al., Recommended standards for reports dealing
with lower extremity ischemia: revised version, 517-38, Copyright 1997, with permission from Elsevier (518).
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minus 8%. The relationship between the increase in serum
creatinine and mortality is complex and multifactorial. Not
only do the severity of RAS and the severity of systemic ath-
erosclerosis serve as contributors to mortality, but the degree
of proteinuria, parenchymal renal disease, and other comor-
bidities (such as diabetes mellitus) play an important role
(12,647).
3.2. Clinical Clues to the Diagnosis of RAS
RECOMMENDATIONS 
Class I
1. The performance of diagnostic studies to identify clin-
ically significant RAS is indicated in patients with the
onset of hypertension before the age of 30 years. (Level
of Evidence: B)
2. The performance of diagnostic studies to identify clin-
ically significant RAS is indicated in patients with the
onset of severe hypertension [as defined in The Sev-
enth Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure: the JNC-7 report (294)] after
the age of 55 years. (Level of Evidence: B)
3. The performance of diagnostic studies to identify clin-
ically significant RAS is indicated in patients with the
following characteristics: (a) accelerated hypertension
(sudden and persistent worsening of previously con-
trolled hypertension); (b) resistant hypertension
(defined as the failure to achieve goal blood pressure
in patients who are adhering to full doses of an appro-
priate 3-drug regimen that includes a diuretic); or (c)
malignant hypertension (hypertension with coexistent
evidence of acute end-organ damage, i.e., acute renal
failure, acutely decompensated congestive heart fail-
ure, new visual or neurological disturbance, and/or
advanced [grade III to IV] retinopathy). (Level of
Evidence: C)
4. The performance of diagnostic studies to identify clin-
ically significant RAS is indicated in patients with new
azotemia or worsening renal function after the admin-
istration of an ACE inhibitor or an angiotensin recep-
tor blocking agent (see text). (Level of Evidence: B)
5. The performance of diagnostic studies to identify clin-
ically significant RAS is indicated in patients with an
unexplained atrophic kidney or a discrepancy in size
between the 2 kidneys of greater than 1.5 cm. (Level of
Evidence: B)
6. The performance of diagnostic studies to identify clin-
ically significant RAS is indicated in patients with
sudden, unexplained pulmonary edema (especially in
azotemic patients). (Level of Evidence: B)
Class IIa
The performance of diagnostic studies to identify clin-
ically significant RAS is reasonable in patients with
unexplained renal failure, including individuals start-
ing renal replacement therapy (dialysis or renal trans-
plantation). (Level of Evidence: B)
Class IIb
1. The performance of arteriography to identify signifi-
cant RAS may be reasonable in patients with multi-
vessel coronary artery disease and none of the clinical
clues (Figure 17) or PAD at the time of arteriography.
(Level of Evidence: B)
2. The performance of diagnostic studies to identify clin-
ically significant RAS may be reasonable in patients
with unexplained congestive heart failure or refracto-
ry angina (see Section 3.5.2.4). (Level of Evidence: C)
Several clinical features raise the suspicion of RAS and
provide relative indications for application of more specific
diagnostic testing strategies. One such indication is the pres-
ence of an atrophic kidney (7 to 8 cm) or discrepancy in renal
sizes (648). In such cases, the atrophy should be otherwise
unexplained by a prior history of pyelonephritis, reflux
nephropathy, trauma, and so on. When such a history is pres-
ent, there is usually not an indication for additional renal
diagnostic tests to define RAS. These clinical indications are
outlined in Figure 17.
3.3. Pathophysiology and Disease Categories
The pathophysiology that results from RAS is mediated by
the degree of renal blood flow impairment. In the acute
phase, unilateral RAS causes a renin-mediated (vasocon-
striction) form of hypertension, although renin increases may
be moderated in the chronic phase of renal hypertension. In
contrast, the effects of bilateral renal artery stenoses or steno-
sis to a solitary kidney are predominantly due to an increase
in extracellular fluid volume. Exceptions to this include
longstanding unilateral RAS and contralateral renal dysfunc-
tion (e.g., due to hypertensive nephrosclerosis or hyperfiltra-
tion injury) wherein the physiology mimics that of a patient
with a single functioning kidney or those with bilateral dis-
ease. Inasmuch as renal blood flow and filtration rate are
maintained, in part, by angiotensin II-induced efferent arteri-
olar vasoconstriction, agents that cause efferent arteriolar
dilation, such as ACE inhibitors or angiotensin II receptor
blockers, can cause acute renal failure. They do so by
decreasing transglomerular hydrostatic pressure and thus
glomerular filtration rate. In addition, because the glomeru-
lar filtration rate falls but renal blood flow changes very lit-
tle, the filtration fraction decreases. Under these circum-
stances, blood is shunted from the afferent arteriole to the
efferent arteriole because there is not an adequate hydrostat-
ic pressure to maintain filtration. Thus, use of ACE inhibitors
or angiotensin receptor-blocking medications in patients
with bilateral RAS, stenosis to a solitary kidney, or decom-
pensated congestive heart failure in a sodium-depleted state
can result in acute renal failure (649-652). This pathophysi-
ology underlies both the caution required in the therapeutic
use of angiotensin-pathway antagonists in patients with RAS
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1 cm of the main renal artery, that is, an intrinsic renal plaque
extending to and contiguous with the aorta. 
3.3.2. Fibromuscular Dysplasia
Fibromuscular dysplasia (FMD) is a nonatherosclerotic, non-
inflammatory disease that most commonly affects the renal
arteries and is the second most common cause of RAS
(11,654-657). The most common clinical presentation is that
of hypertension in a young woman, although FMD can occur
in both genders at any age. Whereas atherosclerotic lesions
usually involve the origin and proximal portion of the renal
arteries, FMD characteristically involves the middle and dis-
tal two thirds of the main renal artery and may involve renal
artery branches. 
Medial fibroplasia is the histological finding in nearly 80%
to 85% of all cases of FMD. This form of FMD tends to
occur in 25- to 50-year-old women and often involves both
renal arteries. It has a characteristic angiographic “string of
and the diagnostic clue to RAS provided when severe
hypotension or azotemia is provoked by use of these classes
of medications. It should be noted that short-term changes in
renal function are often multifactorial, and that clinicians
have differing thresholds for defining significant new
azotemia. Clinically significant azotemia has been defined as
a greater than 50% rise in serum creatinine that persists or
worsens after hypoperfusion states are corrected (e.g., vol-
ume depletion, nonsteroidal anti-inflammatory drug use,
heart failure) (652a).
3.3.1. Atherosclerosis
Approximately 90% of all renovascular stenotic lesions are
due to atherosclerosis (653). Although isolated atherosclerot-
ic RAS may be found, it is more commonly a manifestation
of systemic atherosclerosis that involves the aorta, coronary,
cerebral, and peripheral arteries. Atherosclerotic RAS most
often affects the aorto-ostial segment, including the proximal
Figure 17. Clinical clues to the diagnosis of renal artery stenosis (RAS). *For definition of hypertension, please see Chobanian AV,
Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure: the JNC-7 report. JAMA 2003;289:2560-72 (294). †For example, atrophic kidney due to chronic pyelonephri-
tis is not an indication for RAS evaluation. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocking agent;
CT, computed tomography; LOE, level of evidence; MRA, magnetic resonance angiography.
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beads” appearance (Table 28). The “bead” diameter is typi-
cally larger than the adjacent, less-affected artery. Bilateral
disease occurs in 60% of patients, including 10% to 15% in
whom the lesions are functionally important and warrant
treatment. In 25% of patients, the disease extends into the
segmental arteries. Intimal fibroplasia is, by comparison, rel-
atively rare. Its stenosis appears as a thin, discrete web.
Perimedial dysplasia often affects women a decade older
than those with medial fibrodysplasia. Segmental perimedial
dysplasia is uncommon (658-660).
Fibromuscular dysplasia also affects other arteries, includ-
ing the carotid and vertebral arteries, and less commonly, the
iliac and mesenteric arteries. There appears to be an associa-
tion between carotid and vertebral FMD and intracranial
aneurysmal disease, with prevalence as high as 51%
(661,662). However, the prevalence of cerebral aneurysms
may be falsely elevated because of selection bias. When
patients who presented with subarachnoid hemorrhage were
excluded from the prevalence estimates, the prevalence of
incidental, asymptomatic cerebral aneurysms in patients with
internal carotid or vertebral artery FMD was 7.3% in one
contemporary series (662).
Magnetic resonance angiography of the head should be
performed in all patients with cervicocranial FMD. The
prevalence of FMD in nonreferral populations is poorly elu-
cidated, and thus, the relative efficacy of screening for FMD
in nonrenal arterial beds, in the presence of renal FMD, is
beyond the scope of this guideline (661,662).
3.3.3. Other Causes of Renal Artery Disease
Renovascular hypertension may also be caused by renal
artery aneurysms. Renal artery aneurysms may require surgi-
cal or endovascular treatment to obviate risk of rupture or to
diminish their contribution to a renin-mediated form of
hypertension. Aneurysm rupture is of greatest concern with
noncalcified aneurysms larger than 2 cm in diameter, partic-
ularly in premenopausal women because of the increased
risk of aneurysm rupture during pregnancy (663,664).
The other causes of renovascular disease are myriad (663-
673) and include Takayasu’s arteritis (671-673), atheroem-
boli, thromboemboli, William’s syndrome (669,671), neu-
rofibromatosis (670,671), spontaneous renal artery dissec-
tion, arteriovenous malformations or fistulas, trauma (e.g.,
lithotripsy, direct injury, or surgery), and prior abdominal
radiation therapy (665-668). Rarely, retroperitoneal fibrosis
producing external compression has also been associated
with RAS.
3.4. Diagnostic Methods
RECOMMENDATIONS
Class I
1. Duplex ultrasonography is recommended as a screen-
ing test to establish the diagnosis of RAS. (Level of
Evidence: B)
2. Computed tomographic angiography (in individuals
with normal renal function) is recommended as a
Table 28. Classification of Fibromuscular Dysplasia
Classification Frequency Pathology Angiographic Appearance
Medial dysplasia
Medial fibroplasia 80% Alternating areas of thinned  “String of beads” appearance in which diameter 
media and thickened fibromuscular of "beading" is larger than diameter of artery
ridges containing collagen; 
internal elastic membrane 
may be lost in some areas
Perimedial fibroplasia 10% to Extensive collagen deposition “Beading” in which “beads” are smaller than
15% in outer half of media diameter of artery
Medial hyperplasia 1% to True smooth muscle cell hyper- Concentric smooth stenosis (similar to
2% plasia without fibrosis intimal disease)
Intimal fibroplasia Less Circumferential or eccentric Concentric focal band; long, smooth narrowing
than deposition of collagen in the 
10% intima; no lipid or inflammatory 
component; internal elastic 
lamina fragmented or duplicated
Adventitial (periarterial) Less Dense collagen replaces fibrous tissue So rare that classic angiographic findings 
fibroplasia than of adventitia and may extend into are not known
1% surrounding tissue
Reprinted with permission from Begelman SM, Olin JW. Fibromuscular dysplasia. Curr Opin Rheumatol 2000;12:41-7 (11).
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inhibition (674). The accuracy of captopril renography in
identifying patients with renovascular disease has been vari-
able, with reported sensitivities of approximately 85% (range
45% to 94%) and specificities of approximately 93% (range
81% to 100%) (674-685). 
In patients with azotemia, bilateral RAS, or RAS of a soli-
tary functioning kidney, the sensitivity and specificity of cap-
topril renography is poor. Many investigators have excluded
from captopril testing those patients with a serum creatinine
value that exceeds 2.5 to 3.0 mg per dL. In patients with a
serum creatinine greater than or equal to 1.5 mg per dL and
less than or equal to 3.0 mg per dL, Fommei et al. reported a
reduction in the positive predictive value from 88% to 57%,
whereas there was a minimum reduction in sensitivity/speci-
ficity in patients with serum creatinine of 1.5 mg per dL
(678). 
When captopril renography was compared with catheter
angiography in a clinical practice setting, the sensitivity was
only 74%, and the specificity was only 59% (686). Thus,
captopril renography may not be a very useful test for screen-
ing most patients for RAS but may retain some value in the
assessment of renal artery stenoses of borderline angio-
graphic severity for which the physiological functional sig-
nificance is unclear.
3.4.2. Duplex Ultrasound
Duplex (Doppler with B-mode) ultrasound, compared with
angiography, has a sensitivity of 84% to 98% and a speci-
ficity of 62% to 99% for detecting RAS (687-693). An end-
diastolic velocity of more than 150 cm per second predicts
severe (greater than 80%) RAS (694). Other criteria used
include direct peak systolic velocity greater than 18 to 200
cm per second, renal to aortic ratio greater than 3.5, rise time
greater than 0.07 seconds, acceleration index less than 300
cm per second, and difference in renal or segmental resistive
index greater than 0.15. These criteria have correlated with a
stenosis exceeding 60% in most published series. Renal
artery duplex ultrasonography is an excellent test to monitor
renal artery patency after endovascular treatment or surgical
revascularization of RAS (695,696). Unlike MRA, in which
most stents currently cause artifacts, ultrasound transmission
through a stent is not a problem. Limitations of renal artery
duplex ultrasonography include its absolute dependence on
operator skill, the diminished ability to visualize accessory
renal arteries, and the difficulty or inability to image obese
patients or patients with intervening bowel gas (696).
Renal artery duplex ultrasonography may be used to meas-
ure the renal artery resistive index (RRI). An increased RRI
suggests structural abnormalities in the small blood vessels
of the kidney. Such small-vessel disease has been document-
ed in the context of longstanding hypertension associated
with nephrosclerosis or glomerulosclerosis (697). There have
been conflicting reports regarding the usefulness of RRI to
predict individual patient response to revascularization. A
retrospective study has demonstrated that an elevated resist-
ance index greater than 0.80 predicted a lack of improvement
screening test to establish the diagnosis of RAS. (Level
of Evidence: B)
3. Magnetic resonance angiography is recommended as
a screening test to establish the diagnosis of RAS.
(Level of Evidence: B)
4. When the clinical index of suspicion is high and the
results of noninvasive tests are inconclusive, catheter
angiography is recommended as a diagnostic test to
establish the diagnosis of RAS. (Level of Evidence: B)
Class III
1. Captopril renal scintigraphy is not recommended as a
screening test to establish the diagnosis of RAS. (Level
of Evidence: C)
2. Selective renal vein renin measurements are not rec-
ommended as a useful screening test to establish the
diagnosis of RAS. (Level of Evidence: B)
3. Plasma renin activity is not recommended as a useful
screening test to establish the diagnosis of RAS. (Level
of Evidence: B)
4. The captopril test (measurement of plasma renin
activity after captopril administration) is not recom-
mended as a useful screening test to establish the diag-
nosis of RAS. (Level of Evidence: B)
Renal artery stenosis is best diagnosed with an imaging
modality. The ideal tool should evaluate both the main and
accessory renal arteries, assess the hemodynamic signifi-
cance of the demonstrated lesions, identify the site and sever-
ity of the stenosis, and identify associated perirenal patholo-
gy, including the presence of an AAA or renal or adrenal
masses. Direct imaging modalities such as duplex ultra-
sound, CTA, and MRA are best suited to serve as effective
diagnostic screening methods. The choice of imaging proce-
dure will depend on the availability of the diagnostic tool, the
experience and local accuracy of the chosen modality, and
patient characteristics (e.g., body size, renal function, con-
trast allergy, and presence of prior stents or metallic objects
that may serve as contraindications to MRA or CTA tech-
niques).
3.4.1. Renal Scintigraphy
Captopril renography yields both scintigraphic images and
computer-generated time-activity curves to provide informa-
tion about renal size, perfusion, and excretory capacity.
Typical methods to perform this examination include the oral
administration of captopril 50 mg taken 60 minutes before
performance of renal scintigraphic imaging with technetium-
99m mercaptoacetyltriglycine or technetium-99m diethylen-
etriaminepentaacetic acid. The diagnostic criteria for RAS
are (a) delayed time to maximal activity (TMax greater than
or equal to 11 minutes after captopril administration), (b) sig-
nificant asymmetry of peak activity of each kidney, (c)
marked cortical retention of the radionuclide after captopril
administration, and (d) marked reduction in calculated
glomerular filtration rate of the ipsilateral kidney after ACE
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Comparisons with catheter-based contrast angiography have
indicated a range of sensitivities from 90% to 100% and
specificities of 76% to 94% for detection of RAS. Many ear-
lier flow-related artifacts are avoided almost entirely with the
use of gadolinium as a contrast agent. Magnetic resonance
angiography may be less effective in the assessment of
patients with more subtle beading and changes of FMD
because of current resolution limits balanced against the size
of the distal renal artery and its branches. Occasionally, bead-
ing artifacts may appear when none exist (on angiography).
However, as improvements in acquisition speed, pulse
sequences, scanner technologies, and novel contrast formu-
lations continue to evolve, many of these technical limita-
tions may be overcome (717).
Summary of Noninvasive Renal Artery 
Diagnostic Imaging Strategies
There are relative advantages and disadvantages to each of
the aforementioned imaging modalities. Captopril renogra-
phy has been validated in a large number of patients but is
limited in value to a subset of all potential renovascular
patients, and it is of limited value in patients with significant
azotemia, bilateral RAS, or RAS to a single functioning kid-
ney. Duplex renal sonography, because of the critical role of
the sonographer, is accurate in experienced laboratories and
is thus ideally performed in high-volume accredited labora-
tories. The diagnostic accuracy of these ultrasound-based
examinations is further limited in patients with large body
habitus or intestinal gas obscuring visualization of the entire-
ty of the renal artery. Computed tomographic angiography
currently provides higher spatial resolution than MRA and
may be more readily available; however, the requirement to
use iodinated contrast makes it an unattractive modality in
patients with impaired renal function. Gadolinium-enhanced
MRA provides excellent and less-nephrotoxic characteriza-
tion of the renal arteries, surrounding vessels, renal mass,
and perhaps renal function, but it remains the most costly
renal artery examination. It is far less useful in patients who
have had a metallic renal artery stent placed because of the
inability to image inside of the stent to detect restenosis.
Comparisons of contrast-enhanced 3D MRA and multidetec-
tor CTA with digital subtraction catheter angiography in a
large number of arterial segments have demonstrated equal-
ly high sensitivities for detection of hemodynamically sig-
nificant stenoses for MRA and computed tomography
(greater than 90%), with excellent interobserver and inter-
modality agreement (kappa equals 0.88 to 0.90) (241).
3.4.5. Catheter Angiography
Renal catheter-based contrast arteriography, the longstanding
“gold standard” for the diagnosis of RAS, has been largely
replaced as a practical first-line modality by the previously
described noninvasive imaging studies. The indications for
catheter-based contrast renal angiography include (a) indi-
viduals in whom there are prespecified indications to suspect
clinically important RAS (“clinical clues”) in whom defini-
in blood pressure and renal function after revascularization
(698). A limitation of that study was its retrospective design,
lack of prespecified end points, and inclusion of a large
majority of patients who received balloon angioplasty as
their method of treatment. Renal angioplasty without stent
placement is now generally recognized as a less optimal
method of renal revascularization (699-701), and thus, the
outcomes in response to renal revascularization therapy may
have been underestimated in that report. 
A prospective study of renal stent placement in 241 patients
demonstrated that patients with an elevated RRI did have a
favorable blood pressure response to intervention (702).
Furthermore, serum creatinine improved 15% to 23% in
patients with mild to moderate (RRI 0.7 to 0.8) and severe
(RRI greater than 0.80) nephrosclerosis, respectively.
Notably, only 18% of those with severe nephrosclerosis had
serum creatinines greater than 2.5 mg per dL. Resistive
indices may prove useful in identifying severe parenchymal
disease, which might limit the value of renal revasculariza-
tion. The database regarding the predictors of a beneficial
clinical outcome to renal revascularization remains incom-
plete and will require future prospective randomized, con-
trolled trials.
3.4.3. Computed Tomographic Angiography 
Computed tomographic angiography produces excellent 3D
images of the aorta and renal arteries. Computed tomograph-
ic angiography has a sensitivity and specificity for detecting
significant RAS of 59% to 96% and 82% to 99%, respec-
tively, compared with catheter-based contrast angiography
(703-709). Current multidetector-row scanners acquire up to
16 simultaneous interweaving helices; 32- and 64-row and
flat-panel scanners are in development. With current CTA
techniques, sensitivity for detecting renal artery stenoses
reached 91% and 92% (readers 1 and 2), and the specificity
was 99% for both readers (241). Computed tomographic
angiography is capable of providing high-resolution nonin-
vasive detection of RAS while supplying associated 3D
angiographic images of the aorta, renal, and visceral arteries.
Computed tomographic angiography requires the administra-
tion of 100 to 150 cc of iodinated contrast and therefore is
not an ideal screening method for patients with renal insuffi-
ciency because of the risk of inducing contrast nephropathy.
However, as computed tomography scanner technology
advances, particularly with regard to the development of
scanners with increasing numbers of conventional and newer
flat-panel detectors, spatial resolution will improve, scanning
time will decrease, and the administered contrast load may
be reduced. One advantage of CTA over the MRA technique
is that metal stents may be imaged with CTA and in-stent
restenosis detected.
3.4.4. Magnetic Resonance Angiography
Contrast-enhanced MRA is performed with gadolinium, a
less-nephrotoxic contrast agent, to obtain visualization of the
renal arteries and abdominal vasculature (710-716).
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tive diagnostic noninvasive images cannot be obtained and
(b) individuals in whom these prespecified clinical indica-
tions and patient consent have been documented and in
whom concomitant angiographic access has been obtained
for peripheral angiography or coronary angiography. 
Catheter-based contrast angiography is associated with a
low rate of serious adverse outcomes in individuals with nor-
mal renal function. These include contrast-induced acute
renal failure, contrast-related allergic reactions, atheroma-
tous renal and distal (lower extremity) embolization, and
access-related complications such as pseudoaneurysm, arte-
riovenous fistula, bleeding, and hematoma. However, the
risk of contrast-induced acute renal failure is magnified in
certain clinical groups, particularly those with diabetes and
chronic kidney disease. In general, the incidence of contrast-
induced acute renal failure is less than 3% in patients with
neither diabetes nor chronic kidney disease; 5% to 10% in
those with diabetes; 10% to 20% in those with chronic kid-
ney disease (and greater with more advanced stages), and
20% to 50% in those with both diabetes and chronic kidney
disease (717a,717b).
Iodinated contrast-related acute renal failure can be miti-
gated with fluids (i.e., avoiding dehydration, using preproce-
dure intravenous fluids to stimulate urine output) and the use
of alternative imaging agents such as carbon dioxide or
gadolinium. One randomized trial in diabetic patients with
elevated serum creatinine (1.5 to 3.5 mg per dL) levels
demonstrated that iodixanol, an iso-osmolar nonionic con-
trast agent, was associated with significantly fewer nephro-
toxic effects than iohexol, a low-osmolar nonionic contrast
agent (276). Renal protection has also been demonstrated
with the use of oral acetylcysteine (600 mg 2 times per day)
in a randomized, controlled trial of patients with chronic
renal impairment (serum creatinine greater than 1.2 mg per
dL or creatinine clearance less than 60 mL per min) under-
going coronary angiography (278). Additionally, hemofiltra-
tion performed both before and after coronary intervention in
patients with chronic renal failure has been reported to mate-
rially reduce the incidence of deterioration in renal function
in this patient population (281). 
Given the high prevalence of RAS in individuals with coro-
nary artery disease (621,718,719) and peripheral vascular
disease (619,624-630) that warrant catheter angiography, the
use of screening flush aortography (not selective renal
angiography) at the time of coronary and peripheral vascular
angiography has been proposed. Such studies may be appro-
priate (by operators skilled in the performance and evalua-
tion of RAS using flush aortography) when individuals who
will be undergoing coronary or limb angiography have clin-
ical indicators for significant renal arterial occlusive disease.
The performance of renal angiography in these individuals,
in whom arterial catheterization of the aorta has been per-
formed, provides anatomic access to the renal arteries with
relatively low incremental risk (720). To date, studies have
not demonstrated a measurable incremental risk to the use of
nonselective renal angiography in conjunction with coronary
angiography or peripheral vascular arteriography in individ-
uals in whom indications for these procedures exist.
Controlled studies demonstrating the benefit of identifying
these lesions need to be performed.
3.4.6. Renin
3.4.6.1. Selective Renal Vein Renin Studies
Renal vein renin measurements are now performed very
infrequently because of their limited clinical utility and need
for invasive catheterization. The utility of the examination
depends on the ability to differentiate the unilateral elevation
of renin concentration from the renal vein that drains the kid-
ney with renal artery disease from the systemic plasma renin
levels and/or renal vein renin levels collected from the con-
tralateral (normal) kidney. The test is performed with direct
catheterization and collection of blood samples from within
each renal vein and from the inferior vena cava cephalad and
caudal to the renal veins at baseline. The test is typically
repeated after stimulation of renin release by administration
of either oral captopril or furosemide. To maximize the accu-
racy of this plasma biochemical marker of renal hypoperfu-
sion, all medications that can affect renal renin secretion
must be stopped, including all antihypertensive drugs, diuret-
ics, and nonsteroidal anti-inflammatory drugs, for at least 2
weeks. In addition, the patient should be kept on a dietary
sodium intake of 100 to 200 mmol per day. If it is considered
unsafe to stop all antihypertensive agents, a calcium-channel
blocker or alpha-1 adrenergic blocker can be used (721). 
One study by Hughes et al. showed that if there was later-
alization of the renal vein renin ratio of more than 1.4:1 and
a duration of hypertension less than 5 years, the cure rate of
hypertension after revascularization was 95% (722).
Nevertheless, renal vein renin measurements have been
largely supplanted by the aforementioned noninvasive imag-
ing modalities. Renal vein renin measurements may have
more utility in establishing an indication for nephrectomy in
patients with renal artery occlusion than in identifying
patients with RAS who may derive benefit from revascular-
ization (721); for pediatric patients with questionably severe
RAS before revascularization; or for patients with very
marked aortoiliac-renal atherosclerosis, in whom revascular-
ization could carry unusually high risk.
3.4.6.2. Plasma Renin Activity: Captopril Test
This study is performed as follows: after a baseline plasma
renin level is obtained, 50 mg of captopril is given orally, and
a second plasma renin level is obtained 60 minutes later. The
overall sensitivity of this test is 61%, with a specificity of
86% for the detection of renal artery disease. However, this
test is less accurate in patients who are volume expanded or
who have chronic renal failure, bilateral renal artery disease,
or disease to a solitary functioning kidney. In addition, the
same principles regarding medication withdrawal apply to
this test as with renal vein renin measurement. In one large
study involving 540 patients, the false-negative rate for ele-
vation of the plasma renin activity was 43% and the false-
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2. Angiotensin receptor blockers are effective medica-
tions for treatment of hypertension associated with
unilateral RAS. (Level of Evidence: B)
3. Calcium-channel blockers are effective medications
for treatment of hypertension associated with unilat-
eral RAS. (Level of Evidence: A)
4. Beta-blockers are effective medications for treatment
of hypertension associated with RAS. (Level of
Evidence: A)
Multiple studies have now shown that ACE inhibitors and
calcium-channel blockers are effective in the treatment of
hypertension in the presence of RAS (724-728). These
results address primarily the treatment of hypertension, but
diminution in the progression of renal disease has also been
demonstrated. There is also evidence that alternative thera-
pies, based largely on chlorothiazide, hydralazine, and beta-
blockers, appear effective to achieve target blood pressures
in individuals with RAS. The beneficial effects of medical
therapy in these studies on the progression of atherosclerotic
renal arterial disease contributed by smoking cessation, treat-
ment of dyslipidemia, and the use of aspirin are difficult to
differentiate from improvement in blood pressure control
alone. In addition, although the angiotensin II receptor
blockers also have an evidence base of efficacy for normal-
ization of blood pressure in individuals with RAS, their
positive rate was 34% (723). Elevated plasma renin activity
may be present in approximately 15% of patients with essen-
tial hypertension. Plasma renin activity is not recommended
as a useful screening test to establish the diagnosis of RAS.
3.5. Treatment of Renovascular Disease: 
Renal Artery Stenosis
Treatment of renal arterial disease should serve to aid in the
normalization of blood pressure and to preserve renal func-
tion, and possibly to reduce risk of cardiovascular events and
mortality. Both medical (pharmacological) and revascular-
ization strategies should be considered for patients with doc-
umented renal arterial disease. The relative efficacy and safe-
ty of medical and endovascular strategies remains an area of
active clinical investigation. A treatment algorithm based on
the current evidence base is provided in Figure 18. 
3.5.1. Medical Treatment
RECOMMENDATIONS
Class I
1. Angiotensin-converting enzyme inhibitors are effec-
tive medications for treatment of hypertension associ-
ated with unilateral RAS. (Level of Evidence: A)
Figure 18. Indications for renal revascularization. *Viable means kidney linear length greater than 7 cm. †It is recognized that renal
artery surgery has proven efficacy in alleviating RAS due to atherosclerosis and fibromuscular dysplasia. Currently, however, its role
is often reserved for individuals in whom less invasive percutaneous RAS interventions are not feasible. CHF indicates congestive
heart failure; CRI, chronic renal insufficiency; LOE, level of evidence; PTA, percutaneous transluminal angioplasty.
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effects need to be tested further in large randomized trials.
There are currently few objective clinical clues that permit
selection of specific patient cohorts that would best be treat-
ed by medical therapy versus renal arterial revascularization,
which remains an area of active clinical investigation.
Individuals with atherosclerotic disease and hypertension
should be treated according to goals of the Seventh Report of
the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (294).
3.5.2. Indications for Revascularization
3.5.2.1. Asymptomatic Stenosis
RECOMMENDATIONS
Class IIb
1. Percutaneous revascularization may be considered for
treatment of an asymptomatic bilateral or solitary
viable kidney with a hemodynamically significant
RAS. (Level of Evidence: C)
2. The usefulness of percutaneous revascularization of
an asymptomatic unilateral hemodynamically signifi-
cant RAS in a viable kidney is not well established and
is presently clinically unproven. (Level of Evidence: C)
Hemodynamically significant asymptomatic (incidental)
renal artery stenosis is defined as RAS in the absence of end-
organ dysfunction (e.g., idiopathic pulmonary edema, stroke,
visual loss, hypertension, or refractory angina) but in the
presence of (a) greater than or equal to 50% to 70% diame-
ter stenosis by visual estimation with a peak translesional
gradient (measured with a less than or equal to 5-Fr catheter
or pressure wire) of greater than or equal to 20 mm Hg or a
mean gradient greater than or equal to 10 mm Hg, (b) any
stenosis greater than or equal to 70% diameter stenosis, or (c)
greater than or equal to 70% diameter stenosis by intravas-
cular ultrasound measurement (688). 
Incidental (asymptomatic) RAS found at coronary or
peripheral angiography (abdominal aortography) is more
common than previously suspected (Tables 29 and 30) (621-
623,625,630,643,719). Screening angiography has demon-
strated renal artery stenoses (defined as greater than 50%
diameter stenosis) in 18% of 196 consecutive patients under-
going coronary angiography for suspected coronary artery
disease (623). In patients with established coronary artery
disease, the incidence of incidental, unsuspected RAS
climbed to 22%. One large study examined the incidence of
RAS diagnosed by screening angiography during coronary
angiography and found incidental renal artery narrowing in
30% of 1235 consecutive angiograms (621). Significant uni-
lateral RAS (greater than 50% diameter stenosis) was docu-
mented in 15% of individuals, and bilateral RAS was
observed in 33% of these subjects. Multivariate predictors of
the presence of high-grade renal artery disease included age,
associated coronary artery disease, congestive heart failure,
female gender, and PAD. Hypertension was not an associat-
ed predictive variable.
Univariate predictors of RAS in 14152 patients undergoing
abdominal aortography at the time of cardiac catheterization
are summarized in Table 31 (643). A trial of screening renal
angiography at the time of cardiac catheterization in 177
consecutive patients found measurable RAS in 25% of the
patients, with hemodynamically significant lesions observed
in 11% of this population (622). Multivariate analysis
demonstrated that the extent of coronary artery disease was
the strongest predictor of concomitant RAS (Table 32) (622).
The use of renal angiography screening during peripheral
vascular angiography has also demonstrated a much higher
than expected incidence of asymptomatic or incidental RAS
(Table 30) (625,630,719). In 394 consecutive patients under-
going angiographic evaluation of clinically suspected PAD
(aortoiliac and lower extremity), without the usual clinical
clues to suggest RAS, 33% to 39% had significant (greater
than 50% diameter stenosis) RAS (Table 33) (625).
Incidental (asymptomatic) RAS was discovered in 28% of
346 patients undergoing evaluation for AAA or peripheral
arterial occlusive disease.
Whereas the presence of coronary atherosclerosis predicts
the presence of significant atherosclerotic renal artery dis-
ease, there is a converse ability of atherosclerotic renal arte-
rial disease to predict the severity of coronary artery disease.
Asymptomatic (incidental) RAS found at peripheral angiog-
Table 29. Prevalence of Incidental RAS Found at Cardiac Catheterization
No. of RAS Greater
First Author Reference Patients RAS (%) Than 50% (%) Bilateral (%)
Crowley (643) 14 152 11.4 6.3 21
Harding (621) 1302 30 15 36
Jean (623) 196 29 18 NR
Vetrovec (729) 116 NR 23 29
Conlon (730) 3987 34 9.1 17
Rihal (720) 297 25 19 4
Weber-Mzell (622) 177 11 8
NR indicates not reported.
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The tendency for RAS to progress or worsen appears unaf-
fected by medical therapy to control blood pressure. Renal
artery occlusion generally causes irreversible loss of renal
excretory function, although this loss may not be evident in
the elevation of serum creatinine (653). Over a 7-year peri-
od, 24 312 patients underwent cardiac catheterization, of
whom 14 152 (58%) had abdominal aortograms to screen
them for asymptomatic RAS (643). The likelihood of new
lesions appearing or of known lesions to progress was
assessed in a cohort of 1189 patients who underwent 2
abdominal aortograms separated by at least 6 months. The
average time separating the 2 angiograms was 2.6 plus or
minus 1.6 years. A new RAS or RAS progression was seen
in 11.1% of the patients (Table 35) (643). Progression from
normal to greater than 75% stenosis in 1 or more arteries was
associated with a decline in renal function and with a signif-
icantly higher serum creatinine (141 plus or minus 114
micromoles per liter) than in those patients without lesion
progression (97 plus or minus 44 micromoles per liter, p
equals 0.01). Lesion progression is more likely to occur in
more severe stenoses (637,642). Notably, these studies were
limited to individuals in whom coronary angiography was
performed twice, presumably because of progressive clinical
disease, and thus may not be representative of the larger pop-
ulation of individuals with RAS. 
raphy is strongly associated with the presence of coronary
artery disease (630). The presence of asymptomatic (inci-
dental) RAS is a strong predictor of subsequent mortality
(719). Conlon and coworkers performed screening abdomi-
nal aortography on 3987 patients undergoing cardiac
catheterization (730). Significant (at least 50% diameter
stenosis) RAS was found in 362 patients (9.1%), and severe
(at least 75% diameter stenosis) RAS was found in 191
(4.8%). Approximately one fifth (n equals 33) of patients
with severe RAS had bilateral involvement. In that study, the
4-year survival rate for patients with asymptomatic, severe
(at least 75% diameter stenosis) RAS incidentally discovered
at cardiac catheterization was diminished to 57% compared
with the 89% survival rate in patients without severe RAS
(730). The presence of severe RAS was independently asso-
ciated with mortality. In a multivariate model, the negative
impact of incidental RAS on survival persisted even in those
individuals who had undergone revascularization for coro-
nary artery disease. As the severity of RAS increased in 3
disease severity groups (from 50% to 75%, from 75% to
95%, and greater than 95%), the 4-year patient survival rate
decreased from 70% to 68% and 48%, respectively (Table
34) (730). Patients with bilateral severe (at least 75% diame-
ter stenosis) RAS had the lowest 4-year survival rate of 47%
compared with 59% for those with unilateral disease. 
Table 30. Prevalence of Incidental RAS Found at Abdominal Aortography
No. of % RAS Greater
First Author Reference Patients RAS (%) Than 50% (%) Bilateral (%)
Olin (625) 318 NR 38 13
Valentine (630) 346 NR 28 NR
Leertouwer (719) 386 NR 33 26
NR indicates not reported; RAS, renal arterial stenosis.
Table 31. Univariate Predictors of RAS in Individuals Undergoing Cardiac Catheterization
Variable OR (95% CI) p
Coronary artery disease 4.8 (3.9 to 5.9) 0.000001
Elevated creatinine 4.5 (2.8 to 7.2) 0.000001
Peripheral arterial disease 2.6 (2.2 to 3.0) 0.000001
Cerebrovascular disease 2.3 (2.0 to 2.7) 0.000001
Hypertension 2.3 (2.0 to 2.6) 0.000001
Ejection fraction less than 30% 1.5 (1.2 to 1.8) 0.001
Diabetes mellitus 1.5 (1.3 to 1.7) 0.000001
Female sex 1.4 (1.2 to 1.6) 0.000001
Family history of CAD 1.2 (1.0 to 1.4) 0.009
CAD indicates coronary artery disease; CI, confidence interval; OR, odds ratio; RAS, renal arterial disease.
Reprinted with permission from Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery stenosis in patients under-
going cardiac catheterization. Am Heart J. 1998;136:913-8 (643).
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There are no well-controlled prospective, randomized
investigations to measure the relative risk and benefit of
endovascular interventions (or associated medical therapies)
in individuals with asymptomatic renal artery disease, and
thus the role of such interventions remains controversial.
Recommendations regarding the role of percutaneous revas-
cularization of asymptomatic renal disease are made largely
on the basis of expert opinion and are not based on evidence
that treatment of asymptomatic RAS improves any renal or
systemic outcome, including renal preservation, blood pres-
sure, or cardiovascular morbidity or mortality. Therefore,
these recommendations are still considered controversial and
must be individualized for the patient by each treating physi-
cian. The recommendations will likely be modified once
controlled prospective data become available.
3.5.2.2. Hypertension
RECOMMENDATIONS
Class IIa
Percutaneous revascularization is reasonable for
patients with hemodynamically significant RAS and
accelerated hypertension, resistant hypertension,
malignant hypertension, hypertension with an unex-
plained unilateral small kidney, and hypertension
with intolerance to medication. (Level of Evidence: B)
Control of hypertension is an important component of all
atherosclerosis risk reduction. Most hypertension is not due
to RAS (essential hypertension) and routine evaluation for
RAS is not indicated. However, there are clinical clues that
can be useful in identifying the small subset of individuals in
whom directed evaluation for renal artery disease may be
useful (see Section 3.2 and Figure 17). It should be noted that
“resistant hypertension” is defined as the failure to achieve
goal blood pressure in patients who are adhering to full doses
of an appropriate 3-drug regimen that includes a diuretic
(from p. 2570 of Chobanian et al., 294).
Renovascular hypertension remains the most common
form of correctable hypertension. Percutaneous techniques
have largely replaced surgical revascularization for athero-
sclerotic renovascular hypertension (731). The DRASTIC
trial (Dutch Renal Artery Stenosis Intervention Cooperative)
was an attempt to determine the efficacy of medical therapy
compared with percutaneous transluminal renal angioplasty
for blood pressure control in renovascular hypertension
(732). There was an advantage for the percutaneous translu-
minal renal angioplasty group at 3 months. The intention-to-
treat analysis at 1 year was limited in this study by the high
proportion (greater than 40%) of patients who were assigned
to the “medical treatment” cohort who crossed over to per-
cutaneous transluminal renal angioplasty, thus potentially
underestimating the benefit of percutaneous transluminal
renal angioplasty. In addition, the percutaneous technique
applied in this trial did not consistently utilize stents. Another
Table 32. Multivariate Logistic Regression of Univariate Predictors of Renal Arterial Stenosis in Patients
Undergoing Cardiac Catheterization for Suspected Coronary Artery Disease (CAD)
Regression Odds
Coefficient Ratio 95% CI p
Extent of CAD 0.801 2.227 1.204 to 4.119 0.011
Glomerular filtration rate –0.04 0.961 0.925 to 0.998 0.038
Systolic blood pressure 0.025 1.026 0.996 to 1.057 0.078
Age –0.01 0.99 0.917 to 1.069 0.802
Diabetes mellitus 0.091 1.095 0.570 to 2.071 0.781
CI indicates confidence interval.
Reprinted with permission from Weber-Mzell D, Kotanko P, Schumacher M, et al. Coronary anatomy predicts presence or absence of renal
artery stenosis: a prospective study in patients undergoing cardiac catheterization for suspected coronary artery disease. Eur Heart J.
2002;23:1684-91 (622).
Table 33. Prevalence of RAS in Individuals With Systemic Atherosclerotic Syndromes*
Infrainguinal 
AAA (n=108) AOD (n=21) PAD (n=189) RAS (n=76)
All patients with greater 41 (38%) 7 (33%) 74 (39%) 53 (70%)†
than 50% stenosis
*Significant renal arterial stenosis (RAS) was defined as greater than 50% stenosis.
†p<0.01 versus other 3 groups.
AAA indicates abdominal aortic aneurysm; AOD, aortic occlusive disease; n, total sample size; and PAD, peripheral arterial disease.
Adapted with permission from Olin JW, Melia M, Young JR, et al. Prevalence of atherosclerotic renal artery stenosis in patients with athero-
sclerosis elsewhere. Am J Med. 1990;88(1N):46N-51N (625).
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hemodynamically significant stenosis defined as (a) 50% to
70% diameter stenosis by visual estimation with a peak
translesional gradient (measured with a 5F or smaller
catheter or pressure wire) of at least 20 mm Hg or a mean
gradient of at least 10 mm Hg; (b) any stenosis of at least
70% diameter; or (c) greater than or equal to 70% diameter
stenosis by intravascular ultrasound measurement (718).
It has been assumed that the outcome variability of the cur-
rent investigational database is attributable to both the het-
erogeneity of patient selection criteria for inclusion in these
clinical trials and the lack of standard reporting criteria. One
trial demonstrated that patients with the highest baseline sys-
tolic blood pressures had the greatest decrease in systolic
pressure, but the variables of age, sex, race, severity of steno-
sis, number of vessels treated, baseline diastolic pressure, or
baseline serum creatinine did not correlate with blood pres-
sure improvement after renal stent placement (13). Another
multivariate logistic regression analysis demonstrated that 2
variables, bilateral RAS (OR equals 4.6, p equals 0.009) and
mean arterial pressure greater than 110 mm Hg (OR equals
2.9, p equals 0.003), predicted a beneficial blood pressure
response after renal artery stent placement (736). No differ-
ence has been demonstrated in the blood pressure response
after stent placement in older (75 years and older) versus
younger (less than 75 years) patients or in women versus
men (740,741). 
The current evidence base suggests that patients with
severe atherosclerotic RAS and accelerated, resistant, and
malignant hypertension may expect to receive some clinical
benefit, including improved blood pressure control, the need
for fewer medications, or both. However, “cure” of hyper-
tension is rare, improvement in blood pressure control is
common, and a moderate fraction of individuals do not
achieve measurable benefit (Table 36).
3.5.2.3. Preservation of Renal Function
RECOMMENDATIONS
Class IIa
Percutaneous revascularization is reasonable for
patients with RAS and progressive chronic kidney dis-
ease with bilateral RAS or a RAS to a solitary func-
tioning kidney. (Level of Evidence: B)
criticism of the DRASTIC trial is that there was no proof of
hemodynamic significance of stenoses of 50% to 70%.
Therefore, some patients may have been treated with renal
revascularization for nonhemodynamically significant
stenoses. This would decrease the overall benefit for the
treatment group. Since publication of this trial, stent place-
ment has emerged as a superior technique to balloon angio-
plasty alone for the treatment of atherosclerotic ostial RAS.
In a meta-analysis comparing the clinical benefits of balloon
angioplasty and stent therapy, stent therapy demonstrated a
better blood pressure response and a lower restenosis rate
(699).
The single randomized, controlled trial that compared renal
stent placement with balloon treatment alone demonstrated
procedural superiority for primary stent placement (700).
The burden of reintervention in the percutaneous translumi-
nal renal angioplasty group (48%) compared with that of the
stent group (14%) also supported the cost efficacy of stent
placement during the primary procedure. The reduced
restenosis with stenting compared with angioplasty alone
seen in this study was not associated with differences in
either hypertension or renal function benefit. A number of
studies have confirmed the high technical success rates (95%
or higher) for primary renal stent placement (733-739).
As noted above, the indications for renal artery revascular-
ization presume the presence of clinical indications with a
Table 35. Multivariate Analysis of Risk Factors Associated With Progression of
Renal Arterial Stenosis
Variable OR (95% CI) p
Female sex 1.9 (1.5 to 2.2) 0.002
Increased age 1.6 (1.4 to 1.8) 0.0001
Coronary artery disease 1.3 (1.2 to 1.4) 0.004
Time between angiograms, yr 1.3 (1.2 to 1.4) 0.0001
CI indicates confidence interal; and OR, odds ratio. 
Reprinted with permission from Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery steno-
sis in patients undergoing cardiac catheterization. Am Heart J. 1998;136:913-8 (643).
Table 34. Four-Year Survival for Individuals With Incidental
(Asymptomatic) RAS as Documented at Cardiac
Catheterization
Severity of Four-Year
Incidental RAS Survival (%)
No RAS 90
50% to 75% 70
75% to 95% 68
Greater than 95% 48
RAS indicates renal arterial stenosis. 
Reprinted with permission from Conlon PJ, Little MA, Pieper K, et al. Severity of
renal vascular disease predicts mortality in patients undergoing coronary angiog-
raphy. Kidney Int. 2001;60:1490-7 (730).
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Class IIb
Percutaneous revascularization may be considered for
patients with RAS and chronic renal insufficiency
with unilateral RAS. (Level of Evidence: C)
Atherosclerotic RAS is an important cause of or contribu-
tor to renal failure (632,740,742,743). It is unclear how many
patients enter dialysis secondary to RAS. In one study,
patients with renovascular disease as the cause of their renal
failure had survival rates of 56% at 2 years (640). As indi-
viduals with progressive worsening renal function are evalu-
ated for reversible etiologies (including RAS), it should be
noted that the National Kidney Foundation defines chronic
kidney disease as a decrease in estimated glomerular filtra-
tion rate to less than 60 mL/min per 1.73 m2 (modified
Modification of Diet in Renal Disease formula) that persists
for at least 3 months. Moreover, it may be inappropriate for
many patients with new end-stage renal disease to be con-
sidered as candidates for evaluation for RAS when signifi-
cant intrinsic kidney disease is a major contributor to renal
failure.
Revascularization is effective in stabilizing or improving
renal function in patients with symptomatic atherosclerotic
RAS (701,744-748). Several trials have documented that
renal artery stent placement improves or stabilizes renal
function in patients with atherosclerotic RAS (749-752).
Significant improvement in renal function up to 1 year after
unilateral renal artery stent placement was demonstrated by
Leertouwer and coworkers (701). They demonstrated that the
glomerular filtration rate in the revascularized kidney
improved significantly but that overall glomerular filtration
rate from both kidneys did not change (721). Prospective
randomized trials of stenting for unilateral RAS in an effort
to preserve renal function are needed.
Harden and colleagues (750) reported a series of 32
patients (33 kidneys) with unexplained renal insufficiency
and hemodynamically significant RAS who underwent stent
placement. The majority of patients had bilateral or unilater-
al solitary RAS, although unilateral disease was present in 7
patients. Improvement and stabilization of renal function
were demonstrated by plotting the slope of serial reciprocal
serum creatinine values. This study was limited by a rela-
tively short median follow-up of only 8 months. The authors
concluded that stent placement slowed the progression of
RAS (750). Ultimately, large-scale prospective, controlled
trials better defining the role, thresholds, and patient subsets
that warrant revascularization in the setting of chronic kid-
ney disease need to be performed. 
Improvement of renal function was demonstrated in 33
patients undergoing successful renal artery stent placement
for bilateral or unilateral solitary RAS (greater than or equal
to 70%) with a baseline serum creatinine between 1.5 and 4.0
mg per dL (751). When reciprocal creatinine plots were used,
all patients at baseline had deteriorating renal function man-
ifested by the negative calculated renal function slope.
Follow-up data at greater than or equal to 8 months were
available in 25 patients, all of whom had either a positive or
less-negative reciprocal slope of the creatinine, which indi-
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recurrent, unexplained congestive heart failure or
sudden, unexplained pulmonary edema (see text).
(Level of Evidence: B)
Class IIa
Percutaneous revascularization is reasonable for
patients with hemodynamically significant RAS and
unstable angina (see text). (Level of Evidence: B) 
Alterations in circulatory homeostasis can be prominent in
individuals with significant RAS and may provoke exacer-
bations of coronary ischemia and/or congestive heart failure
due to peripheral arterial vasoconstriction, direct effects of
angiotensin II on the myocardium, and/or volume overload.
Renovascular disease may also complicate the long-term
management of cardiac patients (e.g., those with hyperten-
sion or left ventricular systolic dysfunction) by preventing
administration of angiotensin antagonist therapies. 
Individuals with RAS may experience sudden-onset or
“flash” pulmonary edema (756-761). Patients with hemody-
namically severe bilateral or solitary RAS may manifest a
volume-overload state because they lack normal renal func-
tion to respond to pressure natriuresis (762,763). Patients
with unilateral renal stenosis may also experience pulmonary
edema due to increased left ventricular afterload secondary
to angiotensin-mediated vasoconstriction. Unilateral RAS
may contribute to the development of unstable coronary syn-
dromes by causing sudden increases in myocardial oxygen
demand in patients with coronary disease secondary to
peripheral vasoconstriction; this mechanism is distinct from
the usual assumption underlying other mechanisms of acute
coronary syndromes (e.g., plaque rupture or progressive ath-
erosclerosis) (764,765). 
This pathophysiology underpins the potential therapeutic
benefit of renal artery stent placement in the treatment of
some manifestations of congestive heart failure or unstable
coronary syndromes (766,767). These patients were charac-
terized by having at least 1 renal artery with a hemodynami-
cally significant stenosis and established coronary artery dis-
ease. Successful renal stent placement resulted in a signifi-
cant decrease in blood pressure and control of anginal symp-
toms in 88% of all patients (42 of 48). Some patients under-
went both coronary and renal intervention, whereas others
had only renal artery stent placement because their coronary
atherosclerotic lesions were unsuitable for revascularization.
Outcomes were assessed acutely and at 8 months with the
Canadian Cardiovascular Society angina classification and
the New York Heart Association functional classification.
There was no incremental therapeutic advantage gained for
the group that underwent coronary intervention with renal
stent placement compared with the group that underwent
renal stent placement alone. 
These potential benefits of renal revascularization for indi-
viduals with severe angina or with exacerbations of heart
failure have been observed in small prospective case series
but have not been evaluated in prospective, randomized clin-
ical trials. In addition, the individuals enrolled in these inter-
ventional case series were carefully selected and are not rep-
cated improvement and stabilization of renal function. This
small study also demonstrated preserved renal mass by ultra-
sound measurements. 
Using a serum creatinine value greater than or equal to 1.5
mg per dL and a negative slope of the reciprocal of the serum
creatinine in the preceding 12 months, Rocha-Singh et al.
documented reversal of declining renal function with stent
placement; this benefit was sustained over 30 months (752).
The improvement in renal function was associated with
lower blood pressure and fewer medication requirements.
These authors concluded that renal stent revascularization
should be considered a valid therapeutic option for the long-
term treatment of ischemic nephropathy.
Several factors may argue against renal revascularization
or predict poorer outcomes. These include the presence of
proteinuria greater than 1 g every 24 hours, renal atrophy,
severe renal parenchymal disease, and severe diffuse
intrarenal arteriolar disease. In addition, several studies have
shown that renal function can deteriorate after renal artery
angioplasty, especially in patients with stable renal function
prior to the intervention (752a,752b). Thus, the risks and
benefits of renal revascularization must be carefully evaluat-
ed in each individual.
The adverse consequences of renal atheroembolization at
the time of surgical revascularization have been documented
(753). Similar potentially severe atheroembolization may be
provoked by renal percutaneous revascularization methods
(754). The contribution of procedure-related renal artery
atheroembolization to decrements in renal function after
revascularization can be difficult to quantitate and distin-
guish from the nephrotoxic effects of iodinated contrast, par-
ticularly in patients with initially elevated serum creatinine
and limited renal reserve. These potential limitations empha-
size the need for preprocedural volume expansion and strict
use of contrast-sparing techniques (e.g., highly diluted con-
trast), the use of alternative agents (e.g., carbon dioxide or
gadolinium), preprocedure oral acetylcysteine administra-
tion, and high levels of operator experience when revascu-
larization is performed in individuals with renal insufficien-
cy. In a preliminary study, Henry and coworkers used embol-
ic protection devices during percutaneous renal revascular-
ization and demonstrated atheroembolic debris in all 32
arteries treated (755). The value of embolic protection
devices is being tested in clinical trials to determine whether
these devices can decrease (or increase) the frequency of
clinically important atheroemboli to the kidneys. Ultimately,
large-scale prospective, controlled trials better defining the
role, thresholds, and patient subsets that warrant revascular-
ization in the setting of chronic kidney disease need to be
performed.
3.5.2.4. Impact of RAS on Congestive 
Heart Failure and Unstable Angina
RECOMMENDATIONS
Class I
Percutaneous revascularization is indicated for
patients with hemodynamically significant RAS and
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resentative of the majority of patients with “accelerated angi-
na” or with “recurrent congestive heart failure.” Angina is
known to accelerate via many mechanisms that are unrelated
to renal hemodynamics (e.g., simple progressive coronary
atherosclerosis and instability of coronary plaque), and these
mechanisms are predominant. Thus, clinicians are cautioned
to carefully explore these other mechanisms before presum-
ing that renal artery disease is the major mechanism under-
lying the exacerbation of coronary symptoms. Similarly,
heart failure is frequently caused by nonatherosclerotic
mechanisms, and exacerbations of heart failure symptoms
are multifactorial (e.g., due to progressive remodeling, pro-
gressive coronary disease, dietary changes, or medical non-
compliance). The recommendations in the present guideline
are intended to apply to individuals in whom these nonrenal
factors have been explored and in whom there are clinical
indications to suggest the presence of RAS (e.g., systemic
atherosclerosis).
In summary, the potential physiological benefits of renal
stent placement include reperfusion of the ischemic kid-
ney(s), resulting in a reduction in the stimulus to renin pro-
duction, which decreases angiotensin and aldosterone pro-
duction, thereby decreasing peripheral arterial vasoconstric-
tion and the tendency to develop an expanded extracellular
fluid volume. Improvement in renal perfusion enhances
glomerular filtration and therefore promotes natriuresis.
Finally, in patients with a solitary kidney or bilateral RAS,
the ability of the patient to tolerate long-term administration
of angiotensin antagonist medications may be facilitated by
relief of a hemodynamic renal artery obstruction.
3.5.3. Catheter-Based Interventions
RECOMMENDATIONS
Class I
1. Renal stent placement is indicated for ostial athero-
sclerotic RAS lesions that meet the clinical criteria for
intervention. (Level of Evidence: B)
2. Balloon angioplasty with bailout stent placement if
necessary is recommended for FMD lesions. (Level of
Evidence: B)
Percutaneous transluminal renal balloon angioplasty is the
treatment of choice for symptomatic RAS caused by FMD
(744,768-770). However, in atherosclerotic RAS, balloon
angioplasty alone is associated with a lower procedural suc-
cess rate and a higher restenosis rate (745,771-777). Aorto-
ostial stenoses represent the most common atherosclerotic
lesions and are prone to vascular recoil due to confluent
plaque that extends from the wall of the aorta into the ostium
of the renal artery. These atherosclerotic aorto-ostial lesions
are generally considered unsuitable for treatment by balloon
angioplasty alone (769,770,778).
Stent placement has consistently proven superior to balloon
angioplasty in the treatment of renal artery atherosclerotic
lesions. Balloon angioplasty was compared with stent place-
ment in atherosclerotic RAS by Dorros and coworkers (779).
Quantitative vascular angiography and translesional pressure
gradients were measured in 18 patients who served as their
own controls. Stents were significantly more effective than
balloon angioplasty in these atherosclerotic renal artery
lesions (Table 37) (779). 
The superiority of renal stent placement over balloon
angioplasty was confirmed in a randomized, controlled trial
in hypertensive patients by van de Ven and coworkers (700).
A total of 42 patients and 51 arteries were randomized to bal-
loon angioplasty (with bailout stenting), and 42 patients and
52 arteries were randomized to receive primary stent therapy.
Procedure success and long-term patency markedly favored
the stent group (Table 38) (700). Over the course of the
study, 12 (29%) patients in the balloon group crossed over to
the stent group. This large percentage of crossover patients
confounded the analysis of the clinical end point at 1 year. 
The authors calculated that a renal bailout (provisional)
stent strategy would avoid a stent during the initial procedure
40% of the time. However, 45% of the patients would ulti-
mately require a second procedure with a stent and also
would incur additional complications that would make the
strategy of primary stent placement more efficient. For the
balloon group to achieve a 90% patency rate at 6 months,
62% of all patients would ultimately require a stent, and 57%
of all patients would need a second or third procedure. To
obtain a 90% 6-month patency rate in the primary stent
group, only 12% would need a second procedure. This ran-
domized, controlled trial clearly demonstrated the superiori-
ty of renal stents over balloons in hypertensive patients with
atherosclerotic RAS for procedure success, late patency, and
cost-effectiveness (700). 
A meta-analysis of 10 renal stent studies performed
between 1991 and 1997 demonstrated procedural success
rates greater than or equal to 96% with a procedure-related
mortality rate of less than 1% (780). The average restenosis
rate, evaluated between 6 and 12 months after the procedure,
was 16%. A second meta-analysis, comparing renal stent
Table 37. Renal Artery Intervention: The Posttreatment Efficacy of Primary Balloon Versus Stent Interventions
Baseline Balloon Stent
Stenosis (%) 82 plus or minus 12 29 plus or minus 14 3 plus or minus 6*
Mean gradient, mm Hg 50 plus or minus 22 8 plus or minus 6 1 plus or minus 3*
Peak gradient, mm Hg 94 plus or minus 33 23 plus or minus 19 1 plus or minus 3*
*p less than 0.05.
Reprinted with permission from Dorros G, Jaff M, Mathiak L, et al. Four-year follow-up of Palmaz-Schatz stent revascularization as treatment
for atherosclerotic renal artery stenosis. Circulation. 1998;98:642-7 (779).
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736). Two series have addressed the long-term durability and
patency of renal stents (733,735). In those series, the 5-year
primary patency rates of renal stents were 79% and 84.5%,
and the secondary patency rates were 92.4% and 98%.
Almost all occurrences of stent restenosis occurred during
the first year after stent implantation, with restenosis later
than 2 years an unusual occurrence.
3.5.4. Surgery for RAS
RECOMMENDATIONS
Class I
1. Vascular surgical reconstruction is indicated for
patients with fibromuscular dysplastic RAS with clin-
ical indications for interventions (same as for PTA),
especially those exhibiting complex disease that
extends into the segmental arteries and those having
macroaneurysms. (Level of Evidence: B)
2. Vascular surgical reconstruction is indicated for
patients with atherosclerotic RAS and clinical indica-
tions for intervention, especially those with multiple
small renal arteries or early primary branching of the
main renal artery. (Level of Evidence: B)
3. Vascular surgical reconstruction is indicated for
patients with atherosclerotic RAS in combination with
pararenal aortic reconstructions (in treatment of aor-
tic aneurysms or severe aortoiliac occlusive disease).
(Level of Evidence: C)
placement and balloon angioplasty, for atherosclerotic RAS
was performed by Leertouwer and colleagues (700). They
confirmed a significantly higher procedural success rate for
stents (98%) than for balloon angioplasty (77%; p less than
0.001) and a lower restenosis rate for stents (17%) than for
balloon angioplasty (26%; p less than 0.001). A survey of the
literature suggests that restenosis rates for renal stenting are
often lower (Table 39). 
Renal resistive index has been suggested as a marker for
selecting patients likely to respond to intervention. However,
there are conflicting data regarding the ability of the RRI to
predict treatment response. A retrospective study in which
most patients were treated by balloon angioplasty alone by
Radermacher and coworkers (698) suggested that an elevat-
ed resistance index greater than 0.80 was associated with a
low probability of improved blood pressure control or renal
function preservation after revascularization. This study has
been criticized for its retrospective nature without use of pre-
specified end points and for its reliance on the use of balloon
angioplasty as the primary method of treatment. These data
have been challenged recently by a prospective uncontrolled
study of renal stent placement in 241 patients by Zeller and
associates (702). These investigators clearly demonstrated
that patients with an elevated RRI were also able to achieve
a favorable blood pressure response and renal functional
improvement after renal arterial intervention. 
For renal artery atherosclerotic lesions, the larger the post-
stent minimal lumen diameter, as measured by quantitative
vascular angiography, the better the late stent patency (738).
Similar to coronary stents, larger diameter renal arteries have
lower restenosis rates than smaller diameter vessels (698,
Table 38. Balloon Versus Stent: Randomized, Controlled Trial
Balloon (n=51) Stent (n=52) p Value
Procedure success 63% 90% Less than 0.05
Restenosis 48% 14% Less than 0.05
van de Ven PJ, Kaatee R, Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised
trial. Lancet. 1999;353:282-6. (700). Reprinted with permission from Elsevier.
Table 39. Renal Stent Placement Procedural Outcomes
First Author Date Reference Arteries (n) Success* (%) Restenosis (%)
White 1997 (738) 133 99 18.8
Blum 1997 (733) 74 100 11
Tuttle 1998 (734) 148 98 14
Henry 1999 (735) 209 99 11.4
van de Ven 1999 (700) 43 90 14
Rocha-Singh 1999 (736) 180 97 12
Lederman 2001 (739) 358 100 21
*Definitions of procedural success vary in each study.
n indicates number of patients. 
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surgical operation, it can result in secondary nephrectomy
(794).
Operative therapy, when undertaken for arteriosclerotic
renovascular disease, must consider the status of the aorta. A
nonanatomic bypass is appropriate in the case of a hostile
aorta due to intrinsic disease that is nontreatable without
inordinate patient risks or in instances of very poor cardiac
function where aortic cross-clamping would be hazardous. In
patients who require open surgical treatment of AAAs or
severe aortoiliac occlusive disease, a concomitant aortic
reconstruction and an aortorenal bypass or endarterectomy
may be performed (782,792,795-797). These latter 2 options
also exist in the case of a normal aorta, with an aortorenal
bypass favored in treatment of single renal artery disease and
aortorenal endarterectomy favored for treatment of multiple
renal arteries to the same kidney, as well as in treatment of
bilateral disease.
Nonanatomic bypass is an important means of renal revas-
cularization in select patients, provided that flow within the
donor artery is normal. When hepatorenal or splenorenal
bypasses are created, no significant celiac artery stenoses
should be present. For iliorenal bypasses, no pressure gradi-
ents across the aorta or proximal iliac arteries should be pres-
ent, lest they impair graft flow.
Aortorenal bypass is the most common open surgical
means of treating arteriosclerotic renovascular disease
(782,795). Reversed saphenous vein is the favored conduit
when small renal arteries are being bypassed or multiple ves-
sel reconstructions are being performed. For reconstruction
of a large poststenotic renal artery, especially when the graft
originates from a concurrently placed synthetic aortic pros-
thesis, use of a PTFE or polyester filament graft is accept-
able.
Aortorenal endarterectomy is preferred by many surgeons,
especially when undertaken in concert with an aortic recon-
structive operation (797). This form of renal revasculariza-
tion is generally considered more technically demanding
than a nonanatomic bypass or a conventional bypass (796). It
is often performed through an axial aortotomy that extends
from the level of the superior mesenteric artery to the
infrarenal aorta or through the transected aorta at the time of
the aortic reconstruction. The axial transaortic approach has
particular applicability for treatment of bilateral and multiple
renal artery ostial stenoses, as well as when coexistent celiac
and superior mesenteric arterial stenoses need to be treated.
A direct renal arteriotomy and endarterectomy has certain
advantages for treatment of complex disease that extends
into early branchings of the renal artery, but it is performed
much less often than transaortic endarterectomy.
Secondary nephrectomy should only be done after recon-
structive failures are deemed impossible to salvage with
reoperation (798,799). Irreparable ischemic atrophy or injury
in some patients may be a consequence of advanced arte-
riosclerotic occlusive disease. It is most likely to exist when
(a) radionuclide scan evidence exists that the kidney con-
tributes less than 10% of the total renal function, (b) the kid-
ney length is less than 5 cm, or (c) there is evidence of exten-
3.5.4.1. Fibromuscular Dysplasia
Operative therapy for treatment of FMD, be it performed in
situ or ex vivo, is undertaken in 2 basic modes with either (a)
an aortorenal bypass or (b) a nonanatomic bypass (781,782).
In situ revascularizations are preferred in that disruption of
preexisting collateral vessels does not accompany this type
of reconstructive procedure. However, ex vivo revasculariza-
tions are appropriate in certain patients with complex dis-
ease, especially that which affects multiple segmental vessels
or that is associated with macroaneurysmal disease of these
smaller arteries (783).
Age and the status of the aorta become important determi-
nants of the type of in situ operation. In patients less than 21
years of age, vein grafts are avoided because of the potential
for late aneurysmal degeneration (784). Internal iliac artery
grafts are favored in younger patients and in occasional older
patients. Vein grafts are favored in most patients 21 years and
older in whom the aorta is relatively normal. In patients with
no suitable vein, synthetic conduits of PTFE or polyester fil-
ament may be used, but these materials are not favored over
autologous grafts in younger individuals.
In patients with an aorta encased in scar tissue from previ-
ous surgery or in whom clamping of the aorta would be haz-
ardous because of severe ventricular dysfunction, a
nonanatomic revascularization, in the form of a hepatorenal,
splenorenal, or iliorenal reconstruction, would be appropriate
(785). A normal, undiseased celiac artery is necessary for the
performance of a hepatorenal or splenorenal bypass.
A secondary nephrectomy may be necessary to provide
adequate blood pressure control in those patients whose pri-
mary operation has failed when attempts at re-revasculariza-
tion have been unsuccessful (3,12). In rare circumstances, a
kidney will initially appear to be hypoplastic or will exhibit
irreparable ischemic atrophy. When the contralateral kidney
appears normal, a primary nephrectomy may be performed.
Dysplastic renal artery stenoses in pediatric-aged patients are
usually treated by open surgery, although balloon angioplas-
ty or transcatheter alcohol ablation of the renal parenchyma
beyond isolated intrarenal webs may be successfully used in
select patients (786-788).
3.5.4.2. Arteriosclerotic Renal Artery 
Occlusive Disease
Unilateral isolated nonostial RAS in the case of normal renal
function is usually treated by percutaneous balloon angio-
plasty with stenting in lieu of operative therapy (789-791),
although with abnormal renal function, surgical treatment
may be performed in select patients (782,792,793).
Unilateral and bilateral ostial stenoses account for most arte-
riosclerotic renovascular disease. In the case of unilateral
disease and normal renal function, either balloon angioplas-
ty or operative therapy provides acceptable results, although
less-invasive endovascular therapy is usually the preferred
modality. If restenosis after PTA is severe enough to warrant
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were seen in twice as many surgical patients (34%) as bal-
loon angioplasty patients (17%). The authors concluded that
in patients with RAS who were candidates for either surgery
or balloon angioplasty, balloon angioplasty should be the
first choice of therapy. One retrospective trial comparing out-
comes and costs associated with endovascular and surgical
revascularization described similar clinical outcomes but a
nearly 6-fold greater initial cost for surgery (807).
4. MESENTERIC ARTERIAL DISEASE
All diseases and conditions that affect the arteries have been
reported in the arteries that supply the intestines, including
atherosclerosis, arteritis, aneurysms, arterial infections,
FMD, dissections, arterial emboli, and thrombosis. The evi-
dence and recommendations in this section of the guideline
are directed at the various causes and treatment of the most
common vascular problem affecting the intestines, ischemia.
Because there are major differences in presentation, the sec-
tions are divided into acute and chronic intestinal ischemia.
Acute intestinal ischemia is most frequently caused by arte-
rial obstruction but also occurs in the absence of intestinal
arterial obstruction (e.g., nonocclusive mesenteric ischemia
seen in low flow states). Chronic intestinal ischemia is
always the result of arterial obstruction. Regardless of cause,
intestinal ischemia is rare. This means that there are no ran-
domized or controlled trials of diagnosis or therapy for intes-
tinal ischemia, acute or chronic, regardless of cause. There
are important gaps in our knowledge of the natural history of
intestinal ischemia, especially with regard to the number of
persons with asymptomatic intestinal arterial obstructions
who eventually become symptomatic. Despite this, the con-
dition and the primary diagnoses responsible for most cases
have been known for decades. Numerous series documenting
the results of surgical treatment have been reported, and
recently, the clinical course of a number of patients’ case
series treated by percutaneous intervention has also been
documented. These largely retrospective clinical reviews
form the basis for our knowledge of and recommendations
for treatment of intestinal ischemia.
4.1. Acute Intestinal Ischemia
4.1.1. Acute Intestinal Ischemia Caused by
Arterial Obstruction
4.1.1.1. Etiology
Acute obstructive intestinal ischemia occurs when the intes-
tinal arteries are suddenly blocked to a degree that all or part
of the intestine has insufficient perfusion for viability. The
many possible causes include embolism from cardiac or
proximal arterial sources (including arterial debris dislodged
during percutaneous interventions) and arterial thrombosis,
either of arteries chronically stenosed by atherosclerosis or
as a result of a hypercoagulable state or an acute arterial dis-
section (807-812). 
sive cortical infarction. In such circumstances, especially if
the serum creatinine is less than 3 mg per dL, a primary
nephrectomy may be appropriate. Renal revascularizations
are unlikely to improve either blood pressure control or renal
function in these patients.
Primary nephrectomy is performed in select patients in
whom operative or catheter-based procedures are not possi-
ble, and only when a benefit, especially regarding blood
pressure control, is expected after removal of the kidney
(800,801). The technique of primary intracapsular nephrec-
tomy is the same as with secondary nephrectomy.
3.5.4.3. Results of Operative Therapy
Renal preservation and maintenance of renal function are
important in the assessment of clinical experiences.
Nephrectomy will usually not offer as much benefit as revas-
cularization. Even when nephrectomy provides good results,
it leaves the patient at considerable risk if contralateral dis-
ease occurs later. Improved renal function after revascular-
ization is well recognized and is most likely to occur among
patients exhibiting arteriosclerotic disease with a relatively
sudden onset of renal function impairment.
Surgical treatment of renovascular hypertension affords
good clinical outcomes (802-806). The risk of surgery
increases in patients who require concomitant aortic recon-
struction, in patients with renal insufficiency, and when aor-
tic grafts are used as a source of the bypass graft. The need
for reoperation has been reported in 5% to 15% of patients,
with survival in 65% to 81% of patients (802-806).
Differences among most individual experiences reflect vari-
ations in the prevalence of different renovascular disease cat-
egories. Arterial fibrodysplastic renovascular hypertension
(Table 40) is more likely to benefit from surgical revascular-
ization than is arteriosclerotic renovascular hypertension
(Table 41). This is probably a reflection of coexistent essen-
tial hypertension in older patients with arteriosclerotic dis-
ease. Arteriosclerotic renovascular hypertension occurs in 2
subgroups of patients: (a) those with focal renal artery dis-
ease whose only clinical manifestation of arteriosclerosis is
secondary hypertension and (b) those with clinically overt
extrarenal arteriosclerosis that affects the coronary artery,
carotid artery, aorta, or extremity vessels. The severity and
duration of hypertension, age, and gender in these 2 sub-
groups are similar, yet the surgical outcome regarding ame-
lioration of hypertension is worse in patients with overt
extrarenal arteriosclerotic disease.
Surgery was compared with balloon angioplasty for renal
artery revascularization in a randomized clinical trial in
hypertensive patients with atherosclerotic RAS (731). At the
2-year follow-up interval, the surgery group had a higher pri-
mary patency rate than the balloon angioplasty group (95%
vs. 75%, p equals 0.05); however, there was no difference in
the secondary patency rate between the groups (balloon 90%
vs. surgery 97%, p equals 0.61). The clinical end points of
hypertension control and renal function preservation were
not different for angioplasty or surgery. Major complications
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Regardless of the cause, patients with acute intestinal
ischemia have severe abdominal pain that is initially out of
proportion to any physical findings that may be present. This
is because peritoneal irritation that leads to abdominal ten-
derness takes hours to develop, and distention, rigidity,
guarding, and systemic symptoms of vascular collapse may
take days to manifest and are best correlated with intestinal
perforation.
4.1.1.2. Diagnosis
RECOMMENDATIONS
Class I
1. Patients with acute abdominal pain out of proportion
to physical findings and who have a history of cardio-
vascular disease should be suspected of having acute
intestinal ischemia. (Level of Evidence: B)
Table 41. Surgical Revascularization of Arteriosclerotic Renovascular Hypertension in Adults
Operative Outcome (%)
No. of Surgical Mortality 
Institution Patients Cured Improved Failed (30-Day) Rate (%)
Baylor College of Medicine 360 34 31 35 2.5
Bowman Gray 152 15 75 10 1.3
University of Michigan 135 29 52 19 4.4
University of California, 
San Francisco 84 39 23 38 2.4
Cleveland Clinic 78 40 51 9 2
Columbia University 67 58 21 21 Unstated
University of Lund, 
Malmo, Sweden 66 49 24 27 0.9
Hospital Aiguelongue, 
Montpellier, France 65 45 40 15 1.1
Vanderbilt University 63 50 45 5 9
Adapted with permission from Stanley JC. The evolution of surgery for renovascular occlusive disease. Cardiovasc Surg. 1994;2:195-202 (781).
Table 40. Surgical Revascularization of Fibrodysplastic Renovascular Hypertension in Adults
Operative Outcome (%)
No. of Surgical Mortality 
Institution Patients Cured Improved Failed (30-Day) Rate (%)
University of Michigan 144 55 39 6 0
Baylor College of Medicine 113 43 24 33 0
Cleveland Clinic 92 58 31 11 Unstated
University of California, 
San Francisco 77 66 32 1.3 0
Mayo Clinic 63 66 24 10 Unstated
University Hospital Leiden, 
the Netherlands 53 53 34 13 2
Vanderbilt University 44 72 24 4 2.3
Columbia University 42 76 14 10 Unstated
Bowman Gray 40 33 57 10 0
University of Lund, 
Malmo, Sweden 40 66 24 10 0
Adapted with permission from Stanley JC. The evolution of surgery for renovascular occlusive disease. Cardiovasc Surg. 1994;2:195-202 (781).
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pain requires administration of intravenous iodinated con-
trast material, which may affect later arteriography, this test
is not the best initial examination for suspected acute intes-
tinal ischemia, although it is frequently performed before
consideration of the mesenteric ischemia diagnosis. 
ARTERIOGRAPHY. Arteriography is the most helpful diagnos-
tic test in patients suspected of having acute intestinal
ischemia; however, its use is controversial because of the
time required for its performance in the emergency setting.
In patients suspected of having intestinal ischemia, arteriog-
raphy can be diagnostic and can differentiate occlusive from
nonocclusive ischemia. Furthermore, catheter-directed thera-
py of arterial occlusions with intra-arterial vasodilators,
thrombolysis, or mechanical thrombectomy devices is possi-
ble in some patients with acute ischemia. If surgical treat-
ment is required, knowledge of the extent and nature of intes-
tinal arterial lesions is helpful. 
The decision for arteriography is probably best individual-
ized in patients suspected of having acute intestinal ischemia.
For those with a very acute presentation, a high likelihood of
arterial obstruction, and suspected bowel infarction, immedi-
ate laparotomy by a surgeon capable of intestinal revascular-
ization is the best approach. In patients with acute onset in
whom angiography can be performed rapidly and without
delay, this is a reasonable approach. For those with a more
delayed presentation or a high likelihood of nonocclusive
ischemia, initial arteriography is indicated. In these cases, the
advantages of the additional information provided by arteri-
ography outweigh the time required for its performance.
4.1.1.3. Natural History
All series of acute intestinal ischemia patients include some
who had a history of chronic abdominal pain and weight loss.
The frequency with which chronic intestinal ischemia caused
by arterial obstruction becomes acute intestinal ischemia
(presumably by thrombosis) is unknown.
The natural history of acute intestinal ischemia caused by
obstruction of intestinal arteries in the absence of treatment
is nearly always fatal. Intestinal ischemia leads to infarction,
perforation, peritonitis, and death in the vast majority of
patients. A few exceptions occur in which the ischemic injury
may be confined to the mucosal layer of the intestine, or in
which the gradual development of collateral circulation may
result in resolution of the ischemia before infarction.
Although such patients are well recognized, they are rare
compared with those who do not recover. The exact percent-
age is unknown (808,809,813-818). The focus of treatment
in patients with acute mesenteric ischemia is to provide an
aggressive and rapid diagnosis to minimize the amount of
ischemic bowel that will progress to infarction, while rapid-
ly instituting appropriate therapy. 
2. Patients who develop acute abdominal pain after arte-
rial interventions in which catheters traverse the vis-
ceral aorta or any proximal arteries or who have
arrhythmias (such as atrial fibrillation) or recent MI
should be suspected of having acute intestinal
ischemia. (Level of Evidence: C)
Class III
In contrast to chronic intestinal ischemia, duplex
sonography of the abdomen is not an appropriate
diagnostic tool for suspected acute intestinal ischemia.
(Level of Evidence: C)
CLINICAL PRESENTATION. Approximately two thirds of
patients with acute intestinal ischemia are women, with a
median age of 70 years. Most patients have a history of pre-
existing cardiovascular disease (807-810). Abdominal pain is
always present; its nature, location, and duration are variable,
but most commonly, the pain is anterior, periumbilical, and
sufficiently severe that medical attention is sought immedi-
ately. Initially, signs of peritoneal irritation are absent, which
is classically referred to as “pain out of proportion to physi-
cal findings.”
LABORATORY FINDINGS. Laboratory evaluation most frequent-
ly shows leukocytosis and lactic acidosis, and amylase is ele-
vated in approximately 50% of patients; approximately 25%
of patients have occult blood in the stool. Abdominal radi-
ographs most frequently show some dilated loops of intes-
tine. There are no specific laboratory or plain radiograph
findings for acute intestinal ischemia.
ULTRASOUND. Because duplex ultrasound scanning is capable
of identifying occlusive lesions of the intestinal arteries, this
test is theoretically attractive for diagnosis of acute intestin-
al ischemia. In practice, it is not very helpful. This is because
duplex scanning of the deeply located intestinal arteries is
technically demanding, requiring ideal conditions for suc-
cess (e.g., fasting patients and early morning examinations to
avoid excessive intestinal gas). The abdominal distention and
fluid frequently present with acute ischemia precludes suc-
cessful scanning in most patients. Because of the need for
emergent treatment in acute ischemia and the time required
to attempt duplex scanning, this test is contraindicated.
COMPUTED TOMOGRAPHIC SCANNING. Computed tomographic
scans are frequently performed in patients with acute abdom-
inal pain. Computed tomographic findings suggestive of
intestinal ischemia include atherosclerotic disease of intes-
tinal arteries and obvious thrombosis of proximal intestinal
arteries, as well as intestinal distention, intestinal wall thick-
ening, intraabdominal fluid, and intestinal perforation. These
findings may also be present in patients without intestinal
ischemia. Computed tomographic findings suggestive of
intestinal ischemia include pneumatosis intestinalis and por-
tal venous air, both of which are late findings. Because com-
puted tomographic scanning for evaluation of abdominal
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Because most patients with acute intestinal ischemia have at
least some nonviable intestine at the time of presentation,
most will still require laparotomy and surgical assessment of
the intestinal viability. This approach may be required even
if percutaneous therapy is successful in relieving the obstruc-
tion. However, re-establishment of flow to infarcted bowel
may cause a sudden systemic release of endotoxins, which
may be associated with the sudden onset of disseminated
intravascular coagulation, adult respiratory distress syn-
drome, and sudden cardiovascular collapse. Therefore, in the
presence of infarcted bowel or markedly elevated lactic acid
levels, initial percutaneous treatment should be weighed
against surgical options in which control of the venous out-
flow (and the endotoxins) from the infarcted bowel segment
can be achieved.
Although only a few cases have been reported, further
exploration of this approach to acute ischemia seems appro-
priate. Percutaneous treatment of the arterial obstruction
greatly reduces the magnitude of the surgical procedure that
is required, and the high mortality associated with the stan-
dard approach means that investigation of alternative
approaches is appropriate.
4.1.2. Acute Nonocclusive Intestinal Ischemia
4.1.2.1. Etiology
RECOMMENDATIONS
Class I
1. Nonocclusive intestinal ischemia should be suspected
in patients with low flow states or shock, especially
cardiogenic shock, who develop abdominal pain.
(Level of Evidence: B)
2. Nonocclusive intestinal ischemia should be suspected
in patients receiving vasoconstrictor substances and
medications (e.g., cocaine, ergots, vasopressin, or nor-
epinephrine) who develop abdominal pain. (Level of
Evidence: B)
3. Nonocclusive intestinal ischemia should be suspected
in patients who develop abdominal pain after coarcta-
tion repair or after surgical revascularization for
intestinal ischemia caused by arterial obstruction.
(Level of Evidence: B)
Acute intestinal ischemia sufficient to produce infarction
also occurs in the absence of fixed arterial obstruction. The
most frequent setting is severe systemic illness with systemic
shock, usually as a result of reduced cardiac output (808,823-
827). In this situation, the intestinal ischemia has been shown
to be the result of severe and prolonged intestinal arterial
vasospasm. Before modern intensive care and vasodilator
treatment of congestive heart failure, nonocclusive intestinal
ischemia was quite common. With the advent of this therapy,
it has become rare. 
Intestinal vasospasm sufficient to produce ischemia/infarc-
tion also occurs as a result of cocaine ingestion and ergot poi-
soning (828,829). Therapeutic drugs may produce intestinal
4.1.1.4. Surgical Treatment
RECOMMENDATION
Class I
Surgical treatment of acute obstructive intestinal
ischemia includes revascularization, resection of
necrotic bowel, and, when appropriate, a “second
look” operation 24 to 48 hours after the revascular-
ization. (Level of Evidence: B)
Despite treatment, acute intestinal ischemia caused by arte-
rial obstruction is most often fatal. Various surgical series
show both that treatment outcome has changed little during
the past several decades and that mortality averages approx-
imately 70% (808,809,813-817). The reason for this grim
prognosis is found in the time course of the signs and symp-
toms of the disease. Because patients present initially with
abdominal pain and few findings, diagnosis is often delayed.
By the time the diagnosis is obvious because of abdominal
distention, perforation, shock, and so on, ischemia is far
advanced, and survival is doubtful, despite treatment.
Surgical treatment consists of laparotomy, revasculariza-
tion of the ischemic intestine either by embolectomy or
bypass grafting, assessment of the viability of the intestine
after revascularization, resection of nonviable intestine, and
intensive care. Frequently, some intestine is clearly viable,
some is clearly nonviable, and some is questionable. No
intraoperative diagnostic test has yet been described that is
superior to the clinical judgment of experienced surgeons in
determining intestinal viability (819). Scheduled “second
look” operations, 24 to 48 hours after the initial procedure,
are the best way to avoid both excessive resection of poten-
tially viable bowel and failure to resect nonviable intestine.
4.1.1.5. Endovascular Treatment
RECOMMENDATION
Class IIb
Percutaneous interventions (including transcatheter
lytic therapy, balloon angioplasty, and stenting) are
appropriate in selected patients with acute intestinal
ischemia caused by arterial obstructions. Patients so
treated may still require laparotomy. (Level of
Evidence: C)
Acute intestinal ischemia caused by arterial obstructions is
most frequently the result of occlusion of the proximal por-
tion of the superior mesenteric artery either by thrombosis at
the site of atherosclerosis or by localized arterial embolism.
It is reasonable to consider the role of lytic therapy, balloon
angioplasty/stenting, or both as definitive treatment, espe-
cially in view of the dismal results associated with standard
surgical therapy. 
Several isolated reports of percutaneous interventional
treatment of superior mesenteric artery obstruction produc-
ing acute intestinal ischemia have been published (820-822).
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diac output/peripheral perfusion, is the most reliable way to
relieve the inappropriate vasospasm. 
Administration of vasodilators by percutaneously placed
catheters at the site of inappropriate vasospasm has been
associated with relief of vasospasm/ischemic symptoms in
multiple patients (823). Because of the complete absence of
any controlled trials, it is not possible to determine whether
the improvement that occurred was the result of the systemic
or local effects of the vasodilators or the result of simultane-
ous treatment of the systemic condition.
Transcatheter administration of vasodilators is especially
appropriate in nonocclusive mesenteric ischemia caused by
drugs such as ergot or cocaine, in which systemic shock may
not coexist (831). Abdominal symptoms/findings that persist
after relief of intestinal arterial vasospasm are an indication
for laparotomy/resection of necrotic intestine.
There are few level I or II data on treatments for acute
mesenteric ischemia caused by mesenteric venous throm-
boses, internal or external hernias, vasculitides, or aortic dis-
sections, and therefore, a formal discussion of these causes is
not included in this document.
4.2. Chronic Intestinal Ischemia
4.2.1. Etiology
Although atherosclerotic disease of the celiac and mesenteric
vessels is common, the clinical presentation of chronic intes-
tinal ischemia is rare. It is nearly uniformly caused by ather-
osclerosis (832). Other rare causes include Buerger’s disease
(812,833), fibromuscular dysplasia/dissection, and aortic
dissection, but these are very rare causes of an already rare
syndrome. The celiac, superior mesenteric, and inferior
mesenteric arteries are all extensively interconnected, to a
degree that means that in usual circumstances, proximal
occlusion by atherosclerosis of any one is well tolerated
(832). Although classic clinical approaches to the diagnosis
of intestinal ischemia have often suggested that this syn-
drome requires occlusion or stenosis of at least 2 of the 3
intestinal arteries, this is not entirely true (833,834). Well-
documented cases of intestinal ischemia occur as a result of
single-vessel disease, virtually always of the superior mesen-
teric artery. Patients in whom some of the normal collateral
intestinal arterial connections have been interrupted by pre-
vious surgery are especially vulnerable to single-vessel
occlusions. 
Patients with chronic intestinal ischemia are most often
female (70%) and classically complain of severe abdominal
pain induced by eating. The pattern of pain is quite variable,
however, and the relationship to food is not always clear, at
least by history. What is clear is that patients voluntarily vast-
ly reduce their food intake, so that weight loss occurs, and
this may be profound. Vomiting, diarrhea, and constipation
are all present in a minority of patients. A majority have a
history of cardiovascular disease, and 30% to 50% have had
previous operations for atherosclerotic disease (most fre-
quently coronary and lower extremity bypass) (835,836).
ischemia from vasospasm, especially when vasopressors are
used in high doses to treat circulatory shock. 
Intestinal ischemia can also occur as a result of mesenteric
arterial spasm after repair of aortic coarctation (830) and
occasionally occurs after revascularization procedures for
chronic mesenteric ischemia (825). The mechanism of this
apparently paradoxical spasm is unknown. 
4.1.2.2. Diagnosis
RECOMMENDATION
Class I
Arteriography is indicated in patients suspected of
having nonocclusive intestinal ischemia whose condi-
tion does not improve rapidly with treatment of their
underlying disease. (Level of Evidence: B)
Nonocclusive mesenteric ischemia should be suspected
whenever patients with circulatory shock, especially cardio-
genic shock, develop abdominal pain and/or distention.
Because such patients are seriously ill, often with a
decreased level of consciousness, diagnosis may be delayed. 
In modern practice, nearly all ergot poisoning is the result
of use/misuse of therapeutic ergot preparations intended to
treat migraine headaches. The diagnosis of nonocclusive
intestinal ischemia should be suspected in persons using
cocaine or amphetamines who have abdominal pain.
There are no physical findings or laboratory tests specific
for nonocclusive intestinal ischemia. Arteriography is the
“gold standard” study. It can demonstrate the characteristic
mesenteric arterial vasospasm and allow direct intra-arterial
instillation of vasodilator medications (824,826,829).
4.1.2.3. Treatment
RECOMMENDATIONS
Class I
1. Treatment of the underlying shock state is the most
important initial step in treatment of nonocclusive
intestinal ischemia. (Level of Evidence: C)
2. Laparotomy and resection of nonviable bowel is indi-
cated in patients with nonocclusive intestinal ischemia
who have persistent symptoms despite treatment.
(Level of Evidence: B)
Class IIa
Transcatheter administration of vasodilator medica-
tions into the area of vasospasm is indicated in
patients with nonocclusive intestinal ischemia who do
not respond to systemic supportive treatment and in
patients with intestinal ischemia due to cocaine or
ergot poisoning. (Level of Evidence: B)
Initial treatment of nonocclusive intestinal ischemia should
be directed at treatment of the underlying shock state. The
most intensive hemodynamic monitoring possible, including
appropriate fluid/pharmacological therapy to improve car-
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Computed Tomography/MRA
Both contrast-enhanced CTA and gadolinium-enhanced
MRA are well suited for visualizing the typical atheroscle-
rotic lesions at the origins of the intestinal arteries that are
implicated in most cases of chronic intestinal ischemia.
These techniques are presently less suited for visualizing the
more distal intestinal arteries and for diagnosis of some of
the more unusual causes of intestinal ischemia.
Arteriography
Arteriograms provide definitive diagnosis of intestinal arteri-
al lesions. Lateral aortography is best suited for display of
the typical origin lesions, which may not be apparent on
frontal projections. The presence of an enlarged “arc of
Riolan” (an enlarged collateral vessel connecting the left
colic branch of the inferior mesenteric artery with the supe-
rior mesenteric artery) is an arteriographic sign of proximal
mesenteric arterial obstruction that is visible on anteroposte-
rior aortograms. Selective arteriography of the intestinal ves-
sels may fail to visualize the typical atherosclerotic origin
lesions because the selective catheter may be positioned
beyond them in the affected vessel.
Approach to Diagnosis
Although multiple diagnostic techniques are available to
demonstrate diseased intestinal vessels, such lesions are
actually quite common, whereas symptomatic intestinal
ischemia is rare. At present, there are no diagnostic tests that
establish the diagnosis definitively. Rather, it is the combina-
tion of the typical clinical presentation of abdominal pain
and weight loss, with other evidence of cardiovascular dis-
ease, and the finding of intestinal arterial obstruction in the
absence of other obvious cause of the symptoms that should
lead to consideration of the diagnosis.
4.2.3. Natural History
Significant atherosclerotic obstruction of the intestinal arter-
ies is present in 6% to 10% of unselected autopsies and in
14% to 24% of patients undergoing abdominal arteriography.
The fact that nearly all such patients have no symptoms of
intestinal ischemia is a reflection of the extensive collateral
connections present among the intestinal arteries (832). Only
one study (841) has addressed the issue of how many patients
with asymptomatic intestinal arterial lesions ultimately
develop intestinal ischemia. Of 980 abdominal aortograms,
there were 15 patients who had severe stenosis or occlusions
of all 3 intestinal vessels, of whom 4 developed symptomatic
intestinal ischemia with a mean follow-up of 2.6 years. No
patients who had fewer than 3 severely affected vessels
developed symptoms (841).
Development of symptomatic intestinal ischemia in
patients with asymptomatic intestinal arterial obstruction
after abdominal surgery for other reasons has been described
(842). The presumed mechanism is division of vital collater-
4.2.2. Diagnosis
RECOMMENDATIONS
Class I
1. Chronic intestinal ischemia should be suspected in
patients with abdominal pain and weight loss without
other explanation, especially those with cardiovascu-
lar disease. (Level of Evidence: B)
2. Duplex ultrasound, CTA, and gadolinium-enhanced
MRA are useful initial tests for supporting the clinical
diagnosis of chronic intestinal ischemia. (Level of
Evidence: B)
3. Diagnostic angiography, including lateral aortogra-
phy, should be obtained in patients suspected of hav-
ing chronic intestinal ischemia for whom noninvasive
imaging is unavailable or indeterminate. (Level of
Evidence: B)
Clinical Presentation
Because there are many common causes of abdominal pain
and weight loss, and because chronic intestinal ischemia is
rare, diagnosis is delayed in most patients. Many patients in
whom the diagnosis is made have been symptomatic for
months or even years and have undergone the gamut of
abdominal diagnostic procedures, including contrast X-ray
studies, endoscopy, and multiple scans. The profound weight
loss that occurs suggests a diagnosis of malignancy, which
leads to further imaging studies.
Laboratory Testing
Although multiple tests of intestinal absorption and others
have been proposed for diagnosis of chronic intestinal
ischemia, none has proven worthwhile. At present, there are
no laboratory abnormalities that are diagnostic.
Duplex Scanning
The atherosclerotic lesions that typically produce intestinal
arterial obstruction are usually located at the origin of the
vessels from the aorta and are actually protruding aortic
plaques in most (833). This feature makes the lesions suit-
able for diagnosis by duplex ultrasound. Duplex scanning of
visceral vessels is technically difficult but can be accom-
plished in more than 85% of subjects in the elective setting.
The test has an overall accuracy of approximately 90% for
detection of greater than 70% diameter stenoses or occlu-
sions of the celiac and superior mesenteric arteries when per-
formed in highly experienced laboratories (837-839).
Although the expected increase in intestinal arterial flow that
results from food ingestion can be detected and quantified by
duplex scanning, this information has not added to the diag-
nostic accuracy of the test for establishing whether abdomi-
nal symptoms that are present are the result of intestinal
ischemia (840).
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surgery, recurrent symptoms have nearly always indicated
recurrent arterial obstruction.
4.2.5. Surgical Treatment
RECOMMENDATIONS
Class I
Surgical treatment of chronic intestinal ischemia is
indicated in patients with chronic intestinal ischemia.
(Level of Evidence: B)
Class IIb
Revascularization of asymptomatic intestinal arterial
obstructions may be considered for patients undergo-
ing aortic/renal artery surgery for other indications.
(Level of Evidence: B)
Class III
Surgical revascularization is not indicated for patients
with asymptomatic intestinal arterial obstructions,
except in patients undergoing aortic/renal artery sur-
gery for other indications. (Level of Evidence: B)
Surgical treatment of chronic intestinal ischemia is accom-
plished by endarterectomy or bypass grafting, with the
majority of surgeons preferring the latter approach (836,851-
858). The overall operative mortality and durability of revas-
cularization in chronic cases described by multiple contem-
porary reports are listed in Table 42. Long-term patency and
relief of symptoms are the rule, with few recurrences; how-
ever, long-term follow-up is mandatory. Essentially all
symptomatic recurrences are the result of recurrent stenosis
or occlusion of visceral arteries or the reconstructions.
5. ANEURYSMS OF THE ABDOMINAL
AORTA, ITS BRANCH VESSELS, AND THE
LOWER EXTREMITIES
Although their causes may be diverse, arterial aneurysms
share many of the same atherosclerotic risk factors and pose
als during the surgical procedure. This sequence of events
has been most frequently recognized after abdominal vascu-
lar surgery (e.g., aortic aneurysm or renal artery repair). The
frequency with which this complication occurs is unknown.
The natural history of symptomatic chronic intestinal
ischemia is known in part. An unknown percentage of
patients progress to acute intestinal ischemia, and the
remainder have progressive weight loss with ultimate death
from inanition. Although it is reasonable to postulate that
some of the affected patients must experience spontaneous
recovery, no such case has been documented in the literature.
4.2.4. Interventional Treatment
RECOMMENDATION
Class I
Percutaneous endovascular treatment of intestinal
arterial stenosis is indicated in patients with chronic
intestinal ischemia. (Level of Evidence: B)
Percutaneous treatment of symptomatic intestinal ischemia
was first reported in 1980 (843). Since then, a large number
of reports in the literature have documented that percuta-
neous interventional treatment of intestinal arterial obstruc-
tions is possible with a high technical success rate and few
complications in properly selected cases (844-849). Most
procedures have been performed to treat intestinal arterial
stenoses, with few attempting to treat occlusions. To date,
there have been no prospective therapeutic trials, and follow-
up information is limited; that which exists indicates that
elimination of the arterial obstruction is reliably followed by
relief of symptoms and weight gain. Several reports of con-
current series treated by angioplasty/stenting or surgery indi-
cate that recurrences after percutaneous procedures have
been more frequent than after open surgery, but many of the
recurrences can be managed by percutaneous interventions
(850). The results of several series are listed in Table 42. The
reported recurrence rates mandate careful follow-up of
patients treated with angioplasty and stents. As with open
Table 42. Single-Institution Comparisons of Mesenteric Angioplasty/Stenting Versus Surgery
Successfully 30-Day
First Author No. of Revascularized Mortality Recurrence
and Procedure Year Reference Patients (%) (%) (%)
Kasirajan* 2001 (850)
Angioplasty 28 93 11 27
Surgery 85 98 8 24
Rose† 1995 (850a)
Angioplasty/stenting 8 80 13 33
Surgery 9 100 11 22
Bowser‡ 2002 (850b)
Angioplasty/stenting 18 88 11 46
Surgery 22 100 9 19
*Surgical controls were historic; mean postprocedure follow-up was 3 years for both groups.
†Mean follow-up for surgery was 3 years; for angioplasty/stenting, 9 months.
‡Mean follow-up was 14 months.
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to 4.9 cm in diameter ranges from 1.3% for men aged 45 to
54 years to up to 12.5% for men 75 to 84 years of age.
Comparable prevalence figures for women are 0% and 5.2%,
respectively. 
Race also appears to influence the prevalence of AAAs and
iliac aneurysms. These aneurysms are rarely encountered in
population-based screening studies in Japan, where the
prevalence of traditional risk factors for atherosclerosis is
lower than in white populations (876,877). In a United
Kingdom community in which 14% of the population was of
Asian descent, a review of medical records identified 233
cases of AAA, none of which occurred in the Asian popula-
tion (878).
5.2.1.1. Generalized Arteriomegaly
Generalized arteriomegaly reflects a systemic alteration of
the elastic component of the arterial wall, which results in
dilation and elongation of many arteries. Patients with local-
ized AAA are relatively unlikely to have generalized arteri-
omegaly (879), but the familial pattern of generalized arteri-
omegaly is similar. In one series, there was a family history
of aneurysms in 10% (4/40) of patients with peripheral
aneurysms, in 22% (19/86) of patients with AAA, and in
36% (5/14) of patients with generalized arteriomegaly (880).
5.2.2. Etiology
Most aortic and peripheral aneurysms represent a manifesta-
tion of aortic medial degeneration, which has complex bio-
logical mechanisms. Traditional views held that most
aneurysms were caused by degenerative atherosclerotic dis-
ease, but other data (see Section 5.2.2.3) suggest that many
aneurysms form in response to altered tissue metallopro-
teinases that diminish the integrity of the arterial wall.
5.2.2.1. Hereditary Risk Factors
A genetic predisposition to AAA formation has been sug-
gested by studies of familial incidence, and an analysis of
313 pedigrees confirms the importance of familial factors
(881). In a series of 542 patients undergoing AAA repair dur-
ing a 9-year period, 15% had first-degree relatives with
aneurysms compared with 2% of a control group of similar
age and gender (p less than 0.001) (882). Other series have
found first-degree relatives similarly affected in up to 28% of
cases (883). A family history of AAAs is particularly relevant
for male siblings of male probands, in whom the relative risk
for AAA is as high as 18 (881), which suggests a single dom-
inant gene effect (Table 45). Among the offspring of patients
with ruptured AAA, 21% of sons older than 45 years and 4%
of daughters older than 42 years had aortic enlargement to a
diameter of at least 3.0 cm (884). First-degree male relatives
of patients with AAA have 2 to 4 times the normal risk for
AAA. Female first-degree relatives appear to be at similar
risk, but the data are less certain. One study found that
patients with familial aneurysms were more often female
than those without (35% vs. 14%) (885). Familial aneurysms
similar threats to life, limb, and vital organ function as occlu-
sive arterial disease. Like occlusive disease, the presence of
most common aneurysms can be suspected on the basis of an
attentive physical examination and subsequently confirmed
by noninvasive, widely available imaging studies. Just as
important, there are now a variety of therapeutic options that
include both traditional open surgery and endovascular tech-
niques such that relatively few large aneurysms should mere-
ly be observed until morbid events occur. For all of these rea-
sons, current guidelines for the diagnosis and management of
arterial aneurysms may be useful to clinicians irrespective of
their primary care or specialty training.
5.1. Definition
According to some sources, the diagnosis of AAA should be
determined by formulas that adjust for age or body surface
area or by calculating the ratio between normal and dilated
aortic segments (859-863). Generally, however, an AAA is
considered to be present when the minimum anteroposterior
diameter of the aorta reaches 3.0 cm. The size of the aorta
can be measured in any plane that is perpendicular to the ves-
sel axis, but in practice, the anteroposterior diameter is meas-
ured most easily and reproducibly. Accordingly, most screen-
ing studies define AAA in this manner (859).
There is abundant information concerning normal diame-
ters of the abdominal aorta and its branches in healthy adults,
which indicates enlargement with age and body size and
larger diameters in men than in women (Table 43) (864-866).
A diameter of 2.7 cm represents the 95th percentile for the
nonaneurysmal infrarenal aorta in men 65 to 83 years of age
(867), and 2.9 cm exceeds the upper limit of normal irre-
spective of age, gender, or body surface area (868). Women
have slightly smaller normal aortic diameters than men
(862), and although this difference in baseline aortic diame-
ter between women and men is not great enough to influence
the minimum size of 3.0 cm that customarily is used to
define a small AAA, it may influence recommendations for
the size at which larger aneurysms should be repaired.
5.2. Abdominal Aortic and Iliac Aneurysms
5.2.1. Prevalence
The prevalence of AAA varies with a number of demograph-
ic factors (Table 44), including advancing age, family histo-
ry, male gender, and tobacco use. A necropsy study in
Malmo, Sweden, where autopsies are performed after nearly
all hospital deaths, revealed that the incidence of AAAs larg-
er than 3.0 cm in diameter increased at ages over 50 years,
reaching a maximum prevalence of 5.9% in men 80 to 85
years of age and 4.5% for women over 90 years of age (868).
Most population-based ultrasound screening surveys have
been performed among white men and women, particularly
those of Northern European and Scandinavian ancestry. A
variety of threshold diameters have been used in these inves-
tigations, which makes it difficult to establish consistent esti-
mates of prevalence. In general, the prevalence of AAAs 2.9
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2. Patients with aneurysms or a family history of
aneurysms should be advised to stop smoking and be
offered smoking cessation interventions, including
behavior modification, nicotine replacement, or
bupropion. (Level of Evidence: B)
It is widely recognized that patients with AAAs have a sig-
nificantly higher prevalence of smoking, hypertension, MI,
heart failure, and carotid artery and/or lower extremity PAD
than do age- and gender-matched controls. The lipopro-
tein(a) serum level, an indicator of atherosclerosis, is elevat-
ed in patients with AAA independent of cardiovascular risk
factors and the extent of atherosclerosis, whereas patients
with dissecting thoracic aortic aneurysms have levels com-
parable to those of healthy individuals (893).
Thoracic aortic atheromata detected by transesophageal
echocardiography may independently predict AAA (894). In
a study of 364 patients, 14% of those with thoracic athero-
mata had AAAs compared with only 1.4% of those without
(OR 11.4, p less than 0.0001). Another indicator of general-
ized atherosclerosis, common carotid arterial intima-media
thickness, was 0.98 plus or minus 0.34 mm in patients with
occlusive arterial disease compared with 0.91 plus or minus
0.20 mm in patients with AAAs (an age- and gender-adjust-
do not expand more rapidly than nonfamilial AAA, nor are
they differently located, but they may develop at an earlier
age (see Section 5.2.4.6) (886). 
Polycystic kidney disease, an autosomal dominant disease
that affects 0.5 million people, and 8% to 10% of long-term
hemodialysis cases in the United States have been associated
with abdominal aneurysms (891,892). The association of
cardiovascular lesions with polycystic kidney disease sug-
gests involvement of the extracellular matrix in this disorder,
but the main cause of aortic aneurysms is degenerative.
Patients with renal disease may be prone to aortic aneurysm
because of hypertension and connective tissue disorders, and
yet an independent association between AAA and autosomal-
dominant polycystic kidney disease is unproven.
5.2.2.2. Atherosclerotic Risk Factors
RECOMMENDATIONS
Class I
1. In patients with AAAs, blood pressure and fasting
serum lipid values should be monitored and con-
trolled as recommended for patients with atheroscle-
rotic disease. (Level of Evidence: C)
Table 43. Dimensions of Normal Arteries
Females Males
Mean Standard Mean Standard 
First Author Diameter, Deviation, Diameter, Deviation, Assessment 
and Procedure cm, Range cm, Range cm, Range cm, Range Method
Abdominal aorta, 2.10 to 2.31 0.27 2.50 to 2.72 0.24 to 0.35 Computed tomography
supraceliac
Abdominal aorta, 1.86 to 1.88 0.09 to 0.21 1.98 to 2.27 0.19 to 0.23 Computed tomography
suprarenal
Abdominal aorta, 1.66 to 2.16 0.22 to 0.32 1.99 to 2.39 0.30 to 0.39 Computed tomography, 
infrarenal IV arteriography
Abdominal aorta, 1.19 to 1.87 0.09 to 0.34 1.41 to 2.05 0.04 to 0.37 B-mode ultrasound, 
infrarenal computed tomography, 
IV arteriography
Celiac 0.53 0.03 0.53 0.03 B-mode ultrasound
Superior mesenteric 0.63 0.04 0.63 0.04 B-mode ultrasound
Common iliac 0.97 to 1.02 0.15 to 0.19 1.17 to 1.23 0.20 Computed tomography
Internal iliac 0.54 0.15 0.54 0.15 Arteriography
Common femoral 0.78 to 0.85 0.07 to 0.11 0.78 to 1.12 0.09 to 0.30 Computed tomography, 
B- or M-mode ultrasound
Popliteal NA NA 0.9 0.2 B-mode ultrasound
Posterior tibial NA NA 0.3 0.01 M-mode ultrasound
IV indicates intravenous; and NA, not available.
Adapted from J Vasc Surg, 13, Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial
Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery, 452-58, Copyright © 1991,
with permission from Elsevier (863).
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Table 44. Prevalence of Abdominal Aortic Aneurysms in Population-Based Screening Studies
Number % Prevalence/
Country/Study First Author Reference Screened Age, y Criteria Gender Relative Risk
Western Australia Jamrozik (869) 12 203 65 to 69 Larger than 3.0 cm 4.8/Male Higher risk:
Current or ex-smokers
80 to 83 Larger than 3.0 cm 10.8/Male Established PAD, CAD
65 to 83 Larger than 5.0 cm 0.69/Male Waist-hip ratio larger than 0.9
Lower risk:
Mediterranean born versus 
Australian born (OR 0.6)
Regular vigorous exercise
Veterans Affairs Lederle (870) 126 196* 50 to 79 Larger than 4.0 cm 1.3/Male Higher risk:
Cooperative Study and female Increased age per 7 years (OR 1.7)
Smoking history (OR 5.17)
50 to 79 Larger than 4.9 cm 0.45/Male Family history (OR 1.9)
and female Established atherosclerosis 
(OR 1.6)
50 to 79 Larger than 5.4 cm 0.27/Male Lower risk:
and female Female (OR 0.18; 2.7% of total)
Black race (OR 0.59)
Diabetes mellitus (OR 0.50)
Norway Singh (871) 6386 25 to 84 Larger than 2.9 cm 8.9/Male; Higher risk: 
2.2/female Increased age
45 to 54 Larger than 2.9 cm 1.9/Male; Smoker older than 40 y vs. never-
0/female smoker (OR 8.0)
55 to 64 6.0/Male; 
1.1/female
65 to 74 12.8/Male; 
2.8 female
75 to 84 18.5/Male; 
4.8/female
55 to 64 Larger than 3.9 cm 1.1/Male; 
0.1/female
65 to 74 4.1/Male; 
0.7/female
75 to 84 8.6/Male; 
1.0/female
The Netherlands Pleumeekers (872) 5283† Older than 54 3.4 to 3.6 cm or 2.8/Male; Higher risk:
distal dilation 0.5/female Smoker
greater than 49% High serum cholesterol
Older than 54 Larger than 4.0 cm 1.6/Male; Established cardiovascular disease
0.3/female
Belgium Vazquez (873) 716‡ 65 and 75 Larger than 3 cm 3.8/Male Higher risk:
Larger than 4 cm 0.3/Male Arterial hypertension (p less than 0.05)
Prior CABG (p less than 0.01)
Smoker (p less than 0.06)
Continued on Next Page
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Table 44. Continued
Number % Prevalence/
Country/Study First Author Reference Screened Age, y Criteria Gender Relative Risk
The Netherlands Boll (874) 2419§ 60 to 80 Larger than 2.9 cm 8.1/Male
Larger than 4.9 cm 1.7/Male
United Kingdom Wilmink¶ (875)
Oxford 426 65 to 74 Larger than 4.0 cm 5.4/Male
or 5 mm larger 
than SRA
65 to 74 Larger than 4.0 cm 2.3/Male
Liverpool Older than 55 Larger than 3.0 cm 2.9/Male
Gloucestershire 4232 65 Larger than 2.5 cm 8.4/Male
65 Larger than 4.0 cm 1.3/Male
Birmingham 2669 65 to 75 Larger than 2.9 cm 8.4/Male
65 to 75 Larger than 4.0 cm 3.0/Male
Chichester 5394 65 to 80 Larger than 2.9 cm 7.6/Male
65 to 80 1.3/Female
Northumberland 628 65 to 79 Larger than 2.9 cm 6.7/Male
Huntingdon 7493 Older than 49 Larger than 2.9 cm 5.2/Male
Japan Takei (876) 348 60 to 79 — 0
Japan Adachi (877) 1591 — — 0.3/Male
*52 745 plus prior report of 73 451. 
†Of 10 215 eligible. 
‡Of 1764 eligible. 
§Of 2914 eligible. 
¶This portion of table adapted from Wilmink and Quick (875).
CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; OR, odds ratio; SRA, suprarenal aneurysm.
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Table 45. Prevalence in Families of Patients With Abdominal Aortic Aneurysms (AAAs)
Screened
With Age, y Incidence/
Country First Author Reference Study Group Ultrasound (Gender) Criteria Risk Factor
United Kingdom Adams (887) Relatives of 100 76 of 110 Older than 50 Larger 0
patients with known eligible than
AAA 4.0 cm
Older than 50 2.5 21% of male first-
to degree relatives; 
3.9 27% of sons; 
cm 17% of brothers; 
4% of sisters; 0%
of daughters
Sweden Bengtsson (884) Offspring of patients 62 of 90 45 to 75 Larger than 21% of sons
who died of ruptured eligible (males) 2.9 cm
AAA
45 to 80 Larger than 4% of daughters
(female) 2.9 cm
45 to 80 Larger than 3% (1 male 
(female) 5.0 cm aged 53 y)
Ireland Fitzgerald (888) Siblings of patients 125 of Older than 3.1 to 22% of brothers;
with known AAA 234 eligible 80 6.8 cm 3% of sisters
Netherlands Van Der Graf (889) Brothers of patients  210 of Older than New AAA 12.30%
having elective 571 eligible 50
surgery for AAA Older than Larger than 3.80%
50 4.9 cm
Finland Jaakkola (890) Families of patients with 123 of 41 to 82 Larger than 2.9 cm 10% of brothers; 
surgery for AAA 172 eligible or history of repair 3% of sisters
or rupture
United States Webster (883) First-degree relatives of 103 of Older than 55 Larger than 3.0 cm 16% of first-
patients with surgery for 202 eligible or I/S diameter degree relatives; 
AAA ratio greater 25% of men; 
than 1.5 6.9% of women
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tase–alpha 1–antitrypsin complexes in patients with COPD,
and the concentration of serum elastin peptide, therapy with
beta-agonist bronchodilator medication, and forced expirato-
ry volume in 1 second correlated with the degree of expan-
sion. The high prevalence of AAA among patients with
COPD might therefore be related more to medication use and
coexisting diseases than to a common pathogenic mecha-
nism.
Upregulation of genes involved in oxidative stress (e.g.,
heme oxygenase, inducible nitric oxide synthase, 12-lipoxy-
genase, and heart cytochrome c oxydase subunit VIa) and the
downregulation of antioxidant genes (e.g., superoxide dis-
mutase, reduced nicotinamide adenine dinucleotide-
cytochrome b-5 reductase, and glutathione S-transferase)
may play a role in the progression of AAAs (904). In patients
with small, asymptomatic AAAs, prolonged administration
of doxycycline was associated with reduced plasma matrix
metalloproteinase (MMP-9) levels (905), but further studies
are needed to evaluate the long-term effects of doxycycline
on the rate and extent of aneurysm growth and the potential
use of plasma MMP-9 levels as a biomarker of aneurysm dis-
ease progression.
The HMG coenzyme-A reductase inhibitors (statins)
reduce the expression of matrix metalloproteinases inde-
pendently of their cholesterol-lowering effect. One such
agent (cerivastatin, 0.001 to 0.1 micromoles per liter) signif-
icantly reduced tissue levels of both total and active MMP-9
(p less than 0.001) (906). Cerivastatin suppressed MMP-9
production by inhibiting the activation of neutrophils and
macrophages. It remains to be determined whether statin
therapy could be useful for prevention or treatment of AAA.
5.2.2.4. Congenital Aneurysms
Over the course of normal aging, degenerative changes occur
throughout most of the length of the aorta, which leads to a
mild form of cystic medial necrosis. Although physiological,
this process develops more rapidly in patients with bicuspid
aortic valves and during pregnancy, and very markedly in the
Marfan syndrome, in which more than 11% of patients sus-
tain dissections of the aorta. The mechanisms by which the
medial layer of the aorta is subject to accelerated degenera-
tion are a topic of molecular genetic investigation. Gsell (in
1928) and Erdheim (in 1929) first described cystic medial
necrosis, which is associated with histological evidence of
severe elastic fiber degeneration, necrosis of muscle cells,
and cystic spaces filled with mucoid material (907, 908).
This is most often encountered in the ascending aorta
between the aortic valve and the innominate artery, although
similar changes can also occur in the remainder of the aorta.
The Marfan syndrome, an inherited disorder characterized by
dolichostenomelia, ligamentous redundancy, ectopia lentis,
ascending aortic dilatation, and incompetency of the aortic
and/or mitral valve (909), is frequently associated with cys-
tic medial necrosis of the aorta. The syndrome is linked to an
autosomal dominant anomaly in fibrillin type 1 (910), a
structural protein that directs and orients elastin in the devel-
ed mean difference of 0.18 mm; 95% CI 0.08 to 0.28 mm)
(895). The difference remained 0.11 mm (95% CI 0.01 to
0.21 mm) after adjustments for other cardiovascular risk fac-
tors. The smaller common carotid intimal-medial thickness
in patients with AAAs than in patients with occlusive disease
is independent of other determinants of intimal-medial thick-
ness and probably reflects other pathophysiological mecha-
nisms, such as hypertension.
5.2.2.3. Collagenase, Elastase, Metalloproteases
The striking histological feature of aortic aneurysms is
destruction of the media and elastic tissue. Excessive prote-
olytic enzyme activity in the aortic wall may promote deteri-
oration of structural matrix proteins, such as elastin and col-
lagen (896). Smooth muscle cells derived from patients with
AAAs display increased migration, perhaps related to over-
production of the matrix metalloproteinase MMP-2, which
may lead to extracellular matrix remodeling and medial dis-
ruption (897). Abnormal biochemical elastolytic and active
proteolytic activity has also been identified in aneurysmal
aortas (898). An abnormal accumulation of macrophages
(899) and elevated levels of cytokines (900) indicate that an
inflammatory process may contribute to their pathogenesis.
Cultured smooth muscle cells from aneurysmal aortas pro-
duce elevated levels of the plasminogen activators urokinase
plasminogen activator and tissue plasminogen activator
(901), which could increase proteolysis. In aggregate, the
data suggest a major role for matrix metalloproteinases and
their inhibitors in the loss of aortic wall structural integrity
that leads to AAA formation and expansion.
Chronic obstructive pulmonary disease (COPD) and AAA
share several risk factors. In 240 patients with thoracic
aneurysms or AAAs, forced expiratory volume/forced vital
capacity and carbon monoxide diffusing capacity were lower
than in a control group (p less than 0.01) (902). The propor-
tion with airway obstruction (forced expiratory volume in 1
second less than 70% of normal) was higher in the AAA
group (100 of 240, or 42%) than in those without overt car-
diovascular disease (51 of 223, or 23%) or in patients with
coronary artery disease matched for age, gender, smoking,
and other atherosclerotic risk factors (43 of 238, or 18%). By
multiple logistic regression analysis, the presence of AAA
(OR 2.928, 95% CI 1.722 to 4.979) and male gender (OR
1.622, 95% CI 1.055 to 2.493) were most strongly associat-
ed with COPD.
The association between AAA and COPD has been attrib-
uted to elastin degradation caused by tobacco smoking.
Among 4404 men 65 to 73 years of age with a 4.2% preva-
lence of AAA, 7.7% of those with COPD had aortic
aneurysms (903). The overall mean annual expansion rate
was 2.7 mm per year irrespective of COPD, but it was 4.7
mm per year among patients treated with corticosteroid
agents compared with 2.6 mm per year among those who
were not treated (p less than 0.05). There was a negative cor-
relation between the forced expiratory volume in 1 second
and concentrations of serum elastin peptide and plasma elas-
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diagnosis of inflammatory AAA in 31% of the cases.
Compared with patients with noninflammatory atheroscle-
rotic aneurysms, those with inflammatory aneurysms were
more likely to have symptoms (66% vs. 20%, p less than
0.0001), weight loss (20.5% vs. 10%, p less than 0.05), a
higher erythrocyte sedimentation rate (73% vs. 33%, p less
than 0.0001), and a higher operative mortality rate (7.9% vs.
2.4%, p less than 0.002).
5.2.2.6. Infectious Aneurysms
Primary infection of the aortic wall is a rare cause of
aneurysms, which are more often saccular than fusiform.
Infectious, or “mycotic,” aneurysms may arise secondarily
from infection of pre-existent aneurysm (925). Staphylo-
coccus and Salmonella are the most frequent pathogens that
cause primary aortic infections (926), and tuberculosis has
been described in association with aortic pseudoaneurysms
(927).
An infectious etiology also has been postulated for con-
ventional atherosclerotic aneurysms. Antibodies against
Chlamydia pneumoniae have been detected by polymerase
chain reactions in conjunction with atherosclerosis and
expanding AAA (928), but it has not been possible to docu-
ment that C pneumoniae antigens react with anti–C pneumo-
niae membrane proteins. Sixty-six percent of specimens
from atherosclerotic arteries collected during various periph-
eral arterial operations (including AAA repair in 28 patients)
revealed severe atherosclerosis and positive immunohisto-
chemical staining for specific antibodies against C pneumo-
niae (929). Because there were no differences in cardiovas-
cular risk factors, the prevalence of coronary heart disease or
previous vascular surgery, or inflammatory serum markers
between patients with and without C pneumoniae antibodies,
this organism has been considered a concomitant phenome-
non rather than a causative factor for atherosclerosis.
Although secondary prevention benefits of antibiotic ther-
apy have been demonstrated in some studies, negative stud-
ies have also emerged. In a randomized study, 92 subjects
with small AAAs received the macrolide antibiotic rox-
ithromycin (300 mg orally daily for 28 days) or a matching
placebo. The mean expansion rate of the AAA during the
first year of observation in the intervention group (1.6 mm)
was reduced by 44% compared with the placebo group (2.8
mm, p equals 0.02). During the second year, however, the
difference favoring roxithromycin was only 5% (930). When
adjusted for smoking, diastolic blood pressure, and the
immunoglobulin A level, roxithromycin treatment and the
initial size of the aneurysm were related to AAA expansion.
Logistic regression analysis confirmed a significant differ-
ence in expansion rates exceeding 2 mm annually between
the intervention and placebo groups (OR 0.09, 95% CI 0.01
to 0.83). The results of larger prospective, human antibiotic
intervention trials may help to establish whether or not there
is a causal link between C pneumoniae infection and athero-
sclerotic aortic aneurysms.
oping aorta (911-917). The Marfanoid aorta has markedly
abnormal elastic properties and increased pulse wave veloc-
ities, with progressive stiffening and dilatation (918). Single-
gene mutations have been identified that cause aneurysm for-
mation in the Marfan syndrome and in Ehlers-Danlos syn-
drome type IV (919), but polygenic factors are probably
involved in many cases.
Abnormalities associated with the Marfan syndrome typi-
cally affect the entire length of the aorta, although dissection
most often involves the thoracic portion (920).
Histologically, 10% to 21% of aortic dissections and 43% of
all dissections in patients with Marfan syndrome have severe
degeneration of the medial layer; more than 50% of the wall
area shows features of cystic necrosis. Although most often
encountered in the ascending aorta, cystic medial necrosis
may occur in the abdominal aorta as well. Cystic medial
degeneration may also be associated with other connective
tissue disorders, such as the Ehlers-Danlos syndrome.
5.2.2.5. Inflammatory Aneurysms
Inflammatory AAAs represent a unique clinical entity, typi-
cally consisting of an AAA that is associated with an unusu-
ally thickened aneurysm wall, shiny white perianeurysmal
fibrosis, and intense adherence of adjacent intra-abdominal
structures. This entity was first described in 1972 by Walker
et al. and has since been described by Rasmussen and Hallett
as an extreme manifestation of inflammation present in all
aortic aneurysms (921). Abnormal accumulation of
macrophages and cytokines in aneurysmal aortic tissue sup-
ports an association with inflammation (899,900). In a case-
control study, there were no distinctions between patients
with inflammatory aneurysms and those with noninflamma-
tory aneurysms with respect to risk factors, treatment
requirements, or prognosis, but patients with inflammatory
aneurysms were more often symptomatic and had a higher
erythrocyte sedimentation rate, larger aneurysm diameter,
and more retroperitoneal inflammatory reaction (922). In
another series of 355 patients undergoing surgical repair of
AAA, 5.6% had inflammatory clinical features and 11% had
histological evidence of inflammation (923), but the early
and late results of surgery were no different between the 2
groups.
The triad of chronic abdominal pain, weight loss, and ele-
vated erythrocyte sedimentation rate in a patient with AAA is
highly suggestive of an inflammatory aneurysm.
Inflammatory aortic or iliac aneurysms were present in 4.5%
of the 2816 patients who underwent elective AAA repair at
the Mayo Clinic from 1955 to 1985 (924). More than 90% of
the patients with inflammatory aneurysms were smokers, and
clinical evidence of peripheral arterial occlusive disease and
coronary artery disease was found in 27% and 39%, respec-
tively. Additional aneurysms were discovered in half of these
patients, including iliac aneurysms in 55, thoracic or thora-
coabdominal aneurysms in 17, femoral aneurysms in 16, and
popliteal aneurysms in 10. Excretory urographic findings of
medial ureteral displacement or obstruction suggested the
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that large aneurysms tend to expand more rapidly than small
aneurysms and thus require closer surveillance. According to
the available information, average annual expansion rates are
approximately 1 to 4 mm for aortic aneurysms measuring
less than 4.0 cm in diameter at the time of their discovery, 4
to 5 mm for those measuring 4.0 to 6.0 cm in diameter, and
as much as 7 to 8 mm for larger aneurysms (933,934). An
observed rate of expansion that exceeds these figures usual-
ly is considered to represent a “growth spurt” that may justi-
fy early elective aneurysm repair.
High operative mortality rates alone do not fully reflect the
catastrophic nature of ruptured aortic aneurysms. Given the
number of patients who do not survive even to reach the
operating room, the overall mortality rate for this complica-
tion may be as high as 90% (942-944). In a classic report,
Szilagyi et al. (945) were among the first to recognize that
the risk for spontaneous rupture was a direct function of
aneurysm size. Others have since discovered that additional
factors also may influence the rupture rate, such as hyperten-
sion (946,947), COPD and/or tobacco abuse (946-949),
female gender (882,947), and a family history of aortic
aneurysms, particularly when a woman with an aortic
aneurysm is present in the proband (882). Nevertheless,
aneurysm size remains the single most important predictor
not only for aneurysm rupture, but also for unrelated death
from other cardiopulmonary events (932,950).
Table 47 contains representative data regarding aneurysm
rupture rates and long-term patient survival rates according
to the baseline diameter of AAAs at the time of their discov-
ery. These data suggest that the eventual risk for rupture is
approximately 20% for aneurysms that measure larger than
5.0 cm in diameter, 40% for those measuring at least 6.0 cm
in diameter, and higher than 50% for aneurysms that exceed
7.0 cm in diameter. Taylor and Porter interpreted earlier data
to indicate that the annual rupture rates for aneurysms of
these sizes were in the range of 4%, 7%, and 20%, respec-
tively (938). Conversely, the rupture rate for truly small
aneurysms that are less than 4.0 cm in diameter is quite low,
perhaps because aged patients with such small aneurysms
ordinarily do not survive long enough for this complication
to occur. Watson et al. found that more patients with small
aneurysms died of other causes than ever required surgical
treatment for enlarging aneurysms (951). Bengtsson et al.
have recommended only 1 annual follow-up scan for
aneurysms less than 3.5 cm in diameter because the unrelat-
ed mortality rate in such patients is so high that relatively few
live long enough to incur sufficient aneurysm growth to war-
rant elective surgical treatment (931). Prospective nonran-
domized studies have indicated that small aneurysms may be
safely monitored by annual or semiannual imaging scans,
with a low risk for rupture, provided elective repair is
advised once a diameter of at least 5.0 cm has been docu-
mented (952,953). Katz et al. concluded from a Markov pre-
dictive model that early intervention to repair aneurysms that
measure 4.0 cm in diameter could be justified if operative
mortality rates were 4.6% or lower, but their estimates were
5.2.3. Natural History
The natural history of arterial aneurysms is distinguished by
gradual and/or sporadic expansion in their diameter and by
the accumulation of mural thrombus caused by turbulent
blood flow at their periphery. These features contribute to the
3 most common complications of aneurysms, that is, rupture,
thromboembolic ischemic events, and the compression or
erosion of adjacent structures, which often are quite specific
to their location.
5.2.3.1. Aortic Aneurysm Rupture
RECOMMENDATIONS
Class I
1. Patients with infrarenal or juxtarenal AAAs measur-
ing 5.5 cm or larger should undergo repair to elimi-
nate the risk of rupture. (Level of Evidence: B)
2. Patients with infrarenal or juxtarenal AAAs measur-
ing 4.0 to 5.4 cm in diameter should be monitored by
ultrasound or computed tomographic scans every 6 to
12 months to detect expansion. (Level of Evidence: A)
Class IIa
1. Repair can be beneficial in patients with infrarenal or
juxtarenal AAAs 5.0 to 5.4 cm in diameter. (Level of
Evidence: B)
2. Repair is probably indicated in patients with
suprarenal or type IV thoracoabdominal aortic
aneurysms larger than 5.5 to 6.0 cm. (Level of
Evidence: B)
3. In patients with AAAs smaller than 4.0 cm in diame-
ter, monitoring by ultrasound examination every 2 to
3 years is reasonable. (Level of Evidence: B)
Class III
Intervention is not recommended for asymptomatic
infrarenal or juxtarenal AAAs if they measure less
than 5.0 cm in diameter in men or less than 4.5 cm in
diameter in women. (Level of Evidence: A)
Rupture is the most widely recognized complication of
arterial aneurysms and primarily is associated with those
involving the abdominal aorta, the common iliac arteries,
and the visceral arteries. Before the introduction of B-mode
ultrasonography in the 1970s and computed tomographic
scanning in the 1980s, the expansion rate of aortic, iliac, and
visceral aneurysms could only be determined by standard
plain-film roentgenograms in the presence of mural calcifi-
cation. Modern imaging techniques, which now have been
further supplemented by magnetic resonance imaging/MRA,
currently permit more accurate estimates of expansion rates
that can be used to monitor the growth of aneurysms and to
select patients for preemptive intervention before rupture
occurs. Growth rates have been most widely documented for
aortic aneurysms, several examples of which are presented in
Table 46. These data confirm similar observations (931,932)
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equals 0.03) at a mean follow-up of 8 years, this finding has
been attributed in part to a higher rate of smoking cessation
in the early-surgery group (963). The annual rupture rate was
negligible (0.6%) for observed aneurysms in the VA trial and
was 3.2% in the UK trial. Rupture was more likely to occur
in women in the UK trial (OR 4.0; 95% CI 2.0 to 7.9; p less
than 0.001), accounting for 14% of all deaths in women com-
pared with 4.6% of all deaths in men (p less than 0.001).
Aneurysm size at the time of randomization did not influence
the risk for rupture in the UK trial or the long-term mortali-
ty rate in either trial, but this may reflect the promptness with
which intervention was performed whenever aneurysms
reached a diameter of at least 5.5 cm. More than 60% of the
patients in the nonoperative limb of each of these trials cur-
rently have undergone aneurysm repair because of docu-
mented enlargement, including 81% of the patients whose
aneurysms were 5.0 to 5.4 cm in diameter when they were
recruited into the VA trial. 
Collectively, these 2 randomized trials provide a wealth of
information that otherwise has not been available. For
instance, the finding that rupture has been significantly more
likely to occur among women in the nonoperative cohort of
the UK trial adds further perspective to the lingering contro-
versy concerning whether the indications for elective
aneurysm repair should be slightly more liberal in women
than in men because of the smaller size of the normal aorta
in women. On the basis of the data regarding gender differ-
ences in the UK trial, a guidelines subcommittee of the
American Association for Vascular Surgery and the Society
for Vascular Surgery now has recommended that a diameter
of 4.5 to 5.0 cm is an appropriate threshold for elective repair
confounded by the low reported rupture rate for untreated
aneurysms of this size (954). 
5.2.3.1.1. RANDOMIZED TRIALS. Prospective randomized tri-
als comparing early intervention versus expectant observa-
tion for infrarenal AAAs measuring 4.0 to 5.4 cm in diame-
ter have been conducted in the United Kingdom (UK) and by
the U.S. Department of Veterans Affairs (VA) during the past
decade (947,961-963). By protocol, elective surgical treat-
ment was not offered to patients who were allocated to the
nonoperative cohort in each trial until their aneurysms
exceeded 5.4 cm in size on serial imaging studies. Selected
data from both investigations are summarized in Table 48,
with updated information from the UK trial at a mean follow-
up interval of 8 years (963) compared with 4.6 years when its
findings first were disclosed in 1998. Not surprisingly, the
principal demographic difference between the 2 trials is the
fact that whereas women composed 17% of patients in the
UK study, they represented only 0.8% of the VA population.
Thirty-day operative mortality rates (UK 5.4%; VA 2.1%)
were competitive with those from other multicenter studies
(see Table 49). Endografts were used in 27 patients in the
surgical limb of the UK trial (4.8%) but in just 2 patients in
the VA trial. 
At a mean of 4.9 years of follow-up, early aneurysm repair
had produced no significant benefits with respect to the inci-
dence of either aneurysm-related deaths or deaths due to all
causes in the VA trial. These are the same conclusions that
originally were reached at a mean follow-up of 4.6 years in
the UK trial (960). Although the UK surgical cohort now has
a lower overall mortality rate than the nonoperative cohort (p
Table 46. Annual Rates of Expansion for Abdominal Aortic Aneurysms
No. of Initial Aneurysm Mean Annual
First Author Reference Year Patients Diameter Expansion, mm
Case series
Nevitt (935) 1989 103 3.5 to 5 cm 2.1 
Cronenwett (936) 1990 73 Smaller than 6 cm 4 to 5 
Bengtsson (937) 1993 155 Smaller than 4 cm 0.8 
Larger than or 5.3 
equal to 4 cm
Collective reviews
Taylor (938) 1986 — Larger than or 5 
equal to 5 cm
Hollier (939) 1992 — 3 to 3.9 cm 2.7 
4 to 5.9 cm 4.3 
Larger than 6 cm 7.5 
Hallin (940) 2001 — Smaller than 4 cm 2 to 4 
4 to 5 cm 3 to 5 
Larger than 5 cm 3 to 7 
Randomized trials
Veterans Affairs (941) 2002 — 4 to 5.5 cm 3.2
Small Aneurysm Trial 
(nonoperated cohort)
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Table 47. Rupture and Survival Rates for Patients With Abdominal Aortic Aneurysms
Baseline Aneurysm 
No. of Aneurysm Follow-Up Rupture Survival
First Author Reference Year Patients Diameter Interval Rate (%) Rate (%)
Case series
Szilagyi (945) 1966 82 Less than or equal to 6 cm Mean 34 mo 19 45
141 Larger than 6 cm Mean 17 mo 43 10
Hertzer (955) 1987 24 Smaller than 6 cm 5 y 20 38 Overall
18 At least 6 cm 5 y 69
Nevitt (935) 1989 130 Smaller than 5 cm 5 y 0 NA
46 At least 5 cm 5 y 25 NA
Bengtsson (937) 1993 155 Median 4 cm Median 3.4 y 14 30
Perko (956) 1993 63 Smaller than 6 cm less than 5 NA
At least 6 cm 10 to 15 NA
Galland (957) 1998 267 Smaller than 4 cm 5 y 4 NA
4 to 5.5 cm 5 y 21 NA
Jones (958) 1998 25 5 to 5.9 cm 3 y 28 NA
32 At least 6 cm 3 y 41 NA
Scott (953) 1998 218 3 to 4.4 cm 7 y 2.1 per year NA
and/or operation
4.5 to 5.9 cm 7 y 10 per year NA
and/or operation
Conway (950) 2001 23 5.5 to 5.9 cm 10 y 22 39
62 6 to 7 cm 10 y 34 32
21 Larger than 7 cm 10 y 52 5
Biancari (959) 2002 41 2.5 to 4 cm Median 7.3 y 7.3 59
Collective reviews
Taylor (938) 1986 5 cm NA 4.1 per year NA
5.7 cm NA 6.6 per year NA
7 cm NA 19 per year NA
Hollier (939) 1992 349 Smaller than 5 cm 5 y 4.6 NA
90 Larger than 5 cm 5 y 30 NA
Hallin (940) 2001 54 048 Smaller than 4 cm 4 y 2 NA
4 to 5 cm 4 y 10 NA
Larger than 5 cm 4 y 22 NA
Randomized trials
UK Small Aneurysm (960) 1998 213 4 to 4.4 cm Mean 4.6 y
Trial (nonoperated 169 4.5 to 4.8 cm Mean 4.6 y NA 75%
cohort) 145 4.9 to 5.5 cm Mean 4.6 y NA 72%
NA 64%
UK Small Aneurysm (961) 1999 NA 3 to 3.9 cm 7 y 2.1 NA
Trial (nonoperated NA 4 to 5.5 cm 7 y 4.6 NA
cohort) NA At least 5.6 cm 7 y 20 NA
NA indicates not available; UK, United Kingdom.
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Table 48. Outcomes of Early Elective Repair Versus Nonoperative Surveillance of Asymptomatic Abdominal Aortic
Aneurysms*
UK Trial (2002) VA Trial (2002)
Total patients, n 1090 1136
Early elective repair, n 563 569
Open 536 567
Endovascular 27 2
Nonoperative surveillance, n 527 567
Men 902 1127
Women 188 9
Age 69 plus or minus 68 plus or minus 
4 years 6 years
Operative mortality rate 5.4% (30 days) 2.1% (30 days); 
(surgical cohorts) 2.7% (in-hospital)
Follow-up period, y Range 6 to 10; Range 3.5 to 8.0; 
mean 8 mean 4.9
Survival rate, %
Surgical cohort 57 75
Nonoperative cohort 52 78
(p equals 0.03)
Aneurysm rupture rate 3.2% annually 0.6% annually
(nonoperative cohorts)
Men OR 1.0 (reference set) NA
Women OR 4.0 NA
95% CI 2.0 to 7.9
(p less than 0.001)
Eventual aneurysm repair, 
n (%)
Surgical cohort 520 (92) 527 (93)
Nonoperative cohort 327 (62) 349 (62)
Influence of aneurysm 
diameter (nonoperative 
cohorts)
Survival rate 4.0 to 4.4 cm: 57% 4.0 to 4.4 cm: 79%
4.5 to 4.8 cm: 54% 4.5 to 4.9 cm: 78%
4.9 to 5.5 cm: 43% 5.0 to 5.4 cm: 68%
Eventual repair rate NA 4.0 to 4.4 cm: 27%
4.5 to 4.9 cm: 53%
5.0 to 5.4 cm: 81%
NA indicates not available.
*Results of 2 prospective randomized trials conducted in the United Kingdom (960, 963) and by the United States Department of Veterans Affairs (941).
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Table 49. Operative Mortality Rates for Open Repair of Intact Abdominal Aortic Aneurysms
Year No. of Mortality Rate
First Author Reference (Study Period) Patients (%)
Case series
Crawford (1061) 1981 (1955-1980) Asymptomatic: 531 3.8
Symptomatic intact: 329 6.4
Total: 860 4.8
Hertzer (955) 1987 (1978-1982) 246 4.4
Reigel (1063) 1987 499 2.8
Golden (1065) 1990 500 1.6
Sicard (1071) 1995 145 1.4
Lloyd (1079) 1996 (1980-1995) 1000 2.4
Starr (1060) 1996 (1983-1989) Men: 490 5.1
Women: 92 4.3
Total: 582 5.0
Aune (1058) 2001 (1985-1999) Age less than 66 y: 118 1.7
Age 66 y and older: 333 6.0
Total: 451 4.9
Hertzer (1068) 2002 (1989-1998) 1135 1.2
Menard (1080) 2003 (1990-2000) Low risk: 444 0.0
High risk: 128 4.7
Total: 572 1.0
Randomized trials
UK Small Aneurysm (960) 1998 563 5.8
Trial (surgical cohort)
Lederle (U.S. Veterans (941) 2002 569 2.7
Affairs Small Aneurysm 
Trial; surgical cohort)
Collective reviews
Ernst (1081) 1993 (1981-1992) 6488 4.0
Zarins (973) 1997 (1987-1992) 2162 2.1
Blankensteijn (1074) 1998 (1985-1997) Prospective population: 692 8.2
Prospective hospital: 1677 7.4
Retrospective population: 21 409 3.8
Retrospective hospital: 12 019 3.8
Subset analyses: 1857 3.5
Regional or multicentered studies
Johnston (Canadian 
Aneurysm Group) (1082) 1988 Elective: 541 3.9
Symptomatic intact: 125 7.2
Total: 666 4.5
Richardson (Kentucky (1083) 1991 136 5.9
Medicare)
Hannan (New York statewide) (1084) 1992 (1982-1987) 6042 7.6
Johnston (Canadian (1085) 1994 Men: 545 4.4
Aneurysm Group) Women: 134
5.2
Total: 679 4.6
Katz (Michigan statewide) (1086) 1994 (1980-1990) 8185 7.5
Kazmers (Veterans Affairs) (1087) 1996 (1991-1993) 3419 4.9
Wen (Ontario Aneurysm (1088) 1996 (1988-1992) 5492 3.8
Study)
Kantonen (Finland (1089) 1997 929 5.1
Vascular Registry)
Koskas (French AURC) (1057) 1997 (1989) 1107 4.8
Bradbury (Edinburgh 
Vascular Registry) (1090) 1998 (1976-1996) 492 6.1
Manheim (California 
statewide) (1091) 1998 (1982-1994) 35 130 7.6
Dardik (Maryland statewide) (1092) 1999 (1990-1995) 2335 3.5
Pearce (Florida statewide) (1093) 1999 (1992-1996) 13 415 5.7
Sollano (New York statewide) (1094) 1999 (1990-1995) 9847 5.5
Kazmers (Veterans Affairs) (1095) 2001 (1991-1995) 5833 4.5
Axelrod (Veterans Affairs) (949) 2001 (1997-1998) 1001 3.7
U.S. hospital databases
Lawrence (National Hospital 
Discharge Survey) (1075) 1999 (1994) 32 387 8.4
Heller (National Hospital 
Discharge Survey) (1076) 2000 (1979-1997) 358 521 5.6
Huber (Nationwide 
Inpatient Sample) (1096) 2001 (1994-1996) 16 450 4.2
Dimick (Nationwide 
Inpatient Sample) (1078) 2002 (1996-1997) 13 887 3.8
AURC indicates Association for Academic Research in Vascular Surgery; UK, United Kingdom.
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Most AAAs are asymptomatic and are discovered inciden-
tally on routine physical examination or on an abdominal
roentgenogram (969) or an ultrasound scan that has been per-
formed for other indications. Younger patients are more like-
ly to be symptomatic at the time of diagnosis (970). Pain is
the most frequent complaint in patients with symptomatic
AAAs and usually is located in the hypogastrium or the
lower part of the back. Pain is typically steady, lasting for
hours to days at a time, and has a gnawing quality. In contrast
to musculoskeletal back pain, aneurysm pain is not affected
by movement, although patients may be more comfortable in
certain positions, such as with the knees flexed. Expansion
and impending rupture are heralded by the development of
new or worsening pain, characteristically constant, severe,
and located in the back or lower part of the abdomen, some-
times with radiation into the groin, buttocks, or legs. Rupture
is associated with abrupt onset of back pain, abdominal pain,
and tenderness. Unless they are hypotensive because of
blood loss, many patients with ruptured aneurysms have a
palpable, pulsatile abdominal mass. It must be remembered,
however, that the pathognomonic triad of abdominal/back
pain, pulsatile abdominal mass, and hypotension occurs in
only about one third of cases (971). The symptoms of a rup-
tured aneurysm may mimic those of renal colic, diverticuli-
tis, or a gastrointestinal hemorrhage, thus leading to a misdi-
agnosis that can cost valuable time. 
Hemorrhagic shock may ensue rapidly and is manifested
by hypotension, vasoconstriction, mottled skin, diaphoresis,
mental obtundation, and oliguria. and terminally, by arrhyth-
mias and cardiac arrest. In a few patients who survive with
contained ruptures, the retroperitoneal hematoma may be
accompanied by ecchymosis in the flanks (Grey-Turner sign)
and groin. Free rupture into the peritoneal cavity produces
obvious abdominal distention and often is rapidly fatal,
whereas rupture into the duodenum is manifested by massive
gastrointestinal hemorrhage.
5.2.4.2. Asymptomatic Aortic or Iliac Aneurysms
Patients with even small AAAs have a high prevalence
of risk factors for and clinical manifestations of ath-
erosclerotic cardiovascular disease. A longitudinal
cohort study involving 4734 men and women older
than 65 years of age in 4 US communities correlated
abdominal aortic diameter by ultrasonography with
incidental cardiovascular disease, mortality, and
repair or rupture during a mean follow-up period of
4.5 years (972). The prevalence of aneurysms was
8.8%, of which 88% were at least 3.5 cm in size. The
rates of total mortality (65 vs. 33 per 1000 person-
years), cardiovascular mortality (34 vs. 14 per 1000
person-years), and incidental cardiovascular disease
(47 vs. 31 per 1000 person-years) were higher in par-
ticipants who had aneurysms than in those who did
not. After adjustment for age, risk factors, and the
presence of other cardiovascular disease, the respec-
tive relative risks were 1.32, 1.36, and 1.57, respec-
of asymptomatic infrarenal aortic aneurysms in women
(964).
No randomized trial has yet addressed the size at which
suprarenal, pararenal, or type IV thoracoabdominal aortic
aneurysms should be repaired to prevent rupture. Because of
their higher risk for postoperative death, renal insufficiency,
and other surgical complications, however, there has been a
consensus that elective intervention should be considered for
these aneurysms at a slightly larger diameter than for
infrarenal aortic aneurysms. 
5.2.3.2. Common Iliac Aneurysms
Isolated common iliac aneurysms are unusual in the absence
of a proximal aortic aneurysm, and comparatively little infor-
mation is available with respect to their natural history.
Approximately one third to one half of common iliac
aneurysms are bilateral, and 50% to 85% are asymptomatic
at the time of their discovery (965,966). According to a col-
lective review of 3 clinical series, aneurysm rupture usually
occurs at a diameter of 5.0 cm or larger, whereas common
iliac aneurysms that are less than 3.0 cm in diameter almost
never rupture (966). Therefore, isolated common iliac
aneurysms that are smaller than 3.0 cm probably can be mon-
itored safely with serial noninvasive imaging. Contrast-
enhanced computed tomographic scans or magnetic reso-
nance imaging studies appear to be better suited for this pur-
pose than ultrasonography because many common iliac
aneurysms are situated deep in the pelvis.
5.2.3.3. Local Compression or Erosion
Exceptionally large or inflammatory aortic aneurysms occa-
sionally can be associated with early satiety or gastric outlet
symptoms on the basis of duodenal compression. More cata-
strophically and just as infrequently, an aortic aneurysm may
cause either sudden upper gastrointestinal bleeding on the
basis of a primary aortoenteric fistula or acute congestive
heart failure on the basis of an aortocaval fistula. Far more
commonly, approximately 20% of patients who have large
popliteal aneurysms also have signs of venous insufficiency
in the lower leg on the basis of compression of the adjacent
popliteal veins (967,968).
5.2.4. Diagnosis
5.2.4.1. Symptomatic Aortic or Iliac Aneurysms
RECOMMENDATIONS
Class I
1. In patients with the clinical triad of abdominal and/or
back pain, a pulsatile abdominal mass, and hypoten-
sion, immediate surgical evaluation is indicated.
(Level of Evidence: B)
2. In patients with symptomatic aortic aneurysms,
repair is indicated regardless of diameter. (Level of
Evidence: C)
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operation (5.4 plus or minus 1.5 cm, p equals 0.039). Not
surprisingly, the average size of palpable AAAs was larger
than that of nonpalpable AAAs (6.4 plus or minus 1.2 cm vs.
4.9 plus or minus 1.4 cm, p less than 0.001).
5.2.4.4. Incidental Radiological Findings
5.2.4.4.1. PLAIN FILMS. It is not the current standard of care
to use plain radiographic studies for follow-up surveillance
of AAAs, but 15% to as many as 85% of these aneurysms
initially are discovered because of curvilinear aortic wall cal-
cification that represents an incidental finding on a plain
abdominal film that was obtained for other purposes. The
plain film also may demonstrate a soft tissue mass with oblit-
eration of the psoas margin and/or disruption of mural calci-
fication with extension into a periaortic soft tissue mass,
occasionally suggesting that the aneurysm has ruptured. In
addition, smaller calcified rings sometimes suggest the pres-
ence of visceral artery aneurysms (978-981).
5.2.4.4.2. ULTRASOUND AND OTHER SCANS. Asymptomatic
AAAs also may be discovered incidentally on ultrasound,
computed tomography, and nuclear scans that have been per-
formed for unrelated indications; conversely, computed
tomography or ultrasound may demonstrate incidental non-
vascular lesions during AAA evaluation, notably malignancy
(982-991). The existence of incidental findings is not sur-
prising given the advanced age of many patients undergoing
imaging studies.
Phillips and King reported that 3.1% of male urologic
patients (65 to 80 years of age) undergoing urinary tract
ultrasonography were documented to have unsuspected aor-
tic aneurysms; with deliberate augmentation of the scan to
include the aorta (i.e., opportunistic screening), the incidence
rose to 9.1%, a figure that appeared to exceed random dis-
covery rates (985). Akkersdijk et al. found that incidental
aneurysms with a diameter of at least 3.0 cm, or 1.5 times the
diameter of the proximal aorta, were present in 4.9% of 1687
patients older than 50 years who underwent some form of
abdominal ultrasonography, comprising 8.8% of men, 2.1%
of women, and 11% of men over 60 years of age (988).
Because the symptoms of expanding aneurysms can mimic
urologic symptoms, additional scanning to include the aorta
may be especially prudent in some specific clinical situations
(991). 
5.2.4.4.3. OPPORTUNISTIC SCREENING. In the paradigm of
“opportunistic” screening, abdominal ultrasound studies that
primarily have been performed to obtain information regard-
ing disease states other than aortic aneurysms (e.g., a urolog-
ic evaluation) are extended to include an examination of the
nearby abdominal aorta (985,988,992-994). Studies in this
area of interest have reported the prevalence of incidental
aortic aneurysms to range from 6.5% to 12%, but these stud-
ies have not been rigorously controlled for age or other high-
risk factors, such as tobacco use or a family history of
aneurysms. Some believe that unlike a dedicated screening
tively. In comparison, the rates of repair and rupture
were low in this series. 
Elective surgical repair improves the survival rate for
patients with large aneurysms (945), and approximately 50 000
operations are performed annually for this condition in the
United States, with operative mortality rates that are reported
to be as low as 2% in some centers (973). Even before the
results of randomized trials were available, however, it gener-
ally was accepted that watchful waiting with serial imaging
was a better long-term treatment strategy than early surgical
repair for aneurysms less than 5.0 cm in diameter (939). Up to
13% of patients with aortic aneurysms have multiple
aneurysms elsewhere (974), and 25% to 28% of those with tho-
racic aortic aneurysms have concomitant AAAs (975,976).
Accordingly, patients in whom an aortic aneurysm is discov-
ered at either level should undergo an appropriate examination
of the entire aorta to detect aneurysms in other locations.
5.2.4.3. Physical Examination
A comprehensive physical examination should include pal-
pation of the abdomen and the lower extremity arteries in an
attempt to detect widened pulses that suggest the presence of
aneurysms. Palpation of AAAs is safe and has not been
reported to precipitate rupture. Perhaps the best evidence
regarding the accuracy of abdominal palpation comes from
15 studies of patients who were not previously known to
have AAAs but were screened with both an abdominal exam-
ination and ultrasound scans (977). The pooled sensitivity of
abdominal palpation increased significantly with aortic
diameter (p less than 0.001), ranging from 29% for AAAs of
3.0 to 3.9 cm to 50% for AAAs of 4.0 to 4.9 cm and 76% for
AAAs measuring 5.0 cm or more by ultrasonography. The
positive and negative likelihood ratios were 12.0 (95% CI
7.4 to 19.5) and 0.72 (95% CI 0.65 to 0.81), respectively, for
AAAs that were 3.0 cm or larger and 15.6 (95% CI 8.6 to
28.5) and 0.51 (95% CI 0.38 to 0.67) for AAAs that were
larger than 4.0 cm. The positive predictive value of palpation
was 43% for AAAs that were documented to be at least 3.0
cm in diameter. Intuition and limited data suggest that
abdominal obesity reduces the sensitivity of palpation. In
summary, careful abdominal palpation is moderately sensi-
tive for the detection of AAAs that are large enough to be
referred for surgical intervention, but the physical examina-
tion alone may not be sufficiently reliable for the detection of
smaller AAAs, especially if rupture already is suspected. 
In a 3-year retrospective study of 198 patients with AAAs
that was conducted by Alcorn et al. (860) in a general hospi-
tal setting, 48% of the aneurysms had been discovered clini-
cally, 37% represented incidental findings during radi-
ographic investigation of another condition, and 15% were
encountered during unrelated abdominal operations. Of
those that initially were detected by radiography, 38% were
palpable on subsequent physical examination. The average
size of the AAAs that were discovered clinically (6.5 plus or
minus 1.3 cm) was larger than those that were found by radi-
ography (5.47 plus or minus 1.4 cm, p less than 0.001) or at
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results may vary between or even within centers, especially
with small AAAs (1000,1001). This variability can be
decreased with appropriate quality control and credentialing,
but duplex scanning is more frequently used to evaluate the
femoral or popliteal arteries to distinguish aneurysms from
other vascular and nonvascular masses in these particular
anatomic areas (1002-1008).
Infrarenal Aortic Aneurysms. Ultrasound scanning has been
used in large screening and surveillance programs for both
the initial assessment and subsequent follow-up of small
aneurysms that are not repaired immediately. Multiple stud-
ies have suggested that ultrasound is an appropriate means to
determine the presence or absence of an infrarenal aortic
aneurysm in more than 95% of candidates (870,1009,1010).
The maximum anteroposterior aortic diameter usually is
determined after overnight fasting to aid visualization
(859,1009). Ultrasonography should be performed in the
plane perpendicular to the arterial axis, because oblique
measurements tend to overestimate the true size of the aorta
(863) and represent one source for potential variability. 
Diagnostic specificity for the presence of an aneurysm is
nearly 100% (859,873,1011), with sensitivity ranging from
92% to 99% (859,873,1011). The reproducibility and
intraobserver variability of ultrasound measurements are
quite satisfactory and are similar to those for computed
tomographic scanning (961,1011,1012), although intraob-
server correlation appears to be better near the aortic bifur-
cation than in the proximal infrarenal aorta (1011). Thus,
ultrasonography is an excellent tool for screening and sur-
veillance, both for individual patients and for screening pro-
grams. Modalities such as computed tomographic or MRA
scanning usually are reserved for anatomic mapping before
aneurysm repair because they are more expensive than ultra-
sound scanning and have some risk related to contrast and
radiation. 
Suprarenal Aortic and Iliac Aneurysms. Despite its utility in
establishing the size of infrarenal aortic aneurysms, ultra-
sonography usually does not provide dependable imaging of
aneurysms that extend close to the origins of the renal arter-
ies or into the suprarenal segment of the abdominal aorta
(969,996,998,1013-1015). In one prospective study, the
upper and lower limits of AAAs were accurately demon-
strated by ultrasound in only 47% and 41% of cases, respec-
tively (1015). In another prospective study of 79 patients
with AAAs, ultrasound reliably determined the length of the
infrarenal aortic “neck” in only 20% of inflammatory
aneurysms and 28% of noninflammatory aneurysms.
Furthermore, standard B-mode ultrasound is suboptimal for
imaging the common and internal iliac artery segments in the
context of aneurysm disease, and duplex scanning is able to
detect iliac artery involvement only about 50% of the time. A
spiral computed tomographic scan of the abdomen and pelvis
with 3D reconstruction in special instances is superior to
ultrasonography for this purpose (1016).
program, opportunistic screening can be done at little addi-
tional cost because most of the expense of the aortic imaging
is borne by the baseline ultrasound scan. However, Wolf et
al. noted that the addition of an aortic ultrasound scan to
other unrelated studies in the vascular laboratory prolongs
each examination by 5 minutes per patient and requires 83
minutes of scanning time for each aortic aneurysm that is
detected (36 minutes per male smoker), at a cost of $240 to
$553 per patient (994). In fact, this happens to be in the cost
range of conventional population-based ultrasound screening
(873). Furthermore, at least 1 investigation has indicated that
opportunistic screening successfully demonstrates the aorta
in only 89% of patients (less than the expected rate for most
dedicated screening programs), perhaps because of inade-
quate patient preparation or operator skill (994). Therefore,
because the ultrasound scan represents only a small fraction
of the total expense that is associated with the detection and
treatment of aortic aneurysms, the cost savings of oppor-
tunistic screening may be quite small in the general popula-
tion in which the prevalence of such aneurysms is low. 
There are multiple strategies for utilizing ultrasonography
in a screening program for AAAs. Together with the data that
already are available with respect to the prevalence rate of
these aneurysms in various populations, the publication of 2
large randomized trials regarding aneurysm size and its
influence on surgical indications may encourage computer
modeling to determine the benefit, risks, and cost-effective-
ness of ultrasound screening in targeted patient populations
(947,961-963). This kind of information might also influence
the decisions to be made by third-party payers.
5.2.4.4.4. UNRELATED ARTERIOGRAPHY. Catheter-based arteri-
ography is not used as a primary diagnostic modality for aor-
tic aneurysms, especially since mural thrombus makes it
impossible to determine the true size of the aneurysm with
the diameter of the contrast column. Arteriography instead is
reserved to answer specific anatomic questions before
endovascular management or, increasingly less frequently,
before open AAA repair. However, several incidental find-
ings during unrelated arteriographic studies may suggest the
presence of an AAA, such as mural calcification, slow and/or
turbulent flow, a widened interior lumen that is paradoxical-
ly smooth because of laminated thrombus and occlusions of
its branch vessels (e.g., the inferior mesenteric and lumbar
arteries), “draping” of the superior mesenteric artery over the
contour of the aneurysm, and a thickened aortic wall or soft
tissue mass (995).
5.2.4.5. Diagnostic Imaging
5.2.4.5.1. ULTRASONOGRAPHY. B-mode or real-time ultra-
sound is excellent for imaging many aortic aneurysms
because it has no risk to the patient and is less expensive than
computed tomographic scanning (996-999). Its accuracy for
measuring the aortic diameter below the level of the renal
arteries approaches that of direct intraoperative measure-
ments (997-999). In comparison, the accuracy of duplex
ultrasound can be operator-dependent, and therefore, its
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5.2.4.5.2. CONTRAST-ENHANCED SPIRAL COMPUTED TOMO-
GRAPHIC SCANNING. For many years, transcatheter arteriogra-
phy, including intra-arterial digital subtraction arteriography,
was the “gold standard” for the preoperative assessment of
AAAs. Early studies reported a high radiation dose and con-
trast load with computed tomography compared with digital
subtraction arteriography (1017), but computed tomography
provided additional information about adjacent veins and
soft tissue and eventually supplanted digital subtraction arte-
riography as the preoperative study of choice. Because of
improved techniques, their relatively noninvasive nature, and
their cost advantage over transcatheter angiography, CTA
and MRA have emerged as current “gold standards” in the
preoperative and postoperative evaluation of AAAs (1018).
In comparison, arteriography may be warranted to optimally
define collateral or variant artery anatomy, such as the arteri-
al supply to a horseshoe kidney, or the location and severity
of occlusive disease or associated aneurysms in the visceral,
renal, iliac, or peripheral arteries (997,1019). The decision to
use either CTA or MRA is often locale-specific. Operator
proficiency and the availability of suitable equipment and
protocols may determine which modality is preferred.
Preoperative Aortic Aneurysm Assessment. The preoperative
assessment of AAAs before open or endovascular repair
includes defining the maximum transverse diameter and the
relation of the aneurysm to the renal arteries. The length of
normal-caliber aorta below the renal arteries before the
aneurysm is commonly referred to as the infrarenal neck of
the aneurysm. The length of this segment of normal caliber
aorta as well as its diameter and angulation are particularly
important when endovascular aneurysm repair is contem-
plated. In addition, preoperative imaging should demonstrate
iliac or hypogastric aneurysms, serious occlusive disease in
the iliac or renal arteries, the presence of vascular abnormal-
ities (e.g., accessory renal arteries, duplicate vena cavae, or a
retro-aortic left renal vein), or nonvascular soft tissue anom-
alies, such as horseshoe kidney (1020,1021). If endovascular
AAA repair is under consideration, it is even more important
to obtain precise measurements regarding the diameter and
length of the proximal neck and the tortuosity of the aorta
and the iliac arteries. Contrast-enhanced computed tomo-
graphic scanning provides baseline information in all of
these areas. In select cases, contrast arteriography may be
necessary in defining complicated arterial anatomy before
endovascular aneurysm repair. 
For accurate imaging of the length and diameter of the
infrarenal AAA neck, narrow collimation (i.e., 3 mm or less)
should be used (997,1021-1023). Because narrow collima-
tion limits the aortic length that can be scanned and slows
reconstruction time, typical computed tomography protocols
call for narrow collimation around the renal arteries to define
the superior extent of the aneurysm, combined with 10-mm
collimation for the rest of the abdomen and pelvis (997).
New multidetector computed tomography instrumentation
promises to improve accuracy by being able to acquire more
images in a faster time, with a single breath hold and less
contrast medium (239). Recent helical computed tomograph-
ic techniques and protocols with 3D reconstruction displays
should position computed tomography as a possible sole
imaging modality for either open or endovascular AAA
repair in the future (1024).
5.2.4.5.3. MAGNETIC RESONANCE SCANNING. The presence of
heavy mural calcification is sometimes important, because it
may alter the planned repair. Computed tomography can
accurately demonstrate vascular calcification, but it requires
ionizing radiation and relatively large volumes of iodinated
contrast. The presence of mural calcification can preclude
successful computed tomographic evaluation of the periph-
eral arteries, so either adjunct arteriography or MRA may be
needed. Magnetic resonance angiography presently has the
disadvantage of being a slower scanning procedure than
computed tomography and usually is not appropriate for use
in patients who are claustrophobic or have metal implants.
However, the coronal acquisition mode of current magnetic
resonance techniques may expand its applications in the
future. 
Early MRA protocols depended on 3D time-of-flight imag-
ing, which has a high signal-to-noise ratio but requires mul-
tiple slices and long imaging time because of in-plane flow
saturation. Time-of-flight imaging is performed perpendicu-
lar to flow. The development of breath-held dynamic con-
trast-enhanced MRA has broadened the applicability of mag-
netic resonance by allowing rapid acquisition of images in
any plane independent of flow (1025-1028). By imaging on
the first pass during a breath hold, vascular signals can be
obtained before leakage of contrast into the surrounding soft
tissues, yielding an angiogram with high signal-to-noise ratio
and enhanced detail. Images can be synchronized or sub-
tracted for further enhancement (1028,1029). Similar proto-
cols can be used to enhance contrast between the vessels and
the background fatty tissue and have proven to be better than
3D time of flight for imaging the aortic branch vessels and
the iliac arteries (1030).
In an early, blinded comparison of MRA versus conven-
tional arteriography before elective aortic aneurysm repair,
MRA was thought to be superior for defining the proximal
extent of the AAA and for depicting venous anatomy, intra-
luminal thrombus, and coexistent iliac aneurysms (998).
Subsequent improvement in magnetic resonance technique
has yielded more accurate imaging of the renal arteries
(209,981), a feature that eventually may make MRA as use-
ful as spiral computed tomographic scanning for preopera-
tive assessment before endovascular AAA repair
(1012,1025,1031). In conclusion, the rapid development of
both CTA and MRA makes their respective use for preoper-
ative AAA assessment in large part dependent on local expe-
rience and the availability of the latest scanner. There
presently is no consensus to indicate the superiority of either
technique.
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sion occurred at a rate of more than 1cm per year, or if symp-
toms occurred. More than 27000 (80%) of the 33839 men in
the invited group agreed to screening, and 1333 aneurysms
were detected. There were 65 aneurysm-related deaths
(absolute risk 0.19%) in the invited group and 113 (0.33%)
in the control group (risk reduction 42%; 95% CI 22% to
58%; p equals 0.0002), including a 53% reduction of risk
(95% CI 30% to 64%) among those who actually underwent
screening. The 30-day mortality rate was 6% (24 of 414)
after elective aneurysm repair compared with 37% (30 of 81)
after emergency operations. During the 4 years in which this
trial was conducted, there were 47 fewer deaths related to
AAAs in the screening group than in the control group, but
the additional costs incurred were 2.2 million British pounds
(approximately 3.5 million US dollars). After an adjustment
for censoring and a discount of 6%, the mean additional cost
of screening was 63£ or $98 (95% CI 53.31£ to 73£ or $84
to $116) per patient. The hazard ratio for AAA was 0.58
(95% CI 0.42 to 0.78). Over 4 years, the mean incremental
cost-effectiveness ratio for screening was 28400£ or $45000
per life-year gained, a figure that is equivalent to approxi-
mately 36 000£ or $57 000 per quality-adjusted life-year.
After 10 years, this figure was estimated to decline to
approximately 8000£ or $12 500 per life-year gained (1037).
These values of cost-effectiveness for AAA screening are
at the margin of acceptability according to most current
health services thresholds. Over a longer period, however,
cost-effectiveness is expected to improve substantially,
decreasing to about one fourth of the 4-year figure at 10
years. How to set policy in relation to these values depends
on national and regional health standards. A Canadian cohort
analysis that used a multiprovince life-table model deter-
mined that the most cost-effective rate at which latent AAAs
should be detected is 20% per year, which corresponds to a
screening interval of 5 years by abdominal ultrasonography
for patients over 50 years of age (1038), but the aortic dimen-
sions at which intervention was recommended were larger
than those that recently have been used in influential ran-
domized trials (962,963). In Finland, 74% (238 of 322) of
first-degree relatives of 150 consecutive AAA patients were
screened at a central university hospital to evaluate the effec-
tiveness and costs of treatment (1039). Outcomes were
assessed with the national discharge registry and from sur-
vival analysis of AAA patients who underwent elective or
emergency surgery. The incremental effectiveness in life-
years gained by the screening of male siblings was 92 years,
with an incremental cost-effectiveness ratio of 33 000
Finnish marks or $6200. Given these data, screening of male
siblings of AAA patients was recommended because it
appeared to be associated with improved survival at low cost.
Selected screening of populations with a high prevalence of
AAA (e.g., males 60 years or older who have a family histo-
ry of AAA, in whom the prevalence is approximately 18%,
or men who smoke) and the use of a limited ultrasound scan
are more cost-effective than conventional abdominal imag-
ing of unselected populations. In a small pilot study, the aver-
age time required to perform a limited screening scan was
5.2.4.6. Screening High-Risk Populations
RECOMMENDATIONS
Class I
Men 60 years of age or older who are either the sib-
lings or offspring of patients with AAAs should under-
go physical examination and ultrasound screening for
detection of aortic aneurysms. (Level of Evidence: B)
Class IIa
Men who are 65 to 75 years of age who have ever
smoked should undergo a physical examination and 1-
time ultrasound screening for detection of AAAs.
(Level of Evidence: B)
Aortic diameter can be measured accurately by ultrasound
imaging in more than 97% of subjects (1032,1033).
Screening by this method has the potential to reduce the inci-
dence of aortic rupture and has increasingly become the
focus of population-based screening programs that have
examined the efficacy of targeted AAA detection strategies.
The effectiveness of ultrasound screening studies has been
evaluated in several countries, with specific targeting of
high-risk groups, such as those with hypertension, coronary
disease, or tobacco use. A study of screening for AAAs in
3000 of 6058 males aged 64 to 81 years was underpowered
to demonstrate a reduction in mortality through selective
rescreening or surgical intervention for AAAs (1034). In a
cohort of 52 745 military veterans aged 50 to 79 years who
had no history of aneurysms, AAAs measuring 4.0 cm or
larger in diameter were detected by ultrasound screening in
613 participants (1.2%). When this cohort was combined
with a similar cohort of 73 451 veterans in the same age
range, the ORs for major risk factors were as follows: 1.71
per 7 years of age, 0.18 for female gender, 0.53 for black
race, 1.94 for family history of AAA, 5.07 for smoking, 0.52
for diabetes, and 1.66 for atherosclerotic diseases. The
excess prevalence associated with smoking accounted for
75% of all AAAs 4.0 cm or larger in the combined popula-
tion of 126 196 veterans. The risk factor associations for
smaller AAAs (3.0 to 3.9 cm) were similar but less robust
(870). According to one estimate, if the risk for AAA were
based on age alone, it would be necessary to examine over
half of the elderly male population to obtain 80% of the total
potential benefit among men. If age and smoking were
included, the proportion needed to screen would fall to 35%.
Even if other risk factors, such as coronary disease or hyper-
lipidemia, were included, it still would be necessary to
screen 15% to 20% of the population, and the cost would be
prohibitive (1035). 
In another population-based study, 67 800 men aged 65 to
74 years were randomly allocated to receive an invitation for
an abdominal ultrasound scan (1036). Men in whom aortic
aneurysms at least 3.0 cm in diameter were detected under-
went repeat scans for a mean of 4.1 years. Surgical treatment
was considered when the diameter reached 5.5 cm, if expan-
e118
Hirsch et al. 2005
ACC/AHA Practice Guidelines
ACC - www.acc.org
AHA - www.americanheart.org
5.2.5. Observational Management
5.2.5.1. Blood Pressure Control and Beta-Blockade
RECOMMENDATIONS
Class I
Perioperative administration of beta-adrenergic
blocking agents, in the absence of contraindications, is
indicated to reduce the risk of adverse cardiac events
and mortality in patients with coronary artery disease
undergoing surgical repair of atherosclerotic aortic
aneurysms. (Level of Evidence: A)
Class IIb
Beta-adrenergic blocking agents may be considered to
reduce the rate of aneurysm expansion in patients
with aortic aneurysms. (Level of Evidence: B)
Preclinical models of aneurysm progression have suggest-
ed that beta-adrenergic antagonist agents may reduce the risk
of aneurysm development and expansion. Brophy et al.
(1043) demonstrated that propranolol delays the develop-
ment of aneurysms in a mouse model that is prone to spon-
taneous aortic aneurysms. In that model, drug efficacy
appeared to be independent of reductions in blood pressure
or diminution of the force of left ventricular ejection (dP/dt)
and may have resulted from actions on the connective tissue
structure of the aortic wall. In another animal model in which
AAAs were induced both in normotensive and in genetically
hypertensive rats by perfusion of the isolated infrarenal aorta
with elastase for 2 hours, the aneurysms were significantly
larger in hypertensive rats, with a mean expansion rate (mm
per day) that was nearly twice that of normotensive animals
(1044). In comparison, the aneurysms in the study by Brophy
et al. were significantly smaller in hypertensive propranolol-
treated rats than in placebo-treated controls (p less than
0.05). 
Retrospective clinical studies have suggested that beta-
adrenergic antagonist agents might reduce the risk of
aneurysm expansion and rupture (1045), but these data have
been inconsistent. In one small retrospective analysis, the
mean aneurysm growth rate was 0.17 cm per year in treated
patients versus 0.44 cm per year in untreated patients (1046).
Eight percent of the patients in the beta-blockade group
exhibited a growth rate that exceeded the mean for the over-
all study population, compared with 53% of the patients who
received no treatment. The mean rate of aneurysm expansion
was slower in treated patients, a difference that was most
pronounced in those with large aneurysms. Lindholdt et al.
reported another study of 54 patients who had small AAAs
who were randomized to receive 40 mg of propranolol twice
daily or placebo and were followed up for 2 years (1047).
Sixty percent of the subjects in the propranolol group and
25% of those in the placebo group ultimately withdrew from
this trial, with many subjects in the propranolol group report-
ing problems with dyspnea. Reductions in pulmonary func-
tion, ABI, and quality of life were also observed in the pro-
one sixth that of a conventional study (4 vs. 24 minutes),
with comparable accuracy for the diagnosis of AAA alone
(1040). Reducing the cost of screening tests from $259,
which represents the approximate Medicare reimbursement
for conventional abdominal ultrasound imaging, to $40 for
the limited scan would improve cost-effectiveness.
A meta-analysis of the currently published international
data that might support the use of screening programs to
detect AAA has been completed recently and was summa-
rized by the United States Preventive Services Task Force
(USPSTF). This summary provides a concise focus on the
potential benefit and harm that might be associated with such
targeted AAA screening programs, balancing detection effi-
cacy, interventional risk reduction, and cost-effectiveness
(1041). A version prepared for the Agency for Healthcare
Research and Quality in February 2005 is available online at
www.ahrq.gov/clinic/serfiles.htm. The USPSTF meta-analy-
sis supports the concept that screening for AAA and surgical
repair of large AAAs (5.5 cm or more) in men aged 65 to 75
years who have ever smoked (inclusive of both current and
former smokers) leads to decreased AAA-specific mortality
when abdominal ultrasonography is performed in a setting
with adequate quality assurance (i.e., in an accredited facili-
ty with credentialed technologists). It is notable that the data
do not support the application of AAA screening for men
who have never smoked or for women. The USPSTF analy-
sis balanced the efficacy of AAA detection and potential
diminution of AAA-associated death by surgical repair with
the potential psychological harm and increased morbidity
and mortality of AAA surgery performed in low risk popula-
tions. 
There are important caveats to be applied to any screening
recommendations. These include the need for the screening
intervention to be performed in individuals whose life
expectancy is adequately long for benefit to accrue (thus,
decreasing benefit is gained in more elderly populations with
ages greater than 75 years) and that the use of endovascular
(vs. open surgical) aortic repair is likely no more beneficial
in the long-term risk-benefit calculation, because there are
inadequate data to demonstrate that use of endovascular
techniques would be associated with any greater benefit than
with operative repair. Finally, AAA screening has not been
proven to be linked to an improvement in all-cause mortali-
ty, even when AAA-associated death is diminished. These
limitations may have significant impact on the willingness of
screening candidates to participate in this screening pathway.
Finally, the USPSTF analysis suggested that screening per-
formed as per the Multicentre Aneurysm Screening Study
(MASS) would be associated with a cost-effectiveness ratio
for population-based AAA screening (compared with no
screening) in the range of $14 000 to $20 000 per quality-
adjusted life-year. Although this estimate is promising, addi-
tional data are required to confirm that these estimates are
accurate over longer periods of time in actual (vs. clinical
trial) practice (1042).
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surveillance for aneurysms measuring less than 4.0 cm in
diameter and ultrasound scans every 6 months for those 4.0
to 4.9 cm in diameter, with a recommendation for elective
aneurysm repair in appropriate surgical candidates whenever
an AAA reached a size of at least 5.0 cm. One such study of
99 patients documented a mean expansion rate of 2.2 mm in
the first year of observation, 2.8 mm in the second year, and
1.8 mm in the third year for aneurysms that initially were
smaller than 4.0 cm. The corresponding growth rates for
aneurysms measuring 4.0 to 4.9 cm were 2.7, 4.2, and 2.2
mm, respectively (1052). Given the usual slow rate of expan-
sion for truly small aneurysms, however, Grimshaw et al. and
Santilli et al. have recommended that those measuring less
than 4.0 cm in diameter can be followed up safely with ultra-
sound scans every 2 to 3 years (933,934). 
The available evidence does not support a lower size
threshold for the endovascular repair of AAAs than for con-
ventional surgical repair (1053,1054). No recommendations
currently are available for patients whose aortic diameter is
ectatic but less than 3.0 cm in diameter and thus not truly
aneurysmal. Screening of 12 500 people at a university-affil-
iated VA medical center yielded 223 patients whose aortic
diameters were 2.5 to 2.9 cm (1055). On the basis of serial
ultrasound imaging over 7 years, these ectatic aortas expand-
ed slowly, rupture did not occur, and criteria for operative
repair were infrequently met. No risk factors linked to the
development of aneurysms were identified on multivariate
analysis. Therefore, in patients with ectatic but nonaneurys-
mal aortas, repeat ultrasound imaging was recommended no
more often than 5 years after the initial study. Because of the
potential for late dissection or aneurysm in other areas of the
aorta, however, patients with Marfan syndrome should
undergo serial imaging of the aorta indefinitely after surgical
repair of aneurysmal disease or dissection.
5.2.6. Open Aortic Aneurysm Repair
The management of patients who have AAAs that are large
enough to represent a predictable risk for fatal rupture often
is guided by several considerations. First, the survival rate of
this patient population generally is acknowledged to be sig-
nificantly lower than that for a normal population of the same
age (1056-1059), and Aune has reported that unfavorable late
survival is particularly evident among patients who are 65
years of age or younger at the time that their aortic
aneurysms are discovered (1058). Second, it has long been
recognized that coronary artery disease and its consequences
represent the leading causes of late death in these patients,
superseding even the mortality rate that can be attributed
directly to unoperated aneurysms (945,1060). Therefore, in
addition to their importance regarding early surgical risk,
these observations have long-term implications with respect
to the identification and treatment of underlying coronary
disease before the elective repair of aortic aneurysms.
Finally, the emergence of new technology for transfemoral
endovascular repair of AAAs with a variety of commercially
available, FDA-approved stent grafts now provides an alter-
pranolol group. The mortality rate was 17% in the propra-
nolol group compared with 4.2% in the placebo group (risk
reduction 1.6; 95% CI 1.02 to 2.51). However, the relative
risk of aneurysm expansion at an annual rate of more than 2
mm in the placebo group was 1.17 (95% CI 0.74 to 1.85) by
intention-to-treat analysis and 2.44 (95% CI 0.88 to 6.77)
according to on-treatment analysis. Only 22% of the treated
patients continued to take propranolol for the full 2 years. In
another trial, asymptomatic patients with AAAs measuring
3.0 to 5.0 cm in diameter were randomized in a double-blind
fashion to receive either propanolol (n equals 276) or place-
bo (n equals 272) and then observed for a mean of 2.5 years
(601). Forty-two percent of the patients in the propranolol
group discontinued their medication compared with 27% of
those in the placebo group (p equals 0.0002). The annual
aneurysm growth rate was similar for the propanolol (0.22
cm per year) and placebo (0.26 cm per year, p equals 0.11)
groups. There was a slight trend towards more elective sur-
gical intervention in the placebo group (27% vs. 20%, p
equals 0.11), but there was no difference in mortality rates
(propanolol 12%, placebo 9%; p equals 0.36). Patients in the
propranolol group had significantly poorer quality-of-life
scores. Finally, one prospective randomized trial found that
the expansion rate of AAAs was not attenuated by use of
beta-adrenergic blockers (601).
Long-term prophylactic beta-blockade appears to be effec-
tive in slowing the rate of aortic dilation and decreasing the
incidence of aortic complications in some patients with
Marfan syndrome by reducing the heart rate and the impulse
(i.e., the rate of pressure change in the aortic root) of left ven-
tricular ejection. An open-label, randomized trial of propra-
nolol (mean dose 212 plus or minus 68 mg daily) in adoles-
cent and adult patients with classic Marfan syndrome deter-
mined that the rate of aortic root dilation was significantly
lower in the treatment group than in the control group (0.023
vs. 0.084 cm per year, p less than 0.001) (1048). Clinical end
points were reached in 5 patients in the treatment group and
9 in the control group. The Kaplan-Meier survival curve for
the treatment group differed significantly from that for the
control group during the middle years of the trial and
remained better for the treatment group throughout the study.
It is not clear whether these observations apply to aneurysms
in the abdominal aorta, because patients with Marfan syn-
drome develop aneurysms less commonly in this location
than in the thoracic aorta.
Aside from their effects on aneurysm size, the periopera-
tive administration of beta-blockers may reduce the risk of
adverse cardiac events and death in patients with cardiac risk
factors who undergo AAA repair and other noncardiac vas-
cular surgery (1049-1051).
5.2.5.2. Follow-Up Surveillance
A number of prospective nonrandomized studies that were
reported before the disclosures from the UK Small
Aneurysm Trial and the VA Aneurysm Detection and
Management (ADAM) Trial suggested annual ultrasound
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nias, and wound discomfort than a standard transabdominal
incision (1073).
5.2.6.1.3. EARLY MORTALITY AND COMPLICATION RATES. In a
collective review of nearly 40 000 reported cases, Blanken-
steijn et al. concluded that the operative mortality rate for
elective open aortic aneurysm repair varied according to
whether the individual case series were prospective or retro-
spective in design and whether they were population-based
or hospital-based (1074). Such factors undoubtedly account
for some of the variability in the representative early out-
comes that are summarized in Table 49. Mortality rates from
single centers generally were in the range of 4% to 5% dur-
ing the 1980s, whereas information that has been published
during the 1990s contains several series in which the mortal-
ity rate has declined to less than 2%. In comparison, region-
al or multicenter studies in the United States and elsewhere
generally have been associated with slightly higher mortali-
ty rates, ranging from 5% to 7%. Exceptionally large data-
bases, such as the National Hospital Discharge Survey
(NHDS) and the Nationwide Inpatient Sample, are intriguing
because of their potential sample size but often require con-
siderable editing to distinguish between infrarenal and
suprarenal aortic aneurysms, both of which are classified
under the same ICD-9 (International Classification of
Diseases, 9th Revision) code. Lawrence et al. (1075) used
the NHDS to calculate an operative mortality rate of 8.4%
for 32387 patients in 1994, but as indicated in Table 49, con-
flicting results can be generated from the NHDS and the
Nationwide Inpatient Sample during similar periods of study
(1075-1078). In comparison, the operative mortality rate for
open repair of ruptured AAAs is uniformly grim, ranging
from 40% to 70% regardless of whether it has been reported
from single-center case series, collective reviews, regional or
multicenter studies, or large national databases (Table 50). 
The clinical variables that significantly influence the mor-
tality rate for ruptured aneurysm repair generally reflect a
sudden loss of blood volume, as well as the physiological
resilience of individual patients to withstand such a catastro-
phe. These include a low initial hematocrit, hypotension that
requires resuscitation, cardiac arrest, a high APACHE (Acute
Physiological And Chronic Health Evaluation) score, and
advanced age (1097,1100,1101,1103-1105). In comparison,
certain patient demographics and organ-specific factors take
precedence over hemodynamic instability in the determina-
tion of the surgical risk for elective repair of intact
aneurysms. Some of these considerations are listed below. 
Age. Not surprisingly, higher patient age has been shown to
be directly related to higher operative mortality rates in typ-
ical case series (1058,1060), collective reviews (1106),
regional or statewide audits (1086,1092), and the UK Small
Aneurysm Trial (1107). Although the operative mortality rate
for urgent repair of ruptured aortic aneurysms is no higher
among octogenarians than in younger patients (1099,1108),
the results of 2 relatively large series indicate that the mor-
tality rate for elective aneurysm repair in octogenarians is
native to open surgical treatment in patients with aneurysms
that warrant repair on the basis of their size or expansion
rate. Thus, the contemporary clinician is faced with an array
of choices in the management of aortic aneurysms, each of
which must be tailored to the individual patient.
5.2.6.1. Infrarenal AAAs
5.2.6.1.1. PREOPERATIVE CARDIAC EVALUATION. A number of
studies have demonstrated that the perioperative and long-
term mortality rates in conjunction with open aortic
aneurysm repair are highest among patients who have symp-
tomatic coronary disease (i.e., class III to IV angina pectoris
or congestive heart failure), intermediate in those who have
chronic stable angina and/or a history of remote MI, and low-
est among those who have no indication of coronary disease
whatsoever (955,1061-1064). Glance constructed a Markov
predictive model in which patients at high cardiac risk under-
went coronary arteriography, those at intermediate risk
received noninvasive assessment with dipyridamole-thalli-
um scanning, and those at low risk proceeded directly to
aneurysm repair (1064). The conclusion of this exercise was
that selective screening “may improve 5-year survival and be
cost effective.” Several large clinical series have been report-
ed in which a similar clinical approach has been used (1065-
1068). According to these reports, the mortality rate for open
aortic aneurysm repair can be reduced to less than 2% in a
setting in which approximately 5% to 15% of patients under-
go preliminary coronary artery intervention (1069).
However, the role of coronary artery revascularization in the
context of contemporary medical management appears to be
less than has been traditionally assumed. Intensive medical
therapy and coronary revascularization (including percuta-
neous coronary intervention and coronary artery bypass
grafting), when offered to individuals anticipated to undergo
lower extremity or AAA revascularization surgery, resulted
in equal postoperative rates of cardiovascular ischemic
events in a prospective investigation (1069). A comprehen-
sive discussion of this topic may be found in a previous
guidelines document sponsored by the ACC/AHA (484).
5.2.6.1.2. OPEN SURGICAL APPROACHES. Open aortic
aneurysm repair can be performed by a midline transabdom-
inal approach or an extraperitoneal incision in the left flank,
and Darling et al. have recommended that the flank approach
also be used to gain expeditious suprarenal aortic control for
ruptured infrarenal aneurysms (1070). There is no clear con-
sensus, however, regarding the superiority of either of these
incisions on the basis of prospectively randomized studies.
Sicard et al. found that the extraperitoneal approach was
associated with fewer postoperative complications, a shorter
length of stay, and lower hospital charges (1071). Other ran-
domized institutional trials (1072,1073) have failed to
demonstrate any material advantage to the routine use of the
extraperitoneal approach and have suggested that it may
result in a higher incidence of muscular atony, incisional her-
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NHDS suggests that the elective morality rate is significant-
ly higher among blacks (1076). Similarly, Dardik et al. found
that the elective mortality rate for blacks (6.7%) was higher
than the comparable figure for other races (3.2%, p equals
0.046) in the state of Maryland during the early 1990s
(1092).
Organ-Specific Risk Factors. Reports (1068,1076,1077)
have confirmed the conclusions of countless previous studies
that the mortality rate for elective aneurysm repair is closely
related to the presence of preoperative cardiac risk factors
and the severity of pre-existing renal impairment. In com-
parison, COPD is associated with increased morbidity, the
need for prolonged ventilatory support, and longer lengths of
stay in the hospital but has been shown not to be a predictor
of operative mortality (949).
Volume/Outcome Relationship. During the past 15 years, a
growing number of studies have demonstrated an inverse
relationship between the mortality rate for aortic aneurysm
repair and both the annual hospital volume and the experi-
ence of individual surgeons with these procedures.
only slightly less than 10% (1108,1109). These findings also
are supported by data from the NHDS (1075,1076) and the
Nationwide Inpatient Sample (1077). Nevertheless, the mor-
tality rate for elective operations is so much lower than for
ruptured aneurysms that octogenarians should not be dis-
missed as surgical candidates merely on the basis of their
age, provided their aneurysms are sufficiently large by con-
temporary standards to justify intervention (1108-1110).
Gender. Patient gender did not influence early mortality or
late survival rates in series of approximately 600 patients
from the Canadian Aneurysm Group (1102) or the Cleveland
Clinic (1060), but this experience is far from universal.
According to larger, population-based data sets in Michigan
(1086); Maryland (1092); and Ontario, Canada (1088), the
mortality rate for elective aneurysm repair may be as much
as 50% higher among women and appears to be higher than
in men for ruptured aneurysm repair (1076,1099,1100). 
Race. Patient race has not been found to be an independent
predictor of early mortality after elective aneurysm repair in
the VA system (1111), but another large database from the
Table 50. Operative Mortality Rates for Open Repair of Ruptured Abdominal Aortic Aneurysms
Year No. of Mortality 
First Author Reference (Study Period) Patients Rate (%)
Case series
Johansen (943) 1991 (1980-1989) 180 69
Panneton  (1097) 1995 (1980-1992) 112 49
Seiwert  (1098) 1995 (1986-1993) 119 45
Darling  (1070) 1996 (1988-1995) 104 28
Barry  (1099) 1998 (1982-1993) 258 43
Noel  (1100) 2001 (1980-1998) 413 37
Collective reviews
Taylor (938) 1987 5 Reports 42
Hollier  (939) 1992 (1985-1991) 1040 48
Ernst (1081) 1993 (1981-1992) 1731 49
Zarins (973) 1997 (1988-1996) 1618 42
Regional or multicentered studies
Hertzer (Northeastern Ohio) (1101) 1984 (1978-1981) 213 33
Johnston (Canadian Aneurysm Group) (1102) 1994 147 50
Katz (Michigan statewide) (1086) 1994 (1980-1990) 1829 50
Kazmers (Veterans Affairs) (1087) 1996 (1991-1993) 268 47
Wen (Ontario Aneurysm Study) (1088) 1996 (1988-1992) 1203 40
Kantonen (Finland Vascular Registry) (1089) 1997 454 46
Bradbury (Edinburgh Vascular Registry) (1090) 1998 (1976-1996) 673 37
Manheim (California statewide) (1091) 1998 (1982-1994) 7327 48
Axelrod (Veterans Affairs) (949) 2001 52 31
Kazmers (Veterans Affairs) (1095) 2001 (1991-1995) 427 46
U.S. hospital databases
Lawrence (National Hospital  (1075) 1999 (1994) 6623 68
Discharge Survey)
Heller (National Hospital (1076) 2000 (1979-1997) 67 751 46
Discharge Survey)
Dimick (National Inpatient Sample) (1078) 2002 13 887 47
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were collected from 1989 through 1998, were performed
with monofilament suture material, and included relatively
few aortofemoral grafts (5%). Only 0.4% of these patients
have required reoperations for graft complications.
5.2.6.2. Juxtarenal, Pararenal, and Suprarenal
Aortic Aneurysms
Aneurysms involving the upper abdominal aorta generally
are classified according to their relationship to the renal
arteries. Juxtarenal aneurysms arise distal to the renal arter-
ies but in very close proximity to them; pararenal aneurysms
involve the origin of 1 or both renal arteries; suprarenal
aneurysms encompass the visceral aortic segment containing
the superior mesenteric and celiac arteries, and specifically
are termed type IV thoracoabdominal aneurysms if they
extend upward to the crus of the diaphragm (1121). Open
repair of juxtarenal or pararenal aortic aneurysms may be
accomplished through a midline transabdominal incision
with or without medial visceral rotation of the spleen, the
pancreas, and sometimes the left kidney, depending on the
preference of the surgeon. These aneurysms also can be
repaired with a thoracoretroperitoneal approach, which
almost always is necessary for type IV thoracoabdominal
aneurysms. Irrespective of the incision that is used for their
exposure, the principal technical consideration that is com-
mon to most of these aneurysms is that they require a period
of aortic cross-clamping above the renal arteries.
5.2.6.2.1. EARLY MORTALITY AND COMPLICATION RATES
JUXTARENAL AORTIC ANEURYSMS. Juxtarenal aneurysms rep-
resent the only exception to the requirement for suprarenal
aortic cross-clamping, because some of these aneurysms are
associated with an adequate cuff of relatively normal aorta
for proximal control just below the renal arteries. This is not
always evident on preoperative imaging because of angula-
tion of the aorta or superimposition of the aneurysm over the
infrarenal cuff (1121). Even when suprarenal cross-clamping
is required, it is only for the period of time that is necessary
to construct the proximal anastomosis of the replacement
graft near the uninvolved renal arteries. This feature
undoubtedly accounts for the observation that operative mor-
tality and morbidity rates for juxtarenal aortic aneurysms are
higher than those for standard infrarenal aneurysms but
lower than those for aneurysms that extend above the renal
arteries. Taylor et al. encountered no postoperative deaths
after juxtarenal aneurysm repair, but 7% of their patients
experienced at least transient renal failure (1013). In a series
of 53 juxtarenal aneurysms and 376 infrarenal aneurysms,
Ayari et al. reported early mortality rates of 11% and 3% (p
less than 0.01) and morbidity rates of 51% and 26% (p less
than 0.01), respectively (1122). Faggioli et al. described a
series of 50 juxtarenal or pararenal aneurysms in which the
operative mortality rate of 12% was significantly worse (p
less than 0.02) than the comparable figure for all infrarenal
aneurysm procedures that were done at the same center
(1123).
Representative data showing these relationships for intact
and ruptured aneurysms are summarized in Table 51. Other
studies have reconfirmed these observations with respect to
hospital volume (1094,1111), surgeon experience (1089), or
both (1112). Manheim et al. (1091) and Dimick et al. (1078)
have estimated that the operative mortality rate for elective
aneurysm repair is reduced by approximately 50% in high-
volume hospitals in the United States, and Wen et al. (1088)
have calculated that there is a 6% reduction in the relative
odds for death with every 10 additional elective cases that are
added to the annual hospital volume in Ontario, Canada.
Pearce et al. (1093) discovered that a doubling of the annual
surgeon volume was associated with an 11% reduction in the
relative risk for death after aortic aneurysm repair in Florida,
and Dardik et al. (1092) have determined that hospital
charges are significantly lower in conjunction with the repair
of either intact or ruptured aortic aneurysms by high-volume
surgeons in Maryland.
5.2.6.1.4. LATE SURVIVAL RATES. Representative late survival
rates after open surgical repair of intact and ruptured AAAs
are summarized in Table 52. Five-year survival rates after
intact aneurysm repair generally have ranged from 60% to
75%, with 10-year survival rates of approximately 40% to
50%. Several other studies (1085,1095,1102,1114,1115)
have determined that the long-term mortality rate is substan-
tially higher after ruptured aneurysm repair even among
operative survivors, possibly because some of these patients
may have serious medical comorbidities that discouraged
earlier elective intervention for their aneurysms. Several risk
factors have been shown to be significant in more than 1 of
these studies, including advanced age, ischemic heart disease
manifested by congestive heart failure or electrocardiograph-
ic evidence of myocardial ischemia, an elevated serum crea-
tinine level, COPD, and cerebrovascular disease
(1057,1068,1085,1095,1102,1116). 
5.2.6.1.5. LATE GRAFT COMPLICATIONS. Late graft complica-
tions (e.g., aortic pseudoaneurysms, graft infections and/or
enteric fistulas, and graft limb occlusions) are exceedingly
unusual after open aortic aneurysm repair. Hallett et al.
(1120) reported graft-related complications in only 9.4% of a
population-based series of 307 patients who underwent open
aneurysm repair at the Mayo Clinic between 1957 and 1990,
which included anastomotic pseudoaneurysms in 3.0%, graft
thrombosis in 2.0%, enteric fistulas in 1.6%, and graft infec-
tions in 1.3%. In another long-term study that included a sub-
stantial number of aortofemoral grafts, Biancari et al. (959)
calculated survival rates free from graft complications of
94% at 5 years, 88% at 10 years, and 74% at 15 years. Only
2.9% of the patients in that series developed aortic pseudoa-
neurysms, and the higher rates of distal anastomotic
pseudoaneurysms (8.7%) and graft limb occlusions (5.3%)
that occurred in the series almost certainly were related to the
fact that the majority (55%) of the replacement grafts extend-
ed below the inguinal ligament. Hertzer et al. (1068) report-
ed a modern series of 1135 open aneurysm procedures that
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Table 51. Volume/Outcome Relationships for Open Aortic Abdominal Aneurysm Repair
Year No. of Overall Mortality
First Author Reference (Study Period) Patients Rate (%)
Intact aneurysms
Hertzer (Northeastern (1101) 1984 (1978-1981) 840 6.50
Ohio)
Amundsen (Norway) (1113) 1990 279 NA
Hannan (New York statewide) (1084) 1992 (1982-1987) 6042 7.60
Katz (Michigan statewide) (1086) 1994 (1980-1990) 8185 7.50
Kazmers (Veterans Affairs) (1087) 1996 (1991-1993) 3419 4.90
Dardik (Maryland statewide) (1092) 1999 (1990-1995) 2335 3.50
Ruptured aneurysms
Hertzer (Northeastern 
Ohio) (1101) 1984 (1978-1981) 213 33
Amundsen (Norway) (1113) 1990 165 NA
Katz (Michigan statewide) (1086) 1994 (1980-1990) 1829 50
Dardik (Maryland statewide) (1092) 1999 (1990-1995) 527 47
NA indicates not available; NS, not significant.
Annual Volume
Hospital Surgeon
NA Low: 4.7%; 
medium: 16%; 
high: 2.9% 
(p less than 0.001)
Low: 11%; NA
high: 4.8% 
(p equals 0.05)
Low: 12%; Low: 11%;
medium: 6.8%; medium: 7.3%;
high: 5.6% high: 5.6%
Low: 8.9%  NA
High: 6.2% 
(p less than 0.001)
Low: 6.7%; NA
high: 4.2%
(p less than 0.05)
Low: 4.3%; Very low: 9.9%; 
medium: 4.2%; low: 4.9%; 
high: 2.5% medium: 2.8%; 
(p equals 0.08) high: 2.9%
NA Low: 32%; 
medium: 39%; 
high: 27% 
(p equals NS)
Low: 73%; NA
high: 52% 
(p equals 0.03)
Low: 54%; NA
high: 46% 
(p equals 0.0026)
Low: 46%; Low: 51%;
medium: 49%; medium: 47%;
high: 47% high: 36%
(p equals NS) (p equals 0.05)
Table 52. Late Survival Rates After Open Aortic Abdominal Aneurysm Repair
No. of 
First Author Reference Year Patients
Intact aneurysms
Case series
Crawford (1061) 1981 816
Hertzer (955) 1987 236
Hallett (1056) 1993 130
Stonebridge (1117) 1993 311
Soisalon-Soininen (1114) 1995 706
Cho (1115) 1998 116
Aune (1058) 2001 Younger than age 
66 y: 118
66 y or older: 333
Total: 451
Biancari (959) 2002 208
Hertzer (1068) 2002 1135
Menard (1080) 2003 Low risk: 444
High risk: 128
Total: 572
Collective reviews or 
multicenter studies
Ernst (collective review) (1081) 1993 3226
Johnston (Canadian Aneurysm Group) (1085) 1994 680
Feinglass (Veterans Affairs (1116) 1995 280
1995 280
Koskus (French AURC) (1057) 1997 794
Norman (collective review) (1118) 2001 32 Reports
Ruptured aneurysms
Case series
Stonebridge (1117) 1993 227
Soisalon-Soininen (1114) 1995 Operative survivors: 364
Cho (1115) 1998 Operative survivors: 116
Evans (1119) 1999 Operative survivors: 115
Collective reviews or multicenter studies
Johnston (Canadian aneurysm study) (1102) 1994 147
AURC indicates Association for Academic Research in Vascular Surgery.
Survival Rates
1 Year 3 Years 5 Years 10 Years Other
63% 38% 15 y: 18%
72%
61%
8 y: 45%
67%
97% 74% 43%
8 y: 69%
8 y: 47%
15 y: 18%
67% 39%
94% 75% 49%
68%
74%
46%
92% 67% 40%
91% 81% 68% 6 y: 60%
89% 64%
89% 64%
94% 84% 67%
70%
8 y: 40%
60%
86% 64% 33%
88% 59% 26%
6 y: 22%
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sheath placement in most patients, and extraperitoneal inci-
sions occasionally are necessary to construct temporary
access conduits to 1 or both iliac arteries if the external iliac
arteries are too small or tortuous for transfemoral cannula-
tion. Endovascular AAA repair can avoid a major transab-
dominal procedure, can be performed under regional or even
local anesthesia, and clearly represents a major advance in
the management of patients with AAA who have severe car-
diopulmonary disease or other risk factors, such as advanced
age, morbid obesity, or a hostile abdomen from multiple pre-
vious operations. Once its feasibility had been demonstrated
in such patients, however, endovascular repair also has been
offered at many centers to low- or average-risk patients who
have no particular contraindications to conventional surgical
treatment. This has resulted in a distinct shift in the paradigm
for management of infrarenal aortic aneurysms in some geo-
graphic areas during a relatively short period of time.
According to statewide data from New York, for example,
53% of patients who underwent AAA repair received endo-
grafts in 2002 compared with 40% in 2001 (1135).
Driven by necessity and a competitive medical market-
place, the design of aortic stent grafts has passed through
several iterations. Most contemporary stent grafts are sup-
ported by a metallic skeleton that is secured to the fabric of
the graft during the manufacturing process to maintain linear
stability once the device has been implanted and to avoid
kinking that can result in graft limb occlusion with unsup-
ported grafts. To better accommodate the aortoiliac anatomy
and facilitate graft deployment, the majority of modern endo-
grafts also are modular in construction. Thus, the aortic stem
and a contiguous iliac limb are inserted through 1 femoral
artery, with the opposite iliac limb then being positioned by
a separate delivery system through the contralateral femoral
artery. The absence of an adequate length of relatively nor-
mal aorta below the renal arteries historically has excluded
patients from consideration for endovascular repair because
of the high risk for proximal attachment failure, graft migra-
tion, and endoleak. 
In an attempt to overcome the risk of distal migration and
proximal attachment failure, a growing number of new
devices now incorporate barbed hooks that are sufficiently
long to secure the metallic frame of the stent graft to the vis-
ceral segment of the aorta above the renal arteries. Better
graft stability with a transrenal attachment will likely
improve results but does not necessarily mean that patients
with aneurysms with shorter necks can be treated, because
the proximal seal of the endovascular graft continues to be
infrarenal in all currently approved devices. In aggregate,
modular externally supported bifurcation endografts are
more widely applicable, less prone to migrate from their sites
of attachment, and more likely to remain patent than was the
case with the first generation of unsupported endografts only
a few years ago. Some aspects of endovascular aneurysm
repair remain problematic, however, and will require further
refinements in the future. In addition to the vexing problem
of metal fatigue (1136,1137), these include anatomic limita-
Pararenal/Suprarenal and Type IV Thoracoabdominal
Aortic Aneurysms. Selected but representative data regarding
the operative mortality and complication rates for all upper
AAAs involving the renal arteries are presented in Table 53.
In aggregate, the mortality for elective repair of type IV tho-
racoabdominal aneurysms is approximately twice as high as
that for pararenal or “low” suprarenal aneurysms. All of
these aneurysms share the requirement for suprarenal aortic
cross-clamping and usually for additional reconstruction of
the left renal artery, either by reimplantation or with the use
of an independent renal artery graft that originates from the
aortic prosthesis. Accordingly, a period of renal ischemia is
unavoidable unless continuous kidney perfusion is used, and
for this reason, postoperative renal insufficiency is the most
common organ-specific complication that is generic to the
repair of any aortic aneurysm arising at or above the level of
the renal arteries. A transient elevation in the serum creati-
nine can be expected in 20% to 30% of these patients, with
temporary hemodialysis support being necessary in 3% to
15%. Fortunately, however, permanent renal failure general-
ly has been reported in fewer than 5% of patients. The risk of
spinal cord ischemia with paraplegia is less than 5% for type
IV thoracoabdominal aneurysms but otherwise is distinctly
uncommon. 
The operative mortality rate for aneurysms that involve the
upper abdominal aorta has been shown to be related to
patient age and the presence of coronary artery disease
(1123), as well as to whether the aneurysm extends to the
level of the diaphragm and/or requires urgent rather than
elective surgical treatment (1133). The risk for postoperative
renal insufficiency can be correlated with the severity of
intrinsic renal artery disease and the extent of revasculariza-
tion that is necessary to correct it, particularly when both
renal arteries require additional reconstruction (1124,1125).
5.2.6.2.2. LATE SURVIVAL RATES. According to the data that
are available, the late survival rate after repair of juxtarenal,
pararenal, or suprarenal aortic aneurysms may be slightly
lower than after operations for infrarenal aortic aneurysms.
Schwartz et al. (1131) and Martin et al. (1133) have reported
5-year survival rates of 50%, whereas the 5-year survival rate
was only 40% in the series described by Faggioli et al.
(1123).
5.2.7. Endovascular Aortic Aneurysm Repair
5.2.7.1. Introduction
The technique of transfemoral catheter-based repair of
infrarenal AAAs was first reported by Parodi et al., original-
ly as an alternative for the management of patients whose
medical comorbidities made them poor candidates for con-
ventional surgical treatment (1134). A variety of proprietary
stent grafts and delivery systems now have been used for
more than a decade throughout the world, 4 of which
presently have market approval by the FDA and remain com-
mercially available in the United States. Open exposure of
the common femoral arteries conventionally is used for
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Table 53. Operative Mortality and Postoperative Complication Rates for Open Repair of Pararenal, Suprarenal, and Type IV Thoracoabdominal Aortic Aneurysms
Year No. of Mortality Rate 
First Author Reference (Study Period) Patients (%)
Pararenal or suprarenal
Qvarfordt (1124) 1986 77 1.3
Nypaver  (1125) 1993 (1985-1992) 53 3.8
Faggioli  (1123) 1998 50 12
Jean-Claude  (1126) 1999 (1977-1997) 257 5.8
Anagnostopoulos  (1127) 2001 (1986-1999) 65 0
Type IV thoracoabdominal
Crawford  (1121) 1986 (1960-1985) 145 4.8
Cox  (1128) 1992 (1966-1991) 42 Total: 31
Elective: 12
Urgent: 55
Svensson  (1129) 1993 (1960-1991) 346 5.8
Coselli  (1130) 1995 (1984-1993) 35 14 (reoperations)
Schwartz  (1131) 1996 (1977-1994) 58 5.3
Dunning  (1132) 1999 (1995-1998) 26 12
Martin  (1133) 2000 (1989-1998) 165 Total: 11
Elective: 7.2
Urgent: 22
NA indicates not available.
Postoperative Complication Rates (%)
Renal Paraplegia Other
Transient: 23 NA 5
Dialysis: 2.5
Transient: 23 NA NA
Dialysis: 5.7
NA NA NA
Transient: 30 0.4 31
Sustained: 9.3
Dialysis: 7.0
Total: 42 0 NA
Dialysis: 9.2
Permanent: 1.5
Dialysis: 5.5 2.1 NA
NA Total: 11 NA
Elective: 4.3
Urgent: 20
Total: 22 4.3 NA
None permanent 2.9 NA
Transient: 31 1.8 42
Sustained: 28
Dialysis: 8.8
Permanent: 1.9
Dialysis: 3.8 3.8 42
Transient: 19 3.6 56
Dialysis: 14
Permanent: 3.0 
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aneurysm expansion, therapeutic embolization of feeding
branches through a translumbar approach to the aneurysm
sac has been successful. Type III endoleaks are caused by
midgraft defects from fabric tears or the junctional disruption
of modular graft components, especially if these components
become buckled as the excluded aneurysm sac shrinks and
foreshortens. Type III endoleaks are considered to have the
same potential for delayed aneurysm rupture as type I
endoleaks and therefore should be repaired promptly at the
time of their discovery. Type IV endoleaks are the result of
high graft porosity and diffuse leakage through its interstices,
usually occur within 30 days of implantation, and are rare
compared with the frequency of other endoleaks. Finally, the
term “endotension” has been applied to those circumstances
in which the excluded sac continues to enlarge and appears
to remain pressurized despite the absence of any visible
endoleaks on contrast-enhanced computed tomographic
scans. 
In summary, it is largely because of the uncertainties relat-
ed to intrasac endoleaks that clinical investigators and the
FDA consider follow-up imaging to be mandatory every 6 to
12 months for any patient whose aortic aneurysm is treated
with an endovascular stent graft (1144,1149). If persistent
endoleaks or continued aneurysm expansion is demonstrat-
ed, further studies are necessary to determine the cause.
Perhaps the most active area of current interest in this regard
is related to the management of type II endoleaks, largely
because of the frequency with which they occur and both the
inconvenience and expense of their treatment. According to
European collaborators registry on stent-graft techniques for
abdominal aortic aneurysm repair (EUROSTAR) data for
follow-up intervals as long as 6 years, the presence of type II
endoleaks has not been associated with a significant inci-
dence of any adverse clinical events other than the secondary
interventions that are performed at the discretion of the
attending physicians (1150). Similar findings have led
Steinmetz et al. to conclude that selective intervention should
be considered only for type II endoleaks that have persisted
for at least 6 months on serial noninvasive imaging (1151).
5.2.7.1.3. GRAFT OCCLUSION. Occlusion of the iliac limbs of
bifurcation endografts was not uncommon with early
devices, occurring in 10% of some series (1152). After find-
ing that further intraluminal stenting was necessary to elimi-
nate torsion or kinking in 36% of all unsupported grafts,
Amesur et al. adopted the use of routine intraoperative
intravascular ultrasonography to identify these potential
problems and to correct them before thrombosis occurred
(1153). Graft occlusion may become a less frequent compli-
cation in the future, because the stability of a metallic skele-
ton tends to prevent the kinds of graft distortion that can lead
to subsequent thrombosis. Although Baum et al. encountered
limb kinking in a total of 12% of grafts in their series, they
were able to document this finding in only 5% of externally
supported grafts compared with 44% of unsupported grafts
(1154). In a multicenter study of 242 unsupported bifurcation
endografts that were implanted from 1995 through 1998,
tions, intrasac endoleaks, graft occlusion, and aortic neck
expansion.
5.2.7.1.1. ANATOMIC LIMITATIONS. Even with suprarenal fixa-
tion of its metallic exoskeleton, the fabric component of an
endograft obviously cannot be permitted to overlap the ori-
gins of the renal arteries. Accordingly, at least 1 cm of prox-
imal aortic cuff (1.5 cm for commercially available grafts)
presently is optimal for elective endograft repair below the
renal arteries. For devices without a suprarenal fixation
device, the optimum infrarenal aortic diameter at the time of
this writing is 25 mm or less, and for devices with a
suprarenal fixation component, it is 28 mm or less. Because
of the inflexibility of externally supported grafts, this seg-
ment of the aorta must not be severely angulated. This
requirement may impose a gender bias in patient selection,
because in addition to the fact that their small external iliac
arteries often present problems with respect to vascular
access, women also appear to have a higher prevalence of
short, angulated aneurysm necks than men (1138,1139).
Considering all of these criteria, Carpenter et al. reported that
a disproportionate number of women were excluded from
endograft repair because of anatomic limitations (60% of
women vs. 30% of men; p equals 0.0009) (1140). Becker et
al. (1141) also found that significantly fewer women quali-
fied for endovascular aneurysm repair (26% of women vs.
41% of men), and Mathison et al. (1142) were forced to
abandon more attempted endograft procedures in women
(17%) than in men (2.1%; p less than 0.01). Wolf et al.
described comparable eligibility rates for endograft repair in
women (49%) and in men (57%), but the women in that
series had a higher incidence of intraoperative complications
than men (31% vs. 13%, p less than 0.05) and required more
adjunctive arterial reconstructions (42% vs. 21%, p less than
0.05) to correct those complications (1143).
5.2.7.1.2. INTRASAC ENDOLEAKS. Endoleaks represent
sources of continued blood flow into the excluded aneurysm
sac and are of such importance that they justified a consen-
sus conference of experts in endovascular aneurysm repair in
2000 (1144). Type I endoleaks are caused by incompetent
proximal or distal attachment sites, produce high intrasac
pressure that can lead to rupture, and should be repaired with
intraluminal extender cuffs or conversion to an open proce-
dure as soon as they are discovered. Type II endoleaks are the
result of retrograde flow from branch vessels (e.g., lumbar
arteries and the inferior mesenteric artery), occur in as many
as 40% of patients at some point in time after endograft
implantation, and often may be corrected by selective arteri-
al catheterization and therapeutic embolization. More than
half of all type II endoleaks will seal spontaneously, howev-
er, and although isolated examples of aneurysm rupture on
the basis of persistent type II endoleaks have been reported
(1145,1146), they do not yet appear to influence the risk for
rupture during 18 to 36 months of surveillance in large series
of patients (1147,1148). If an intervention is necessary for
the few type II endoleaks that persist or are associated with
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higher intraoperative cardiac index (p less than 0.01) and a
lower intraoperative stroke work index (p equals 0.04) than
open procedures (1162). Although the number of adverse
cardiac events was comparable, postoperative electrocardio-
grams and transesophageal echocardiograms revealed signif-
icantly more evidence of myocardial ischemia after open
operations (57% vs. 33% after endograft repair; p equals
0.01). On the basis of admittedly incomplete data, elective
endovascular aortic aneurysm repair in unselected patients
probably should be considered as an “intermediate or low
surgical risk procedure” according to the previous
ACC/AHA guideline update for perioperative cardiovascular
evaluation for noncardiac surgery (484). 
5.2.7.3. Early Mortality and Complication Rates
Table 54 contains representative data regarding the proce-
dural mortality rate for endovascular aneurysm repair, the
incidence of early endoleaks, and the risk for immediate con-
version to an open operation. This information has been col-
lected from case series, from FDA- and industry-sponsored
device trials in the United States, and from EUROSTAR, a
cooperative archive for endograft data that are submitted vol-
untarily by nearly 60 participating centers. The study periods
for the references that are cited in Table 54 help to identify
the generation of devices that were under investigation, and
they also provide points of reference during an era in which
rapid advances in technology tend to make the preceding
iteration of stent grafts and delivery systems obsolete as soon
as new devices are introduced. With the exception of the spe-
cific device trials, most of these reports describe results with
a wide variety of proprietary endografts, each of which
appears to be associated with a declining complication rate
after sufficient experience has been accumulated with its use
at individual centers (1141,1163-1166). Data regarding vol-
ume/outcome relationships are not yet available for endovas-
cular aneurysm repair. 
The early mortality rate for endograft repair generally has
been less than 3%, but May et al. (1165) have shown this to
be substantially lower than the mortality rate for a concurrent
series of open procedures. The comparative safety of endo-
graft repair is difficult to assess, however, because it often is
difficult to determine from published reports whether aortic
stent grafts were offered only to high-risk surgical patients or
to a mix of high-, average-, and low-risk patients. Using a
scoring system for preoperative risks that ranged from zero
(low) to 3 (high) in a large series of 305 patients, Becker et
al. (1141) calculated the mortality rates for endovascular
repair to be 2.5%, 0.8%, 3.4%, and 6.5%, respectively.
Several EUROSTAR studies have demonstrated that both
early mortality rates and nonfatal complication rates were
significantly higher among patients who were deemed to be
unfit for open repair or general anesthesia (1163,1166,1192),
as well as among those who needed adjunctive procedures in
addition to the placement of an aortic stent graft (1163).
Walker et al. also found significant differences between mor-
tality rates for endovascular repair in high- and low-risk
Fairman et al. reported an overall primary patency rate of
62% at a mean follow-up interval of 31 months (1155). The
primary-assisted and secondary patency rates for this series
were 94% and 97%, however, because of successful intraop-
erative (28%) or postoperative (12%) graft limb interven-
tions that were necessary in 40% of the 242 patients. 
5.2.7.1.4. AORTIC NECK EXPANSION. Endograft migration
from the proximal attachment site has been reported in a
wide range of 1.5% to 16% of patients (1024,1156,1157).
One of the factors that could lead to graft migration or
delayed type I endoleaks is further expansion of the proximal
aorta, a finding that Makaroun et al. have documented by
serial imaging studies in 13% of patients at 1 year after
endovascular aneurysm repair, in 21% at 2 years, and in 19%
at 3 years (1158). According to Matsumura et al., the mean
increase in aortic neck diameter after endografting is 0.7 plus
or minus 2.1 mm at 1 year and 0.9 plus or minus 1.9 mm at
2 years (1159). Even when device diameters are purposeful-
ly oversized by as much as 20% in an attempt to accommo-
date future aortic neck expansion, Conners et al. have found
that endograft migration still can occur (1157). The implica-
tions of these observations are a source of some concern, but
the maximum follow-up period of approximately 3 years for
most reported endograft series is too short for their influence
on late clinical outcomes to be known.
5.2.7.2. Preoperative Cardiac Evaluation
The preoperative cardiac evaluation before endovascular
aneurysm repair may be dictated by patient selection,
because severe cardiac disease already will have been docu-
mented in many patients who are treated at centers where
endografting is restricted to high-risk cases. Perhaps for this
reason, relatively little published information is available on
this topic. In an unselected series of 83 endovascular and 63
open repairs in patients who had an identical number of
Eagle Criteria risk factors, de Virgilio et al. found no differ-
ences in the incidence of postoperative cardiac events (6%
and 4.8%, respectively) or mortality rates (3.6% and 4.8%,
respectively) (1160). Among patients who received endo-
grafts, the only predictors of cardiac events were a history of
congestive heart failure (p equals 0.005) or the presence of a
Q wave on the preoperative electrocardiogram. More recent-
ly, Aziz et al. have reported that perioperative cardiac events
were associated with certain Eagle risk factors, such as age
70 years or older (p equals 0.026) and a history of either MI
(p equals 0.024) or congestive heart failure (p equals 0.001),
after aortic endografting in 365 patients (1161). Moreover,
the lack of preoperative beta-blockade was associated with a
higher risk for perioperative events in this nonrandomized
series (p equals 0.007). 
At least one study appears to confirm the intuitive impres-
sion that endografting should have less cardiac risk than a
major transabdominal operation. In a concurrent series of 71
open and 49 endovascular aneurysm repairs, Cuypers et al.
found that endovascular procedures were associated with a
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Table 54. Representative Early Results for Endovascular Repair of Infrarenal Aortic Abdominal Aneurysms
Immediate 
First Author Year No. of Open 
(Study/Sponsor) Reference (Study Period) Patients Conversion (%)
Case series
Blum (1167) 1997 (1994-1996) 295 1.7
Stelter (1152) 1997 (1994-1997) 201 2
May (1168) 1998 (1992-1996) Endo: 108 12
Open: 195
Amesur (1169) 1999 (1996-1998) 54 NA
Becquemin (1170) 2000 (1995-1999) Endo: 73 None
Open: 195
Chuter (1164) 2000 (1996-1999) High risk: 116 None
Zarins (1171) 2000 (1996-2000) 149 1.30
Blum (1172) 2001 (1994-2001) 1994-1996: 111 3.6
1996-1997: 159 0.6
1998-2001: 28 None
Becker (1141) 2001 (1994-2001) 305 1.30
Fairman (1173) 2001 (1998-1999) 75 None
Holzenbein (1174) 2001 173 1.2
Howell (1175) 2001 215 None
Mathison (1142) 2001 (1994-2000) 305 1.3
May (1165) 2001 (1995-1998) Endo: 148 0.7
Open: 135
Sicard (1176) 2001 (1997-2000) Endo: 260 0.8
Open: 210
Abraham (1146) 2002 (1998-2001) 116 None
Dattilo (1177) 2002 (1994-2000) 362 1.40
Sampram (1178) 2003 (1996-2002) 703 NA
Ouriel (1179) 2003 (1996-2002) 606 Men NA
98 Women NA
Shames (1180) 2003 (1999-2001) 302 Men 0.5
42 Women 14
Anderson (New (1135) 2004 Endo: 1706 NA
York State) (2000-2002) Open: 3063
Continued on Next Page
Postoperative Complication Rates (%)
Procedural 
Mortality Rate 
Total Persistent (%)
8.1 NA 0.7
9 NA 3.5
14 11 5.6
5.6
39 13 NA
23 9.6 2.7
2.8
NA 10 1.7
36 18 1.3
14 NA Total: 8.1
3.1 NA
11 NA
23 17 2.6
44 20 0
4.6 (Type I) NA 2.8
42 11 0
23 NA 2.6
6.8 5.4 2.7
5.9
13 3 1.9
2.9
15 11 0.9
NA NA 1.5
NA NA 1.7
NA NA 1.3
NA NA 3.1
NA NA 1.5
NA NA 2.3
NA NA 1.1
4.0
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Table 54. Continued
Immediate 
First Author Year No. of Open 
(Study/Sponsor) Reference (Study Period) Patients Conversion (%)
Device trials
Moore (Endovascular (1181) 1996 (1993-1994) 46 15
Technologies)
Coppi (Stentor, (1182) 1998 (1995-1996) 66 6.10
Mintec)
Matsumura (1159) 1998 (1993-1995) 68 13
(Endovascular 
Technologies)
Becquemin (Vanguard, (1183) 1999 (1996-1997) 75 None
Boston Scientific)
Zarins (AneuRx, (1184) 1999 (1996-1997) Endo: 190 None
Medtronic) Open: 60
Zarins (AneuRx, (1185) 2000 (1997-1998) 425 1.20
Medtronic)
Beebe (Vanguard, (1186) 2001 (1997-1998) Endo: 268 1.90
Boston   Scientific) Open: 98
Greenberg (Zenith, (1156) 2001 (1995-2000) 528 0.80
Cook)
Faries (Talent, (1187) 2002 (1999-2001) 368 1.10
Medtronic/AVE-
Worldmedical)
Matsumura (Excluder; (1188) 2003 (2000-2002) Endo: 235 None
WL Gore & Open: 99
Associates
EUROSTAR
Buth (1163) 2000 (1994-1999) 1554 1.70
Harris (1189) 2000 (1996-2000) 2464 1.30
Vallabhaneni (1190) 2001 (1994-2000) 2812 NA
Buth (1166) 2002 (1996-2001) 3075 1.70
Peppelenbosch (1191) 2004 (1996-2002) 1962 (4.0 cm to 5.4 cm) 1.1
1528 (5.5 cm to 6.4 cm) 1.4
902 (over 6.4 cm) 2.3
EUROSTAR indicates European collaborators registry on stent-graft techniques for abdominal aortic aneurysm repair; NA, not available.
Postoperative Complication Rates (%)
Procedural 
Mortality Rate 
Total Persistent (%)
44 21 0
6.1 3 1.5
47 24 0
31 9.3 0
21 8.9 2.6
0
Centers: 38; 13 1.4
core lab: 50
5.70 2.7 1.5
3.1
16 5.5 0.2
12 4.8 1.9
22 17 0.9
0
16 0.9 2.6
17 8.3 3.2
NA NA 2.9
17 NA 2.5
3.7 (Type I) NA 1.6
6.8 (Type I) NA 2.6
9.9 (Type I) NA 4.1
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patients (16% vs. 3.7%, p equals 0.02) (1193). Consequently,
the perceived margin of safety for endovascular aneurysm
repair in truly high-risk candidates may be slightly overesti-
mated by results from nonuniform patient populations.
Irrespective of case mix, however, the comparatively low
early mortality rate for endograft repair of aortic aneurysms
in New York State deserves close attention. According to
data reported by Anderson et al., the mortality rate for endo-
graft procedures was significantly lower than for open pro-
cedures in New York during both 2001 (1.1% vs. 3.6%, p
equals 0.0018) and 2002 (0.8% vs. 4.2%, p less than 0.0001)
(1135).
Immediate conversion to an open operation presently is
necessary in only 1% of patients, and approximately half of
all early endoleaks appear to resolve spontaneously within a
period of 30 days. Several reports have indicated that
endovascular procedures have fewer early complications
than open operations, require less intensive care, and are
associated with correspondingly shorter lengths of stay in the
hospital (1194-1196). Nevertheless, these and other studies
(1197-1199) also have suggested that the total costs of
endovascular repair probably exceed those for open repair,
especially when the expense of subsequent follow-up imag-
ing, further intervention, and secondary hospital admissions
is added to the base cost ($6000 to $12 000 US) of most
endografts. Despite its shorter length of stay and an earlier
return to normal activity, aortic endografting does not appear
to be associated with superior late functional outcome or
longer quality-adjusted life expectancy than open surgical
treatment (1200,1201).
5.2.7.4. Late Survival and Complication Rates
Representative data regarding late survival rate and the inci-
dence of aneurysm rupture, delayed or persistent endoleaks,
and endograft reinterventions are provided in Table 55. The
follow-up interval is 3 years or less for much of the informa-
tion in Table 55, and the methods that were used to calculate
outcomes (i.e., crude vs. cumulative) are inconsistent. In
addition, according to a 1999 report (1202), only 45% of the
expected 18-month follow-up results for the first 899 aortic
endografts in the EUROSTAR experience had been submit-
ted to its central registry office. The current acquisition rate
for this database is not known. 
5.2.7.4.1. SURVIVAL RATES. Intermediate-term survival rates
after endovascular aortic aneurysm repair primarily are influ-
enced by antecedent risk factors, being lowest in series for
which high surgical risk was a criterion for patient selection
(1164,1170). Again using their scoring system (0 to 3) for
stratifying incremental risk, Becker et al. (1141) calculated
actuarial 1-year survival rates of 98%, 94%, 87%, and 81%,
respectively. On the basis of EUROSTAR data, Buth et al.
found that the cumulative 3-year survival rate was signifi-
cantly lower for patients who had been deemed unfit for open
repair or for general anesthesia than for the remainder of the
registry population (68% vs. 83%, p equals 0.0001) (1166). 
5.2.7.4.2. ENDOGRAFT-RELATED COMPLICATIONS. Secondary
interventions are common after endovascular aortic
aneurysm repair and often are performed within months for
limb ischemia, within 1 year for endoleaks, and after 2 years
or more for graft migration (1207). Aneurysm rupture is a
rare event in most series, possibly because of the recognized
importance of serial computed tomography scanning to
detect continued aneurysm expansion. Delayed rupture has
occurred at a rate of 1% per year in the EUROSTAR popula-
tion; has been significantly associated with the presence of
type I or type III endoleaks, graft migration, or postoperative
endograft kinking; and has a postoperative mortality rate of
58% (1189,1190). Persistent and/or delayed endoleaks occur
in a wide range of approximately 5% to more than 20% of
patients and are the indication for most reinterventions after
endografting. Becker et al. documented endoleaks in 23% of
their series (1141). Nearly half (43%) of these required inter-
vention, whereas the remainder either resolved spontaneous-
ly (24%) or remain untreated (31%). Holzenbein et al. also
reported reinterventions in 22% of their series, of which 46%
were performed within 1 year of the index procedure and
74% within 2 years (1174). Ninety percent of these reinter-
ventions were necessary to control endoleaks, whereas the
remaining 10% were done to restore endograft patency.
Some sources in the United States have found that graft-
related complications appear to occur with greater frequency
after specific devices that previously were used only in the
setting of clinical trials receive market approval by the FDA.
The proposed explanation for this finding is that the stringent
anatomic criteria that were necessary for inclusion in the
clinical trials, especially those concerning the allowable
length, diameter, and angulation of the proximal infrarenal
neck, may be interpreted more liberally once these devices
become commercially available (1208,1209). 
Zarins et al. have described further aneurysm enlargement
after endograft repair in 46 (12%) of the 383 patients who
entered the phase II AneuRx clinical trial from 1997 through
1998 (1210). Not surprisingly, patients with aneurysm
enlargement were more likely to undergo secondary inter-
ventions (21 [46%] of 46 patients) than those with either no
change (33 [17%] of 199 patients) or a reduction in posten-
dograft aneurysm size (16 [12%] of 138 patients; p equals
0.0001). Open surgical conversion was performed in a total
of 18 (4.7%) of the 383 patients, including 9 (20%) of the 46
patients who had experienced aneurysm enlargement after
their original endograft procedures (p less than 0.0001). The
postoperative mortality rate after open conversion was 33%
in these 9 patients. According to EUROSTAR data, the annu-
al incidence of late endograft conversion to an open opera-
tion is 2.1%, with a postoperative mortality rate of 24%
(1189,1190). Overall, the crude rate of device-related com-
plications submitted to the EUROSTAR registry declined
from 22% in 1994 to 7.3% in 2000. Nevertheless, patients
who had these complications were nearly 14 times more like-
ly to require conversion procedures and were 2.4 times more
likely to die than patients who did not have device-related
complications (1211).
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Table 55. Representative Late Results for Endograft Repair of Infrarenal Abdominal Aortic Aneurysms
First Author Year No. of Aneurysm Late 
(Study/Sponsor) Reference (Study Period) Patients Rupture Endoleaks
Case series
Stelter (1152) 1997 (1994-1997) 201 None 9.50%
May (1168) 1998 (1992-1996) Endo: 108 None 6.30%
open: 195
Amesur (1169) 1999 (1996-1998) 54 None 13%
Amesur (1153) 2000 (1996-1999) 130 Limbs NA NA
Becquemin (1170) 2000 (1995-1999) Endo: 73; open: 107 4.1% NA
Baum (1154) 2000 Unsupported: 27 limbs; NA NA
supported: 122 limbs
Chuter (1164) 2000 (1996-1999) High risk: 116 0.9% 7.8%
Zarins (1147) 2000 (1996-2000) 149 None
Becker (1141) 2001 (1994-2001) 305 0.7% NA
Holzenbein (1174) 2001 173 0.6% NA
Howell (1175) 2001 215 None 12%
May (1165) 2001 (1995-1998) Endo: 148; open: 135 1.4% 5.4%
Ohki (1203) 2001 (1992-2000) 239 0.8% 8.8%
Sicard (1176) 2001 (1997-2000) Endo: 260; open: 210 None 4.2%
Abraham (1146) 2002 (1998-2001) 116 0.9% 4.3%
Datillo (1177) 2002 (1994-2000) 362 0.8% NA
Sampram (1178) 2003 (1996-2002) 703 0.4% 23%
Ouriel (1204) 2003 (1996-2002) 416 (Size less 0.2% 1.4% (Type I)
than 5.5 cm)
284 (Size 5.5 0.7% 6.4%(Type I)
cm or more)
Ouriel (1179) 2003 (1996-2002) 606 Men; Men: 0.3%; Men: 30%; 
98 women women: 1.0% women: 35% (12 mo)
Shames (1180) 2003 (1999-2001) 203 Men; None Men: 11%; 
42 women women: 21%
Continued on Next Page
Endograft Reinterventions
Endo Open Survival Rate
11% 10% NA
Total 7.4% 
(median, 29 mo) NA
17% None NA
36% of limbs None NA
Total 21% Endo: 82%; 
cumulative (1 y) open: 96% (1 y)
Unsupported: 44%; NA NA
supported: 5% 
(p less than .001)
15% 2.6% 82% (Mean, 
16 mo)
Total 17% 90%
(median, 11 mo)
Total 9.8% 70% (5 y)
Total 22% 
(median, 18 mo) NA
Total 10% 
(maximum, 2 y) 94%
4.7% 2.7% Endo: 96%;
open: 85% (3 y)
5.9% 3.8% 78% (Mean, 16 mo)
2.7% 1.2% Endo: 91%; 
open: 86% (3 y)
2.6% 2.6% NA (mean, 10 mo)
11% 2.2% Late conversion NA
15% (Total) 70% (3 y)
NA 1.4% Conversion 86% (24 mo)
NA 8.2% Conversion 71% (24 mo)
Men: 24%; Men: 80%; 
women: 21% (total) women 78% (24 mo)
Men: 9%; Men: 95%; 
women: 29% women: 90% 
(total) (mean, 11 mo)
Table 55. Continued
First Author Year No. of Aneurysm Late 
(Study/Sponsor) Reference (Study Period) Patients Rupture Endoleaks
Device trials
Becquemin (1183) 1999 (1996-1997) 75 1.3% 6.70%
(Vanguard; 
Boston
Scientific)
Zarins (AneuRx; (1184) 1999 (1996-1997) Endo: 190; open: 60 None 9.00%
Medtronic)
Zarins (AneuRx; (1185) 2000 (1996-1999) 1046 0.7% (mean, 16 mo) NA
Medtronic)
Zarins (AneuRx; (1171) 2000 (1997-1998) 398 0.3% 13% (Centers)
Medtronic) 20% (core lab)
Beebe (Vanguard; (1186) 2001 (1997-1998) Endo: 268; open: 98 None 16% Cumulative
Boston Scientific) (24 mo)
Zarins (AneuRx; (1148) 2001 (1996-1999) 1192 0.8% NA
Medtronic)
Faries (Talent; (1187) 2002 (1999-2001) 368 0.5% 4.8% (12 mo)
Medtronic/AVE-
Worldmedical)
Matsumura   (1188) 2003 (2000-2002) Endo: 235; open: 99 None 20% (24 mo)
(Excluder; 
WL Gore)
Zarins (AneuRx; (1137) 2003 (1996-1999) 1193 1.3% 14%
Medtronic)
EUROSTAR 
Cuypers (endoleak (1202) 1999 (1994-1998) 899 NA 26% total
study) 10% persistent
Cuypers (conversion (1205) 2000 (1994-1999) 1871 NA NA
study)
Harris (1189) 2000 (1996-2000) 2464 1% annual 15%
Laheij (1206) 2000 (1996-1999) 1023 NA NA
Vallabhaneni (1190) 2001 (1994-2000) 2464 0.01% annual NA
Buth (1166) 2002 (1996-2001) 3075 0.7% NA
Harris (1150) 2004 (1996-2003) 4242 1.4% 30% total
10% persistent
Peppelenbosch (1191) 2004 (1996-2002) 1962 (4.0 to 5.4 cm); 0.4% 5.3% (Type I)
1528 (5.5 to 6.4 cm); 0.6% 4.9% (Type I)
902 (over 6.4 cm) 1.8% 10% (Type I)
Endo indicates endovascular repair; EUROSTAR indicates European collaborators registry on stent-graft techniques for abdominal aortic aneurysm repair; NA, not available 
Endograft Reinterventions 
Endo Open Survival Rate
24% 4% 86% (25 mo)
5.9% None Endo: 96%; 
open: 97% (1 y) 
NA NA NA
4% 2% 95% (18 mo)
Total 31%; Endo: 85%; 
cumulative (24 mo) open: 80% 
(24 mo)
Total 12%; 86% (3 y)
cumulative (3 y)
3% 3% 89% (7.3 mo)
11% 1.7% Endo: 87%; 
open: 93% 
(24 mo)
NA 4.1% Late conversion 62% (4 y)
NA NA 88% (18 mo)
NA 2.6% overall NA
conversion
NA 2.1% annual 75% (4 y)
conversion
14% 4% NA
NA 2.1% annual NA
conversion
NA 3.1% conversion No risk: 88%;
high risk: 75% 
(2 y)
Total 22% 80% (5 y)
cumulative (5 y)
NA 6.6% conversion 84% (5 y)
NA 6.8% conversion 70% (5 y)
NA 14% conversion 62% (5 y)
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ment in 98%, no persistent or secondary endoleaks, and
patency rates of 95% and 88% at 3 and 4 years of follow-up,
respectively (1213). 
5.2.8. Prevention of Aortic Aneurysm Rupture
Aside from their infrequent other complications (e.g., periph-
eral or visceral embolism, aortocaval or primary aortoenteric
fistula), the single most compelling reason to repair AAAs is
to prevent fatal rupture. The first step in this process is to
identify the presence of these aneurysms, beginning with a
thorough physical examination or their recognition as an
incidental finding on unrelated abdominal imaging studies.
This is especially important in certain high-prevalence popu-
lations, such as those with known popliteal aneurysms or a
family history of aortic aneurysms. The next step is to estab-
lish, on the basis of ultrasonography or computed tomogra-
phy/magnetic resonance scanning, whether a particular aor-
tic aneurysm already is large enough to warrant intervention
or instead should be placed under periodic surveillance to
determine its rate of expansion. Brown et al. have shown in
a prospective but nonrandomized study that observation
alone is a safe approach until an aneurysm undergoes a
growth spurt or attains a threshold diameter of 5.0 cm (952).
The success of watchful waiting is predicated on patient
cooperation, however. In a similar study of 101 patients with
aneurysms measuring less than 5.0 cm in diameter, Valentine
et al. encountered no ruptures among patients who complied
with their follow-up program compared with a 10% rupture
rate among those who did not (1217). If continued surveil-
lance is recommended, measures should be taken to control
hypertension and to discourage smoking, because these risk
factors are associated with accelerated rates of aneurysm
growth (936,961). Ultimately, once an infrarenal aortic
aneurysm reaches an appropriate size for graft replacement,
a choice must be made between a traditional open operation
or endovascular repair. Like all other aspects of aneurysm
management, this decision requires a balanced judgment of
relative risks.
5.2.8.1. Management Overview
RECOMMENDATIONS
Class I
1. Open repair of infrarenal AAAs and/or common iliac
aneurysms is indicated in patients who are good or
average surgical candidates. (Level of Evidence: B)
2. Periodic long-term surveillance imaging should be
performed to monitor for an endoleak, to document
shrinkage or stability of the excluded aneurysm sac,
and to determine the need for further intervention in
patients who have undergone endovascular repair of
infrarenal aortic and/or iliac aneurysms. (Level of
Evidence: B)
Ouriel and associates have made several observations
regarding late complication rates in a large series of 703
patients who underwent endovascular repair of AAAs with
either investigational or commercially available stent grafts
at a single center during a 6-year period of study beginning
in 1996 (1204). First, certain complications (i.e., graft limb
occlusions, fabric tears, and type II endoleaks) appeared to
occur more commonly with some grafts than with others and
therefore may be device-specific (1204). Second, endograft
repair of aneurysms that were larger than 5.4 cm in diameter
was associated with a higher incidence of type I endoleaks
(6.4% vs. 1.4%, p equals 0.011), device migration (13% vs.
4.4%, p equals 0.006), and conversion to open surgical repair
(8.2% vs. 1.4%, p equals 0.031) than was the case with
smaller aneurysms. Patients with larger aneurysms also had
a lower survival rate (71% vs. 86%, p less than 0.001) and a
higher risk for aneurysm-related death (6.1% vs. 2.6%, p
equals 0.011) at 24 months of follow-up (1212). Finally,
although there were no gender differences in the overall inci-
dence of secondary interventions, graft limb occlusions
occurred more frequently in women than in men (11% vs.
3.3%, p equals 0.022) (1179). 
Others have reported similar data with respect to aneurysm
size and patient gender. Peppelenbosch et al. found that
EUROSTAR patients with aneurysms larger than 5.4 cm in
diameter were more likely to be older and to have more pre-
operative risk factors, early complications, and late unrelated
deaths than patients with smaller aneurysms (1191). In addi-
tion, large aneurysms often were associated with arterial
anatomy (such as angulated or ectatic infrarenal necks and
iliac aneurysms) that was less favorable for endograft repair
and probably contributed to the significantly higher overall
incidence of type I endoleaks, conversion to open surgical
repair, and late rupture and/or aneurysm-related deaths that
were documented in the group of patients who had large
aneurysms. In another study of endograft repair in 245
patients (42 women), Shames et al. also determined that graft
limb occlusions were more common among women (12% vs.
2.5%, p equals 0.05) (1180). Unlike Ouriel and associates
(1179), however, these investigators found that women also
had a higher incidence of all technical complications (17%
vs. 8.3%, p less than 0.05) and secondary procedures (29%
vs. 9.0%, p equals 0.001).
5.2.7.4.3. TECHNICAL SUCCESS RATES. The technical success
rate is a useful way to express endograft results because it
condenses a number of events into a single outcome value
that ordinarily is calculated with the life-table method. Table
56 summarizes the early and intermediate-term technical
success rates from 16 previous reports. These data reconfirm
that longer follow-up will be necessary to determine the rel-
ative merit of endovascular repair compared with open oper-
ations for AAAs. In comparison, the technical success rate
for endograft repair of isolated iliac aneurysms appears to be
quite favorable according to the scant follow-up information
that is available. Scheinert et al. described a series of 53 such
aneurysms in 48 patients with successful endograft deploy-
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Table 56. Technical Success Rates for Endograft Repair of Infrarenal Abdominal Aortic Aneurysms
Criteria for
Author Year Technical 
Device/Vendor Reference (Study Period) n Success
Case Series
Blum  (1167) 1997 154 Successful deployment
(1994-1996) No endoleaks
Stelter  (1152) 1997 201 NA
(1994-1997)
Coppi  (1182) 1998 66 Successful deployment
(1995-1996) No endoleaks
No deaths
Hausegger  (1214) 1999 30 Successful deployment
No endoleaks
Becquemin (1170) 2000 Endo: 73 No endoleaks
(1995-1999) Open: 107 No re-intervention
Chuter  (1164) 2000 High risk: 116 Successful deployment
(1996-1999) No endoleaks
Howell  (1215) 2000 56 NA
Blum  (1172) 2001 111 Successful deployment
(1994-2001) (1994-1996) No endoleaks
159
(1996-1997)
28
(1998-2001)
Ohki  (1203) 2001 239 Successful deployment 
(1992-2000) No endoleaks
Device Trials
Zarins  (1184) 1999 190 Successful deployment
AneuRx™ No endoleaks
/Medtronic (1996-1997) No deaths
Zarins  (1171) 2000 398 Survival free of aneurysm 
AneuRx™/ (1997-1998) rupture, open conversion, or re-
Medtronic intervention for endoleaks or 
graft thrombosis
Continued on Next Page
Technical Success Rates
Early Late
87%
89%
86% (30 days)
83% primary
93% secondary
74% (p=.001)
94% (1 year)
86% (2 weeks)
83% primary
85% secondary (6 
months)
82%
96%
89%
89%
77%
88% (18 months)
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Table 56. Continued
Criteria for
Author Year Technical 
Device/Vendor Reference (Study Period) n Success
Device Trials (Continued)
Beebe  (1186) 2001 240 Successful deployment
Vanguard™/ No endoleaks
Boston Scientific Graft patent
No deaths
Criado  (1216) 2001 High risk: 127 Successful deployment
Talent™/ (1997-2001) Low risk: 151 No endoleaks
Medtronic World 
Medical
EUROSTAR 
Cuypers  (1202) 1999 899 Endoleak-free survival
(1994-1998)
Buth  (1163) 2000 1,554 Successful deployment
(1994-1999) No endoleaks
No deaths
Laheij  (1206) 2000 1,023 Freedom from any
(1996-1999) secondary intervention
EUROSTAR indicates European collaborators registry on stent-graft techniques for abdominal aortic aneurysm repair; n, number of patients;  NA, not available.
Technical Success Rates
Early Late
89% (30 days)
86% (96% at 30 days)
88% (97% at 30 days) 
79% (18 months,
cumulative)
72% (30 days)
1 yr: 89%
3 yrs: 67%
4 yrs: 62% A
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Class IIa
Endovascular repair of infrarenal aortic and/or com-
mon iliac aneurysms is reasonable in patients at high
risk of complications from open operations because of
cardiopulmonary or other associated diseases. (Level
of Evidence: B)
Class IIb
Endovascular repair of infrarenal aortic and/or com-
mon iliac aneurysms may be considered in patients at
low or average surgical risk. (Level of Evidence: B)
An overview of the management of AAAs is depicted in
Figure 19. This algorithm incorporates the results of the ran-
domized UK and VA trials and takes into account the rela-
tively limited information that yet is available regarding the
long-term outcome of endograft repair for infrarenal
aneurysms. It must be conceded from the outset that there
could be honest scientific disagreement regarding a few of
the recommended pathways that are illustrated in this algo-
rithm. Some clinicians may be convinced that infrarenal
aneurysms should continue to be repaired at a size of only
5.0 cm or larger, whereas others could believe that the con-
clusions of the UK and VA trials are not directly applicable
to aortic aneurysms that involve the renal arteries and that
these aneurysms should be even larger than 5.5 cm in diam-
eter before elective surgical treatment is advised, to warrant
its additional risks. In addition, there undoubtedly are many
who believe that the present technology of endovascular
repair is at a state of development that justifies its general use
in low- and average-risk patients and in those who appear to
be at high risk for conventional open operations. There is
nothing unfavorable about its early safety to discourage this
opinion. As an example from northern California and
Nevada, proctored endovascular aneurysm repair was under-
taken at 22 community hospitals in a series of 257 patients,
only 29% of whom had medical contraindications to con-
ventional operations, with 2 immediate open conversions and
a 30-day mortality rate of 1.2% (1218). However, this report
shares the current liability of many studies concerning aortic
stent grafts. The mean follow-up period for these patients
was only 9.6 months, during which another 8% of them
required reintervention.
5.3. Visceral Artery Aneurysms
RECOMMENDATIONS
Class I
Open repair or catheter-based intervention is indicat-
ed for visceral aneurysms measuring 2.0 cm in diam-
eter or larger in women of childbearing age who are
not pregnant and in patients of either gender under-
going liver transplantation. (Level of Evidence: B)
Class IIa
Open repair or catheter-based intervention is proba-
bly indicated for visceral aneurysms 2.0 cm in diame-
ter or larger in women beyond childbearing age and in
men. (Level of Evidence: B)
Visceral aneurysms are insidious because they usually can-
not be detected by physical examination, are easily over-
looked on plain roentgenograms unless mural calcification is
present, and occur so infrequently that they may not be fully
appreciated during incidental computed tomography/mag-
netic resonance imaging scanning. Not surprisingly, there-
fore, several studies have indicated that approximately half
of all visceral artery aneurysms present with rupture (Table
57). In comparison, spontaneous rupture appears to be an
unusual event for renal artery aneurysms, possibly because
exceptionally large renal artery aneurysms may be discov-
ered on the basis of nonacute symptoms, such as hyperten-
sion or hematuria. Although rare under any circumstances,
both visceral and renal artery aneurysms most commonly
occur in multiparous women (1219,1220). Furthermore,
some studies have suggested that the incidence of splenic
artery aneurysms is particularly high among patients who
have portal hypertension or a history of previous liver trans-
plantation (1221-1223). The mortality rate for surgical repair
of ruptured visceral aneurysms is sufficiently ominous (25%
or higher) that patients who have these risk factors probably
should be investigated for visceral artery aneurysms in the
presence of unexplained abdominal symptoms.
5.3.1. Splenic Artery Aneurysms
Splenic artery aneurysms historically have been considered
to be the most common visceral artery aneurysms (Table 58),
but an increasing incidence of hepatic artery pseudoa-
neurysms has been described in relation to percutaneous and
laparoscopic biliary procedures, as well as improved imaging
techniques (1229,1230). Most splenic artery aneurysms are
asymptomatic at the time they are recognized as an inciden-
tal finding during some type of abdominal imaging, but
approximately 20% of patients present with either chronic
upper abdominal pain or acute rupture (Table 59). An
increasing number of splenic artery aneurysms also are being
discovered in women undergoing ultrasound evaluations
during pregnancy. The mortality rate for ruptured splenic
artery aneurysms in patients who are not pregnant ranges
from 10% to 25%, but the risk of maternal death from rup-
ture during pregnancy has been estimated to be as high as
70%, with a fetal mortality rate of more than 90% (1231).
The natural history of splenic artery aneurysms followed up
through pregnancy is unknown because no large series of
such patients has been collected. Nevertheless, the literature
contains many case reports of pregnant women who were
known to have splenic artery aneurysms that were at least 2.0
cm in diameter and that eventually ruptured during their
pregnancies. 
5.3.2. Superior Mesenteric Artery Aneurysms
Superior mesenteric artery aneurysms represent only 6% to
7% of all visceral aneurysms (1226,1229). Stone et al. have
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Figure 19. Management of abdominal aortic aneuryms. CT indicates computed tomography; MR, magnetic resonance imaging.
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described the largest series of superior mesenteric
aneurysms, comprising just 21 patients who were collected
from 2 large institutions during a 19-year study period
(1226). Men and those patients with noncalcified aneurysms
appeared to have the highest risk for rupture. Interestingly,
no ruptured aneurysms happened to occur among patients
who were receiving beta-blockade. The operative mortality
rate for ruptured aneurysms was 38%, but there were no
deaths after elective intervention (e.g., ligation, catheter
embolization, or prosthetic replacement grafting) in 8
patients. None of the patients who underwent elective liga-
tion or catheter embolization developed intestinal ischemia.
This probably implies that these patients were selected very
carefully on the basis of the collateral circulation that was
demonstrated by their initial arteriograms, but it could also
suggest that revascularization after ligation or catheter
embolization sometimes can be deferred unless there is clin-
ical evidence of ischemia. Five patients in this series who
had small (diameter of 1.0 to 2.4 cm) aneurysms have been
followed up with computed tomographic or ultrasound scans
for 2 to 147 months without complications.
Table 58. Site of Visceral Artery Aneurysms
Aneurysm %
Splenic 60
Hepatic 20
Superior mesenteric 6
Celiac 4
Others 10
Reprinted from Semin Vasc Surg, 8, Hallett JW, Jr., Splenic artery
aneurysms, 321-6, Copyright 1995, with permission from Elsevier
(1229).
Table 59. Demographics of Splenic Artery
Aneurysms (n=100)
Characteristic Value (Range)
Gender 87:13
Women:men
Mean age (years) 58.2 (16 to 81)
Mean number of pregnancies 4.5 (1 to 16)
Aneurysm size (cm) 2.1 (0.6 to 30)
Symptoms (%)
Asymptomatic 83
Chronic 13
Rupture 4
n indicates number of patients.
Reprinted from Semin Vasc Surg, 8, Hallett JW, Jr., Splenic artery
aneurysms, 321-6, Copyright 1995, with permission from Elsevier
(1229).T
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5.3.3. Management Options
An array of open surgical and laparoscopic approaches has
been reported for visceral artery aneurysms, with varying
mortality rates depending on the clinical setting.
Percutaneous catheter-based therapy with coil embolization
leading to thrombosis of visceral aneurysms has been
described for elective patients and for those who present with
acute rupture. The technical success rate for these nonsurgi-
cal options ranges from 67% to 100%, with few fatalities or
complications (850,1232,1233). One concern that should be
recognized related to the catheter-based management of vis-
ceral artery aneurysms is the limited ability to assess the end
organ after aneurysm treatment. This is in contrast to open
surgical visceral artery aneurysm repair, in which the end
organ may be visualized and assessed, a point that appears to
be especially important in the treatment of mesenteric artery
aneurysms, for which there is potential risk for bowel
ischemia. Therefore, patients undergoing catheter-based
intervention for visceral artery aneurysms should be watched
closely after the procedure for the development of abdominal
pain in the setting of mesenteric or splenic artery aneurysms
and flank pain in the setting of renal artery aneurysms.
5.4. Lower Extremity Aneurysms
5.4.1. Etiology
As illustrated in Figures 20 and 21, the diameters of periph-
eral arteries increase approximately 20% to 25% between the
ages of 20 and 70 years (865,1234). Coexistent AAAs have
been reported in 85% of patients with femoral aneurysms
(1235) and in 62% of those with popliteal aneurysms (1236),
whereas femoral or popliteal aneurysms are present in 3% to
7% of patients who have AAAs. It is not known whether
these patients are specifically prone to diffuse aneurysm dis-
ease because of genetic or other factors or whether certain
aneurysms are associated with generalized arterial ectasia
elsewhere (1237-1239). The possibility that arterial
aneurysm disease is a generalized process in the vascular
system is supported by studies showing defective mechanical
properties in the walls of distant arteries that usually do not
undergo dilatation (1240,1241). When dilatation of the
peripheral arteries was described in patients with AAAs
more than a decade ago, the normal diameters of the studied
regional arteries were unknown (1242,1243). 
In an angiographic study in which arterial luminal diame-
ters were measured, dilatation in the iliac artery was identi-
fied in patients with AAA, but the peripheral arteries in the
leg were not affected (1244). The tunica media of the femoral
and popliteal arteries consists largely of smooth muscle cells.
The mechanical properties (and thus the integrity) of arterial
Figure 20. Predicted diameter of common femoral artery (CFA)
in male and female subjects. Select appropriate curve for age
marked on right and follow curve to appropriate body surface
area (BSA) on horizontal axis. Predicted diameter is shown on
vertical axis. Reprinted from J Vasc Surg, 29, Sandgren T,
Sonesson B, Ahlgren R, et al., The diameter of the common
femoral artery in healthy human: influence of sex, age, and body
size, 503-10, with permission from Elsevier (1234).
Figure 21. Predicted diameter of popliteal artery in males. To
use this nomogram, select the appropriate age curve marked on
the right and follow the curve to the appropriate body surface
area (BSA) on the horizontal axis. The vertical axis shows the
predicted diameter. Sandgren T, Sonesson B, Ahlgren AR, et al.
Factors predicting the diameter of the popliteal artery in healthy
humans. J Vasc Surg. 1998;28:284-9, with permission from
Elsevier (865).
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walls are based on the matrix components, elastin and colla-
gen, whereas smooth muscle cells have the potential to mod-
ulate wall mechanics. Therefore, the systemic implications
of an aortic aneurysm may be different in central arteries
than in peripheral arteries. In another investigation by
Sandgren et al., ultrasound measurements of the anteroposte-
rior diameters of the peripheral arteries of the right legs of
183 consecutive patients who were referred for elective
repair of AAA revealed 8 common femoral aneurysms and 4
popliteal aneurysms, all in men (879). Of those in whom
femoral and popliteal aneurysms were identified, occlusive
PAD was present in 46% and 49%, respectively. After exclu-
sion of those with either peripheral aneurysms or occlusive
disease, no dilating diathesis was found in the limb vessels of
the remaining patients with AAA.
5.4.2. Natural History
Unlike AAAs, the natural history of extremity-artery
aneurysms is not one of expansion and rupture but one of
thromboembolism or thrombosis.
RECOMMENDATION
Class I
In patients with femoral or popliteal aneurysms,
ultrasound (or computed tomography or magnetic
resonance) imaging is recommended to exclude con-
tralateral femoral or popliteal aneurysms and AAA.
(Level of Evidence: B)
5.4.2.1 Popliteal Artery Aneurysms
Popliteal aneurysms account for 70% of all aneurysms in the
lower extremities and have an estimated incidence of 0.1% to
2.8% (1245,1246). Approximately 5% of small aortic
aneurysms are discovered because of lower extremity
ischemia caused by distal embolization of mural thrombus
(1247). However, thromboembolic complications are much
more common with popliteal aneurysms, which also may be
associated with arteriomegaly involving the common
femoral and superficial femoral arteries. Before the introduc-
tion of modern arterial bypass grafting, Gifford et al. report-
ed a series of 69 patients with 100 popliteal aneurysms, of
which 45% were bilateral and 65% were symptomatic
(1248). Only 21% of these aneurysms were treated surgical-
ly. Very few (7%) of the remaining aneurysms eventually
ruptured, but 21% ultimately were associated with ischemic
complications, and 23% of the 69 patients required amputa-
tions. 
Although rupture has continued to be distinctly unusual in
some studies, the data in Table 60 confirm many of the other
observations that were made by Gifford et al. (1248). The
vast majority of popliteal aneurysms occur in men, and
approximately half are bilateral. Approximately half of
popliteal aneurysms also are associated with other
aneurysms, principally involving the abdominal aorta. At
least 40% of popliteal aneurysms are symptomatic on dis-
covery because of thrombosis-in-situ of the popliteal artery
or distal emboli to the calf or foot. According to a collective
review of the literature that was conducted by Dawson et al.
(1249), these complications still occur in 36% of patients
whose popliteal aneurysms are merely placed under observa-
tion, a figure that is remarkably similar to the late complica-
tion rate of 34% that was reported by Gifford and his associ-
ates more than 40 years earlier. Furthermore, Dawson et al.
also found that the cumulative incidence of ischemic com-
plications was as high as 70% during 5 to 10 years of follow-
up for popliteal aneurysms that were evaluated at their own
center (1250,1251).
According to data reported by Roggo et al., as many as
50% of previously asymptomatic popliteal aneurysms may
be expected to become symptomatic within 2 years after
their discovery and 75% within 5 years (1254) (Figure 22).
Symptomatic popliteal aneurysms generally exceed 2.0 cm
in diameter, often contain a substantial amount of mural
thrombus on B-mode ultrasound imaging, and frequently are
associated with distal tibioperoneal arterial occlusions that
suggest previous emboli (1252,1253,1255). Probably
because of prior emboli with thrombosis of downstream out-
flow vessels, Poirier et al. reported that 56% of patients con-
tinued to experience distal ischemia despite surgical repair of
symptomatic popliteal aneurysms, and 19% eventually
required amputation (1256). 
The unfavorable consequences of popliteal aneurysms sug-
gest that even asymptomatic popliteal aneurysms with good
distal runoff should be repaired electively, although there is
a lack of prospective studies to support an unqualified rec-
ommendation in this regard, especially for aneurysms meas-
uring less than 2.0 cm in diameter. In fact, there is a pub-
lished consensus that small popliteal aneurysms rarely
become symptomatic and that elective surgical intervention
should be considered only for those measuring at least 2.0
cm in diameter (1245,1254,1255). Stiegler et al. have report-
ed a series of 46 patients who had 65 popliteal artery
aneurysms with a mean diameter of 1.9 cm (range 0.8 to 4.0
cm); the aneurysms were occluded at the time of their dis-
covery in only 8 patients (mean diameter 2.4 cm, range 1.4
to 4.0 cm) (1257). Thirty-six patients with 46 aneurysms
were observed over a period of 2.5 years. The total compli-
cation rate was 6.5%, with a higher incidence in patients
whose aneurysms were larger than 2.0 cm in diameter (14%
vs. 3.1%). Complications also appeared to occur more fre-
quently (14% vs. 0%) in the 19 patients who were treated
with platelet-inhibitor drugs than in 16 others who received
coumarin anticoagulation. The mean increase in diameter
during follow-up was 1.5 mm per year for aneurysms larger
than 2.0 cm versus 0.7 mm per year for smaller aneurysms.
In another regional survey of 19 vascular surgeons who con-
tributed data for 200 popliteal aneurysms in 137 patients dur-
ing a 4-year period of study, Varga et al. determined that 31%
of small, untreated aneurysms eventually required surgical
intervention because of the onset of new symptoms or expan-
sion to a diameter that exceeded 2.0 cm while under surveil-
lance (968).
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Table 60. Presentation and Complication Rates for Popliteal Aneurysms
No. of Patients Bilateral Initial 
and/or Popliteal or Previous Symptoms Surgical 
First Author Reference Year Aneurysms Other Aneurysms Before Presentation Treatment
Case series
Gifford (1248) 1953 69/100 45% bilateral; 65% (34% ischemic; 21%
(66 men) 25% other 12% ruptured
Dawson (1250) 1991 50/71 42% bilateral; NA 65%
32% other
Carpenter (967) 1994 33/54 62% bilateral; 61% (39% ischemic) 83%
61% other
Dawson (1251) 1994 42/42 NA All asymptomatic None
Lowell (1252) 1994 106/161 52% bilateral 42% 31%
(103 men)
Schroder (1253) 1996 217/349 61% bilateral 45% 63%
Duffy (1245) 1998 24/40 66% bilateral 58% 75%
(23 men)
Collective reviews
Dawson (1249) 1997 1673/2445 50% bilateral; 67% NA
(95% men) 37% other
NA indicates not available.
Related 
Amputation
Rate
23% 
(7% early; 
16% late)
NA
11%
7%
7%
NA
None
NA
Complications With
Observation Alone
34% (21% 
ischemic; 7% 
ruptured)
54%
NA
60%
22%
47%
None (smaller 
than 2 cm)
36%
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deep femoral aneurysms appears to be higher than that of
other lower extremity aneurysms, occurring in one third of
the cases reported by Cutler and Darling (1260). Other com-
plications are related to expansion, such as femoral nerve
compression, venous occlusion with phlegmasia cerulea
dolens, and acute leg ischemia secondary to thrombosis or
embolization (1260-1264).
5.4.3. Management
RECOMMENDATIONS
Class I
1. Patients with a palpable popliteal mass should under-
go an ultrasound examination to exclude popliteal
aneurysm. (Level of Evidence: B)
2. Patients with popliteal aneurysms 2.0 cm in diameter
or larger should undergo repair to reduce the risk of
thromboembolic complications and limb loss. (Level
of Evidence: B)
3. Patients with anastomotic pseudoaneurysms or symp-
tomatic femoral artery aneurysms should undergo
repair. (Level of Evidence: A)
Class IIa
1. Surveillance by annual ultrasound imaging is suggest-
ed for patients with asymptomatic femoral artery true
aneurysms smaller than 3.0 cm in diameter. (Level of
Evidence: C)
2. In patients with acute ischemia and popliteal artery
aneurysms and absent runoff, catheter-directed
thrombolysis or mechanical thrombectomy (or both)
is suggested to restore distal runoff and resolve
emboli. (Level of Evidence: B)
3. In patients with asymptomatic enlargement of the
popliteal arteries twice the normal diameter for age
and gender, annual ultrasound monitoring is reason-
able. (Level of Evidence: C)
Thrombosis of popliteal arterial aneurysms accounts for
approximately 10% of acute arterial occlusions in elderly
men. Commonly mistaken for an embolic event, the diagno-
sis is often made intraoperatively at the time of an attempted
embolectomy (518,1258). Severe ischemia usually occurs
because thrombosis occurs suddenly in the absence of collat-
eral enhancement and because the popliteal artery is the sole
axial artery traversing the knee. Given that half of all
popliteal aneurysms are bilateral, the presence of a promi-
nent popliteal pulse in the opposite leg may be a valuable
clue to the underlying etiology of the acute ischemia. Once
suspected, ultrasound imaging is the most rapid means to
confirm the diagnosis. In a series of 33 patients with 54
popliteal artery aneurysms that were followed up over 62
months, thrombosis occurred in 39%, most often in larger
aneurysms (967).
5.4.2.2 Femoral Artery Aneurysms
Femoral artery aneurysms may be discovered incidentally as
a pulsatile mass in the thigh, or they may present with distal
ischemia, and even more rarely, with rupture and bleeding. In
a series of 13 aneurysms of the superficial femoral artery
reported by Jarrett et al., 11 (85%) occurred in men, 9 (69%)
were associated with aortic or iliac aneurysms, and 7 (54%)
were contiguous with common femoral or popliteal
aneurysms (1259). Six patients (46%) presented with distal
ischemia and 4 (31%) with a thigh mass, whereas the remain-
ing 3 (23%) were discovered during investigations for other
vascular conditions. None of these aneurysms had ruptured.
Aneurysms of the deep femoral artery usually are found in
conjunction with an adjacent aneurysm of the common
femoral artery, but isolated aneurysms of the deep femoral
artery account for just 0.5% of peripheral aneurysms and for
only 1% to 2.6% of femoral aneurysms (1260,1261). Twenty
percent of patients with deep femoral aneurysms in 1 series
had 3 or more peripheral aneurysms. The rate of rupture of
Figure 22. Follow-up evaluation of asymptomatic popliteal artery aneurysm (PAAs). Reprinted from Roggo A, Brunner U, Ottinger
LW. The continuing challenge of aneurysms of the popliteal artery. Surg Gynecol Obstet. 1993;177:565-72 (1254).
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conjunction with bypass grafting to exclude the popliteal
aneurysm from the circulation. In the past, this has been done
strictly with thromboembolectomy balloon catheters in the
operating room, often after preoperative arteriograms or
MRA scans have failed to determine whether a target vessel
for revascularization even is present. Some series now have
been reported, however, in which preoperative intra-arterial
thrombolytic therapy has been a valuable adjunct for restor-
ing runoff in the presence of recent thromboembolic events
(881,882,1251,1252). Failure to attain runoff with catheter-
directed thrombolysis suggests that atheroemboli are
involved and/or that a fasciotomy should be considered
because of high muscular compartment pressures that may
be contributing to the occlusion of otherwise normal outflow
vessels. 
The data illustrated in Figure 23 document the 10-year
graft patency, limb salvage, and patient survival rates for a
series of popliteal aneurysm repairs described by Dawson et
al. (1249). The survival rate was lower than that for the gen-
eral population because of the medical comorbidities in such
patients. Nevertheless, these data indicate that it is possible
to achieve limb salvage rates exceeding 90% at 10 years
when the operation is done for asymptomatic aneurysms,
with graft patency rates that are as high as 80% after opera-
tions for symptomatic aneurysms. According to information
collected from 14 other reports (1249), the choice of the
bypass conduit may influence late results (Table 61).
Saphenous vein grafts were associated with superior long-
term patency and limb salvage rates compared with either
polyester filament or PTFE grafts in 6 of these reports, and
in several others, PTFE grafts were approximately twice as
likely as polyester filament grafts to remain patent.
Furthermore, in the absence of adequate runoff, surgical
repair of popliteal artery aneurysms is more likely to be suc-
4. In patients with femoral or popliteal artery
aneurysms, administration of antiplatelet medication
may be beneficial. (Level of Evidence: C)
5.4.3.1. Popliteal Aneurysms
A popliteal mass should be studied by duplex ultrasonogra-
phy to distinguish an aneurysm from other soft-tissue
lesions, such as a synovial (Baker’s) cyst, especially if the
patient has a history of other arterial aneurysms involving the
contralateral lower extremity or the abdominal aorta.
Nonoperative observation with periodic noninvasive surveil-
lance may be appropriate if the aneurysm measures less than
2.0 cm in diameter or contains no thrombus or if the patient
is at high surgical risk or has limited longevity because of
medical comorbidities. If symptoms develop or the aneurysm
enlarges on follow-up duplex scans, the risk of thromboem-
bolic complications and limb loss then must be weighed
against whatever factors originally may have influenced the
decision to postpone surgical treatment. Farina et al. were
unable to identify any controlled trials regarding clinical
management in their review of 29 studies comprising 1673
patients with 2445 popliteal arterial aneurysms (1265). 
In the setting of acute ischemia related to popliteal artery
aneurysm thrombosis or thromboembolism, catheter-direct-
ed thrombolytic therapy is useful to re-establish patency of
the popliteal and tibial trunks to allow for more effective
definitive aneurysm treatment and limb salvage. Largely on
the basis of previous and often unrecognized emboli, one of
the obstacles to a successful surgical outcome is the absence
of adequate arterial outflow in the calf and foot. Because
limb salvage rates can be correlated directly with the number
of available runoff vessels, as much thrombus as possible
must be cleared from the tibioperoneal and plantar arteries in
Figure 23. Long-term graft patency, limb salvage, and patient
survival after popliteal aneurysm repair. —— indicates long-term
graft patency; ............, limb salvage; and - - - - -, patient survival.
From Dawson RB, Sie RB, van Bockel JH. Atherosclerotic
popliteal aneurysm. Br J Surg. 1997;84:293-9. ©John Wiley &
Sons Limited. Reproduced with permission (1249).
e145
ACC - www.acc.org
AHA - www.americanheart.org
Hirsch et al. 2005
ACC/AHA Practice Guidelines
cessful if saphenous vein is used as the conduit and fascioto-
my is performed. 
The algorithm presented in Figure 24 summarizes the man-
agement options for either symptomatic or asymptomatic
popliteal aneurysms. In the presence of mural thrombus, the
diameter of a popliteal aneurysm will appear to be smaller on
an arteriogram than its true diameter on duplex or computed
tomographic imaging, but the value of an arteriogram is to
determine the adequacy of tibioperoneal outflow and
whether the use of catheter-directed thrombolytic therapy
should be considered to restore runoff. The decision to pro-
ceed with elective surgical treatment in the absence of limb-
threatening ischemia is not predicated on aneurysm size
alone. It must also take into account the overall clinical situ-
ation, the severity of symptoms in the leg, and the surgical or
endovascular facilities that are available. 
5.4.3.2. Femoral Aneurysms
The cause of femoral artery aneurysms may be arterial
degeneration (i.e., true aneurysms) or false aneurysms relat-
ed to previous vascular reconstructions or arterial injury.
Femoral artery pseudoaneurysm represents a pulsatile mass
that is contained by incomplete elements of the arterial wall
and surrounding subcutaneous/fibrous tissue and may result
from disruption of a previous femoral suture line, femoral
artery access for a catheter-based procedure, or injury result-
ing from puncture due to self-administered drug abuse.
Regardless of the cause, a pulsatile groin mass should be
evaluated by duplex ultrasound and/or contrast-enhanced
computed tomographic scan. The clinical presentation of true
femoral artery aneurysms is summarized in Table 62 (1272).
Most reports encourage a policy of elective surgical treat-
ment for symptomatic patients if their operative risk is low
and if the patient has a reasonable life expectancy. In 2 series,
however, nonoperative observation has been used twice as
often as elective intervention for asymptomatic femoral
aneurysms and appears to be associated with a relatively low
risk for complications during follow-up periods of 28 to 52
months (1115,1156). Therefore, the stable femoral artery
aneurysm presents a therapeutic dilemma, because its com-
plication rate appears to be substantially lower than that for
Figure 24. Diagnostic and treatment algorithm for popliteal mass. CT indicates computed tomography.
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Table 61. Graft Patency and Limb Salvage Rates for Popliteal Aneurysms
Patency (%) Limb Salvage (%)
Follow-Up                No. of                                                              Symptoms
First Author Reference (y) Patients Total Asymptomatic Symptomatic
Anton (1266) 5 123 – 82 57
10 56 82 48
Carpenter (967) 5 54 71 – –
Cole (1267) 3 59 88 94 81
Dawson (1250) 5 46 75 – –-
10 64 – –
Duffy (1245) 3 30 84 – –
Farina (1265) 5 50 62 80 65
10 62 – –
Inahara (1268) 10 40 76 – –
Lilly (1268a) 5 48 74 91 54
Reilly (1269) 5 167 – – –
Roggo (1254) 5 252 69 85 61 
10 – – –
Schellack (1270) 5 95 75 93 66
Schroder (1253) 4 221 – 89 –
Szilagyi (1255) 5 50 60 –- –-
10 28 – –-
Towne (1271) 5 115 53 – –
*A indicates 34% polyester fiber and 74 % polytetrafluorethylene (PTFE); B, 33% polyester fiber and 64% PTFE.
SV indicates saphenous vein.
Reprinted from Dawson I, Sie RB, van Bockel JH. Atherosclerotic popliteal aneurysm. Br J Surg 1997;84:293-9 (1249). © John Wiley & Sons Limited. Reproduced with permission.
Symptoms Graft Material
Asymptomatic Symptomatic SV Others
93 82 98 75
93 79 98 66
– – – –
– – – –
– – – –
– – 100 88
– – – 0
– – – –
– – – –
– – – –
– – – –
98 92 97 88
96 81 94 74
100 91 – –
100 – – 0
– – –
– – – –
– – – –
Graft Material
SV Others* Total
94 43 83
94 27 83
– – 90
– – –
– – –
84 41 95
– – 96
100 60 A 94
– – –
– – –
– – –
77 30
81 40 B 94
87
92 55 94
– – –
– – –
– – –
– – –
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Table 62. Clinical Presentation of Femoral Aneurysms
AAA/PAA
First Author Reference No. of Patients Aneurysms (n) Males:Females Bilateral (%) Associated (%)
Cutler (1260) 45 63 40:5 47 51/27
Adiseshiah (1273) 16 27 15:1 62 25/31
Baird (1274) 30 36 30:0 20 40/17
Graham (1235) 100 172 100:0 72 85/44
Sapienza (1275) 22 31 21:1 41 50/—
AAA indicates abdominal aortic aneurysm; FAA, femoral artery aneurysm; PAA, popliteal artery aneurysm.
Reprinted from Vascular Surgery (5th ed), Graham L, Femoral and popliteal aneurysms, 1345-56, copyright 2000, with permission from Elsevier (1272).
Presentingii
Symptoms
Local: 29%
Local: 23%;
ischemic: 50%
Local pain: 11%;
mass: 16%;
venous: 8%;
ischemic: 42%
Local: 5%; 
ischemic: 35%
Asymptomatic (%)
29
70
27
40
64
Complications at
Presentation
Acute thrombosis: 16%;
chronic thrombosis: 16%;
rupture: 14%
Embolization: 4%; 
thrombosis: 7%; 
rupture: 15%
Acute thrombosis/emboliza-
tion: 13%; 
rupture: 0%
Embolization: 8%;
acute thrombosis: 1%;
chronic thrombosis: 1%;
rupture: 2%
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popliteal aneurysms of similar size. A wide range of normal
dimensions (see Figure 20) makes it difficult to determine an
arbitrary size at which true femoral aneurysms should be
repaired. By convention, femoral aneurysms measuring 3.0
cm or larger appear most likely to cause compressive symp-
toms and therefore also are most likely to be treated surgi-
cally. Although the presence of mural thrombus conceivably
could represent a risk for distal emboli unless elective repair
is performed, the actual magnitude of this risk is unknown. 
Anastomotic pseudoaneurysms occur with an incidence of
2% to 5%, are encountered most commonly as a late compli-
cation of synthetic aortofemoral bypass grafting, inevitably
continue to enlarge if left untreated, and may require arteri-
ography before repair. Infected femoral pseudoaneurysms
may occur as the result of arterial puncture during drug abuse
and must be treated by extensive operative debridement,
often in conjunction with either autogenous in situ recon-
struction or extra-anatomic bypass grafts to avoid CLI. Skin
erosion or expanding rupture into adjacent soft tissue obvi-
ously is an unstable situation for which urgent surgical repair
is necessary regardless of the cause of the femoral artery
aneurysm or pseudoaneurysm. 
5.4.3.3. Catheter-Related Femoral Artery
Pseudoaneurysms
RECOMMENDATIONS
Class I
1. Patients with suspected femoral pseudoaneurysms
should be evaluated by duplex ultrasonography.
(Level of Evidence: B)
2. Initial treatment with ultrasound-guided compression
or thrombin injection is recommended in patients
with large and/or symptomatic femoral artery
pseudoaneurysms. (Level of Evidence: B)
Class IIa
1. Surgical repair is reasonable in patients with femoral
artery pseudoaneurysms 2.0 cm in diameter or larger
that persist or recur after ultrasound-guided com-
pression or thrombin injection. (Level of Evidence: B)
2. Re-evaluation by ultrasound 1 month after the origi-
nal injury can be useful in patients with asymptomatic
femoral artery pseudoaneurysms smaller than 2.0 cm
in diameter. (Level of Evidence: B)
A pseudoaneurysm is a pulsatile hematoma that communi-
cates with an artery through a defect in the arterial wall.
Femoral pseudoaneurysms are well-recognized complica-
tions of arterial catheterization, occurring after 0.1% to 0.2%
of diagnostic angiograms and after 3.5% to 5.5% of inter-
ventional procedures. Puncture-site pseudoaneurysms are
most commonly associated with longer procedures, the use
of larger-diameter delivery-sheath sizes catheters, systemic
anticoagulation, and difficult arterial access. Some studies
have suggested that more than 60% of catheter-related
femoral pseudoaneurysms are overlooked on the basis of the
physical examination alone. Therefore, although a pulsatile
mass is an obvious indication that a pseudoaneurysm may be
present, a diagnostic duplex scan should be obtained when-
ever the diagnosis is even suspected. 
In the absence of antithrombotic therapy, several studies
have indicated that catheter-related pseudoaneurysms that
are less than 2.0 cm in diameter tend to heal spontaneously
and usually require no treatment. Collectively, 61% of the
small pseudoaneurysms in the 9 series that are summarized
in Table 63 resolved within 7 to 52 days of observation, and
only 11% ultimately required surgical intervention. Figure 25
illustrates the spontaneous closure rate of selected pseudoa-
neurysms that were not repaired immediately, 90% of which
resolved within 2 months. Accordingly, small asymptomatic
pseudoaneurysms probably can be managed conservatively
Table 63. Spontaneous Thrombosis of Femoral Pseudoaneurysms
No. of Spontaneous 
First Author Reference Patients Closure (n) Surgery (n) Comments
Feld (1276) 17 3 2
Fellmeth (1277) 35 4 —
Johns (1278) 6 5 2 7 to 42 days to close
Kazmers (1279) 53 4 3
Kresowik (1280) 7 7 — Less than 28 days to close
Samuels (1281) 11 11 —
Schaub (1282) 54 50 — Approximately 52 days to close
Toursarkissian (1283) 147 86% 14% Approximately 23 days to close
Weatherford (1284) 27 7 10 Median 40 days to close
Total 357 217 38
Fractional percentage 61% 11%
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unless they are still present on a follow-up duplex scan 2
months later. 
At the opposite extreme, large pseudoaneurysms can rup-
ture into the retroperitoneal space or the upper thigh or cause
venous thrombosis or painful neuropathy by compressing the
adjacent femoral vein or the femoral nerve. Urgent surgical
repair clearly is necessary if any of these serious complica-
tions occur, and until recently, it was the mainstay of treat-
ment for most catheter-related femoral artery injuries. Many
reports now have demonstrated, however, that the majority
of uncomplicated pseudoaneurysms can be managed nonop-
eratively with either ultrasound-guided compression therapy
or the injection of miniscule amounts of thrombin directly
into the pseudoaneurysm cavity. Problems with ultrasound-
guided compression therapy include pain at the site of com-
pression, long compression times, and incomplete closure,
each of which is more problematic with large pseudoa-
neurysms. Table 64 contains information from 17 series of
patients who underwent ultrasound-guided compression
therapy with a primary success rate of 86% and surgical
treatment in only 4.9%. Recurrences usually responded to
further compression and most frequently were associated
with pseudoaneurysms that exceeded 4.0 cm in size in
patients who had required larger-diameter delivery sheaths or
periprocedural anticoagulation. 
Pseudoaneurysms ranging in size from 1.5 to more than 7.5
cm may be successfully obliterated by the injection of
thrombin, 100 to 3000 international units, under ultrasound
guidance. Table 65 contains data from 7 institutional series in
which thrombin injection was performed for catheter-related
femoral pseudoaneurysms. In aggregate, the success rate was
93%, and only 4.1% of the patients needed operations.
Thrombin injection can be complicated by distal arterial
thromboembolism in less than 2% of cases and rarely by pul-
Figure 25. Spontaneous closure rates of selected pseudoa-
neurysms. AVF indicates arteriovenous fistula; PSA, pseudoa-
neurysm. Reprinted from J Vasc Surg, 25, Toursarkissian B,
Allen BT, Petinec D, et al. Spontaneous closure of selected
iatrogenic pseudoaneurysms and arteriovenous fistulae, 803-8,
Copyright 1997, with permission from Elsevier (1283).
Table 64. Ultrasound-Guided Compression of Femoral Pseudoaneurysms
First Author Reference Patients (n) Closure (n) Surgery (n) Comments
Chatterjee (1285) 38 37 1 FemoStop used
Coghlan (1286) 10 9 1
Cox (1287) 100 94 2 10 recurrences, 1 to 35 days
Dean (1288) 77 56 14 Size less than 4 cm; twice as 
successful at closure
Feld (1276) 15 10 2
Fellmeth (1277) 29 27 —
Hajarizadeh (1289) 57 54 2 2 recurrences 2 to 10 days
Hertz (1290) 41 36 3 Large catheter sheath size problematic
Kazmers (1279) 33 25 3 2 pseudoaneurysm ruptures
Kumins (1291) 60 52 — 7 recurrences
Langella (1292) 36 27 — 3 recurrences
Paulson (1293) 48 37 —
Perkins (1294) 13 10 —
Schaub (1282) 124 104 5
Sorrell (1295) 11 10 1
Steinkamp (1296) 98 96 2
Weatherford (1284) 11 8 3
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monary embolism. The recurrence rate is approximately 5%
after an initial injection, but recurrent pseudoaneurysms can
be safely reinjected with a high rate of success (1297-1299).
According to a multicenter registry of patients who have
been treated with this technique, thrombin injection ulti-
mately has provided successful treatment for 98% of
pseudoaneurysms and appears to represent an improvement
over ultrasound-guided compression therapy (1300,1301).
One study has been reported in which thrombin injection was
compared concurrently with ultrasound-guided compression
Figure 26. Diagnostic and treatment algorithm for femoral pseudoaneurysm. AV indicates arteriovenous.
Table 65. Thrombin Injection Closure of Femoral Pseudoaneurysms
First Author Reference Patients (n) Thrombin Dose (U) Closure (n) Surgery (n) Comments
Hughes (1303) 9 1000 to 2000 8 0 1 recurrence at 4 days
Kang (1304) 21 500 to 1000 20 1
La Perna (1299) 70 1000 66 2 94% overall success rate
Success maintained in patients 
using antithrombotic medications
Liau (1305) 5 1000 5 0
Mohler (1300) 91 500 to 1000 87 0 98% overall success rate
Second injection required 
for 3 patients
Reeder (1306) 26 50 to 450 25 0 1 recurrence at 4 days
Sacket (1307) 30 100 to 2000 27 3
Taylor (1308) 29 600 27 1
e151
therapy (1302). Thrombin injection took less time and was
associated with lower vascular laboratory costs, but the over-
all hospital costs were equivalent in both groups of patients.
The algorithm illustrated in Figure 26 presents an approach
to the management of catheter-related femoral artery
pseudoaneurysms that is consistent with the current literature
on this topic. 
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NHDS = National Hospital Discharge Survey
OR = odds ratio
p = statistical significance
PAD = peripheral arterial disease
PARTNERS = PAD Awareness, Risk and Treatment:
New Resources for Survival (study)
PGE-1 = prostaglandin E1
phVEGF165 = vascular endothelial growth factor 
plasma DNA
PTA = percutaneous transluminal 
angioplasty
PTFE = polytetrafluoroethylene
PVR = pulse volume recording
RAS = renal artery stenosis
RRI = resistive index
ROS = review of symptoms
SVS/ISCVS = Society for Vascular Surgery/ 
International Society for Cardiac 
Vascular Surgery
TASC = TransAtlantic Inter-Society 
Consensus Working Group
TBI = toe-brachial index
3D = 3-dimensional
UK = United Kingdom
US = United States
USPSTF = United States Preventive Services 
Task Force
VA = Veterans Affairs
VEGF = vascular endothelial growth factor
APPENDIX 3. ABBREVIATIONS
ABI = ankle-brachial index
ACC = American College of Cardiology
ACE = angiotensin-converting enzyme
AHA = American Heart Association
ARIC = Atherosclerosis Risk in 
Communities study
bFGF = basic fibroblast growth factor
CI = confidence interval
CLI = critical limb ischemia
COPD = chronic obstructive pulmonary 
disease
CTA = computed tomographic angiography
DNA = deoxyribonucleic acid
DRASTIC = Dutch Renal Artery Stenosis 
Intervention Cooperative
EDTA = ethylenediaminetetraacetic acid
ESRD = end-stage renal disease
EUROSTAR = EUROpean collaborators on Stent-
graft Techniques for abdominal aortic
Aneurysm Repair
FDA = Food and Drug Administration
FMD = fibromuscular dysplasia
HDL = high-density lipoprotein
HMG = hydroxymethyl glutaryl
ICAVL = Intersocietal Commission for 
Accreditation of Vascular 
Laboratories
INR = international normalized ratio
LDL = low-density lipoprotein
MI = myocardial infarction
MMP = matrix metalloproteinases
MRA = magnetic resonance angiography
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